variant_id	variant_civic_url	gene	entrez_id	variant	summary	variant_groups	chromosome	start	stop	reference_bases	variant_bases	representative_transcript	ensembl_version	reference_build	chromosome2	start2	stop2	representative_transcript2	variant_types	hgvs_expressions	last_review_date	civic_variant_evidence_score	allele_registry_id	clinvar_ids	variant_aliases	assertion_ids	assertion_civic_urls	is_flagged
1	https://civicdb.org/links/variants/1	ABL1	25	BCR::ABL	The BCR-ABL fusion protein, commonly referred to as the Philadelphia chromosome, is one of the most studied fusion genes in cancer. It has widely been considered the initiating event in chronic myelogenous leukemia (CML). However, despite its ability to initiate disease in mice, its status as an initiating mutation is in dispute. In what is commonly used as the poster-child for targeted therapeutics, the development and use of imatinib in the clinic has led to profound improvements in the prognosis of the disease. However, imatinib resistance is still seen in patients with mutations in the ABL kinase domain of the fusion, most notably the T315I variant. In patients resistant to imatinib, either acquired or otherwise, second generation BCR-ABL TKI's (dasatinib and nilotinib) have seen some success in delivering a tumor response. Third generation ABL1 inhibitor ponatinib is the only FDA approved drug with activity against T315I . However due to risk of life-threatening blood clots and severe narrowing of blood vessels ponatinib is ONLY approved for T315I-positive CML or T315I-positive Ph+ ALL or in cases of CML, Ph+ ALL with resistance or intolerance to other approved ABL1 inhibitors.	ABL1 fusions in B-ALL	22	23522397	23632600			ENST00000305877.8	75	GRCh37	9	133729451	133763063	ENST00000318560.5	transcript_fusion	N/A	2022-03-10 22:27:25 UTC	255.5		N/A	T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL			false
2	https://civicdb.org/links/variants/2	ABL1	25	BCR::ABL T315I	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation T315I (aka T334I) has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and ponatinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance	9	133748283	133748283	C	T	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_007313.2:c.1001C>T,NP_005148.2:p.Thr315Ile,ENST00000372348.2:c.1001C>T,NC_000009.11:g.133748283C>T	2022-03-10 19:55:19 UTC	146.0	CA122575	12624	THR334ILE,RS121913459,BCR-ABL THR315ILE,BCR-ABL1 T315I,BCR-ABL1 THR315ILE,BCR-ABL T315I			false
3	https://civicdb.org/links/variants/3	ABL1	25	BCR::ABL E255K	While the efficacy of imatinib has revolutionized chronic myelogenous leukemia (CML) treatment, it is still not a cure-all. Both initial resistance and acquired resistance as a result of selection have been seen in a small subset of CML patients. The ABL kinase domain mutation E255K has been shown to be one such mutation that confers resistance to imatinib. Second generation TKI's (dasatinib and nilotinib) specific to BCR-ABL have shown efficacy in treating resistant cases.	Imatinib Resistance	9	133738363	133738363	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NC_000009.11:g.133738363G>A,NM_005157.5:c.763G>A,NP_005148.2:p.Glu255Lys,ENST00000318560.5:c.763G>A	2022-03-11 04:36:22 UTC	83.0	CA16602551	376090	E274K,RS121913448,BCR-ABL GLU255LYS,BCR-ABL1 E255K,BCR-ABL1 GLU255LYS,BCR-ABL E255K			false
4	https://civicdb.org/links/variants/4	AKT1	207	E17K	AKT1 E17K is a recurrent mutation that has been observed in breast, colorectal, lung, and ovarian cancer. It has been convincingly shown to be an activating mutation resulting in PI3K/AKT/mTOR pathway activity. It has been suggested that this mutation decreases the cell's sensitivity to AKT1 allosteric kinase inhibitors. This, and other AKT1 mutations, are the subject of much research and development for therapeutics.		14	105246551	105246551	C	T	ENST00000407796.2	75	GRCh37					missense_variant	NC_000014.8:g.105246551C>T,NM_001014432.1:c.49G>A,NP_001014432.1:p.Glu17Lys,ENST00000407796.2:c.49G>A	2021-11-12 18:53:34 UTC	33.5	CA123660	13983	GLU17LYS,RS34409589			false
5	https://civicdb.org/links/variants/5	ALK	238	EML4::ALK	The EML4-ALK fusion variant 1 consisting of ALK kinase domain (exons 20-29) fused to EML4 exons 1-13 is the most common EML4-ALK variant, and was discovered in non-small cell lung cancer. Multiple EML4 breakpoint shave been described with differential sensitivity to inhibitors with variant 1 showing greater sensitivity than 3a in cell lines. EML4-ALK is crizotinib sensitive; however, several mutations that confer resistance mutations have been described in case studies. In the only clinical trial for crizotinib that included determination of EML4-ALK variant type in a subset of its participants, a very high response rate was observed, although the numbers were insufficient to validate correlation of variant type to outcome. Preclinical studies with this variant have indicated sensitivity to Hsp90 inhibitors.	ALK Fusions	2	42396490	42522656			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-03-10 21:08:52 UTC	38.0		N/A	EML4-ALK			false
6	https://civicdb.org/links/variants/6	ALK	238	EML4::ALK C1156Y	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, C1156Y has been shown to confer resistance to crizotinib. Case reports indicate that secondary mutations can modulate drug sensitivity. EML4-ALK C1156Y/L1196M maintained crizotinib resistance while the lorlatinib resistant combination EML4-ALK C1156Y/L1198F re-sensitized the tumor to crizotinib treatment.	Crizotinib Resistance,ALK Fusions	2	29445258	29445258	C	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3467G>A,NC_000002.11:g.29445258C>T,NM_004304.4:c.3467G>A,NP_004295.2:p.Cys1156Tyr	2022-03-11 04:10:20 UTC	29.0	CA16602783	376340	EML4-ALK CYS1156TYR,RS1057519859,EML4-ALK C1156Y			false
7	https://civicdb.org/links/variants/7	ALK	238	EML4::ALK L1196M	In patients with non-small cell lung cancer exhibiting EML4-ALK fusion, L1196M has been shown to confer resistance to crizotinib. This was also true in a patient with both EML4-ALK C1156Y & L1196M.	Crizotinib Resistance,ALK Fusions	2	29443631	29443631	G	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3586C>A,NC_000002.11:g.29443631G>T,NM_004304.4:c.3586C>A,NP_004295.2:p.Leu1196Met	2022-03-11 04:05:01 UTC	21.0	CA16602593	376135	EML4-ALK LEU1196MET,RS1057519784,EML4-ALK L1196M			false
8	https://civicdb.org/links/variants/8	ALK	238	F1174L	ALK F1174L has been observed as recurrent in neuroblastoma, non-small cell lung cancer (NSCLC), and other cancer types. Neuroblastoma cells containing this mutation have shown resistance to low doses of criztonib. However, increased dosage can overcome this resistance in cell lines studies. TAE684 has also proven effective in both NSCLC and neuroblastoma F1174L containing cells.	Crizotinib Resistance	2	29443695	29443695	G	T	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3522C>A,NP_004295.2:p.Phe1174Leu,NC_000002.11:g.29443695G>T,ENST00000389048.3:c.3522C>A	2018-11-30 14:45:01 UTC	33.5	CA279586	217851	PHE1174LEU,RS863225281			false
9	https://civicdb.org/links/variants/9	ALK	238	R1275Q	ALK R1275Q has been observed as a recurrent mutation in  neuroblastoma, non-small cell lung cancer (NSCLC), as well as other cancer types. Neuroblastoma cells with this mutation have shown sensitivity to the ALK-inhibitor TAE684. This and the geldanamycin deriviative 17-DMAG have been shown to be effective in NSCLC cell lines.		2	29432664	29432664	C	T	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3824G>A,NP_004295.2:p.Arg1275Gln,NC_000002.11:g.29432664C>T,ENST00000389048.3:c.3824G>A	2018-11-30 14:44:59 UTC	23.0	CA341482	18083	ARG1275GLN,RS113994087			false
10	https://civicdb.org/links/variants/10	ARAF	369	S214C	ARAF S214C has been found to be a recurrent oncogenic mutation in non-small cell lung cancer. It has been shown to confer sensitivity to sorafenib and trametenib in cell lines. In a case study of advanced stage lung adenocarcinoma harboring this mutation, sorafenib also acheived near-complete clinical remission. This case has brought more interest to the variant from a research and clinical perspective.		X	47426121	47426121	C	G	ENST00000377045.4	75	GRCh37					missense_variant	NC_000023.10:g.47426121C>G,NM_001654.4:c.641C>G,NP_001645.1:p.Ser214Cys,ENST00000377045.4:c.641C>G	2018-11-30 14:43:04 UTC	11.0	CA16602595	376137	SER214CYS,RS1057519786			false
11	https://civicdb.org/links/variants/11	BRAF	673	V600D	Patients harboring mutations in valine 600 residue of BRAF have been shown to be sensitive to dabrafenib. For more information on the V600 locus, see the V600E entry.	Other V600's	7	140453135	140453136	CA	AT	ENST00000288602.6	75	GRCh37					missense_variant	NC_000007.13:g.140453135_140453136delinsAT,NM_004333.4:c.1799_1800delTGinsAT,NP_004324.2:p.Val600Asp,ENST00000288602.6:c.1799_1800delTGinsAT	2020-11-21 22:43:17 UTC	47.0	CA16602419	375939	RS121913377,VAL600ASP			false
12	https://civicdb.org/links/variants/12	BRAF	673	V600E	BRAF V600E has been shown to be recurrent in many cancer types. It is one of the most widely studied variants in cancer. This variant is correlated with poor prognosis in certain cancer types, including colorectal cancer and papillary thyroid cancer. The targeted therapeutic dabrafenib has been shown to be effective in clinical trials with an array of BRAF mutations and cancer types. Dabrafenib has also shown to be effective when combined with the MEK inhibitor trametinib in colorectal cancer and melanoma. However, in patients with TP53, CDKN2A and KRAS mutations, dabrafenib resistance has been reported. Ipilimumab, regorafenib, vemurafenib, and a number of combination therapies have been successful in treating V600E mutations. However, cetuximab and panitumumab have been largely shown to be ineffective without supplementary treatment.		7	140453136	140453136	A	T	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1799T>A,NP_004324.2:p.Val600Glu,NC_000007.13:g.140453136A>T,ENST00000288602.6:c.1799T>A	2022-04-01 23:37:24 UTC	1353.5	CA123643	13961,376069	RS113488022,VAL600GLU,V640E,VAL640GLU	23,10,12,20,7	https://civicdb.org/links/assertions/23	https://civicdb.org/links/assertions/10	https://civicdb.org/links/assertions/12	https://civicdb.org/links/assertions/20	https://civicdb.org/links/assertions/7	false
13	https://civicdb.org/links/variants/13	BRAF	673	V600E and V600M	A case study of a single patient harboring both a V600E and a V600M mutation, dabrafenib was shown to acheive clinical response.	Other V600's	7	140453135	140453137			ENST00000288602.6	75	GRCh37					missense_variant		2021-04-14 05:00:56 UTC	2.5		13961,44815				false
14	https://civicdb.org/links/variants/14	BRAF	673	V600E and Amplification	Amplification of BRAF V600E has been shown to confer resistance to MEK inhibitors. For more information on the V600 locus, see the V600E entry.		7	140434279	140624564			ENST00000288602.6	75	GRCh37					missense_variant,transcript_amplification		2021-04-06 21:13:05 UTC	1.0						false
17	https://civicdb.org/links/variants/17	BRAF	673	V600	BRAF mutations of the valine 600 residue have been shown to be recurrent in many cancer types. Of the V600 mutations, V600E is the most widely researched. V600 mutations as a whole have been correlated to poorer prognosis in colorectal and papilarry thyroid cancers. V600 mutations have also been shown to confer sensitivity to the BRAF inhibitor dabrafenib. For a more detailed summary, click the individual mutations.	Other V600's	7	140453136	140453137			ENST00000288602.6	75	GRCh37					protein_altering_variant		2020-12-10 20:13:06 UTC	460.0		13961,44815,376288,40389,376289,44816	VAL600			false
18	https://civicdb.org/links/variants/18	CCND1	595	Amplification	CCND1 amplification has been implicated in poorer prognosis in non-small cell lung cancer.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					transcript_amplification	N/A	2021-02-26 02:15:41 UTC	47.0		N/A		2,1	https://civicdb.org/links/assertions/2	https://civicdb.org/links/assertions/1	false
19	https://civicdb.org/links/variants/19	CCND1	595	Expression	CCND1 expression, and its prognositc impact, is still in dispute. Three experiments in non-small cell lung cancer have shown it to have no impact on survival, but three additional studies have shown it results in poorer prognosis. There is also some ambiguity in how the boundaries between expression and overexpression are defined.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A	N/A	2021-02-26 02:15:46 UTC	30.0		N/A				false
20	https://civicdb.org/links/variants/20	CCND1	595	Overexpression	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		11	69455855	69469242			ENST00000227507.2	75	GRCh37					N/A	N/A	2021-02-26 02:15:51 UTC	116.0		N/A				false
21	https://civicdb.org/links/variants/21	CCND2	894	OVEREXPRESSION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4382938	4414516			ENST00000261254.3	75	GRCh37					N/A		2017-12-01 14:40:28 UTC	16.0		N/A				false
22	https://civicdb.org/links/variants/22	CCND2	894	PROMOTER DEMETHYLATION	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are misregulated are widely variable, and range from genomic amplification to promoter methylation changes. While Cyclin D2 has only been found to be significantly misregulated in glioma, Cyclin D1 in particular seems to be a pan-cancer actor. Cyclin D misregulation has been shown to lead to poorer outcomes in a number of studies, and currently there are no FDA-approved targeted therapies.		12	4381437	4382937			ENST00000261254.3	75	GRCh37					N/A		2017-12-01 14:40:28 UTC	3.0						false
23	https://civicdb.org/links/variants/23	CCND3	896	Loss	Cyclin D has been shown in many cancer types to be misregulated. Well established for their oncogenic properties, the cyclins and the cyclin-dependent kinases (CDK's) they activate have been the focus of major research and development efforts over the past decade. The methods by which the cyclins are deregulated are widely variable, and range from genomic amplification to promoter methylation changes. Cyclin D3 loss has been reported in T-cell acute lymphoblastic leukemia (T-ALL), a seemingly unique trend when compared to the amplifcations and overexpressions of the other cyclin D's. Treating cyclin D3 knockout mice with the targeted therapeutic palbociclib significantly increased the median survival of a Notch-driven model of T-ALL.		6	41902671	41909586			ENST00000372991.4	75	GRCh37					loss_of_function_variant		2022-08-03 16:04:28 UTC	3.0		N/A		35	https://civicdb.org/links/assertions/35	false
24	https://civicdb.org/links/variants/24	CCNE1	898	Overexpression	Cyclin E, while currenly not as widely implicated as its counterpart, cyclin D, has been implicated in various carcinomas, including breast, gastric, stomach and colorectal. High levels of cyclin E, either by gene amplification or overexpression, are correlated with later stage disease and have been shown to lead to poorer prognosis in gastic carcinoma. It has also been shown, in lung cancer specifically, that neoplastic cells with higher levels of the cyclin E/CDK2 complex are more radiosensitive than their lowly expressed counterparts.		19	30302805	30315215			ENST00000262643.3	75	GRCh37					N/A		2021-04-06 21:12:17 UTC	62.0		N/A				false
25	https://civicdb.org/links/variants/25	CDK4	1019	EXPRESSION	CDK4, along with its partner CDK6, are key players in cell cycle progression. The complex has been implicated in a number of cancer types, and is the focus of therapeutic research and development. One targeted therapy for CDK inhibition is palbociclib, which may slow the growth of advanced stage breast cancers. It has also been shown, in mouse, that CDK inhibition may sensitize mutant PIK3CA tumors to PI3K inhibitors.		12	58141510	58146304			ENST00000257904.6	75	GRCh37					N/A		2017-12-01 14:40:28 UTC	8.0		N/A				false
27	https://civicdb.org/links/variants/27	CDKN2A	1029	Promoter Hypermethylation	CDKN2A loss has been shown to be a significant event in a number of cancer types. One mechanism by which this can occur is by hypermethylation of the CDKN2A promoter region. While no targeted therapeutic has been engaged in clinical trials, the prognostic impact has been studied by a number of meta-analyses. The prognostic impact of promoter hypermethylation has been relatively ambiguous. Many studies have shown significant p-values suggesting poorer prognostic outcomes for patients with hypermethylation in colorectal, liver, and younger lung cancer patients. This being said, there is still research to be done before this becomes a widely-accepted prognostic indicator.		9	21974827	21994591			ENST00000498124.1	75	GRCh37					N/A		2021-03-31 20:33:37 UTC	15.0						false
28	https://civicdb.org/links/variants/28	CEBPA	1050	N-TERMINAL FRAME SHIFT	CEBPA N-terminal frame shift mutations that result in a premature stop codon are associated with cytogenetically normal acute myeloid leukemia (CN-AML). CEBPA mutations are associated with a favorable prognosis; however, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications. N-terminal frame shift mutations within amino acids 1-120 have been shown to disrupt expression of the full-length 42kDa isoform while maintaining expression of a 30kDa isoform (translated from the AUG at full-length protein isoform amino acid M120). This 30kDa isoform exhibits dominant negative activity.		19	33792961	33793470			ENST00000498907.2	75	GRCh37					frameshift_truncation,dominant_negative_variant		2017-12-01 14:40:28 UTC	3.0						false
29	https://civicdb.org/links/variants/29	CEBPA	1050	Mutation	CEBPA mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) and a favorable prognosis. However, NPM1 and FLT3 mutations should also be assessed in CN-AML patients as concurrent mutations may have prognostic implications.		19	33790840	33793470			ENST00000498907.2	75	GRCh37					transcript_variant,loss_of_function_variant		2021-02-11 00:57:12 UTC	105.0		N/A				false
30	https://civicdb.org/links/variants/30	CSF1R	1436	MEF2D::CSF1R	MEF2D-CSF1R is a fusion that has been observed in acute lymphocytic leukemia. In cell lines harboring this event, treatment with imatinib has shown notable sensitivity.		1	156446804	156470620			ENST00000348159.4	75	GRCh37	5	149433787	149441412	ENST00000286301.3	transcript_fusion		2022-03-11 17:36:28 UTC	10.5		N/A	MEF2D-CSF1R			false
31	https://civicdb.org/links/variants/31	PRKACA	5566	DNAJB1::PRKACA	This fusion has been found to be very recurrent in the rare form of adolescent liver cancer, fibrolamellar hepatocellular carcinoma. In one study, this fusion was observed in 15/15 FL-HCC cases examined and functional studies found that the fusion retained kinase activity. The presence of this fusion may be used as a diagnostic marker for this rare tumor type.		19	14628951	14629232			ENST00000254322.2	75	GRCh37	19	14202500	14218221	ENST00000308677.4	transcript_fusion		2022-04-14 15:37:22 UTC	75.0		N/A	DNAJB1-PRKACA	24	https://civicdb.org/links/assertions/24	false
32	https://civicdb.org/links/variants/32	DNMT3A	1788	R882	DNMT3A R882 mutations are associated with cytogenetically normal acute myeloid leukemia (CN-AML) with R882H as the most common form. Mutations in DNMT3A have largely been associated with poorer prognosis, however this is not consistent across all studies. This may be a result of patient age or combining R882 and non-R882 mutations during analysis as studies have indicated independent mechanisms of action and differential prognostic implications for these mutation types. One study that independently analyzed R882 and non-R882 mutations showed R882 mutations were associated with poorer prognosis than patients with wildtype and non-R882 mutations, but only in older patients with AML.		2	25457241	25457243			ENST00000264709.3	75	GRCh37					missense_variant		2021-02-24 19:52:43 UTC	510.0		375881,375880,375879,375884,375883,375882	R693,ARG882,ARG693			false
33	https://civicdb.org/links/variants/33	EGFR	1956	L858R	EGFR L858R has long been recognized as a functionally significant mutation in cancer, and is one of the most prevalent single mutations in lung cancer. Best described in non-small cell lung cancer (NSCLC), the mutation seems to confer sensitivity to first and second generation TKI's like gefitinib and neratinib. NSCLC patients with this mutation treated with TKI's show increased overall and progression-free survival, as compared to chemotherapy alone. Third generation TKI's are currently in clinical trials that specifically focus on mutant forms of EGFR, a few of which have shown efficacy in treating patients that failed to respond to earlier generation TKI therapies.		7	55259515	55259515	T	G	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.13:g.55259515T>G,NM_005228.4:c.2573T>G,ENST00000275493.2:c.2573T>G,NP_005219.2:p.Leu858Arg	2021-02-04 23:25:48 UTC	375.0	CA126713	16609,376282,376280	LEU858ARG,RS121434568	5,6	https://civicdb.org/links/assertions/5	https://civicdb.org/links/assertions/6	false
34	https://civicdb.org/links/variants/34	EGFR	1956	T790M	EGFR T790M was one of the very first mutations recognized to confer resistance to targeted therapies in non-small cell lung cancer. While successful in amplified EGFR, the efficacy of the first and second generation TKI's (erlotinib, gefitinib, neratinib) in treating patients harboring this mutation before treatment is notably lower. This lack of efficacy can likely be to blame for the poorer prognosis for patients with this mutation as compared to patients with wildtype EGFR or other types of EGFR mutations. Approximately half of EGFR mutant tumors with acquired resistance to TKI inhibition have been shown to harbor this mutation, implicating it as a mechanism of acquired therapy resistence. A third generation TKI (osimertinib) has been approved for the treatment of EGFR T790M mutant NSCLC. Patients positive for T790M in a plasma-based test have similar outcomes like those with tumor biopsy testing.	EGFR TKI Resistance	7	55249071	55249071	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2369C>T,NM_005228.4:c.2369C>T,NP_005219.2:p.Thr790Met,NC_000007.13:g.55249071C>T	2020-12-16 20:31:40 UTC	386.25	CA090928	16613	THR790MET,RS121434569			false
35	https://civicdb.org/links/variants/35	ERBB2	2064	D769H	ERBB2 D769H was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines were shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	C	ENST00000269571.5	75	GRCh37					missense_variant	NM_001289937.1:c.2305G>C,NP_001276866.1:p.Asp769His,ENST00000269571.5:c.2305G>C,NC_000017.10:g.37880261G>C	2018-11-30 14:44:12 UTC	4.0	CA16602465	375991	ASP769HIS,D739H,D754H,ASP739HIS,ASP754HIS,D769H,RS121913468			false
36	https://civicdb.org/links/variants/36	ERBB2	2064	D769Y	ERBB2 D769Y was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37880261	37880261	G	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2305G>T,NC_000017.10:g.37880261G>T,NM_004448.3:c.2305G>T,NP_004439.2:p.Asp769Tyr	2018-11-30 14:44:52 UTC	4.0	CA16602466	375992	D739Y,D754Y,RS121913468,ASP769TYR,D769Y,ASP754TYR,ASP739TYR			false
37	https://civicdb.org/links/variants/37	ERBB2	2064	L755_T759del	ERBB2 in-frame deletion of 755-759 was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880219	37880233	TTGAGGGAAAACACA		ENST00000269571.5	75	GRCh37					inframe_deletion	ENST00000269571.5:c.2263_2277del,NC_000017.10:g.37880219_37880233del,NP_004439.2:p.Leu755_Thr759del,NM_004448.3:c.2263_2277delTTGAGGGAAAACACA	2020-07-24 18:54:58 UTC	5.0	CA645372623	375990	RS1131692241,LEU755_THR759DEL			false
38	https://civicdb.org/links/variants/38	ERBB2	2064	G309A	ERBB2 G309A was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37868205	37868205	G	C	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.926G>C,NC_000017.10:g.37868205G>C,NM_004448.3:c.926G>C,NP_004439.2:p.Gly309Ala	2018-11-30 14:43:04 UTC	5.0	CA16602660	376205	GLY309ALA,GLY279ALA,GLY294ALA,G294A,G279A,RS1057519787			false
39	https://civicdb.org/links/variants/39	ERBB2	2064	L755S	ERBB2 L755S was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was not shown to be an activating mutation, unlike many of the other variants queried. This mutation was also shown to confer resistance to the tyrosine kinase inhibitor lapatinib in MCF10A cell lines.		17	37880220	37880220	T	C	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2264T>C,NC_000017.10:g.37880220T>C,NM_004448.3:c.2264T>C,NP_004439.2:p.Leu755Ser	2019-10-11 18:55:54 UTC	21.5	CA16602502	376035	LEU755SER,L725S,L740S			false
40	https://civicdb.org/links/variants/40	ERBB2	2064	L755W	ERBB2 L755W was one of the first ERBB2 variants to be functionally classified (Bose et al., 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37880220	37880220	T	G	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2264T>G,NC_000017.10:g.37880220T>G,NM_004448.3:c.2264T>G,NP_004439.2:p.Leu755Trp	2018-11-30 14:43:24 UTC	5.0	CA16602786	376343	LEU755TRP,L725W,L740W,RS121913470			false
41	https://civicdb.org/links/variants/41	ERBB2	2064	P780INS	ERBB2 P780 insertion was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 activating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881011	37881012		GGCTCCCCA	ENST00000269571.5	75	GRCh37					inframe_insertion	ENST00000269571.5:c.2340_2341insGGCTCCCCA,NC_000017.10:g.37881011_37881012insGGCTCCCCA	2020-12-03 18:33:03 UTC	12.5	CA135401	NONE FOUND	PRO780INS			true
42	https://civicdb.org/links/variants/42	ERBB2	2064	R678Q	ERBB2 R678Q was shown to have NO functional effect in tissue culture assay (Bose et al 2013). This conclusion was confirmed by a second, independent lab.		17	37879658	37879658	G	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2033G>A,NC_000017.10:g.37879658G>A,NM_004448.3:c.2033G>A,NP_004439.2:p.Arg678Gln	2018-11-30 14:43:31 UTC	5.0	CA16602787	376344	ARG678GLN,R648Q,R663Q,RS1057519862			false
43	https://civicdb.org/links/variants/43	ERBB2	2064	R896C	ERBB2 R896C was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881616	37881616	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2686C>T,NC_000017.10:g.37881616C>T,NM_004448.3:c.2686C>T,NP_004439.2:p.Arg896Cys	2018-11-30 14:43:04 UTC	5.0	CA8534359	375995	ARG896CYS,R866C,R881C,RS758222990			false
44	https://civicdb.org/links/variants/44	ERBB2	2064	V777L	ERBB2 V777L was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881000	37881000	G	T	ENST00000269571.5	75	GRCh37					missense_variant	NM_004448.3:c.2329G>T,NP_004439.2:p.Val777Leu,ENST00000269571.5:c.2329G>T,NC_000017.10:g.37881000G>T	2018-11-30 14:43:13 UTC	9.0	CA135387	44991	V747L,V762L,VAL777LEU,RS121913471			false
45	https://civicdb.org/links/variants/45	ERBB2	2064	V842I	ERBB2 V842I was one of the first ERBB2 variants to be functionally classified (Bose et al. 2013). This mutation was shown to be an activating mutation in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in MCF10A breast cancer cell lines have been shown to be sensitive to the kinase inhibitor neratinib. More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.	HER2 Activating	17	37881332	37881332	G	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2524G>A,NM_004448.3:c.2524G>A,NP_004439.2:p.Val842Ile,NC_000017.10:g.37881332G>A	2018-11-30 14:43:19 UTC	9.0	CA16602468	375994	VAL842ILE,V812I,V827I,VAL812ILE,VAL827ILE,RS1057519738			false
46	https://civicdb.org/links/variants/46	ESR1	2099	L536Q	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y536Q is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain	6	152419920	152419921	TC	AG	ENST00000440973.1	75	GRCh37					missense_variant	NC_000006.11:g.152419920_152419921delinsAG,ENST00000440973.1:c.1607_1608delinsAG	2018-11-30 14:45:01 UTC	8.0	CA645542628	NONE FOUND	LEU536GLN			false
47	https://civicdb.org/links/variants/47	ESR1	2099	D538G	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. D538G is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain	6	152419926	152419926	A	G	ENST00000206249.3	75	GRCh37					missense_variant	ENST00000206249.3:c.1613A>G,NC_000006.11:g.152419926A>G,NM_000125.3:c.1613A>G,NP_000116.2:p.Asp538Gly	2018-11-30 14:45:02 UTC	18.0	CA366085705	NONE FOUND	ASP538GLY			false
48	https://civicdb.org/links/variants/48	ESR1	2099	Y537C	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537C is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain	6	152419923	152419923	A	G	ENST00000206249.3	75	GRCh37					missense_variant	ENST00000206249.3:c.1610A>G,NC_000006.11:g.152419923A>G,NM_000125.3:c.1610A>G,NP_000116.2:p.Tyr537Cys	2018-11-30 14:45:04 UTC	8.0	CA366085697	NONE FOUND	GLY537CYS			false
49	https://civicdb.org/links/variants/49	ESR1	2099	Y537N	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537N is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain	6	152419922	152419922	T	A	ENST00000206249.3	75	GRCh37					missense_variant	ENST00000206249.3:c.1609T>A,NC_000006.11:g.152419922T>A,NM_000125.3:c.1609T>A,NP_000116.2:p.Tyr537Asn	2018-11-30 14:45:01 UTC	8.0	CA366085693	NONE FOUND	GLY537ASN			false
50	https://civicdb.org/links/variants/50	ESR1	2099	Y537S	ESR1 biology has become a central focus in breast cancer therapy. In ER+ tumors, mutations in the ESR1 ligand binding domain have been shown to confer resistance to hormone therapy. This evidence has led to an increased use of targeted sequencing of the estrogen receptor in breast and ovarian cancer. Y537S is one of these ligand binding domain mutations, and is commonly implicated in this hormone resistance. Preliminary data suggests ER-degrading agents, such as fulvestrant, may be beneficial in treating ESR1 mutant, hormone resistant breast cancers.	ESR1 Ligand-Binding Domain	6	152419923	152419923	A	C	ENST00000206249.3	75	GRCh37					missense_variant	ENST00000206249.3:c.1610A>C,NC_000006.11:g.152419923A>C,NM_000125.3:c.1610A>C,NP_000116.2:p.Tyr537Ser	2018-11-30 14:45:03 UTC	8.0	CA366085696	NONE FOUND	GLY537SER			false
52	https://civicdb.org/links/variants/52	FGFR2	2263	FGFR2::MGEA5	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has idenified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. Cell lines harboring these fusions were shown to respond to pazopanib. Additionally, tumor size reduction was achieved by both ponatinib and pazopanib treatments administered separately in a single patient with intrahepatic cholangiocarcinoma and this fusion. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	10	123243212	123357917			ENST00000457416.2	75	GRCh37	10	103544209	103552700	ENST00000361464.3	transcript_fusion		2022-03-11 00:23:21 UTC	5.0		N/A	FGFR2-MGEA5			false
53	https://civicdb.org/links/variants/53	FGFR3	2261	FGFR3::BAIAP2L1	In a clinical sequencing program for advanced stage cancers, Wu et al (2013, Cancer Discovery) has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	1795039	1810599			ENST00000340107.4	75	GRCh37	7	97991744	97920963	ENST00000005260.8	transcript_fusion		2022-03-11 00:22:53 UTC	3.0		N/A	FGFR3-BAIAP2L1			false
54	https://civicdb.org/links/variants/54	FGFR2	2263	FGFR2::TACC3	In a clinical sequencing program for advanced stage cancers, Wu et al has identified a number of FGFR fusions in patients with many different cancer types. These fusions were also found to retain oligomerization capability, and result in enhanced cell proliferation. These fusions were shown to respond to pazopanib. The authors use these cases to highlight the need for enhanced clinical sequencing efforts.	FGFR fusions	4	123243212	123357598			ENST00000358487.5	75	GRCh37	4	1723266	1741505	ENST00000313288.4	transcript_fusion		2022-04-14 15:37:21 UTC	7.5		N/A	FGFR2-TACC3			false
55	https://civicdb.org/links/variants/55	FLT3	2322	ITD	FLT3-ITD (internal tandem duplications) frequently occur in patients with hematologic malignancies such as chronic myelogenous leukemia, acute myeloid leukemia (AML) and myelodysplastic syndrome, but particularly in cytogenetically normal AML (CN-AML). These duplication events disrupt the juxtamembrane domain of FLT3 and can be the result of a duplication of internal FLT3 sequence or other unrelated sequence resulting in an in-frame duplication event. The length of these duplications can vary widely which may have prognostic consequences, but this has not been conclusively determined. FLT3-ITD mutations overall have generally been associated with poor prognosis. Additional genes associated with CN-AML such as NPM1 may modulate the prognosis associated with this variant.		13	28608219	28608351			ENST00000241453.7	75	GRCh37					inframe_insertion		2020-12-03 00:06:29 UTC	445.5		16270		38	https://civicdb.org/links/assertions/38	false
56	https://civicdb.org/links/variants/56	FLT3	2322	TKD MUTATION	FLT3 tyrosine kinase domain mutations (FLT3-TKD) are much less common than FLT3-ITD (internal tandem duplication) mutations and may not confer the same prognostic impact. Although the majority of mutations are point mutations effecting D835 (most frequently D835Y), a small proportion involve an in-frame deletion of I836. These mutations are within the activation loop of the second tyrosine kinase domain of FLT3 and thought to result in constitutive activation of the receptor.		13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					nonsynonymous_variant	NC_000013.10:g.28592642C>A	2020-12-03 18:33:03 UTC	120.0	CA126347	16276				true
57	https://civicdb.org/links/variants/57	GATA2	2624	EXPRESSION	GATA2 misregulation has been observed in a number of hematologic malignancies, as well as non-small cell lung cancer. Treatment of over-active GATA2 pathways using the proteasome inhibitor bortezomib has shown dramatic tumor regression in lung cancer.		3	128198270	128212028			ENST00000341105.2	75	GRCh37					N/A		2017-12-01 14:40:28 UTC	4.0		N/A				false
58	https://civicdb.org/links/variants/58	IDH1	3417	R132	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes, IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113111	209113113			ENST00000415913.1	75	GRCh37					protein_altering_variant	NC_000002.11:g.209113113G>A,NC_000002.11:g.209113112C>T,NC_000002.11:g.209113113G>C,NC_000002.11:g.209113112C>A,NC_000002.11:g.209113113G>T,NC_000002.11:g.209113112C>G	2022-10-27 19:55:06 UTC	209.0		156444,375891,375890,375889,375893,375892	ARG132			false
59	https://civicdb.org/links/variants/59	IDH1	3417	R132C	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113113	209113113	G	A	ENST00000415913.1	75	GRCh37					missense_variant	NM_005896.3:c.394C>T,NP_005887.2:p.Arg132Cys,NC_000002.11:g.209113113G>A,ENST00000415913.1:c.394C>T	2022-01-28 01:58:11 UTC	53.0	CA16602374	375891	RS121913499,ARG132CYS			false
62	https://civicdb.org/links/variants/62	IDH2	3418	R140	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R140 mutants show mixed results affecting overall survival as compared to their wild-type counterparts. In myelodysplastic syndromes, however, no prognostic link was discovered between IDH2 mutation status and overall survival.		15	90631934	90631934			ENST00000330062.3	75	GRCh37					protein_altering_variant		2022-04-14 15:37:21 UTC	60.0		375988,14716,375989	ARG140			false
63	https://civicdb.org/links/variants/63	IDH2	3418	R172K	IDH2 mutations have been observed in a number of hematologic malignancies. In acute myeloid leukemia, the R172K mutation has been linked with poorer prognosis and worse overall survival than IDH2 wild-type patients. However, in myelodisplastic syndromes, studies did not find a prognostic association between this variant and patient outcomes.		15	90631838	90631838	C	T	ENST00000330062.3	75	GRCh37					missense_variant	NM_002168.3:c.515G>A,NP_002159.2:p.Arg172Lys,NC_000015.9:g.90631838C>T,ENST00000330062.3:c.515G>A	2018-11-30 14:43:17 UTC	35.0	CA16602462	375987	ARG172LYS,R120K,RS121913503			false
64	https://civicdb.org/links/variants/64	JAK2	3717	V617F	JAK2 V617F is a highly recurrent mutation in myeloproliferative diseases. It is found in around 98% of patients with polycythemia vera, and just over half of the patients with essential thrombocythemia and primary myelofibrosis. While less associated with cancer, when it is seen, it is more likely to be in myeloid leukemias than lymphoid leukemias. The V617F mutation is an activating mutation, resulting in increased kinase activity. The mutation seems to be restricted to hematologic malignancies. Treatment of JAK mutant diseases with ruxolitinib has seen some clinical success.		9	5073770	5073770	G	T	ENST00000381652.3	75	GRCh37					missense_variant,gain_of_function_variant	NC_000009.11:g.5073770G>T,NM_004972.3:c.1849G>T,NP_004963.1:p.Val617Phe,ENST00000381652.3:c.1849G>T	2018-11-30 14:43:13 UTC	83.0	CA124183	14662	VAL617PHE,RS77375493			false
65	https://civicdb.org/links/variants/65	KIT	3815	D816V	KIT D816V is a mutation observed in acute myeloid leukemia (AML). This variant has been linked to poorer prognosis and worse outcome in AML patients.	KIT Exon 17	4	55599321	55599321	A	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2447A>T,NP_000213.1:p.Asp816Val,ENST00000288135.5:c.2447A>T,NC_000004.11:g.55599321A>T	2019-08-05 23:11:21 UTC	67.0	CA123513	13852	ASP816VAL,RS121913507			false
66	https://civicdb.org/links/variants/66	KIT	3815	Exon 11 Mutation	c-KIT mutations in exon 11 lie within the juxtamembrane domain, and are very recurrent in gastrointestinal stromal tumors, often bearing a poorer prognosis than other KIT mutations. Cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year. Small cohorts of melanoma patients harboring exon 11 KIT mutations have shown response to imatinib and sunitinib.	KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					coding_sequence_variant		2021-03-31 20:32:51 UTC	177.5						false
67	https://civicdb.org/links/variants/67	KIT	3815	Internal Duplication	c-KIT internal duplications have been observed in exon 11, within the juxtamembrane domain. In a case study of an anal melanoma patient harboring this event, imatinib confered marked response. Also, cells harboring exon 11 mutations have shown sensitivity to the tyrosine kinase inhibitor imatinib, offering a better prognosis to patients treated with the drug in the first year.	KIT Exon 11	4	55593582	55593708			ENST00000288135.5	75	GRCh37					inframe_insertion		2021-03-31 20:33:19 UTC	7.5		N/A				false
69	https://civicdb.org/links/variants/69	KIT	3815	Exon 14 Mutation	c-KIT exon 14 mutations lie within the tyrosine kinase domain of the protein. While relatively rare in primary gastrointestinal tumors, they are notably more prevalent in refractory disease, suggesting a role in imatinib resistance. Unlike mutations in other KIT exons, exon 14 mutations seem relatively rare in melanoma.		4	55595501	55595651			ENST00000288135.5	75	GRCh37					exon_variant		2021-12-30 23:46:31 UTC	15.0						false
72	https://civicdb.org/links/variants/72	KIT	3815	L576P	KIT L576P is an exon 11 mutation that lies within the juxtamembrane domain. It is one of the most recurrent KIT mutations in melanoma, and both in vitro and in vivo studies have shown sensitivity to imatinib.	KIT Exon 11	4	55593661	55593661	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1727T>C,NP_000213.1:p.Leu576Pro,ENST00000288135.5:c.1727T>C,NC_000004.11:g.55593661T>C	2019-08-05 23:05:14 UTC	16.0	CA16602401	375919	RS121913513,LEU576PRO			false
73	https://civicdb.org/links/variants/73	KIT	3815	V654A	KIT V654A is an exon 13 mutation that lies within the tyrosine kinase 1 domain of the protein. It has been shown to be an activating mutation by in vitro studies. This mutation is associated with imatinib resistance in melanoma patients. However, second generation TKI's such as sunitinib and midostaurin (PKC 412) have seen success in acheiving tumor response.	KIT Exon 11	4	55594258	55594258	T	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1961T>C,NP_000213.1:p.Val654Ala,ENST00000288135.5:c.1961T>C,NC_000004.11:g.55594258T>C	2018-11-30 14:45:03 UTC	18.0	CA16602402	375921	RS121913523,VAL654ALA			false
74	https://civicdb.org/links/variants/74	KRAS	3845	EXON 2 Mutations	A study by Li√®vre et al in 2006 showed that colorectal cancer patients with KRAS exon 1 mutations had low cetuximab response rates.		12	25398208	25398329			ENST00000256078.4 (v75)		GRCh37							2022-04-09 01:39:34 UTC	15.0						false
75	https://civicdb.org/links/variants/75	KRAS	3845	Exon 2 Mutation	Exon 2 mutations have been associated with reduced response rates or resistance to EGFR inhibitors in non-small cell lung and colorectal cancer. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS.		12	25398208	25398329			ENST00000256078.4	75	GRCh37					missense_variant		2021-04-24 00:32:35 UTC	168.0						false
76	https://civicdb.org/links/variants/76	KRAS	3845	G12	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398284	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant		2017-12-01 14:40:29 UTC	115.0		45122,12578,12582,12579,12583,12584	GLY12			false
77	https://civicdb.org/links/variants/77	KRAS	3845	G12/G13	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398280	25398285			ENST00000256078.4	75	GRCh37					protein_altering_variant		2020-09-04 15:20:53 UTC	191.0		45122,12578,12582,12579,12583,12580,12584,177778,45123,12593,375968,375967,45124				false
78	https://civicdb.org/links/variants/78	KRAS	3845	G12C	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.	EGFR TKI Resistance	12	25398285	25398285	C	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>T,NP_004976.2:p.Gly12Cys,NC_000012.11:g.25398285C>A,ENST00000256078.4:c.34G>T	2021-03-10 23:47:13 UTC	86.0	CA122528	12578	GLY12CYS,RS121913530			false
79	https://civicdb.org/links/variants/79	KRAS	3845	G12D	While the KRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still actively debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G13 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. The NCCN guidelines for colorectal cancer contain recommendations that the targeted therapies cetuximab and panitumumab should only be used in the context of wild type KRAS. However, cetuximab treatment was shown to extend survival in a single cohort of colorectal patients with G12D mutations. Overall, the interpretation for KRAS mutations in most clinical scenarios is still undecided.	EGFR TKI Resistance	12	25398284	25398284	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>A,NP_004976.2:p.Gly12Asp,NC_000012.11:g.25398284C>T,ENST00000256078.4:c.35G>A	2020-12-07 01:36:02 UTC	162.0	CA122538	12582	GLY12ASP,RS121913529			false
80	https://civicdb.org/links/variants/80	KRAS	3845	G13	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort in patients with colorectal and pancreatic cancer, however this hypothesis is in need of further validation. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, cetuximab treatment was shown to extend survival in a cohort of colorectal patients.		12	25398281	25398282			ENST00000256078.4	75	GRCh37					missense_variant,inframe_insertion		2017-12-01 14:40:29 UTC	20.0		12580,45123,12593,375968,375967,45124,163769,45125	GLY13			false
81	https://civicdb.org/links/variants/81	KRAS	3845	G13D	While the KRAS G13 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated. Often associated with tumors that are wild-type for other drivers (EGFR and ALK specifically), the prognosis for patients with this mutation seems to be worse than the KRAS wild-type cohort. This mutation, along with the mutations affecting the neighboring G12 position, may result in a less responsive tumor when treated with first-generation TKI's like gefitinib. However, results are conflicting with retrospective analyses suggesting a better response to EGFR-Inhibition. A recent prospective phase-II study (12 patients, Schirripa et. al. 2015) could not reproduce this finding and another prospective phase II trial is currently ongoing.		12	25398281	25398281	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_033360.3:c.38G>A,NP_004976.2:p.Gly13Asp,NC_000012.11:g.25398281C>T,ENST00000256078.4:c.38G>A	2021-02-11 00:31:54 UTC	104.5	CA122534	12580	GLY13ASP,RS112445441			false
82	https://civicdb.org/links/variants/82	MAP2K1	5604	P124S	MAP2K1 P124S is a recurrent mutation in melanoma, and is seen in bladder and colon cancer to a lesser degree. The P124S mutation has been shown to contribute to AZD6244 resistance in melanoma cell lines, but considerably less so than its Q56P counterpart.		15	66729162	66729162	C	T	ENST00000307102.5	75	GRCh37					missense_variant	ENST00000307102.5:c.370C>T,NC_000015.9:g.66729162C>T,NM_002755.3:c.370C>T,NP_002746.1:p.Pro124Ser	2018-11-30 14:43:05 UTC	3.0	CA16602456	375981	PRO124SER			false
83	https://civicdb.org/links/variants/83	MAP2K1	5604	Q56P	MAP2K1 Q56P is a recurrent mutation in melanoma and gastric cancer. This mutation has been shown to confer considerable resistance to AZD6244 treatment of melanoma cell lines.		15	66727451	66727451	A	C	ENST00000307102.5	75	GRCh37					missense_variant	ENST00000307102.5:c.167A>C,NC_000015.9:g.66727451A>C,NM_002755.3:c.167A>C,NP_002746.1:p.Gln56Pro	2018-11-30 14:43:05 UTC	3.0	CA16602453	375978	GLN56PRO			false
85	https://civicdb.org/links/variants/85	MGMT	4255	Promoter Methylation	MGMT promoter methylation has been observed to impact tumor progression in glioblastoma multiforme. In patients exhibiting promoter methylation, the akylating agent carmustine has shown efficacy. In patients lacking methylation, combining carmustine with the MGMT inhibitor O(6)-benzylguanine may be effective, but more experiments are required. Clinical trials have also shown selective sensitivity of promoter methylation-positive patients to temozolomide, making a case for wider methylation screening in GBM patients.		10	131264495	131265656			ENST00000306010.7	75	GRCh37					N/A		2021-03-02 23:57:26 UTC	136.0		N/A				false
86	https://civicdb.org/links/variants/86	NPM1	4869	EXON 12 MUTATION	NPM1 exon 12 mutations are frequently identified in patients with cytogenetically normal acute myeloid leukemia (AML) and often co-occur with FLT3-ITD. FLT3 status should also be evaluated as co-occurence with FLT3-ITD may impact prognosis. Exon 12 mutations have been identified as a predictor of good prognostic outcomes in the absence of FLT3-ITD. Due to their high frequency, NPM1 mutations have been retrospectively analyzed in the context of a number of therapies including variable results following ATRA treatment as well as improved response to high-dose daunorubicin or valproic acid. Additionally, multiple groups have shown increased surface expression of CD33 associated with NPM1 mutation, suggesting these patients may respond to anti-CD33 therapy. Cytoplasmic sequestration of NPM1 (NPM1c) is associated with a good response to induction therapy.	NPM1 Exon 12	5	170837531	170837569			ENST00000517671.1	75	GRCh37					exon_variant		2017-12-01 14:40:29 UTC	454.0		N/A				false
87	https://civicdb.org/links/variants/87	NPM1	4869	W288FS	NPM1 W288fs (aka NPM1-A) is located in exon 12 of NPM1 and is the most common NPM1 mutation identified in acute myeloid leukemia. This mutation results in cytoplasmic localization of NPM1 (NPM1c) which is associated with a good response to induction therapy. Although it is the most extensively studied NPM1 exon 12 mutation, it is generally grouped with other exon 12 mutations for patient analysis (see NPM1 Exon 12 variants for more information).	NPM1 Exon 12	5	170837547	170837548		TCTG	ENST00000517671.1	75	GRCh37					frameshift_elongation	NM_002520.6:c.860_863dupTCTG,NC_000005.9:g.170837544_170837547dupTCTG,NP_002511.1:p.Trp288Cysfs,ENST00000517671.1:c.860_863dupTCTG	2022-04-14 15:37:27 UTC	43.75	CA280199	13998	NPM1-A,RS587776806,TRP288FS			false
92	https://civicdb.org/links/variants/92	NRAS	4893	G12	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258747	115258748			ENST00000369535.4	75	GRCh37					missense_variant		2017-12-01 14:40:29 UTC	15.0		40468,39648,177778,219097,40470,40469				false
93	https://civicdb.org/links/variants/93	NRAS	4893	G13D	While the NRAS G12 region is a widely studied recurrent region in cancer, its impact on clinical action is still debated.		1	115258744	115258744	C	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.38G>A,NP_002515.1:p.Gly13Asp,NC_000001.10:g.115258744C>T,ENST00000369535.4:c.38G>A	2018-11-30 14:43:05 UTC	5.0	CA123620	13901	GLY13ASP,RS121434596			false
94	https://civicdb.org/links/variants/94	NRAS	4893	Q61	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. Two melanoma patients, each harboring mutations at this locus (Q61L and Q61R), responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256528	115256530			ENST00000369535.4	75	GRCh37					missense_variant		2020-11-25 00:09:17 UTC	100.0		73058,13900,375874,375871,373003,280409,375875	GLN61			false
95	https://civicdb.org/links/variants/95	NRAS	4893	Q61L	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	A	ENST00000369535.4	75	GRCh37					missense_variant	NP_002515.1:p.Gln61Leu,NC_000001.10:g.115256529T>A,NM_002524.4:c.182A>T,ENST00000369535.4:c.182A>T	2020-11-10 21:54:02 UTC	12.5	CA16602361	375874	GLN61LEU,RS11554290			false
96	https://civicdb.org/links/variants/96	NRAS	4893	Q61R	NRAS Q61 mutations have been found in multiple myeloma, gastrointestinal stromal tumors, melanoma, and others. A melanoma patient harboring a mutation at this locus responded to treatment with the akylating agent temozolomide. However, in colorectal cancer patients, mutations at this locus have been shown to confer resistance to cetuximab. The prognostic impact of mutations at this locus is currently under study.		1	115256529	115256529	T	C	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.182A>G,NP_002515.1:p.Gln61Arg,NC_000001.10:g.115256529T>C,ENST00000369535.4:c.182A>G	2018-11-30 14:43:06 UTC	5.0	CA123618	13900	GLN61ARG,RS11554290			false
98	https://civicdb.org/links/variants/98	PDGFRA	5156	D842I	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152093	GA	AT	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.2524_2525delinsAT,NC_000004.11:g.55152092_55152093delinsAT,NP_006197.1:p.Asp842Ile,NM_006206.5:c.2524_2525delGAinsAT	2018-11-30 14:43:06 UTC	4.0	CA16602522	376055	ASP842ILE			false
99	https://civicdb.org/links/variants/99	PDGFRA	5156	D842V	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. Exogenous expression of the A842V mutation resulted in constitutive tyrosine phosphorylation of PDGFRA in the absence of ligand in 293T cells and cytokine-independent proliferation of the IL-3-dependent Ba/F3 cell line, both evidence that this is an activating mutation. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152093	55152093	A	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2525A>T,NP_006197.1:p.Asp842Val,ENST00000257290.5:c.2525A>T,NC_000004.11:g.55152093A>T	2019-05-03 23:38:41 UTC	100.5	CA123194	13543	ASP842VAL,RS121908585			false
100	https://civicdb.org/links/variants/100	PDGFRA	5156	D842Y	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152092	55152092	G	T	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.2524G>T,NC_000004.11:g.55152092G>T,NM_006206.5:c.2524G>T,NP_006197.1:p.Asp842Tyr	2018-11-30 14:43:17 UTC	4.0	CA16602703	376250	ASP842TYR,RS121913265			false
101	https://civicdb.org/links/variants/101	PDGFRA	5156	I843DEL	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152095	55152097	ATC		ENST00000257290.5	75	GRCh37					inframe_deletion	ENST00000257290.5:c.2527_2529delATC,NC_000004.11:g.55152095_55152097del	2019-02-23 02:08:03 UTC	5.0	CA645526434	NONE FOUND	DELI843			false
102	https://civicdb.org/links/variants/102	PDGFRA	5156	D842_I843delinsVM	PDGFRA D842 mutations are characterized broadly as imatinib resistance mutations. The DI842-843VM variant is the result of a double point mutation. This is most well characterized in gastrointestinal stromal tumors, but other cell lines containing these mutations have been shown to be resistant as well. In imatinib resistant cell lines, a number of other therapeutics have demonstrated efficacy. These include; crenolanib, sirolimus, and midostaurin (PKC412).	Imatinib Resistance	4	55152093	55152097	ACATC	TCATG	ENST00000257290.5	75	GRCh37					missense_variant	NC_000004.11:g.55152093_55152097delinsTCATG	2020-06-18 02:06:36 UTC	4.0	CA658820703	NONE FOUND				false
103	https://civicdb.org/links/variants/103	PIK3CA	5290	E542K	PIK3CA E545K/E542K variants are the second most recurrent PIK3CA mutations in breast cancer and are highly recurrent mutations in many other cancer types. Colorectal cancer patients with the PIK3CA E545K variant, and possibly other variants in the E545 region, may indicate poor prognosis relative to patients with other PIK3CA variants or wild-type PIK3CA. The literature also suggests that E545/E542 variants may confer resistance to EGFR inhibitors (e.g., cetuximab). An FDA approved treatment regimen including a targeted PIK3CA inhibitor is available for specific subtypes of breast cancer. While PIK3CA variants are highly prevalent in many other cancer types, targeted therapies for PIK3CA variants are still in early clinical trial phases in other cancer types.		3	178936082	178936082	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1624G>A,NP_006209.2:p.Glu542Lys,ENST00000263967.3:c.1624G>A,NC_000003.11:g.178936082G>A	2022-01-26 00:28:42 UTC	74.5	CA333572	31944	GLU542LYS,RS121913273			false
104	https://civicdb.org/links/variants/104	PIK3CA	5290	E545K	PIK3CA E545K/E542K are the second most recurrent PIK3CA mutations in breast cancer, and are highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that E545/542 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178936091	178936091	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1633G>A,NP_006209.2:p.Glu545Lys,ENST00000263967.3:c.1633G>A,NC_000003.11:g.178936091G>A	2022-01-26 00:32:06 UTC	76.5	CA123334	13655	GLU545LYS,RS104886003			false
105	https://civicdb.org/links/variants/105	PIK3CA	5290	Exon 21 Mutation	PIK3CA Exon 21 Mutations (e.g., H1047R; often referred to as Exon 20 mutations if counting only coding exons) are among the most recurrent mutations in cancer, especially breast cancer. Of PIK3CA mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between Exon 21 and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178951882	178952495			ENST00000263967.3	75	GRCh37					exon_variant		2021-02-02 23:03:21 UTC	45.0			EXON 20 MUTATION			false
106	https://civicdb.org/links/variants/106	PIK3CA	5290	Exon 10 Mutation	PIK3CA Exon 10 Mutations (e.g. E545K/E542K; often referred to as Exon 9 mutations if counting only coding exons) are the second most recurrent PIK3CA mutations in breast cancer, and highly recurrent mutations in many other cancer types. E545K, and possibly the other mutations in the E545 region, may present patients with a poorer prognosis than patients with either patients with other PIK3CA variant or wild-type PIK3CA. There is also data to suggest that exon 10 mutations may confer resistance to EGFR inhibitors like cetuximab. While very prevalent, targeted therapies for variants in PIK3CA are still in early clinical trial phases.		3	178935998	178936122			ENST00000263967.3	75	GRCh37					exon_variant		2021-02-02 23:02:37 UTC	45.0		31944,13655	EXON 9 MUTATION			false
107	https://civicdb.org/links/variants/107	PIK3CA	5290	H1047R	PIK3CA H1047R is one of the most recurrent single nucleotide variants in cancer, especially breast cancer. Of PIK3CA-mutant breast cancers, over half harbor this mutation. Meta-analyses have shown that patients harboring this mutation may have worse overall survival, but other studies have shown no difference between H1047R and other PIK3CA mutants from a prognostic standpoint. While very prevalent, targeted therapies for this particular mutation are still in early clinical trial phases.		3	178952085	178952085	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3140A>G,NP_006209.2:p.His1047Arg,ENST00000263967.3:c.3140A>G,NC_000003.11:g.178952085A>G	2021-04-09 23:12:52 UTC	96.5	CA123326	13652	HIS1047ARG,RS121913279			false
108	https://civicdb.org/links/variants/108	PML	5371	PML::RARA	The PML-RARA fusion is seen as a diagnostic event in acute promyelocytic leukemia (APL). Both in vitro and in vivo studies have shown sensitivity to ATRA in APL patients harboring the PML-RARa fusion. Recent interest has been shown in combining ATRA and arsenic trioxide for treating these patients, and early results seem promising.		15	74287058	74325755			ENST00000268058.3	75	GRCh37	17	38504568	38513048	ENST00000254066.5	transcript_fusion	N/A	2022-03-10 20:58:15 UTC	132.5		N/A	PML-RARA	15	https://civicdb.org/links/assertions/15	false
110	https://civicdb.org/links/variants/110	PTEN	5728	R233*	PTEN R233* has been shown to be a loss of function mutation, and PTEN loss has been the subject of considerable research in breast cancer. PTEN loss may sensitize cells to PI3K-mTOR inhibition. While still being debated, there is data to support that PTEN loss is both associated with poorer prognosis, and no change in prognosis.	PTEN Loss-of-Function	10	89717672	89717672	C	T	ENST00000371953.3	75	GRCh37					stop_gained,loss_of_function_variant	NM_000314.6:c.697C>T,NP_000305.3:p.Arg233Ter,ENST00000371953.3:c.697C>T,NC_000010.10:g.89717672C>T	2018-11-30 14:43:07 UTC	19.0	CA000549	7813	R233X,ARG233TER,RS121909219			false
112	https://civicdb.org/links/variants/112	RET	5979	C634W	RET C634W has been implicated as an alternate mechanism of activating RET in medullary thyroid cancer. While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the C634W mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib.	Motesanib Resistance	10	43609950	43609950	C	G	ENST00000355710.3	75	GRCh37					missense_variant	NM_020975.4:c.1902C>G,NP_065681.1:p.Cys634Trp,ENST00000355710.3:c.1902C>G,NC_000010.10:g.43609950C>G	2018-11-30 14:45:03 UTC	3.0	CA008378	13918	CYS634TRP			false
113	https://civicdb.org/links/variants/113	RET	5979	M918T	RET M819T is the most common somatically acquired mutation in medullary thyroid cancer (MTC). While there currently are no RET-specific inhibiting agents, promiscuous kinase inhibitors have seen some success in treating RET overactivity. Data suggests however, that the M918T mutation may lead to drug resistance, especially against the VEGFR-inhibitor motesanib. It has also been suggested that RET M819T leads to more aggressive MTC with a poorer prognosis.	Motesanib Resistance	10	43617416	43617416	T	C	ENST00000355710.3	75	GRCh37					missense_variant	NM_020975.4:c.2753T>C,NP_065681.1:p.Met918Thr,ENST00000355710.3:c.2753T>C,NC_000010.10:g.43617416T>C	2019-11-04 16:41:53 UTC	86.0	CA009082	13919	MET918THR,RS74799832			false
114	https://civicdb.org/links/variants/114	SF3B1	23451	K666N	SF3B1 K666N is a variant found in myelodysplastic syndromes, chronic leukemias, and more recently, breast cancer. This somatic mutation has been linked to better overall outcome and event-free survival in MDS patients.	HEAT domain mutation	2	198267359	198267359	C	A	ENST00000335508.6	75	GRCh37					missense_variant	NM_012433.3:c.1998G>T,NP_036565.2:p.Lys666Asn,ENST00000335508.6:c.1998G>T,NC_000002.11:g.198267359C>A	2018-11-30 14:43:08 UTC	2.0	CA280929	219098	LYS666ASN,RS377023736			false
116	https://civicdb.org/links/variants/116	TP53	7157	R175H	While loss-of-function events in TP53 are very common in cancer, the R175H variant seems not only to result in loss of tumor-suppression, but also acts as a gain-of-function mutation that promotes tumorigenesis in mouse models. Cell lines harboring this mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been shown that the R175H mutation is correlated with worse overall survival than wild-type TP53, but is not as detrimental as the R248W variant. This variant is rare in population databases (ACMG code: PM2; 0.000003980 total exome AF gnomAD v2.1.1).		17	7578406	7578406	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.524G>A,NP_000537.3:p.Arg175His,NC_000017.10:g.7578406C>T,ENST00000269305.4:c.524G>A	2022-07-21 17:35:38 UTC	25.0	CA000251	12374	ARG175HIS,RS28934578,R43H,R136H			false
117	https://civicdb.org/links/variants/117	TP53	7157	R248Q	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival. The R248Q mutation has also shown an increased invasive behavior in cell lines. This is specific to the 248Q variant.		17	7577538	7577538	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.743G>A,NP_000537.3:p.Arg248Gln,NC_000017.10:g.7577538C>T,ENST00000269305.4:c.743G>A	2020-06-22 16:57:58 UTC	46.0	CA000387	12356	ARG248GLN,RS11540652			false
118	https://civicdb.org/links/variants/118	TP53	7157	R248W	While loss-of-function events in TP53 are very common in cancer, the R248 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, R248 mutations have been shown to confer worse overall survival.		17	7577539	7577539	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.742C>T,NP_000537.3:p.Arg248Trp,NC_000017.10:g.7577539G>A,ENST00000269305.4:c.742C>T	2018-11-30 14:43:08 UTC	19.0	CA000382	12347	ARG248TRP,RS121912651			false
119	https://civicdb.org/links/variants/119	TP53	7157	R249	This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R249 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577535	7577535	C	G	ENST00000269305.4	75	GRCh37					protein_altering_variant	NC_000017.10:g.7577535C>G	2018-11-30 14:43:09 UTC	30.0	CA16602484	376015	ARG249			false
121	https://civicdb.org/links/variants/121	TP53	7157	R273C	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577121	7577121	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.817C>T,NP_000537.3:p.Arg273Cys,NC_000017.10:g.7577121G>A,ENST00000269305.4:c.817C>T	2022-04-21 08:02:36 UTC	44.5	CA000432	43594	ARG273CYS,RS121913343			false
122	https://civicdb.org/links/variants/122	TP53	7157	R273H	While loss-of-function events in TP53 are very common in cancer, the R273 variants seem not only to result in loss of tumor-suppression, but also act as a gain-of-function mutation that can promote tumorigenesis in mouse models. This mutant is also more responsive to treatment with doxorubicin than its wild-type counterparts. While the prognostic impact of individual TP53 mutations is influenced by the cohort being studied, it has been suggested that the R273 mutants have been correlated with worse overall survival in breast cancer patients when compared to wild-type.		17	7577120	7577120	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.818G>A,NP_000537.3:p.Arg273His,NC_000017.10:g.7577120C>T,ENST00000269305.4:c.818G>A	2020-07-17 20:50:57 UTC	41.0	CA000434	12366	ARG273HIS,RS28934576			false
124	https://civicdb.org/links/variants/124	TSC1	7248	Frameshift Truncation	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					frameshift_truncation		2022-08-02 23:08:28 UTC	18.0						false
125	https://civicdb.org/links/variants/125	TSC1	7248	Loss-of-function	In a small cohort study of bladder cancer, patients with TSC1 mutations showed better responses to and increased treatment duration tolerance with the mTOR inhibitor everolimus. Additionally, patient-derived bladder cancer cell lines with TSC1 or TSC2 mutations are much more sensitive to everolimus treatment than TSC1/TSC2 wildtype cells.	TSC Loss	9	135766735	135820008			ENST00000298552.3	75	GRCh37					loss_of_function_variant		2022-01-13 05:26:15 UTC	15.0		N/A				false
127	https://civicdb.org/links/variants/127	U2AF1	7307	Q157P/R	U2AF1 Q157P/R has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is less common than the S34F mutation, occurs in the second zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44514777	44514777	T	G	ENST00000291552.4	75	GRCh37					missense_variant	NC_000021.8:g.44514777T>G	2017-12-01 14:40:29 UTC	50.0						false
128	https://civicdb.org/links/variants/128	U2AF1	7307	S34Y/F	U2AF1 S34Y/F has been shown to be a recurrent mutation in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and lung adenocarcinomas. This mutation is the most commonly identified variant in MDS, occurs in the first zinc finger domain of U2AF1 and has been demonstrated to alter splicing. The impact of U2AF1 mutations on overall survival in MDS has been debated, however, patients with U2AF1 mutations were shown to be at an increased risk of transformation to secondary AML. The presence of this mutation was not associated with a specific prognostic outcome in AML when compared to U2AF1 wildtype patients.		21	44524456	44524456	G	A	ENST00000291552.4	75	GRCh37					missense_variant	NC_000021.8:g.44524456G>A	2017-12-01 14:40:29 UTC	40.0						false
129	https://civicdb.org/links/variants/129	WT1	7490	Exon 7 Mutation	WT1 exon 7 mutations have been shown to be recurrent in acute myeloid leukemia. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 7 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32417803	32417953			ENST00000332351.3	75	GRCh37					exon_variant		2022-09-27 15:29:19 UTC	130.0		N/A				false
130	https://civicdb.org/links/variants/130	WT1	7490	Exon 9 Mutation	WT1 exon 9 mutations have been shown to be recurrent in acute myeloid leukemia, although at a less frequent rate than their exon 7 counterparts. Many sources have examined the prognostic impact of these, agreeing that the mutant exon 9 cohort is correlated with worse overall survival and a number of poor prognistic outcomes. This may be the result of an overall poor response to chemotherapy from WT1 mutant tumors.		11	32413518	32413610			ENST00000332351.3	75	GRCh37					exon_variant		2022-09-27 15:29:35 UTC	35.0		N/A				false
131	https://civicdb.org/links/variants/131	BRCA1	672	Loss-of-function	BRCA1 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	17	41197646	41277500			ENST00000471181.2	75	GRCh37					loss_of_heterozygosity,loss_of_function_variant		2021-03-18 18:30:02 UTC	104.0		N/A				false
132	https://civicdb.org/links/variants/132	BRCA2	675	Loss-of-function	BRCA2 loss of function mutations have been shown to increase risk of breast and ovarian cancer in those carrying the allele in their germline. Treating BRCA mutant patients with PARP inhibitors such as Olaparib has led to significant response.	BRCA Germline Variants	13	32889611	32973347			ENST00000380152.3	75	GRCh37					loss_of_function_variant		2021-03-18 18:29:52 UTC	126.0		N/A				false
133	https://civicdb.org/links/variants/133	EGFR	1956	Exon 19 Deletion	Deletions within exon 19 of EGFR are most common in lung cancer. These deletions, in non-small cell lung cancer, have been shown to be sensitive to the EGFR tyrosine kinase inhibitors gefitinib, afatinib, and erlotinib. There is also data to suggest that this event is a good prognostic marker in lung adenocarcinoma. Examples of exon 19 deletions include: p.746_A750delELREA, p.747_753delinsS, p.747_752delLREATS, and p.747_751delLREAT.		7	55242415	55242513			ENST00000275493.2	75	GRCh37					inframe_deletion	ENST00000275493.2:c.2185_2283del	2022-12-02 17:32:25 UTC	298.0		N/A				false
134	https://civicdb.org/links/variants/134	EGFR	1956	G719S	While not as recurrent as the L858R mutation, EGFR G719S has also been shown to be an activating mutation. In lung cancer cell lines, it also confers sensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib.		7	55241707	55241707	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2155G>A,NC_000007.13:g.55241707G>A,NM_005228.4:c.2155G>A,NP_005219.2:p.Gly719Ser	2018-11-30 14:43:02 UTC	23.0	CA126722	16612	GLY719SER,RS28929495			false
135	https://civicdb.org/links/variants/135	NOTCH1	4851	D1642H	Activating mutations in NOTCH1, including D1642H, have been shown to be poor prognostic markers in lung cancer.		9	139399219	139399219	C	G	ENST00000277541.6	75	GRCh37					missense_variant	ENST00000277541.6:c.4924G>C,NC_000009.11:g.139399219C>G,NM_017617.4:c.4924G>C,NP_060087.3:p.Asp1642His	2018-11-30 14:43:02 UTC	20.0	CA16602788	376345	ASP1642HIS			false
136	https://civicdb.org/links/variants/136	NOTCH1	4851	R2327W	Activating mutations in NOTCH1, including R2327W, have been shown to be poor prognostic markers in lung cancer.		9	139391212	139391212	G	A	ENST00000277541.6	75	GRCh37					missense_variant	NM_017617.4:c.6979C>T,NP_060087.3:p.Arg2327Trp,NC_000009.11:g.139391212G>A	2018-11-30 14:43:02 UTC	20.0	CA5339772	376346	ARG2327TRP			false
137	https://civicdb.org/links/variants/137	NOTCH1	4851	V2444FS	Activating mutations in NOTCH1, including a frameshift insertion at V2444, have been shown to be poor prognostic markers in lung cancer.		9	139390861	139390861	G	TGT	ENST00000277541.6	75	GRCh37					frameshift_variant	ENST00000277541.6:c.7330delinsACA	2017-12-01 14:40:29 UTC	20.0		NONE FOUND	VAL2444FS			false
138	https://civicdb.org/links/variants/138	NOTCH1	4851	S2275FS	Activating mutations in NOTCH1, including a frameshift insertion at S2275, have been shown to be poor prognostic markers in lung cancer.		9	139391369	139391370		A	ENST00000277541.6	75	GRCh37					plus_1_frameshift_variant	ENST00000277541.6:c.6821_6822insT,NC_000009.11:g.139391369_139391370insA	2018-11-30 14:43:01 UTC	20.0	CA645544343	NONE FOUND				false
139	https://civicdb.org/links/variants/139	DDR2	4921	L63V	Activating mutations in DDR2, including L63V, has been shown to be sensitive to dasatinib in cell lines.		1	162724415	162724415	C	G	ENST00000367922.3	75	GRCh37					missense_variant	NM_006182.2:c.187C>G,NP_006173.2:p.Leu63Val,ENST00000367922.3:c.187C>G,NC_000001.10:g.162724415C>G	2018-11-30 14:43:01 UTC	4.0	CA1217196		LEU63VAL			false
140	https://civicdb.org/links/variants/140	DDR2	4921	L239R	Activating mutations in DDR2, including L239R, has been shown to be sensitive to dasatinib in cell lines.		1	162729630	162729630	T	G	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.716T>G,NC_000001.10:g.162729630T>G	2018-11-30 14:43:01 UTC	4.0	CA16602598	376141	LEU239ARG			false
141	https://civicdb.org/links/variants/141	DDR2	4921	G253C	Activating mutations in DDR2, including G253C, has been shown to be sensitive to dasatinib in cell lines.		1	162729671	162729671	G	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.757G>T,NC_000001.10:g.162729671G>T	2018-11-30 14:43:01 UTC	4.0	CA16602599	376142	GLY253CYS			false
142	https://civicdb.org/links/variants/142	DDR2	4921	G505S	Activating mutations in DDR2, including G505S, has been shown to be sensitive to dasatinib in cell lines.		1	162741822	162741822	G	A	ENST00000367922.3	75	GRCh37					missense_variant	NM_006182.2:c.1513G>A,NP_006173.2:p.Gly505Ser,ENST00000367922.3:c.1513G>A,NC_000001.10:g.162741822G>A	2018-11-30 14:43:02 UTC	4.0	CA1217584	282994	GLY505SER,RS115169993			false
143	https://civicdb.org/links/variants/143	DDR2	4921	I638F	DDR2 I638F has been shown to be a loss of function mutation, but also confers sensitivity to dasatinib in cell lines.		1	162745497	162745497	A	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.1912A>T,NC_000001.10:g.162745497A>T	2018-11-30 14:43:02 UTC	4.0	CA16602600	376143	ILE638PHE			false
144	https://civicdb.org/links/variants/144	DDR2	4921	G774V	Activating mutations in DDR2, including G774V, has been shown to be sensitive to dasatinib in cell lines.		1	162748407	162748407	G	T	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.2321G>T,NC_000001.10:g.162748407G>T	2018-11-30 14:43:02 UTC	4.0	CA16602601	376144	GLY774VAL			false
145	https://civicdb.org/links/variants/145	DDR2	4921	S768R	Activating mutations in DDR2, including S768R, has been shown to be sensitive to dasatinib in cell lines.		1	162748390	162748390	T	A	ENST00000367922.3	75	GRCh37					missense_variant	ENST00000367922.3:c.2304T>A,NC_000001.10:g.162748390T>A	2018-11-30 14:43:17 UTC	7.5	CA16602365	375878	SER768ARG			false
148	https://civicdb.org/links/variants/148	KRAS	3845	G12A	KRAS G12A, like EGFR T790M, has been shown to be capable of driving acquired resistance to tyrosine kinase inhibitors in lung adenocarcinoma.	EGFR TKI Resistance	12	25398284	25398284	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>C,NP_004976.2:p.Gly12Ala,NC_000012.11:g.25398284C>G,ENST00000256078.4:c.35G>C	2020-11-25 00:51:56 UTC	63.0	CA135567	45122	GLY12ALA,RS121913529			false
151	https://civicdb.org/links/variants/151	BCL2	596	IGH::BCL2	The typically reciprocal t(14;18)(q32;q21) translocation involves rearrangement between the immunoglobulin heavy chain locus on chromosome 14 and the 3' UTR of BCL2 on chromosome 18, leading to the overexpression of BCL2. This rearrangment is observed in >80% of patients with follicular lymphoma.		14	106032614	107288051				75	GRCh37	18	60794268	60987019	ENST00000333681.4	transcript_fusion,transcript_regulatory_region_fusion		2022-03-11 00:07:28 UTC	20.0		N/A	RECIPROCAL T(14;18)(Q32;Q21),IGH-BCL2			false
152	https://civicdb.org/links/variants/152	BCL2	596	Overexpression			18	60790579	60987361			ENST00000398117.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	40.0		N/A				false
153	https://civicdb.org/links/variants/153	FOXP1	27086	AMPLIFICATION	Amplication in FOXP1 has been shown to be associated with the ABC subtype of DLBCL.		3	71003844	71633140			ENST00000318789.4	75	GRCh37					transcript_amplification		2017-12-01 14:40:29 UTC	15.0		N/A				false
154	https://civicdb.org/links/variants/154	REL	5966	AMPLIFICATION			2	61108709	61149800			ENST00000295025.8	75	GRCh37					transcript_amplification		2022-04-12 21:22:01 UTC	20.0		N/A				false
155	https://civicdb.org/links/variants/155	RUNX1	861	Mutation	RUNX1 mutations are associated with poor prognosis in patients with acute myeloid leukemia or adult T-cell acute lymphocytic leukemia. In younger (<60 years old) AML patients, allogeneic stem cell transplant at complete remission led to much better relapse-free survival than repetitive cycles of high-dose cytarabine.		21	36160098	36421641			ENST00000300305.3	75	GRCh37					transcript_variant,loss_of_function_variant		2021-02-11 00:57:08 UTC	110.0		N/A				false
156	https://civicdb.org/links/variants/156	IGF2	3481	Overexpression			11	2150348	2170833			ENST00000300632.5	75	GRCh37					N/A	N/A	2022-04-12 21:22:06 UTC	6.0		N/A				false
157	https://civicdb.org/links/variants/157	TET2	54790	Mutation	TET2 mutations are commonly found in acute myeloid leukemia occurring in 9-23% of cases with many occurring in the elderly. Generally these mutations are loss-of-function which have been shown in mouse models to impair hematopoietic stem cell differentiation and cause aberrant hematopoiesis. These mutations have been found to be mutually exclusive with MLL and IDH1/2 mutations and have been associated with shortened event-free-survival and disease-free-survival when co-occurring with NPM1+/FLT3- genotypes. Overall Survival has been found to be shorter when occurring with NPM1+/FLT3+ genotypes. Studies involving "CN AML" and "de novo AML" however have been unable to elucidate a clinical impact.		4	106067450	106200973			ENST00000513237.1	75	GRCh37					gene_variant,loss_of_function_variant		2021-02-11 00:57:03 UTC	120.0		N/A				false
158	https://civicdb.org/links/variants/158	AURKA	6790	EXPRESSION			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	30.0		N/A				false
159	https://civicdb.org/links/variants/159	VHL	7428	Loss-of-function			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant	N/A	2022-04-12 21:22:01 UTC	15.0		N/A				false
160	https://civicdb.org/links/variants/160	VHL	7428	Mutation			3	10182692	10193904			ENST00000256474.2	75	GRCh37					gene_variant,loss_of_function_variant		2022-08-02 23:02:11 UTC	105.0		N/A				false
161	https://civicdb.org/links/variants/161	PBRM1	55193	Mutation			3	52581857	52719852			ENST00000394830.3	75	GRCh37					transcription_variant,loss_of_function_variant		2022-04-12 21:22:06 UTC	30.0		N/A				false
163	https://civicdb.org/links/variants/163	EZH2	2146	Mutation			7	148504477	148581370			ENST00000320356.2	75	GRCh37					protein_altering_variant		2022-04-12 21:22:01 UTC	35.0		N/A				false
164	https://civicdb.org/links/variants/164	FLI1	2313	EWSR1::FLI1 e7-e6	Although multiple fusion transcripts have been described, type 1 consists of EWSR1 exon 7 fused to FLI1 exon 6, the most common arrangement in Ewings Sarcoma.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	11	128675261	128683162	ENST00000527786.2	transcript_fusion		2022-02-17 22:51:31 UTC	20.0		N/A	EWSR1-FLI1 TYPE 1,EWSR1-FLI1 E7-E6			false
165	https://civicdb.org/links/variants/165	EZH2	2146	Y646	Mutations of Y646 are associated with a diagnosis of Germinal Center B type DLBCL and Follicular non-Hodgkin Lymphoma. In vitro experimental findings suggest that this may be due to reduced methyltransferase activity of EZH2 on protein H3K27 (Morin et al., 2010).		7	148508726	148508728			ENST00000320356.2	75	GRCh37					protein_altering_variant		2021-08-26 17:31:51 UTC	45.0		376218,76768,376217,76769	Y641,TYR646			false
167	https://civicdb.org/links/variants/167	KMT2D	8085	Loss-of-function			12	49412758	49449107			ENST00000301067.7	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:01 UTC	15.0		N/A				false
168	https://civicdb.org/links/variants/168	BTK	695	C481S			X	100611165	100611165	A	T	ENST00000308731.7	75	GRCh37					missense_variant	ENST00000308731.7:c.1441T>A,NC_000023.10:g.100611165A>T,NM_000061.2:c.1441T>A,NP_000052.1:p.Cys481Ser	2022-04-12 21:22:04 UTC	40.0	CA16602659	376204	CYS481SER,RS1057519826			false
169	https://civicdb.org/links/variants/169	AKT1	207	Q79K			14	105243048	105243048	G	T	ENST00000407796.2	75	GRCh37					missense_variant	NC_000014.8:g.105243048G>T,NM_001014432.1:c.235C>A,NP_001014432.1:p.Gln79Lys,ENST00000407796.2:c.235C>A	2022-04-12 21:22:04 UTC	16.0	CA16602625	376168	Q17K,GLN79LYS,RS1057519804			false
170	https://civicdb.org/links/variants/170	ALK	238	EML4::ALK and Amplification			2	42396490	42528380			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion,transcript_amplification	N/A	2022-04-12 21:22:06 UTC	15.5		N/A	EML4-ALK AND AMPLIFICATION			false
171	https://civicdb.org/links/variants/171	ALK	238	ALK Fusion G1202R	ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.		2	29443613	29443613	C	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3604G>A,NC_000002.11:g.29443613C>T,NM_004304.4:c.3604G>A,NP_004295.2:p.Gly1202Arg	2021-04-09 19:00:02 UTC	23.5	CA16602592	376134	ALK FUSION GLY1202ARG,RS1057519783			false
172	https://civicdb.org/links/variants/172	ALK	238	EML4::ALK S1206Y		Crizotinib Resistance	2	29443600	29443600	G	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3617C>A,NC_000002.11:g.29443600G>T,NM_004304.4:c.3617C>A,NP_004295.2:p.Ser1206Tyr	2022-04-12 21:22:04 UTC	6.0	CA16602591	376133	EML4-ALK SER1206TYR,RS1057519782,EML4-ALK S1206Y			false
173	https://civicdb.org/links/variants/173	ALK	238	EML4::ALK T1151INST	The ALK fusion variant with insertion of T at amino acid 1151 was found in an ALK rearranged lung adenocarcinoma which had progressed after responding to crizotinib treatment. The mutation was absent in tumor sample taken before crizotinib treatment. Characterization of the variant using cell lines expressing EML4-ALK with 1151 T insert found the variant to be highly crizotinib resistant, and other work demonstrated resistance to next generation inhibitor alectinib, while resistance to tool compound TAE684 indicates potential resistance to the next generation ALK inhibitor ceritinib which is derived from TAE684. Other experiments suggest theraputic potential for HSP90 inhibitors, as EML4-ALK T1151 Tins sensitivity to 17-AAG has been observed.		2	29445271	29445272		CGT	ENST00000389048.3	75	GRCh37					inframe_insertion,transcript_fusion	NC_000002.11:g.29445271_29445272insCGT	2022-03-10 21:10:08 UTC	18.0	CA645528802		T1151_L1152INST,EML4-ALK T1151INST			false
174	https://civicdb.org/links/variants/174	APC	324	Mutation			5	112043218	112181936			ENST00000457016.1	75	GRCh37							2022-08-02 23:07:26 UTC	7.0						false
175	https://civicdb.org/links/variants/175	AR	367	F877L			X	66943549	66943549	T	C	ENST00000374690.3	75	GRCh37					missense_variant	ENST00000374690.3:c.2629T>C,NC_000023.10:g.66943549T>C,NM_000044.4:c.2629T>C,NP_000035.2:p.Phe877Leu	2022-04-12 21:22:01 UTC	4.0	CA16602789	376347	PHE877LEU			false
176	https://civicdb.org/links/variants/176	AR	367	W742			X	66937370	66937372			ENST00000374690.3	75	GRCh37					missense_variant		2022-04-12 21:22:02 UTC	4.0		NONE FOUND	TRP742			false
177	https://civicdb.org/links/variants/177	ASXL1	171023	Mutation	ASXL1 mutations are most frequently observed in the absence of FLT3-ITD and NPM1 mutations in acute myeloid leukemia (AML) patients and seem to be enriched in older patients (>60 years). These mutations are associated with poor prognosis with respect to both survival and compete remission rates.		20	30946155	31027122			ENST00000375687.4	75	GRCh37					protein_altering_variant		2021-02-11 00:57:27 UTC	100.0		N/A				false
178	https://civicdb.org/links/variants/178	ATM	472	Mutation			11	108093559	108239826			ENST00000278616.4	75	GRCh37					transcription_variant,loss_of_function_variant		2022-04-12 21:22:02 UTC	90.5		N/A				false
179	https://civicdb.org/links/variants/179	ATM	472	Underexpression			11	108093559	108239826			ENST00000278616.4	75	GRCh37					N/A		2022-04-12 21:22:06 UTC	39.0		N/A				false
180	https://civicdb.org/links/variants/180	AURKA	6790	Amplification			20	54944446	54967393			ENST00000395913.3	75	GRCh37					transcript_amplification		2022-08-02 14:37:26 UTC	0.75		N/A				false
181	https://civicdb.org/links/variants/181	AURKA	6790	Overexpression			20	54944446	54967393			ENST00000395913.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	38.0		N/A				false
182	https://civicdb.org/links/variants/182	BAP1	8314	EXPRESSION			3	52435029	52444366			ENST00000460680.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
183	https://civicdb.org/links/variants/183	BAP1	8314	Mutation	BAP1 is a tumor suppressor gene, mutations in this gene have been observed in a number of cancers including melanoma, and renal cancers. These mutations generally lead to loss-of-function and mutations in the UHC domain of BAP1 have been shown to lead to structural instability and Œ≤-amyloid aggregation in models. Germline mutations are associated with an increased risk of tumorgenesis and can lead to the development of "atypical Spitz tumours (ASTs), cutaneous melanoma (CM), epithelioid malignant mesothelioma (MM) and clear cell RCC".		3	52435029	52444366			ENST00000460680.1	75	GRCh37					protein_altering_variant,loss_of_function_variant		2021-02-11 01:51:25 UTC	73.5		N/A				false
184	https://civicdb.org/links/variants/184	BRAF	673	AKAP9::BRAF		BRAF Fusions	7	91570181	91625114			ENST00000356239.3	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion	N/A	2022-04-12 21:22:01 UTC	20.0		N/A	AKAP9-BRAF			false
185	https://civicdb.org/links/variants/185	BRCA1	672	Mutation			17	41197646	41277500			ENST00000471181.2	75	GRCh37					gene_variant,loss_of_function_variant		2022-07-30 18:21:58 UTC	335.0		N/A				false
186	https://civicdb.org/links/variants/186	BRCA2	675	Mutation			13	32889611	32973347			ENST00000380152.3	75	GRCh37					gene_variant,loss_of_function_variant		2022-07-30 18:50:17 UTC	332.5		N/A				false
187	https://civicdb.org/links/variants/187	CCNE1	898	Amplification			19	30302805	30315215			ENST00000262643.3	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	27.0		N/A				false
189	https://civicdb.org/links/variants/189	DNMT3A	1788	Mutation	DNMT3A mutations occur in a variety of myeloid malignancies. These mutations are associated with adverse prognosis in acute myeloid leukemia (AML), particularly in the context of NPM1 and FLT3-ITD mutations, which often co-occur. Early results indicate AML patients with DNMT3A mutations may respond better to decitabine than those with wild-type. Shorter survival has been indicated in patients with T-cell acute lymphoblastic leukemia and myelodysplastic syndrome, however, larger cohorts are required to verify this finding. DNMT3A mutations have been suggested as a pre-leukemic lesion and found in older individuals with clonal hematopoiesis but no overt malignancy.		2	25455845	25565459			ENST00000264709.3	75	GRCh37					transcript_variant		2021-02-11 00:56:29 UTC	115.0		N/A				false
190	https://civicdb.org/links/variants/190	EGFR	1956	Amplification			7	55086794	55279321			ENST00000275493.2	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:06 UTC	133.0		N/A				false
191	https://civicdb.org/links/variants/191	EGFR	1956	Copy Number Variation			7	55086794	55279321			ENST00000275493.2	75	GRCh37					copy_number_change		2022-04-12 21:22:02 UTC	60.0		N/A				false
193	https://civicdb.org/links/variants/193	EGFR	1956	Overexpression			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	145.0		N/A				false
194	https://civicdb.org/links/variants/194	ERG	2078	EWSR1::ERG	EWSR1-ERG is found in 5% of patients with Ewing Sarcoma and considered to be diagnostic of this disease, a small tumor more often found in bone, but less frequently in soft tissue. To better identify EWSR1-ERG in patients, conventional cytogenetics methods were analyzed: FISH and RT-PCR. Ultimately concluding that more than one method is needed to accurately diagnose patients due to the strengths and weaknesses of each individual method.		22	29664007	29683123			ENST00000397938.2	75	GRCh37	21	39751949	39755845	ENST00000398907.1	transcript_fusion		2022-03-11 00:34:37 UTC	25.0		N/A	EWSR1-ERG			false
195	https://civicdb.org/links/variants/195	ERG	2078	TMPRSS2::ERG	TMPRSS2 fusions are prevalent in Prostate Cancer. TMPRSS2 fusion with ETS family members such as ERG are among the most common. Fusion of TMPRSS2 with ERG may result in overexpression of ERG driven by the TMPRSS2 androgen-responsive promoter elements. Due to the high prevalence of this fusion, it may have diagnostic utility for prostate cancer, especially ERG expression positive prostate cancer.		21	42879877	42879992			ENST00000398585.3	75	GRCh37	21	39751949	39817544	ENST00000398910.1	transcript_fusion		2022-03-10 21:41:18 UTC	15.0		N/A	TMPRSS2-ERG			false
198	https://civicdb.org/links/variants/198	FOXL2	668	C134W	The variant C134W on the FOXL2 gene was revealed to have a high frequency (95-97%) in the adult form of granulosa cell tumors that comprises 5% of ovarian cancers. Due to the mutation's high frequency, future therapeutics might target for this single apparent mechanism. However, the consequence of this mutation remain unknown.		3	138665163	138665163	G	C	ENST00000330315.3	75	GRCh37					missense_variant	NC_000003.11:g.138665163G>C	2018-11-30 14:45:24 UTC	70.0	CA16602790					false
199	https://civicdb.org/links/variants/199	IDH2	3418	R172	IDH2 R172 is a gain-of-function mutation commonly observed in acute myeloid leukemia and is enriched in those patients which are cytogenetically normal. R172 is analogous to IDH1 R132 mutations and leads to neomorphic enzymatic activity. Specifically this mutation "catalyzes the conversion of alpha ketoglurarate to beta-hydrozyglutarate" leading to increased levels of beta-hydrozyglutarate. This in turn leads to hypermethylation of target genes and an inhibition of cellular differentiation. R172 mutations generally lead to worse overall survival and higher rates of relapse compared to the most common IDH2 mutations in AML (R140).		15	90631837	90631839			ENST00000330062.3	75	GRCh37					protein_altering_variant		2017-12-01 14:40:30 UTC	105.0		N/A	ARG172			false
200	https://civicdb.org/links/variants/200	IKZF1	10320	Deletion	IKZF1 deletions have been reported in a variety of cancer types including pediatric B-cell precursor acute lymphoblastic leukemia (BCP ALL), Chronic Myeloid Leukemia, diffuse large B-cell lymphoma, myelodysplastic syndrome, T-cell ALL as well as solid tumors of the large intestine, lung, and liver. The clinical impact of these deletions is unknown for many cancer types however a poor outcome has been observed in leukemia based disease. This gene has been strongly implicated as a regulator for "normal hematopoiesis". In regards to BCP ALL, mouse models have shown that mutations in IKZF1 are not sufficient in and of themselves to cause disease. Haploinsuffeciency in combination with BCR-ABL1 however, will accelerate leukemiagenesis possibly indicating that at least in regards to BCP ALL these are secondary events that may be necessary for the development of leukaemic clones.		7	50344378	50472799			ENST00000331340.3	75	GRCh37					transcript_ablation		2022-12-02 03:01:14 UTC	220.0				28	https://civicdb.org/links/assertions/28	false
201	https://civicdb.org/links/variants/201	KIT	3815	M541L			4	55593464	55593464	A	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1621A>C,NP_000213.1:p.Met541Leu,ENST00000288135.5:c.1621A>C,NC_000004.11:g.55593464A>C	2022-04-12 21:22:04 UTC	25.0	CA160347	41599	MET541LEU,RS3822214			false
202	https://civicdb.org/links/variants/202	KIT	3815	V560DEL	V560 Resides within the Juxtamembrane domain on exon 11 of KIT. In melanoma this region is one 4 hotspots and is the 3rd highest recurrently mutated region. Mouse models have shown that mutations in this hotspot lead to  constitutive phosphorylation of KIT which will induce a stronger activation of the PI3K pathway however it is currently unknown if deletions follow the same model. Case studies in Gastrointestinal Stromal Tumors with V560DEL have reported a sensitivity when treated with imatinib and regorafenib.		4	55593612	55593614	GTT		ENST00000288135.5	75	GRCh37					amino_acid_deletion,inframe_deletion	NC_000004.11:g.55593612_55593614del,ENST00000288135.5:c.1675_1677delGTT,NM_000222.2:c.1675_1677delGTT,NP_000213.1:p.Val560del	2019-02-25 19:11:08 UTC	14.5	CA123529	13859	VAL560DEL,V559DEL,V555DEL,V556DEL			false
203	https://civicdb.org/links/variants/203	KRAS	3845	Q61			12	25380275	25380277			ENST00000256078.4	75	GRCh37					protein_altering_variant		2022-04-12 21:22:06 UTC	40.0		177881,177777,45116,375966,45115,376324,45117	GLN61			false
204	https://civicdb.org/links/variants/204	NCOA3	8202	AMPLIFICATION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	15.0		N/A				false
205	https://civicdb.org/links/variants/205	NCOA3	8202	OVEREXPRESSION			20	46130646	46285621			ENST00000372004.3	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	15.0		N/A				false
206	https://civicdb.org/links/variants/206	NOTCH1	4851	Mutation			9	139388896	139440314			ENST00000277541.6	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	100.0		N/A				false
207	https://civicdb.org/links/variants/207	NOTCH1	4851	P2514FS	This mutation disrupts the C-terminal PEST domain that in normal conditions promotes degradation,  resulting in accumulation of an active NOTCH1 isoform sustaining deregulated signaling.		9	139390649	139390650			ENST00000277541.6	75	GRCh37					frameshift_truncation	NC_000009.11:g.139390649_139390650del	2022-04-14 15:37:21 UTC	35.0		NONE FOUND	PRO2514ARGFS			false
208	https://civicdb.org/links/variants/208	NRAS	4893	Mutation			1	115247090	115259515			ENST00000369535.4	75	GRCh37					transcript_variant,gain_of_function_variant		2022-04-12 21:22:06 UTC	213.0		N/A				false
209	https://civicdb.org/links/variants/209	PAX8	7849	PAX8::PPARG	PAX8-PPAR gamma is a oncogene caused by a translocation between 2q13 and 3p25 resulting in an in-frame fusion between the two genes. It has been observed in Follicular Thyroid Cancer (FTC) and is one of two known fusion products involving PPAR gamma in FTC indicating this region may be a breakpoint hotspot. Studies have indicated that the fusion product increases cell viability and proliferation and decreases apoptosis.		2	113992971	114036521			ENST00000429538.3	75	GRCh37	3	12329400	12475810	ENST00000397015.2	transcript_fusion		2022-04-14 15:37:27 UTC	15.0		N/A	T(2;3)(Q13;P25),PAX8-PPARG			false
210	https://civicdb.org/links/variants/210	PGR	5241	Expression			11	100900355	101001255			ENST00000325455.5	75	GRCh37					N/A		2022-04-12 21:22:06 UTC	60.0		N/A				false
212	https://civicdb.org/links/variants/212	PIK3CA	5290	Amplification			3	178866311	178957881			ENST00000263967.3	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	45.0		N/A				false
213	https://civicdb.org/links/variants/213	PTEN	5728	Deletion			10	89622870	89731687			ENST00000371953.3	75	GRCh37					transcript_ablation		2022-04-12 21:22:02 UTC	55.0		NONE FOUND				false
214	https://civicdb.org/links/variants/214	PTEN	5728	Loss			10	89622870	89731687			ENST00000371953.3	75	GRCh37					loss_of_function_variant	N/A	2022-04-12 21:22:02 UTC	291.0		N/A				false
215	https://civicdb.org/links/variants/215	SF3B1	23451	Mutation			2	198254508	198299815			ENST00000335508.6	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	130.0		N/A				false
216	https://civicdb.org/links/variants/216	SMAD4	4089	Mutation			18	48556583	48611409			ENST00000342988.3	75	GRCh37					transcript_variant,loss_of_function_variant		2022-08-02 23:02:24 UTC	25.0		N/A				false
217	https://civicdb.org/links/variants/217	SMARCA4	6597	MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					gene_variant,loss_of_function_variant		2022-04-12 21:22:01 UTC	25.0		N/A				false
218	https://civicdb.org/links/variants/218	SMARCA4	6597	INACTIVATING MUTATION			19	11071598	11172958			ENST00000358026.2	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:01 UTC	20.0						false
219	https://civicdb.org/links/variants/219	TERT	7015	Amplification			5	1253282	1295162			ENST00000310581.5	75	GRCh37					transcript_amplification		2022-04-12 21:22:01 UTC	15.0		N/A				false
220	https://civicdb.org/links/variants/220	TERT	7015	Promoter Mutation	TERT promoter mutations are activating and commonly found at two hotspots within the TERT promoter region which occur 124 and 146 base pairs (hg19) upstream of the translation start site. These hotspots, termed C228T and C250T are observed in many cancer types and have a particularly high prevalence in glioblastoma (83%), melanoma (71%), bladder cancer (66%) and hepatocelluar carcinoma (HCC) (47%). The two mutations are usually heterozygous and mutually exclusive and result in an increased similarity to an ETS binding domain and may act as a binding site to an ETS transcription factor. These mutations are thought to be early events in tumorgenesis and aid in cellular immortality. Decreased overall survival in patients with these mutations have been observed in medulloblastoma, thyroid cancer, urogenital cancer, melanoma, and laryngeal tumors. The presence of these mutations has also been shown to be predictive of malignant/premalignant nodules in HCC and meningiomas.		5	1295161	1295373			ENST00000310581.5	75	GRCh37					regulatory_region_variant		2022-03-02 21:47:06 UTC	105.0			-124C>T,-146C>T			false
221	https://civicdb.org/links/variants/221	TP53	7157	Deleterious Mutation	Deleterious mutations are mutations of TP53 with prior characterization demonstrating significant deleterious effect on TP53 protein function. Inactivating TP53 mutations prevent on target activity and efficacy of MDM2-TP53 interaction inhibitors.		17	7571720	7590856			ENST00000269305.4	75	GRCh37					N/A		2021-03-02 23:57:53 UTC	78.0						false
222	https://civicdb.org/links/variants/222	TP53	7157	Mutation			17	7571720	7590856			ENST00000269305.4	75	GRCh37					protein_altering_variant		2022-07-22 21:39:15 UTC	425.0		N/A				false
223	https://civicdb.org/links/variants/223	TP53	7157	Truncating Mutation			17	7573998	7579714			ENST00000269305.4	75	GRCh37					frameshift_truncation		2022-04-12 21:22:01 UTC	40.0		N/A				false
224	https://civicdb.org/links/variants/224	TTF1	7270	AMPLIFICATION			9	135251008	135282209			ENST00000334270.2	75	GRCh37					transcript_amplification		2022-04-12 21:22:01 UTC	15.0		N/A				false
230	https://civicdb.org/links/variants/230	CHEK2	11200	Loss-of-function			22	29083732	29137832			ENST00000328354.6	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	25.0		N/A				false
236	https://civicdb.org/links/variants/236	CDK12	51755	Loss-of-function			17	37618292	37691399			ENST00000447079.4	75	GRCh37					loss_of_function_variant		2022-08-03 16:06:00 UTC	4.0		N/A				false
238	https://civicdb.org/links/variants/238	NT5C2	22978	R367Q			10	104852955	104852955	C	T	ENST00000343289.5	75	GRCh37					missense_variant	NC_000010.10:g.104852955C>T	2022-04-12 21:22:05 UTC	17.0	CA16602791	376349	ARG367GLN			false
239	https://civicdb.org/links/variants/239	NT5C2	22978	K359Q			10	104852980	104852980	T	G	ENST00000343289.5	75	GRCh37					missense_variant	NC_000010.10:g.104852980T>G,NM_012229.4:c.1075A>C,NP_036361.1:p.Lys359Gln,ENST00000343289.5:c.1075A>C	2022-04-12 21:22:02 UTC	28.0	CA16602792	376350	LYS359GLN			false
240	https://civicdb.org/links/variants/240	NT5C2	22978	D407A			10	104850745	104850745	T	G	ENST00000343289.5	75	GRCh37					missense_variant	NC_000010.10:g.104850745T>G,NM_012229.4:c.1220A>C,NP_036361.1:p.Asp407Ala,ENST00000343289.5:c.1220A>C	2022-04-12 21:22:04 UTC	8.0	CA16602793	376351	ASP407ALA			false
241	https://civicdb.org/links/variants/241	ABL1	25	BCR::ABL F317L	BCR-ABL F317L, like the similar BCR-ABL T315I mutation, is becoming a common clinical marker for resistance to front-line therapies in CML. It has been shown to confer resistance to dasatinib, but responds well to ponatinib and other second generation inhibitors.	Imatinib Resistance	9	133748288	133748288	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NC_000009.11:g.133748288T>C,NP_005148.2:p.Phe317Leu,NM_005157.5:c.949T>C,ENST00000318560.5:c.949T>C	2022-03-11 04:28:24 UTC	114.5	CA16602794	376352,376094	F336L,F317L,RS1057519773,BCR-ABL F317L			false
242	https://civicdb.org/links/variants/242	TP53	7157	DNA Binding Domain Mutation			17	7577149	7578443			ENST00000269305.4	75	GRCh37					DNA_binding_site		2022-04-12 21:22:02 UTC	35.0		N/A				false
243	https://civicdb.org/links/variants/243	ATM	472	S2289*	A frameshift mutation at the DNA level predicted to cause truncation before the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain at amino acid 2289.		11	108196840	108196841	TC		ENST00000278616.4	75	GRCh37					frameshift_truncation	ENST00000278616.4:c.6863_6864delTC	2020-11-21 21:41:33 UTC	7.5	CA10588507	NONE FOUND	V2288FS*1			false
244	https://civicdb.org/links/variants/244	ATM	472	N2875H	A missense mutation within the C-terminal phosphoinositide 3-kinase (PI3K) catalytic domain		11	108218044	108218044	A	C	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.8623A>C,NC_000011.9:g.108218044A>C,NM_000051.3:c.8623A>C,NP_000042.3:p.Asn2875His	2018-11-30 14:43:14 UTC	7.5	CA16602795	376353	ASN2875HIS,RS1057519869			false
245	https://civicdb.org/links/variants/245	NF2	4771	Y177fs			22	30051593	30051594		T	ENST00000338641.4	75	GRCh37					frameshift_elongation	ENST00000338641.4:c.527_528insT,NC_000022.10:g.30051593_30051594insT	2022-04-12 21:22:04 UTC	7.5	CA645601016	NONE FOUND	TYR177FS			false
247	https://civicdb.org/links/variants/247	PDGFRA	5156	V561A			4	55141036	55141036	T	C	ENST00000257290.5	75	GRCh37					missense_variant	ENST00000257290.5:c.1682T>C,NC_000004.11:g.55141036T>C,NM_006206.5:c.1682T>C,NP_006197.1:p.Val561Ala	2022-04-12 21:22:04 UTC	3.0	CA16602796	376354	VAL561ALA,RS121908586			false
248	https://civicdb.org/links/variants/248	TERT	7015	C228T			5	1295228	1295228	G	A	ENST00000310581.5	75	GRCh37					regulatory_region_variant	NC_000005.9:g.1295228G>A	2022-04-12 21:22:04 UTC	40.0	CA557858711	NONE FOUND	-124C>T			false
249	https://civicdb.org/links/variants/249	XRCC1	7515	R194W			19	44057574	44057574	G	A	ENST00000262887.5	75	GRCh37					missense_variant	NM_006297.2:c.580C>T,NP_006288.2:p.Arg194Trp,ENST00000262887.5:c.580C>T,NC_000019.9:g.44057574G>A	2022-04-12 21:22:04 UTC	20.0	CA9488737	376355	RS1799782,ARG194TRP			false
250	https://civicdb.org/links/variants/250	GSTP1	2950	Deletion			11	67351066	67354131			ENST00000398606.3	75	GRCh37					transcript_ablation		2022-08-02 23:10:37 UTC	4.0						false
251	https://civicdb.org/links/variants/251	BIRC7	79444	Amplification			20	61867235	61871859			ENST00000217169.3	75	GRCh37					transcript_amplification		2022-08-02 22:57:58 UTC	4.0		N/A				false
252	https://civicdb.org/links/variants/252	EGFR	1956	Exon 4 Deletion			7	55214299	55214433			ENST00000275493.2	75	GRCh37					exon_loss_variant	ENST00000275493.2:c.425_559del	2022-04-12 21:22:02 UTC	4.0		N/A				false
254	https://civicdb.org/links/variants/254	KRAS	3845	RS61764370	Germline variant in the 3' UTR of KRAS that predicts resistance to platinum-based therapy.		12	25360224	25360224	A	C	ENST00000311936.3	75	GRCh37					3_prime_UTR_variant	NM_004985.4:c.*2505T>G,NC_000012.11:g.25360224A>C,ENST00000311936.3:c.*2505T>G	2018-11-30 14:43:01 UTC	30.0	CA10637079	308084				false
255	https://civicdb.org/links/variants/255	ERCC5	2073	RS751402			13	103498198	103498198	A	G	ENST00000355739.4	75	GRCh37					5_prime_UTR_variant,SNP	NC_000013.10:g.103498198A>G	2022-04-12 21:22:04 UTC	15.0	CA10642711	310903				false
256	https://civicdb.org/links/variants/256	KIT	3815	rs17084733			4	55604940	55604940	G	A	ENST00000288135.5	75	GRCh37					3_prime_UTR_variant	NC_000004.11:g.55604940G>A	2022-04-12 21:22:07 UTC	15.0	CA10621234		3' UTR MUTATION			false
257	https://civicdb.org/links/variants/257	EZH2	2146	Intron 6 Mutation			7	148524752	148524752	C	C	ENST00000320356.2	75	GRCh37					intron_variant	NC_000007.14:g.148827660C=,NC_000007.13:g.148524752C=,ENST00000320356.7:c.626-394G=,ENSP00000320147.2:n.626-394G=,NM_004456.5:c.626-394G=,NP_004447.2:n.626-394G=	2022-04-12 21:22:02 UTC	20.0	CA1139771703	NONE FOUND	RS3757441			false
258	https://civicdb.org/links/variants/258	MTHFR	4524	A222V			1	11856378	11856378	G	A	ENST00000376592.1	75	GRCh37					missense_variant	NM_005957.4:c.665C>T,NP_005948.3:p.Ala222Val,ENST00000376592.1:c.665G>A,NC_000001.10:g.11856378G>A	2022-04-12 21:22:04 UTC	55.0	CA170990	3520	RS1801133,C677T,ALA222VAL			false
259	https://civicdb.org/links/variants/259	GSTP1	2950	I105V			11	67352689	67352689	A	G	ENST00000398606.3	75	GRCh37					missense_variant	NM_000852.3:c.313A>G,NP_000843.1:p.Ile105Val,ENST00000398606.3:c.313A>G,NC_000011.9:g.67352689A>G	2022-04-12 21:22:04 UTC	20.0	CA6142790	37340	ILE105VAL			false
260	https://civicdb.org/links/variants/260	ABCG2	9429	Q141K			4	89052323	89052323	G	T	ENST00000237612.3	75	GRCh37					missense_variant	NC_000004.11:g.89052323G>T,NM_004827.2:c.421C>A,NP_004818.2:p.Gln141Lys,ENST00000237612.3:c.421C>A	2022-04-12 21:22:04 UTC	15.0	CA129179	30389	GLN141LYS,RS2231142			false
261	https://civicdb.org/links/variants/261	XRCC1	7515	Q399R	XRCC1 Q399R germline polymorphism (NM_006297.2:c.1196A>G) is associated with better outcome for patients with NSCLC and increased response to chemotherapy for patients with cervical cancer.		19	44055726	44055726	T	C	ENST00000262887.5	75	GRCh37					missense_variant	NM_006297.2:c.1196A>G,NP_006288.2:p.Gln399Arg,NC_000019.9:g.44055726T>C,ENST00000262887.5:c.1196A>G	2019-03-22 01:41:07 UTC	40.0	CA9488516	225976	GLN399ARG,RS25487			false
262	https://civicdb.org/links/variants/262	ABCB1	5243	S893T			7	87160618	87160618	A	T	ENST00000265724.3	75	GRCh37					missense_variant	NM_000927.4:c.2677T>A,NP_000918.2:p.Ser893Thr,NC_000007.13:g.87160618A>T,ENST00000265724.3:c.2677T>A	2022-04-12 21:22:02 UTC	15.0	CA179696	166619	A893S,SER893THR,RS2032582			false
263	https://civicdb.org/links/variants/263	ABCB1	5243	I1145I	ABCB1 I1145I is a germline polymorphism that has improved responses in cancer. Specifically, it can indicate sensitivity to platinum-based chemotherapies for patients with NSCLC or better outcome for HER2-positive metastatic breast cancer patients.		7	87138645	87138645	A	G	ENST00000265724.3	75	GRCh37					synonymous_variant	NM_000927.4:c.3435T>C,NP_000918.2:p.Ile1145=,NC_000007.13:g.87138645A>G,ENST00000265724.3:c.3435T>C	2019-03-22 01:39:44 UTC	25.0	CA4327768	225939	T3435C,RS1045642,3435C-T,ILE1145=			false
264	https://civicdb.org/links/variants/264	ERCC2	2068	K751Q			19	45854919	45854919	T	G	ENST00000391945.4	75	GRCh37					missense_variant	NC_000019.9:g.45854919T>G	2022-04-12 21:22:04 UTC	35.0	CA158782	134105	LYS751GLN			false
265	https://civicdb.org/links/variants/265	TYMS	7298	5' TANDEM REPEAT			18	657604	657742			ENST00000323274.10	75	GRCh37					5_prime_UTR_variant,short_tandem_repeat_variation		2022-04-12 21:22:02 UTC	15.0						false
266	https://civicdb.org/links/variants/266	LRP1B	53353	EXON 12-22 DELETION			2	141665446	141777671			ENST00000389484.3	75	GRCh37					exon_loss_variant	ENST00000389484.3:c.1790_3520del	2022-04-12 21:22:06 UTC	3.0		N/A				false
267	https://civicdb.org/links/variants/267	FGFR1	2260	Amplification	FGFR1 amplifications are the most common aberrations of the FGFR family in cancer. One study reports FGFR1 aberrations in 3.5% of 4,853 patients of which most are FGFR1 amplifications (Helsten et. al., 2016). Preclinically, FGFR1 amplifications have also been shown to confer sensitivity to FGFR1 inhibitors (Weiss et. al., 2010). Clinical studies are currently ongoing (e.g. NCT01004224).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					transcript_amplification	N/A	2021-02-13 04:55:45 UTC	170.5		N/A				false
268	https://civicdb.org/links/variants/268	FGFR1	2260	Expression	FGFR1 high expression has been reported in 11.8% (178 patients) of oral squamous cell carcinoma patients, and was enriched in early stages (Freier et. al., 2007). Another study reports FGFR1 expression in 35% of primary HNSSC (353 patients) (G√∂ke et. al., 2015). In both studies, FGFR1 gene amplification and expression do not correlate well with about 35% of samples with FGFR1 amplification overexpressing FGFR1 (G√∂ke et. al., 2015). FGFR1 expression also correlated with sensitivity to FGFR1 inhibitors in preclinical models of lung cancer (Wynes et. al., 2014), HNSSC (G√∂ke et. al., 2015) and urothelial carcinoma (Lamont et. al., 2011).		8	38268656	38325363			ENST00000425967.3	75	GRCh37					N/A	N/A	2021-02-13 04:55:52 UTC	46.0		N/A				false
269	https://civicdb.org/links/variants/269	ROS1	6098	Rearrangement	ROS1 is a receptor tyrosine kinase that frequently forms gene fusions in several cancer types. Approximately 2% of NSCLC patients harbor a ROS1 gene fusion. Several fusion partners have been described with a constant ROS1-breakpoint, maintaining the kinase domain (Solomon B, 2015). Following case-studies and retrospective analyses, an expansion cohort of a phase-1 study showed clinical benefit of crizotinib in ROS1 rearranged NSCLC. The benefit was independent of the type of ROS1-rearrangement (Shaw et. al.,2014).		6	117609463	117747018			ENST00000368508.3	75	GRCh37					transcript_fusion		2022-08-02 14:46:51 UTC	108.0		N/A				false
270	https://civicdb.org/links/variants/270	MET	4233	Amplification			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	81.5		N/A				false
271	https://civicdb.org/links/variants/271	ATR	545	I774FS	Single A insertion or deletion in the 10 A mononucleotide run in exon 10 of ATR results in a frameshift of codon I774. In patients with endometrial cancer, this mutation has only been observed in patients with microsatellite instability.		3	142274740	142274740			ENST00000350721.4	75	GRCh37					frameshift_truncation	NC_000003.11:g.142274740del	2022-04-14 15:37:21 UTC	20.0						false
272	https://civicdb.org/links/variants/272	CDKN2A	1029	p16 Expression	CDKN2A (p16) expression is a surrogate marker of HPV infection in oropharyngeal squamous cell carcinoma. CDKN2A and p53 are inactivated through HPV proteins E6 and E7 and therefore not altered in expression level in HPV-associated carcinomas. However, there is no perfect overlap between p16 expression and HPV status with some 10-12.5% of HPV-negative tumors expressing p16. (Seiwert, T JCO, 2014). p16 positivity is a well-established positive prognostic factor in squamous cell cancer of the head and neck in the primary and, as increasing evidence suggests, recurrent/metastatic disease settings. Predictive information from HPV status have not been established to date. A lack of benefit from EGFR-inhibitors has been proposed by some studies. Other studies were not able to reproduce this finding.		9	21968055	21974865			ENST00000498124.1	75	GRCh37					N/A		2021-03-31 20:35:04 UTC	180.0		N/A				false
273	https://civicdb.org/links/variants/273	RET	5979	KIF5B::RET	In a study by Takeuchi et. al. a fusion screen was performed in 1529 lung cancer samples. 14 adenocarcinomas with KIF5B-RET and CCDC6-RET fusions were identified. (Takeuchi K et. al., 2012)		10	32306071	32345359			ENST00000302418.4	75	GRCh37	10	43609928	43625799	ENST00000355710.3	transcript_fusion		2022-03-11 00:00:34 UTC	10.0		N/A	KIF5B-RET			false
274	https://civicdb.org/links/variants/274	HRAS	3265	G13D			11	534285	534285	C	T	ENST00000451590.1	75	GRCh37					missense_variant	NC_000011.9:g.534285C>T,NP_005334.1:p.Gly13Asp,NM_005343.3:c.38G>A,ENST00000451590.1:c.38G>A	2022-04-12 21:22:04 UTC	7.5	CA256488	12604	GLY13ASP,RS104894226			false
275	https://civicdb.org/links/variants/275	HRAS	3265	Mutation			11	533873	534289			ENST00000451590.1	75	GRCh37					coding_transcript_variant		2022-08-02 23:02:50 UTC	23.0		376033,12613,12602,35554,180848,160364				false
276	https://civicdb.org/links/variants/276	CD274	29126	Expression			9	5450525	5470547			ENST00000381577.3	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	330.0		N/A				false
277	https://civicdb.org/links/variants/277	MTOR	2475	Mutation			1	11166592	11322564			ENST00000361445.4	75	GRCh37					protein_altering_variant		2022-08-02 23:02:56 UTC	22.5		N/A				false
278	https://civicdb.org/links/variants/278	AKT2	208	EXPRESSION			19	40736224	40791302			ENST00000392038.2	75	GRCh37					N/A		2022-04-12 21:22:03 UTC	15.0		N/A				false
279	https://civicdb.org/links/variants/279	NF2	4771	K159fs			22	30050674	30050674	A		ENST00000338641.4	75	GRCh37					frameshift_truncation	NC_000022.10:g.30050674del,NC_000022.11:g.29654685del,NM_000268.3:c.476del,NP_000259.1:p.Lys159SerfsTer15	2022-04-12 21:22:02 UTC	7.5	CA915940524	NONE FOUND	LYS159FS*16			false
281	https://civicdb.org/links/variants/281	FBXW7	55294	Mutation			4	153245446	153332714			ENST00000281708.4	75	GRCh37					protein_altering_variant,loss_of_function_variant		2022-08-02 23:03:08 UTC	20.0						false
282	https://civicdb.org/links/variants/282	SMAD4	4089	Underexpression			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A		2022-08-02 14:53:51 UTC	3.0		N/A				false
283	https://civicdb.org/links/variants/283	MTOR	2475	H1968Y			1	11188519	11188519	G	A	ENST00000361445.4	75	GRCh37					missense_variant,gain_of_function_variant	ENST00000361445.4:c.5902C>T,NC_000001.10:g.11188519G>A,NM_004958.3:c.5902C>T,NP_004949.1:p.His1968Tyr	2022-04-12 21:22:04 UTC	3.0	CA16602797	376357	HIS1968TYR			false
284	https://civicdb.org/links/variants/284	MTOR	2475	P2213S			1	11184580	11184580	G	A	ENST00000361445.4	75	GRCh37					missense_variant,gain_of_function_variant	ENST00000361445.4:c.6637C>T,NC_000001.10:g.11184580G>A,NM_004958.3:c.6637C>T,NP_004949.1:p.Pro2213Ser	2022-04-12 21:22:04 UTC	3.0	CA16602798	376358	PRO2213SER			false
285	https://civicdb.org/links/variants/285	BRAF	673	AGK::BRAF		BRAF Fusions	7	141250989	141255367			ENST00000355413.4	75	GRCh37	7	140434279	140494267	ENST00000288602.6	transcript_fusion	N/A	2022-04-12 21:22:03 UTC	7.0		N/A	AGK-BRAF			false
286	https://civicdb.org/links/variants/286	BRAF	673	PAPSS1::BRAF		BRAF Fusions	4	108603171	108641608			ENST00000265174.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	gene_fusion,transcript_fusion		2022-04-12 21:22:02 UTC	6.0		N/A	T(4;7)(Q24;Q34),PAPSS1-BRAF			false
287	https://civicdb.org/links/variants/287	BRAF	673	TRIM24::BRAF		BRAF Fusions	7	138145079	138239711			ENST00000343526.4	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion		2022-04-12 21:22:02 UTC	6.0		N/A	TRIM24-BRAF			false
288	https://civicdb.org/links/variants/288	BRAF	673	L597R		Other V600's	7	140453145	140453145	A	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1790T>G,NP_004324.2:p.Leu597Arg,NC_000007.13:g.140453145A>C,ENST00000288602.6:c.1790T>G	2022-04-12 21:22:05 UTC	12.0	CA123649	13968	LEU597ARG,RS121913366			false
289	https://civicdb.org/links/variants/289	ERBB3	2065	Overexpression			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	37.0		N/A				false
290	https://civicdb.org/links/variants/290	NT5E	4907	Overexpression			6	86159809	86205496			ENST00000257770.3	75	GRCh37					N/A		2022-08-02 14:22:13 UTC	15.0		N/A				false
291	https://civicdb.org/links/variants/291	EZH2	2146	Overexpression			7	148504477	148581370			ENST00000320356.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
292	https://civicdb.org/links/variants/292	MYD88	4615	Overexpression			3	38179969	38184510			ENST00000417037.2	75	GRCh37					N/A		2022-08-02 22:56:27 UTC	2.0		N/A				false
294	https://civicdb.org/links/variants/294	PIK3CA	5290	P471L			3	178928226	178928226	C	T	ENST00000263967.3	75	GRCh37					missense_variant	ENST00000263967.3:c.1412C>T,NC_000003.11:g.178928226C>T,NM_006218.3:c.1412C>T,NP_006209.2:p.Pro471Leu	2022-04-12 21:22:04 UTC	7.5	CA16602799	376359	PRO471LEU,RS1057519872			false
296	https://civicdb.org/links/variants/296	RIT1	6016	OVEREXPRESSION			1	155870065	155880706			ENST00000368322.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
297	https://civicdb.org/links/variants/297	RIT1	6016	Mutation			1	155870065	155880706			ENST00000368322.3	75	GRCh37					transcript_variant		2022-08-02 14:44:48 UTC	3.0		N/A				false
298	https://civicdb.org/links/variants/298	MYCN	4613	Amplification			2	16080686	16087129			ENST00000281043.3	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	46.0		N/A				false
299	https://civicdb.org/links/variants/299	SMO	6608	D473H			7	128849189	128849189	G	C	ENST00000249373.3	75	GRCh37					missense_variant	NM_005631.4:c.1417G>A,NP_005622.1:p.Asp473His,ENST00000249373.3:c.1417G>A,NC_000007.13:g.128849189G>C	2022-04-12 21:22:04 UTC	13.5	CA16602418	375938	ASP473HIS			false
300	https://civicdb.org/links/variants/300	SMO	6608	Mutation			7	128828713	128853386			ENST00000249373.3	75	GRCh37					coding_transcript_variant		2022-04-12 21:22:01 UTC	44.0		N/A				false
301	https://civicdb.org/links/variants/301	PTCH1	5727	Mutation			9	98205262	98270943			ENST00000331920.6	75	GRCh37					gene_variant,loss_of_function_variant		2022-08-02 23:02:29 UTC	25.0						false
302	https://civicdb.org/links/variants/302	PTCH1	5727	LOH			9	98205262	98270943			ENST00000331920.6	75	GRCh37					loss_of_heterozygosity		2022-04-12 21:22:02 UTC	10.0		N/A				false
303	https://civicdb.org/links/variants/303	STK11	6794	EXON 1-2 MUTATION			19	1205740	1218499			ENST00000326873.7	75	GRCh37					exon_variant		2022-04-12 21:22:01 UTC	20.0						false
304	https://civicdb.org/links/variants/304	STK11	6794	Underexpression			19	1205740	1228428			ENST00000326873.7	75	GRCh37					N/A		2022-08-03 16:01:52 UTC	2.0		N/A				false
305	https://civicdb.org/links/variants/305	SYK	6850	OVEREXPRESSION			9	93564069	93660831			ENST00000375754.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
306	https://civicdb.org/links/variants/306	ERBB2	2064	Amplification	Her2 (ERBB2) amplifications are seen in up to 20% of breast cancers and were associated with aggressive disease and poor prognosis when discovered. Trastuzumab first found considerable success, and was approved for treatment, in HER2 positive metastatic breast cancer (MBC) which had progressed under chemotherapy. These metastatic cancers nonetheless progressed under trastuzumab, and other forms of therapy were studied for next line treatments, including tyrosine kinase inhibitors. Lapatinib, a reversible inhibitor of tyrosine kinase activity in ErbB1 and ErbB2, and afatinib, an irreversible inhibitor of all 4 ErbB forms were shown to have activity in trastuzumab-progressed HER2 MBC. Interestingly trastuzumab itself also turned out to remain effective in treatment of trastuzumab-progressed HER2 MBC. The LUX-Breast 1 trial compared a TKI-based treatment (afatinib) to a trastuzumab-based treatment of trastuzumab-progressed HER2 MBC, and the LUX-Breast 3 trial addressed TKI application in the context of HER2 MBC with difficult to treat brain metastases. In neither of these cases was the TKI more effective, making successful future replacement of trastuzumab-based therapy with a TKI in trastuzumab-progressed HER2 MBC seem unlikely. Instead, a potential role for TKIs in this disease context is revealed in preclinical work suggesting synergism between TKI and trastuzumab action, and clinical trials with lapatinib or afatinib combined with trastuzumab indicate that dual HER2 blockade may be an effective therapy. Dual antibody HER2 blockade with pertuzumab instead of TKI in HER2 MBC has also recently shown strong results in the CLEOPATRA trial. HER2 overexpression is targeted in neoadjuvant breast cancer treatment, and has also been successfully targeted in gastric cancer.		17	37856333	37884915			ENST00000269571.5	75	GRCh37					transcript_amplification	N/A	2022-05-12 21:34:43 UTC	886.0		N/A	OVEREXPRESSION	32	https://civicdb.org/links/assertions/32	false
307	https://civicdb.org/links/variants/307	ALK	238	EML4::ALK L1152R			2	29445270	29445270	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3455T>G,NC_000002.11:g.29445270A>C,NM_004304.4:c.3455T>G,NP_004295.2:p.Leu1152Arg	2022-04-12 21:22:04 UTC	10.0	CA16602594	376136	EML4-ALK LEU1152ARG,RS1057519785,EML4-ALK L1152R			false
308	https://civicdb.org/links/variants/308	ALK	238	EML4::ALK G1269A	The EML4-ALK G1269A mutation has been identified in non-small cell lung cancer patients resistant to crizotinib. Cell line data from multiple groups have shown this mutation enhances resistance to crizotinib treatment in vitro.		2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala	2022-03-11 04:06:48 UTC	17.5	CA16602590	376132	EML4-ALK GLY1269ALA,RS1057519781,EML4-ALK G1269A			false
310	https://civicdb.org/links/variants/310	ERBB4	2066	Mutation	ERBB4 mutations have been identified in melanoma, lung adenocarcinoma and medulloblastoma. In-vitro studies suggest that melanoma cell lines harboring an ERBB4 mutation are sensitive to ERBB4 inhibition with lapatinib.		2	212295697	212578308			ENST00000342788.4	75	GRCh37					transcript_variant,gain_of_function_variant		2022-08-02 23:07:33 UTC	4.0						false
311	https://civicdb.org/links/variants/311	PIK3CA	5290	Mutation	PIK3CA mutations are observed in many cancers among the most prevalent are breast cancer, colorectal cancer, and head and neck squamous cell carcinoma. These mutations have been observed in up to 40%, 20%, and 21% respectively for each of these cancer types with mutations commonly occurring within the helical exon 9 and kinase domain of exon 20. In breast cancer PIK3CA mutations have been associated with better prognosis, and a greater survival outcome, however the PI3K pathway is also associated with increased drug resistance (trastuzumab/lapatinib). PIK3CA mutations in both HNSCC and CRC have been associated with resistance to anti-EGFR therapeutic agents and mutations in exon 9 and 20 are associated with a poorer prognosis in CRC. Interestingly PIK3CA mutations in HNSCC have been observed to be absent from a number of ethnic groups including greek, german, and vietnamese populations.		3	178866311	178957881			ENST00000263967.3	75	GRCh37					transcript_variant,gain_of_function_variant		2021-12-31 01:52:55 UTC	454.0		N/A		22	https://civicdb.org/links/assertions/22	false
312	https://civicdb.org/links/variants/312	EGFR	1956	VIII	The EGFRvIII variant is an oncogenic mutation that has been reported in several cancers including glioblastoma multiforme, breast, lung, head and neck, ovarian and prostate. In high-grade gliomas, EGFRvIII has been reported in about 30% of cases with EGFR amplification. The EGFRvIII mutation leads to deletion of the receptor ectodomain exons 2-7. The presence of this variant has been linked with clinical response to EGFR TKI. (Arteaga and Engelmann, 2014)		7	55087058	55223523			ENST00000275493.2	75	GRCh37					disruptive_inframe_deletion	NM_005228.3:c.89_881del,NP_005219.2:p.Val30_Arg297delinsGly,NC_000007.13:g.55209979_55221845del	2020-07-17 21:29:16 UTC	69.0						false
313	https://civicdb.org/links/variants/313	PTEN	5728	Expression			10	89622870	89731687			ENST00000371953.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	54.5		N/A				false
314	https://civicdb.org/links/variants/314	NRG1	3084	Expression			8	31497942	32622294			ENST00000523534.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	37.0		N/A				false
315	https://civicdb.org/links/variants/315	AREG	374	Expression			4	75310851	75320726			ENST00000395748.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	58.0		N/A				false
316	https://civicdb.org/links/variants/316	TGFA	7039	EXPRESSION			2	70674412	70781147			ENST00000295400.6	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
317	https://civicdb.org/links/variants/317	EGFR	1956	G724S			7	55241722	55241722	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2170G>A,NC_000007.13:g.55241722G>A,NM_005228.4:c.2170G>A,NP_005219.2:p.Gly724Ser	2022-04-12 21:22:04 UTC	4.0	CA16602800	376360	GLY724SER,RS1051753269			false
318	https://civicdb.org/links/variants/318	EREG	2069	EXPRESSION			4	75230860	75254468			ENST00000244869.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	35.5		N/A				false
320	https://civicdb.org/links/variants/320	MAPK1	5594	E322K			22	22127164	22127164	C	T	ENST00000215832.6	75	GRCh37					missense_variant,gain_of_function_variant	ENST00000215832.6:c.964G>A,NC_000002.11:g.22127164C>T,NP_002736.3:p.Glu322Lys,NM_002745.4:c.964G>A	2022-04-12 21:22:05 UTC	10.0	CA16602885	376450	GLU322LYS			false
321	https://civicdb.org/links/variants/321	MAPK1	5594	Amplification			22	22108789	22221919			ENST00000215832.6	75	GRCh37					transcript_amplification		2022-08-02 22:58:04 UTC	4.0		N/A				false
322	https://civicdb.org/links/variants/322	KRAS	3845	A146V			12	25378561	25378561	G	A	ENST00000256078.4	75	GRCh37					missense_variant	ENST00000256078.4:c.437C>T,NC_000012.11:g.25378561G>A,NP_004976.2:p.Ala146Val,NM_004985.4:c.437C>T	2022-04-12 21:22:04 UTC	8.0	CA16602440	375962	ALA146VAL,RS1057519725			false
323	https://civicdb.org/links/variants/323	MET	4233	Mutation			7	116312459	116436396			ENST00000318493.6	75	GRCh37					transcription_variant,gain_of_function_variant		2022-04-12 21:22:01 UTC	15.0		N/A				false
324	https://civicdb.org/links/variants/324	MET	4233	Exon 14 Skipping Mutation	Exon 14 mutations have been observed in ~3% of patients with NSCLC (28/933 reported by Awad et al J Clin Onc 2016), confirmed to cause exon skipping when available, and associated with concurrent MET amplification. Responses to the c-MET inhibitor crizotinib have been reported in preclinical models and in individual case reports as well as a small-scale clinical trial (17 patients treated, Drilon et al., 2016 (suppl; abstr 108; ASCO ID 167889-176)). Larger studies are needed but enrollment of patients with MET exon 14 skipping mutation in trials with MET inhibitors or off-label treatment is encouraged (Paik et al., 2015 (suppl; abstr 8021)).		7	116411903	116412043			ENST00000318493.6	75	GRCh37					exon_loss_variant		2022-11-14 15:19:24 UTC	88.5		N/A				false
325	https://civicdb.org/links/variants/325	FGFR3	2261	Overexpression			4	1795039	1810599			ENST00000440486.2	75	GRCh37					N/A		2022-05-26 21:31:19 UTC	6.0		N/A				false
326	https://civicdb.org/links/variants/326	CBLC	23624	EXPRESSION			19	45281126	45303891			ENST00000270279.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0		N/A				false
327	https://civicdb.org/links/variants/327	PTPRD	5789	Mutation			9	8314246	10033790			ENST00000381196.4	75	GRCh37					transcript_variant,loss_of_function_variant		2022-08-02 23:07:39 UTC	3.0		N/A				false
328	https://civicdb.org/links/variants/328	DEFA1	1667	EXPRESSION			8	6835172	6837602			ENST00000382692.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0						false
329	https://civicdb.org/links/variants/329	ERCC1	2067	Expression			19	45916692	45926824			ENST00000013807.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	30.0		N/A				false
330	https://civicdb.org/links/variants/330	NOTCH1	4851	Amplification			9	139388896	139440314			ENST00000277541.6	75	GRCh37					transcript_amplification		2022-08-02 22:57:29 UTC	12.0		N/A				false
331	https://civicdb.org/links/variants/331	WEE1	7465	RS3910384			11	9599943	9599943	A	G	ENST00000450114.2	75	GRCh37					intron_variant,polymorphic_sequence_variant	NC_000011.9:g.9599943A>G,ENST00000450114.2:c.1141+1133A>G	2022-04-12 21:22:04 UTC	15.0	CA15681425	NONE FOUND	INTRON POLYMORPHISM			false
332	https://civicdb.org/links/variants/332	FNTB	2342	RS11623866			14	65453063	65453063	G	C	ENST00000246166.2	75	GRCh37					regulatory_region_variant	NC_000014.8:g.65453063G>C	2022-04-12 21:22:04 UTC	10.0	CA13941207					false
333	https://civicdb.org/links/variants/333	PTPRT	11122	Promoter Hypermethylation															N/A		2022-08-03 16:03:26 UTC	2.0						false
334	https://civicdb.org/links/variants/334	VEGFA	7422	Decreased Peri-therapeutic Expression			6	43738444	43752346			ENST00000372055.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
335	https://civicdb.org/links/variants/335	DNMT1	1786	EXPRESSION			19	10244022	10305811			ENST00000340748.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	18.0		N/A				false
336	https://civicdb.org/links/variants/336	KRAS	3845	Mutation			12	25362365	25403737			ENST00000256078.4	75	GRCh37					protein_altering_variant		2022-04-12 21:22:05 UTC	545.5		N/A				false
337	https://civicdb.org/links/variants/337	PDCD4	27250	EXPRESSION	A new study, a retrospective analysis of 77 patients, has implicated PDCD4 expression in the sensitivity to paclitaxel. However, this finding came from a large proteome screen and has not yet been replicated in independent patient sets.		10	112631596	112659763			ENST00000393104.2	75	GRCh37					N/A		2017-12-01 14:40:31 UTC	20.0		N/A				false
338	https://civicdb.org/links/variants/338	MGMT	4255	RS16906252			10	131265545	131265545	C	T	ENST00000306010.7	75	GRCh37					synonymous_variant	NC_000010.10:g.131265545C>T	2022-04-12 21:22:04 UTC	15.0	CA5747879					false
339	https://civicdb.org/links/variants/339	TFF3	7033	EXPRESSION			21	43731777	43735761			ENST00000518498.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
340	https://civicdb.org/links/variants/340	DKK1	22943	NUCLEAR EXPRESSION			10	54074056	54077417			ENST00000373970.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0						false
341	https://civicdb.org/links/variants/341	CD44	960	CD44s Expression			11	35160728	35251574			ENST00000428726.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
342	https://civicdb.org/links/variants/342	EGF	1950	EXPRESSION			4	110834047	110933422			ENST00000265171.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
343	https://civicdb.org/links/variants/343	MDM2	4193	EXPRESSION			12	69201956	69239214			ENST00000462284.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
344	https://civicdb.org/links/variants/344	HMOX1	3162	EXPRESSION			22	35776828	35790207			ENST00000216117.8	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
345	https://civicdb.org/links/variants/345	SPHK1	8877	OVEREXPRESSION			17	74380731	74383936			ENST00000323374.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
346	https://civicdb.org/links/variants/346	CASP8	841	Overexpression			2	202122759	202152434			ENST00000358485.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
347	https://civicdb.org/links/variants/347	TYMS	7298	Overexpression			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	40.0		N/A				false
348	https://civicdb.org/links/variants/348	PBK	55872	OVEREXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
349	https://civicdb.org/links/variants/349	SMARCA4	6597	Underexpression			19	11071598	11172958			ENST00000358026.2	75	GRCh37					N/A		2022-08-02 14:52:24 UTC	30.0		N/A				false
350	https://civicdb.org/links/variants/350	SETBP1	26040	Exon 4 Mutation			18	42531877	42531918			ENST00000282030.5	75	GRCh37					exon_variant		2022-04-12 21:22:01 UTC	15.0						false
351	https://civicdb.org/links/variants/351	SETBP1	26040	G870S			18	42531913	42531913	G	A	ENST00000282030.5	75	GRCh37					missense_variant	NM_015559.2:c.2608G>A,NP_056374.2:p.Gly870Ser,ENST00000282030.5:c.2608G>A,NC_000018.9:g.42531913G>A	2022-04-12 21:22:04 UTC	3.0	CA114719	1035	GLY870SER,RS267607040			false
352	https://civicdb.org/links/variants/352	ALK	238	EML4::ALK C1156Y-L1198F	EML4-ALK C1156Y alone is resistant to crizotinib in non-small cell lung cancer (NSCLC) which has been shown to be modulated (both increased sensitivity and resistance) by additional ALK mutations. A case report showed that an NSCLC harboring EML4-ALK C1156Y-L1198F was resistant to lorlatinib but this second mutation re-sensitized this tumor to crizotinib.		2	29443625	29445258			ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion		2022-02-17 21:32:01 UTC	20.0			EML4-ALK C1156Y-L1198F			false
354	https://civicdb.org/links/variants/354	EGFR	1956	Expression			7	55086794	55279321			ENST00000275493.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	60.0		N/A				false
355	https://civicdb.org/links/variants/355	CDKN1A	1026	EXPRESSION			6	36646487	36655108			ENST00000405375.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
356	https://civicdb.org/links/variants/356	ALCAM	214	EXPRESSION			3	105085753	105295744			ENST00000306107.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
357	https://civicdb.org/links/variants/357	STMN1	3925	EXPRESSION			1	26211931	26232957			ENST00000426559.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
358	https://civicdb.org/links/variants/358	RSF1	51773	Amplification			11	77371041	77532063			ENST00000308488.6	75	GRCh37					transcript_amplification		2022-08-02 22:57:41 UTC	10.0		N/A				false
359	https://civicdb.org/links/variants/359	AR	367	OVEREXPRESSION			X	66764465	66950461			ENST00000374690.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
360	https://civicdb.org/links/variants/360	CDKN1B	1027	CYTOPLASMIC MISLOCALIZATION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0						false
361	https://civicdb.org/links/variants/361	ERBB3	2065	EXPRESSION			12	56473645	56497289			ENST00000267101.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	6.0		N/A				false
362	https://civicdb.org/links/variants/362	AR	367	V7 EXPRESSION			X	66764662	66915917			ENST00000504326.1	75	GRCh37							2022-04-12 21:22:01 UTC	15.0						false
363	https://civicdb.org/links/variants/363	UGT1A	7361	EXPRESSION			2	234526291	234681956			ENST00000373450.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
364	https://civicdb.org/links/variants/364	ERBB4	2066	NUCLEAR TRANSLOCATION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0		N/A				false
365	https://civicdb.org/links/variants/365	ERBB4	2066	EXPRESSION			2	212240446	213403565			ENST00000342788.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	5.0		N/A				false
366	https://civicdb.org/links/variants/366	SLFN11	91607	EXPRESSION			17	33677324	33700639			ENST00000394566.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
367	https://civicdb.org/links/variants/367	RAC1	5879	P29S			7	6426892	6426892	C	T	ENST00000356142.4	75	GRCh37					missense_variant	ENST00000356142.4:c.85C>T,NC_000007.13:g.6426892C>T	2022-04-12 21:22:04 UTC	4.0	CA16602801	376362	PRO29SER			false
368	https://civicdb.org/links/variants/368	BIRC5	332	NUCLEAR EXPRESSION			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
369	https://civicdb.org/links/variants/369	TP53	7157	Wildtype			17	7571720	7590856			ENST00000269305.4	75	GRCh37					wild_type		2022-04-12 21:22:01 UTC	68.0		N/A				false
370	https://civicdb.org/links/variants/370	MRE11	4361	Loss			11	94152895	94227074			ENST00000323929.3	75	GRCh37					loss_of_function_variant		2022-08-03 16:04:33 UTC	2.0		N/A				false
371	https://civicdb.org/links/variants/371	TOP1	7150	Amplification			20	39657458	39753127			ENST00000361337.2	75	GRCh37					transcript_amplification		2022-08-02 14:36:15 UTC	5.0		N/A				false
372	https://civicdb.org/links/variants/372	CDKN1B	1027	EXPRESSION			12	12870058	12875305			ENST00000228872.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
373	https://civicdb.org/links/variants/373	AGR2	10551	EXPRESSION			7	16831435	16844704			ENST00000419304.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	5.0		N/A				false
374	https://civicdb.org/links/variants/374	NAPRT	93100	Promoter Hypermethylation															N/A		2022-08-03 16:03:09 UTC	3.0						false
375	https://civicdb.org/links/variants/375	EGFR	1956	Exon 18 Overexpression			7	55237999	55238735			ENST00000344576.2	75	GRCh37					exon_variant		2022-04-12 21:22:06 UTC	10.0		N/A				false
376	https://civicdb.org/links/variants/376	ZEB1	6935	Expression			10	31608101	31818741			ENST00000361642.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	5.0		N/A				false
377	https://civicdb.org/links/variants/377	TIMP1	7076	Overexpression			X	47441712	47446188			ENST00000218388.4	75	GRCh37					N/A		2022-08-02 14:22:44 UTC	12.0		N/A				false
378	https://civicdb.org/links/variants/378	PTP4A3	11156	OVEREXPRESSION			8	142402093	142441394			ENST00000521578.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
379	https://civicdb.org/links/variants/379	TYMS	7298	Amplification			18	657604	673578			ENST00000323274.10	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:06 UTC	15.0		N/A				false
380	https://civicdb.org/links/variants/380	IGF1R	3480	EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0		N/A				false
381	https://civicdb.org/links/variants/381	EPHB4	2050	EXPRESSION			7	100400187	100425121			ENST00000358173.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
382	https://civicdb.org/links/variants/382	TYMS	7298	Underexpression			18	657604	673578			ENST00000323274.10	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	20.0		N/A				false
383	https://civicdb.org/links/variants/383	TOP2A	7153	EXPRESSION			17	38544768	38574202			ENST00000423485.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
384	https://civicdb.org/links/variants/384	TOP1	7150	EXPRESSION			20	39657458	39753127			ENST00000361337.2	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	25.0		N/A				false
385	https://civicdb.org/links/variants/385	PRKAA2	5563	T172 PHOSPHORYLATION			1	57159476	57159478			ENST00000371244.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	0.5						false
386	https://civicdb.org/links/variants/386	HSPA5	3309	EXPRESSION			9	127997132	128003609			ENST00000324460.6	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	20.0		N/A				false
387	https://civicdb.org/links/variants/387	EIF4EBP1	1978	PHOSPHORYLATION			8	37888200	37914663			ENST00000338825.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	4.0						false
388	https://civicdb.org/links/variants/388	KIT	3815	Mutation			4	55524085	55606881			ENST00000288135.5	75	GRCh37					transcript_variant		2022-08-02 14:43:04 UTC	17.0		N/A				false
389	https://civicdb.org/links/variants/389	TUBB3	10381	EXPRESSION			16	89989687	90002505			ENST00000315491.7	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	12.0		N/A				false
390	https://civicdb.org/links/variants/390	EGFR	1956	Y1092 PHOSPHORYLATION	Although referred to as Y1068 in the literature, based on the recognition peptide described, this tyrosine occurs at Y1039 (ENST00000454757.2 v75) or Y1092 (ENST00000275493.2 v75).		7	55272951	55272953			ENST00000275493.2	75	GRCh37					N/A		2017-12-01 14:40:31 UTC	15.0			Y1039 PHOSPHORYLATION			false
391	https://civicdb.org/links/variants/391	IGF1R	3480	NUCLEAR EXPRESSION			15	99192200	99507759			ENST00000268035.6	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
392	https://civicdb.org/links/variants/392	CFLAR	8837	EXPRESSION			2	201980827	202041410			ENST00000309955.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
393	https://civicdb.org/links/variants/393	PROM1	8842	EXPRESSION			4	15969857	16085324			ENST00000510224.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0						false
394	https://civicdb.org/links/variants/394	FOXP3	50943	EXPRESSION			X	49106897	49121288			ENST00000376207.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
395	https://civicdb.org/links/variants/395	RPS6	6194	PHOSPHORYLATION			9	19376309	19376323			ENST00000380394.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0						false
396	https://civicdb.org/links/variants/396	JAK1	3716	OVEREXPRESSION			1	65298912	65432187			ENST00000342505.4	75	GRCh37					N/A		2022-12-13 00:46:45 UTC	11.5		N/A				false
397	https://civicdb.org/links/variants/397	BRCA1	672	Expression			17	41197646	41277500			ENST00000471181.2	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	2.0		N/A				false
398	https://civicdb.org/links/variants/398	DUSP6	1848	EXPRESSION			12	89741009	89747048			ENST00000279488.7	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	3.0		N/A				false
399	https://civicdb.org/links/variants/399	BRAF	673	Mutation			7	140453136	140481403			ENST00000288602.6	75	GRCh37					gene_variant,gain_of_function_variant		2022-04-12 21:22:06 UTC	151.0						false
400	https://civicdb.org/links/variants/400	HSPB1	3315	EXPRESSION			7	75931861	75933612			ENST00000248553.6	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
401	https://civicdb.org/links/variants/401	NQO1	1728	EXPRESSION			16	69743304	69760854			ENST00000320623.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0		N/A				false
402	https://civicdb.org/links/variants/402	NQO1	1728	P187S			16	69745145	69745145	G	A	ENST00000320623.5	75	GRCh37					missense_variant	NM_000903.2:c.559C>T,NP_000894.1:p.Pro187Ser,NC_000016.9:g.69745145G>A	2022-04-12 21:22:04 UTC	2.0	CA126904	16809	PRO187SER			false
403	https://civicdb.org/links/variants/403	BRCA1	672	Underexpression			17	41197646	41277500			ENST00000471181.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
405	https://civicdb.org/links/variants/405	CXCR4	7852	EXPRESSION			2	136871919	136873813			ENST00000409817.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
406	https://civicdb.org/links/variants/406	MAGEH1	28986	EXPRESSION			X	55478538	55479998			ENST00000342972.1	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0						false
407	https://civicdb.org/links/variants/407	ABCC3	8714	Amplification			17	48712218	48769613			ENST00000285238.8	75	GRCh37					transcript_amplification		2022-08-02 22:58:11 UTC	3.0		N/A				false
408	https://civicdb.org/links/variants/408	ABCC10	89845	Overexpression			6	43395292	43418168			ENST00000372530.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
409	https://civicdb.org/links/variants/409	ASNS	440	Amplification			7	97481430	97501854			ENST00000175506.4	75	GRCh37					transcript_amplification		2022-08-02 22:58:22 UTC	2.0		N/A				false
410	https://civicdb.org/links/variants/410	CDX2	1045	EXPRESSION			13	28536274	28545276			ENST00000381020.7	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
411	https://civicdb.org/links/variants/411	STAT3	6774	SH2 DOMAIN MUTATION			17	40465342	40475372			ENST00000264657.5	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	20.0						false
412	https://civicdb.org/links/variants/412	POU5F1	5460	EXPRESSION			6	31132120	31138470			ENST00000259915.8	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
413	https://civicdb.org/links/variants/413	ERBB2	2064	Kinase Domain Mutation			17	37879863	37882870			ENST00000269571.5	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	17.5		N/A				false
414	https://civicdb.org/links/variants/414	ERBB2	2064	Y772_A775DUP	Mutations in the HER2 kinase domain occur at a 2-4% frequency in lung adenocarcinomas, the majority of which are in exon 20 as in-frame duplications or insertions in a small 8 codon region (774-781 or 775-782). These are analogous to the exon 20 alterations found in EGFR TK domain. The M774 insertion, M774insAYVM, represents 62.5% of all HER2 kinase domain mutations identified (when combined with the A775insYVMA mutations as they translate to the identical amino acid sequence changes). As demonstrated in mouse models (Perrera et al., PNAS 2009) and subsequent clinical trials in human lung adenocarcinoma with these insertions, HER2 YVMA mutants predict response to several targeted HER2 agonists such as afatinib, trastuzumab, neratinib and TDM-1 (trastuzumab emtansine) as monotherapy or combined with specific chemotherapies.		17	37880996	37880997		TACGTGATGGCT	ENST00000269571.5	75	GRCh37					inframe_insertion	NM_001005862.2:c.2224_2235dupTACGTGATGGCT,ENST00000269571.5:c.2314_2325dupTACGTGATGGCT,NC_000017.10:g.37880985_37880996dupTACGTGATGGCT,NC_000017.10:g.37880993_37880994insGCTTACGTGATG	2018-11-30 14:45:23 UTC	36.0	CA135369	44985	A775INSYVMA,P.A775_G776INSYVMA,P.E770_A771INSAYVM,TYR772_ALA775DUP,A775_G776INSYVMA,M774INSAYVM			false
415	https://civicdb.org/links/variants/415	EGFR	1956	C797S			7	55249091	55249091	T	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2389T>A,NC_000007.13:g.55249091T>A,NM_005228.4:c.2389T>A,NP_005219.2:p.Cys797Ser	2022-04-12 21:22:02 UTC	17.5	CA16602785	376342	CYS797SER,RS1057519861			false
416	https://civicdb.org/links/variants/416	ERBB2	2064	SERUM LEVELS			17	37856333	37884915			ENST00000269571.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	35.0		NONE FOUND				false
417	https://civicdb.org/links/variants/417	THBS2	7058	UNDEREXPRESSION			6	169615875	169654139			ENST00000366787.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
419	https://civicdb.org/links/variants/419	NTRK1	4914	Fusion		NTRK1 Fusions	1	156844175	156851434			ENST00000524377.1	75	GRCh37					transcript_fusion		2022-12-02 18:09:41 UTC	85.0		N/A		8	https://civicdb.org/links/assertions/8	false
420	https://civicdb.org/links/variants/420	IDH1	3417	R132H	IDH1 R132 mutations have been observed in a number of cancer types, and appear to behave quite differently in different environments. In myelodysplastic syndromes and acute myeloid leukemia (AML), IDH1 R132 mutations have been shown to be associated with worse outcome and shorter overall survival. They have also been linked to cytogenetically normal AML, an intermediate risk subtype of the disease. However, in glioblastoma and astrocytoma, patients with IDH1 mutations have shown better overall survival than patients with wild-type IDH1. Also in contrast to AML, in glioblastoma, IDH1 mutations have been associated with the specific cytogenetic abnormalities, 1p and 19q deletions.		2	209113112	209113112	C	T	ENST00000415913.1	75	GRCh37					missense_variant	NM_001282386.1:c.395G>A,NP_005887.2:p.Arg132His,NC_000002.11:g.209113112C>T,ENST00000415913.1:c.395G>A	2018-11-30 14:43:24 UTC	9.0	CA170874	156444	ARG132HIS,RS121913500			false
421	https://civicdb.org/links/variants/421	TERT	7015	RS2736100			5	1286516	1286516	C	A	ENST00000310581.5	75	GRCh37					coding_transcript_intron_variant,polymorphic_sequence_variant	NC_000005.9:g.1286516C>A,ENST00000310581.5:c.1574-3777G>T,NM_001193376.1:c.1574-3777G>T,NP_001180305.1:p.=	2022-04-12 21:22:04 UTC	10.0	CA11915794	375480				false
422	https://civicdb.org/links/variants/422	STAG2	10735	Underexpression			X	123095568	123236506			ENST00000371157.3	75	GRCh37					N/A		2022-08-02 23:12:52 UTC	14.0		N/A				false
423	https://civicdb.org/links/variants/423	HLA-DRA	3122	EXPRESSION			6	32407619	32412823			ENST00000395388.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0						false
424	https://civicdb.org/links/variants/424	MYD88	4615	L265P			3	38182641	38182641	T	C	ENST00000396334.3	75	GRCh37					missense_variant,gain_of_function_variant	NC_000003.11:g.38182641T>C	2022-04-12 21:22:04 UTC	31.0	CA130043	37055	LEU265PRO,L273P,LEU273PRO			false
425	https://civicdb.org/links/variants/425	KRAS	3845	G12V	KRAS mutations are the most common mutations in pancreatic cancer occurring in > 90% of cases. Of these the G12D activating mutation is the most prevalent and results in a loss of GTPase activity which in turn leads to a constitutively active form of KRAS. This is enough to cause pre-cancerous pancreatic intraepithelial lesions		12	25398284	25398284	C	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.35G>T,NP_004976.2:p.Gly12Val,NC_000012.11:g.25398284C>A,ENST00000256078.4:c.35G>T	2021-02-24 00:58:45 UTC	67.5	CA122540	12583	GLY12VAL,RS121913529			false
426	https://civicdb.org/links/variants/426	BRAF	673	WILD TYPE			7	140434279	140624564			ENST00000288602.6	75	GRCh37					wild_type	N/A	2022-04-12 21:22:02 UTC	10.0		N/A				false
427	https://civicdb.org/links/variants/427	NRAS	4893	Q61K			1	115256530	115256530	G	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.181C>A,NP_002515.1:p.Gln61Lys,NC_000001.10:g.115256530G>T,ENST00000369535.4:c.181C>A	2022-04-12 21:22:02 UTC	24.5	CA151263	73058	GLN61LYS,RS121913254			false
428	https://civicdb.org/links/variants/428	MRE11	4361	Frameshift			11	94152895	94227074			ENST00000323929.3	75	GRCh37					frameshift_variant		2022-08-02 23:08:34 UTC	10.0						false
429	https://civicdb.org/links/variants/429	KIT	3815	EXPRESSION			4	55524085	55606881			ENST00000288135.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
431	https://civicdb.org/links/variants/431	CBFB	865	CBFB::MYH11	CBFB-MYH11 is the result of inv(16)(p13q22) or t(16;16)(p13;q22) and is sufficient for the diagnosis of acute myeloid leukemia (in the correct setting) according to WHO criteria, even when blast counts are <20% (Vardiman et al, Blood 2008). This fusion is typically associated with favorable prognosis relative to other AML subtypes (including cytogenetically normal); however, the impact of additional mutations in the context of this fusion is incompletely understood. AMLs with this fusion are often grouped with other rearrangements affecting genes encoding core binding factor subunits, referred to as CBF AMLs.		16	67063148	67116211			ENST00000412916.2	75	GRCh37	16	15797029	15820911	ENST00000396324.3	transcript_fusion		2022-03-11 04:15:20 UTC	20.0		N/A	INV(16)(P13.1;Q22),T(16;16)(P13.1;Q22),CBFB-MYH11			false
432	https://civicdb.org/links/variants/432	KMT2A	4297	KMT2A::MLLT3															transcript_fusion		2022-04-12 21:22:02 UTC	40.0			T(9;11)(P22;Q23),MLL-MLLT3,KMT2A-MLLT3,MLL::MLLT3,T(9;11)(P21.3;Q23.3)	16	https://civicdb.org/links/assertions/16	false
433	https://civicdb.org/links/variants/433	HIF1A	3091	3' UTR Polymorphism			14	62213848	62213848	T	C	ENST00000394997.1	75	GRCh37					3_prime_UTR_variant,SNP	NC_000014.8:g.62213848T>C	2022-04-12 21:22:04 UTC	10.0	CA7216212					false
434	https://civicdb.org/links/variants/434	HIF1A	3091	OVEREXPRESSION			14	62162258	62214976			ENST00000394997.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	25.0		N/A				false
435	https://civicdb.org/links/variants/435	EPAS1	2034	Overexpression			2	46524541	46613836			ENST00000263734.3	75	GRCh37					N/A		2022-08-02 14:20:18 UTC	25.0		N/A				false
436	https://civicdb.org/links/variants/436	VHL	7428	Loss			3	10182692	10193904			ENST00000256474.2	75	GRCh37					loss_of_function_variant	N/A	2022-08-03 16:03:43 UTC	23.0		N/A				false
437	https://civicdb.org/links/variants/437	FLT3	2322	D835			13	28592642	28592642	C	A	ENST00000241453.7	75	GRCh37					protein_altering_variant	NC_000013.10:g.28592642C>A	2022-04-12 21:22:02 UTC	46.0	CA126347	16276		33	https://civicdb.org/links/assertions/33	false
438	https://civicdb.org/links/variants/438	PSMB8	5696	NUCLEAR EXPRESSION			6	32808494	32812480			ENST00000374881.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
439	https://civicdb.org/links/variants/439	PBK	55872	NUCLEAR EXPRESSION			8	27667137	27695612			ENST00000301905.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
440	https://civicdb.org/links/variants/440	PTTG1	9232	OVEREXPRESSION			5	159848829	159855748			ENST00000352433.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
441	https://civicdb.org/links/variants/441	LEPR	3953	UNDEREXPRESSION			1	65886335	66107242			ENST00000349533.6	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
442	https://civicdb.org/links/variants/442	EGFR	1956	Mutation			7	55086794	55279321			ENST00000275493.2	75	GRCh37					inframe_variant		2022-04-12 21:22:03 UTC	280.0		N/A				false
443	https://civicdb.org/links/variants/443	EGFR	1956	G465R		ECD MUTATION	7	55227926	55227926	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1393G>A,NC_000007.13:g.55227926G>A,NM_005228.3:c.1393G>A,NP_005219.2:p.Gly465Arg	2022-04-12 21:22:02 UTC	20.0	CA367579504	NONE FOUND	GLY465ARG			false
444	https://civicdb.org/links/variants/444	NEDD9	4739	EXPRESSION			6	11185051	11382581			ENST00000504387.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
445	https://civicdb.org/links/variants/445	ETS2	2114	RS461155			21	40191638	40191638	A	G	ENST00000360214.3	75	GRCh37					synonymous_variant	NC_000021.8:g.40191638A>G,NM_005239.5:c.1023A>G,ENST00000360214.3:c.1023A>G,NP_005230.1:p.Pro341=	2022-04-12 21:22:04 UTC	10.0	CA10025650	NONE FOUND	P341P,P481P,PRO341=			false
446	https://civicdb.org/links/variants/446	KRT18	3875	UNDEREXPRESSION			12	53342655	53346684			ENST00000388837.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
447	https://civicdb.org/links/variants/447	FGF13	2258	CYTOPLASMIC EXPRESSION			X	137715011	138286269			ENST00000370603.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
448	https://civicdb.org/links/variants/448	SSX1	6756	SS18::SSX1		SYT-SSX fusions													transcript_fusion	N/A	2022-04-12 21:22:02 UTC	145.0		N/A	T(X;18)(P11.23;Q11),SS18-SSX1			false
449	https://civicdb.org/links/variants/449	SSX2	6757	SS18::SSX2		SYT-SSX fusions													transcript_fusion	N/A	2022-04-12 21:22:02 UTC	85.0		N/A	T(X;18)(P11.21;Q11),SS18-SSX2			false
450	https://civicdb.org/links/variants/450	SSX4	6759	SS18::SSX4		SYT-SSX fusions	18	23612363	23670589			ENST00000415083.2	75	GRCh37	X	48261524	48265521	ENST00000376884.2	transcript_fusion		2022-04-12 21:22:01 UTC	5.0			SS18-SSX4			false
451	https://civicdb.org/links/variants/451	ABCB1	5243	S893A/T	Refer to  https://www.pharmgkb.org/rsid/rs2032582  for more information.		7	87160618	87160618	A	C	ENST00000265724.3	75	GRCh37					missense_variant	NC_000007.13:g.87160618A>C	2018-11-30 14:42:57 UTC	15.0	CA179699	166619,166622	RS2032582			false
453	https://civicdb.org/links/variants/453	EGFR	1956	S492R		ECD MUTATION	7	55228009	55228009	C	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1476C>A,NC_000007.13:g.55228009C>A,NP_005219.2:p.Ser492Arg,NM_005228.4:c.1476C>A	2022-04-12 21:22:01 UTC	23.0	CA16602784	376341	SER492ARG,RS1057519860			false
454	https://civicdb.org/links/variants/454	EGFR	1956	R451C			7	55227884	55227884	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1351C>T,NC_000007.13:g.55227884C>T,NM_001346898.1:c.1351C>T,NP_001333827.1:p.Arg451Cys	2022-04-12 21:22:01 UTC	2.0	CA158917074	NONE FOUND	ARG451CYS,RS377567759			false
455	https://civicdb.org/links/variants/455	EGFR	1956	K467T		ECD MUTATION	7	55227933	55227933	A	C	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.1400A>C,NC_000007.13:g.55227933A>C,NM_005228.3:c.1400A>C,NP_005219.2:p.Lys467Thr	2022-04-12 21:22:04 UTC	6.0	CA367579521	NONE FOUND	LYS467THR			false
456	https://civicdb.org/links/variants/456	FCGR2A	2212	H167R			1	161479745	161479745	A	G	ENST00000271450.6	75	GRCh37					missense_variant	NM_001136219.1:c.500A>G,NP_001129691.1:p.His167Arg,ENST00000271450.6:c.500A>G,NC_000001.10:g.161479745A>G	2022-04-12 21:22:04 UTC	35.0	CA124361	14823	RS1801274,H131R,H166R,HIS167ARG			false
457	https://civicdb.org/links/variants/457	FCGR3A	2214	F212V			1	161514542	161514542	A	C	ENST00000367969.3	75	GRCh37					missense_variant	NC_000001.10:g.161514542A>C,NM_001127593.1:c.526T>G,NP_001121065.1:p.Phe176Val,ENST00000367969.3:c.526T>G	2022-04-12 21:22:04 UTC	35.0	CA1211378	225994	RS396991,V158F,PHE176VAL			false
458	https://civicdb.org/links/variants/458	FCGR2B	2213	I232T			1	161643798	161643798	T	C	ENST00000358671.5	75	GRCh37					missense_variant	NM_004001.4:c.695T>C,NP_003992.3:p.Ile232Thr,ENST00000358671.5:c.695T>C,NC_000001.10:g.161643798T>C	2022-04-12 21:22:04 UTC	20.0	CA117549	5467	RS1050501,ILE232THR			false
460	https://civicdb.org/links/variants/460	EGFR	1956	P753S			7	55242487	55242487	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2257C>T,NC_000007.13:g.55242487C>T,NM_005228.4:c.2257C>T,NP_005219.2:p.Pro753Ser	2022-04-12 21:22:04 UTC	7.5	CA4266020	376081	PRO753SER,RS121913231			false
461	https://civicdb.org/links/variants/461	PML	5371	B2 DOMAIN MUTATION	The B2 domain in PML is the binding site for ATRA. Point mutations in this region have been associated with ATRA resistance in patients with APL.	PML-RARa B2 Domain	15	74315213	74315219			ENST00000268058.3	75	GRCh37					missense_variant		2017-12-01 14:40:32 UTC	20.0						false
462	https://civicdb.org/links/variants/462	PML	5371	PML::RARA A216V	A216V in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315213	74315213	C	T	ENST00000268058.3	75	GRCh37					missense_variant,transcript_fusion	NC_000015.9:g.74315213C>T	2022-03-10 20:59:25 UTC	30.0	CA393121894	NONE FOUND	PML-RARA A216V			false
463	https://civicdb.org/links/variants/463	PML	5371	PML::RARA L218P	L218P in the B2 domain of PML is one of the variants found in a patient with ATRA-resistant APL.	PML-RARa B2 Domain	15	74315219	74315219	T	C	ENST00000268058.3	75	GRCh37					missense_variant,transcript_fusion	NC_000015.9:g.74315219T>C	2022-03-10 21:00:52 UTC	7.5	CA393121927	NONE FOUND	PML-RARA L218P			false
464	https://civicdb.org/links/variants/464	MET	4233	EXON 14 MUTATION and AMPLIFICATION			7	116312459	116436396			ENST00000318493.6	75	GRCh37					exon_loss_variant,transcript_amplification		2022-04-12 21:22:01 UTC	7.5		N/A				false
465	https://civicdb.org/links/variants/465	ROS1	6098	CD74::ROS1 G2032R	The G2032R missense mutation has been observed in patients with crizotinib-resistant non-small cell lung cancer harboring CD74-ROS1 rearrangement. Independent in vitro studies have confirmed that this mutation confers marked resistance to crizotinib cells over CD74-ROS1 alone. Multiple groups have indicated CD74-ROS1 G2032R expressing cell lines are sensitive to both cabozantinib and foretinib individually administered in vitro. One group additionally showed this mutation conferred relative resistance to alectinib, brigatinib, ceritinib, and AZD3463 in vitro.		6	117638347	117638347	C	T	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	NC_000006.11:g.117638347C>T	2022-03-11 04:13:17 UTC	31.5	CA16602597	376139	CD74-ROS1 G2032R			false
466	https://civicdb.org/links/variants/466	FGFR1	2260	ZNF198::FGFR1															transcript_fusion		2022-04-12 21:22:02 UTC	10.0		N/A	T(8;13)(P11;Q12),ZNF198-FGFR1			false
467	https://civicdb.org/links/variants/467	KDR	3791	A1065T			4	55955969	55955969	C	T	ENST00000263923.4	75	GRCh37					missense_variant	NM_002253.2:c.3193G>A,NP_002244.1:p.Ala1065Thr,ENST00000263923.4:c.3193G>A,NC_000004.11:g.55955969C>T	2022-04-12 21:22:04 UTC	3.0	CA2924178	NONE FOUND	ALA1065THR,RS56302315			false
468	https://civicdb.org/links/variants/468	KDR	3791	D717V			4	55968180	55968180	T	A	ENST00000263923.4	75	GRCh37					missense_variant	ENST00000263923.4:c.2150A>T,NC_000004.11:g.55968180T>A	2022-04-12 21:22:04 UTC	3.0	CA356908090	NONE FOUND	ASP717VAL			false
469	https://civicdb.org/links/variants/469	TSC2	7249	Q1178*			16	2130300	2130300	C	T	ENST00000219476.3	75	GRCh37					stop_gained	NM_000548.4:c.3532C>T,NP_000539.2:p.Gln1178Ter,ENST00000219476.3:c.3532C>T,NC_000016.9:g.2130300C>T	2022-04-12 21:22:04 UTC	12.5	CA019253	49263	Q1178X,GLN1178TER,RS45517297			false
470	https://civicdb.org/links/variants/470	MTOR	2475	F2108L			1	11187094	11187094	G	T	ENST00000361445.4	75	GRCh37					missense_variant	ENST00000361445.4:c.6324C>A,NC_000001.10:g.11187094G>T	2022-04-12 21:22:02 UTC	16.5	CA338391533	NONE FOUND	PHE2108LEU			false
471	https://civicdb.org/links/variants/471	RAD51D	5892	R186*			17	33433425	33433425	G	A	ENST00000345365.6	75	GRCh37					stop_gained	NC_000017.10:g.33433425G>A	2022-04-12 21:22:04 UTC	5.0	CA129082	30285	R186X,ARG186TER,RS387906843			false
472	https://civicdb.org/links/variants/472	ALDH1A2	8854	Overexpression			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	30.0		N/A				false
473	https://civicdb.org/links/variants/473	ALDH1A2	8854	Underexpression			15	58245622	58358616			ENST00000249750.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	2.0		N/A				false
474	https://civicdb.org/links/variants/474	CIP2A	57650	EXPRESSION			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
475	https://civicdb.org/links/variants/475	CIP2A	57650	Underexpression			3	108268716	108308299			ENST00000295746.8	75	GRCh37					N/A		2022-08-03 16:00:55 UTC	3.0		N/A				false
476	https://civicdb.org/links/variants/476	MIR218-1	407000	EXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
477	https://civicdb.org/links/variants/477	BRCA1	672	P968FS			17	41244645	41244646		GA	ENST00000471181.2	75	GRCh37					frameshift_truncation	NM_007294.3:c.2902_2903insTC,NP_009225.1:p.Pro968Leufs,NC_000017.10:g.41244645_41244646insGA,ENST00000471181.2:c.2902_2903insTC	2022-04-12 21:22:03 UTC	20.0	CA001889	91602	3021INSTC,PRO968LEUFS,RS398122670			false
479	https://civicdb.org/links/variants/479	KRAS	3845	Q22*			12	25398255	25398255	G	A	ENST00000256078.4	75	GRCh37					stop_gained	ENST00000256078.4:c.64C>T,NC_000012.11:g.25398255G>A,NM_004985.4:c.64C>T,NP_004976.2:p.Gln22Ter	2022-04-12 21:22:01 UTC	5.0	CA384157370	NONE FOUND	Q22X,GLN22TER			false
481	https://civicdb.org/links/variants/481	DDX43	55510	Overexpression			6	74104471	74127292			ENST00000370336.4	75	GRCh37					N/A		2022-08-02 22:51:40 UTC	4.0		N/A				false
482	https://civicdb.org/links/variants/482	KIT	3815	RS3733542			4	55602765	55602765	G	C	ENST00000288135.5	75	GRCh37					synonymous_variant	NM_000222.2:c.2586G>C,NP_000213.1:p.Leu862=,ENST00000288135.5:c.2586G>C,NC_000004.11:g.55602765G>C	2022-04-12 21:22:01 UTC	5.0	CA2923796	255572	LEU862=			false
483	https://civicdb.org/links/variants/483	TBK1	29110	Overexpression			12	64845660	64895888			ENST00000331710.5	75	GRCh37					N/A		2022-08-02 22:55:11 UTC	2.0		N/A				false
485	https://civicdb.org/links/variants/485	STK11	6794	Loss			19	1205740	1228428			ENST00000326873.7	75	GRCh37					loss_of_function_variant		2022-08-03 16:03:33 UTC	23.0		N/A				false
486	https://civicdb.org/links/variants/486	HAVCR2	84868	Overexpression			5	156512843	156536725			ENST00000307851.4	75	GRCh37					N/A		2022-08-02 22:51:11 UTC	10.5		N/A				false
487	https://civicdb.org/links/variants/487	MMP2	4313	SERUM LEVELS			16	55512883	55540603			ENST00000219070.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	25.0						false
488	https://civicdb.org/links/variants/488	MMP9	4318	SERUM LEVELS			20	44637547	44645200			ENST00000372330.3	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0						false
490	https://civicdb.org/links/variants/490	HSPH1	10808	NUCLEAR EXPRESSION			13	31710765	31736064			ENST00000320027.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	11.0						false
491	https://civicdb.org/links/variants/491	HSPH1	10808	T17 DELETION			13	31722621	31722637			ENST00000320027.5	75	GRCh37					short_tandem_repeat_variation		2022-04-12 21:22:01 UTC	10.0						false
492	https://civicdb.org/links/variants/492	ECSCR	641700	EXPRESSION															N/A		2022-04-12 21:22:01 UTC	5.0						false
493	https://civicdb.org/links/variants/493	ROBO4	54538	EXPRESSION			11	124753587	124768177			ENST00000306534.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	5.0						false
494	https://civicdb.org/links/variants/494	PIM1	5292	NUCLEAR EXPRESSION			6	37137979	37143202			ENST00000373509.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
495	https://civicdb.org/links/variants/495	MDM2	4193	SNP309			12	69202580	69202580	T	G	ENST00000462284.1	75	GRCh37					coding_transcript_intron_variant	NC_000012.11:g.69202580T>G	2022-04-12 21:22:04 UTC	10.0	CA123622	13904				false
496	https://civicdb.org/links/variants/496	ERBB2	2064	L866M	This mutation was shown to be an activating mutation and conferred sensitivity to a combination of trastuzumab with neratinib or lapatinib in colorectal cancer patient-derived xenografts.		17	37881404	37881404	C	A	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2596C>A,NC_000017.10:g.37881404C>A,NM_001289937.1:c.2596C>A,NP_001276866.1:p.Leu866Met	2018-11-30 14:43:11 UTC	4.0	CA399304874	NONE FOUND	LEU866MET			false
497	https://civicdb.org/links/variants/497	ERBB2	2064	S310F/Y	ERBB2 S310F/Y was one of the first ERBB2 variants to be functionally classified (Greulich et al. 2012). This mutation was shown to be an activating mutation (through hyperphosphorylation) in an in vitro assay. In the same paper, this mutation (along with other ERBB2 activating mutations) in murine Ba/F3 cells have been shown to be sensitive to the ERBB2 inhibitors (afatinib, lapatinib and neratinib). More recent evidence may show that HER2 acitivating mutations confer sensitivity to a host of tyrosine kinase inhibitors, which is the topic of current clinical trials and research.		17	37868208	37868208			ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.929C>T,NC_000017.10:g.37868208C>T	2022-04-14 15:37:27 UTC	4.0		376189,376188				false
498	https://civicdb.org/links/variants/498	MIR218-1	407000	UNDEREXPRESSION			4	20529898	20530007			ENST00000384999.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
499	https://civicdb.org/links/variants/499	ALK	238	Fusion	Following the initial discovery and characterization of NPM-ALK fusion mutation in anaplastic large cell lymphoma (ALCL), EML4-ALK fusions were found to be driver mutations in a subset of lung adenocarcinomas. ALK fusions bring the C-terminal ALK kinase domain together with the N terminal region of the fusion partner, and have since been found in a range of cancers including inflammatory myofibroblastic tumor, renal cell carcinoma, diffuse large B cell lymphoma and colorectal cancer. In a Phase I trial for crizotinib, a 92% response rate was seen in the subset of patients with a specific EML4-ALK variant, which was higher than the 57% rate in the overall ALK-rearranged population, but the subpopulation numbers were insufficient to correlate variant type with patient response. Due to restricted wild-type ALK expression, and also mild phenotypes seen in ALK knockout mice, ALK fusions are desirable targets. ALK inhibitor TAE684 was used in initial characterizations of ALK fusion cancer drivers, and crizotinib ‚Äì a small molecule ATP-competitor RTK inhibitor which is highly selective for ALK and MET - has been approved as first line therapy in ALK-rearranged NSCLC. ALK-rearrangement defines an NSCLC subtype that makes up 3-5% of NSCLC cases, and is characterized by higher proportions of younger patients and never smokers. EML4-ALK variant 1 is the most common ALK fusion in NSCLC and was the first to be discovered and demonstrate cancer driver properties in vitro and in mouse models. A Phase I study of crizotinib in ALK-rearranged NSCLC demonstrated an increase in overall survival when compared to standard chemotherapy. These and other initial results prompted accelerated approval for crizotinib in NSCLC. Continued clinical work demonstrated benefit with crizotinib over chemotherapy in multi-armed studies, and as first line therapy. Crizotinib was also found to remain beneficial to NSCLC patients who had progressed on crizotinib. Additionally, crizotinib was shown to increase intracranial disease control in brain metastasis occurring from ALK-rearranged NSCLC.	ALK Fusions	2	29415640	29446394			ENST00000389048.3	75	GRCh37					transcript_fusion		2021-04-07 18:03:23 UTC	648.0		N/A	REARRANGEMENT	34,3	https://civicdb.org/links/assertions/34	https://civicdb.org/links/assertions/3	false
500	https://civicdb.org/links/variants/500	ALK	238	EML4::ALK e20-e20	EML4-ALK variant 2 consists of a fusion of the ALK kinase domain (exons 20-29) with EML4 exons 1-20. Variant 2 has cytoplasmic distribution and makes up ~10% of EML4-ALK fusions found in NSCLC,. Although the specific variant is not consistently reported, single cases demonstrating response to crizotinib treatment in NSCLC and a differentiated malignant neoplasm of unknown origin have been reported. In vitro, this variant has shown greater sensitivity to ALK inhibition with TAE684 and crizotinib than the EML4-ALK variants 1 (E13;A20), 3a (E6;A20) and 3b (E6ins33;A20). The variant was reported to be less stable in cells than other variants, and may be a client protein of Hsp90. Along these lines the variant has shown preclinical sensitivity to Hsp90 inhibition.	ALK Fusions	2	42396490	42552694			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-02-17 22:26:53 UTC	16.5		N/A	EML4-ALK E20-E20			false
501	https://civicdb.org/links/variants/501	ALK	238	EML4::ALK e2-e20		ALK Fusions	2	42396490	42472827			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-04-12 21:22:06 UTC	1.75		N/A	EML4-ALK E2-E20			false
502	https://civicdb.org/links/variants/502	KDR	3791	R961W			4	55961059	55961059	G	A	ENST00000263923.4	75	GRCh37					missense_variant	NM_002253.2:c.2881C>T,NP_002244.1:p.Arg961Trp,ENST00000263923.4:c.2881C>T,NC_000004.11:g.55961059G>A	2022-04-12 21:22:04 UTC	2.5	CA2924278	NONE FOUND	ARG961TRP,RS530419081			false
503	https://civicdb.org/links/variants/503	ALK	238	EML4::ALK e6-e20	The EML4-ALK variant 3a consists of the ALK kinase domain fused to EML4 exons 1-6, while the 3b variant has an additional 33bp of intronic EML4 sequence between EML4 and ALK regions. The two variants were found to originate from a single genomic rearrangement, and 3a/3b is found in ~ 30% of EML4-ALK positive NSCLC. Variant 3a has cytoplasmic and nuclear distribution. In vitro, these variants have shown sensitivity to ALK inhibitors TAE684 and crizotinib but less sensitive than other EML4-ALK variants. The H2228 cell line contains 3a and 3b variants and is described as having cyctostatic response to ALK inhibition as opposed to apoptotic. In a study of 31 NSCLC patients with EML4-ALK rearrangements, 4/5 patients with the 3a variant showed a partial response while 1 showed progressive disease (the only PD observed). In cells the 3a variant was reported to be more stable than other variants, less sensitive to crizotinib and not to respond to Hsp90 inhibition.	ALK Fusions	2	42396490	42491871			ENST00000318522.5	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-02-17 22:37:10 UTC	25.0		N/A	EML4-ALK E6-E20			false
504	https://civicdb.org/links/variants/504	TP53	7157	P47S			17	7579548	7579548	G	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.139C>T,NP_000537.3:p.Pro47Ser,NC_000017.10:g.7579548G>A,ENST00000269305.4:c.139C>T	2022-04-12 21:22:02 UTC	0.5	CA000053	43588	PRO47SER,RS1800371			false
505	https://civicdb.org/links/variants/505	GNAQ	2776	Mutation			9	80331003	80646374			ENST00000286548.4	75	GRCh37							2022-08-02 23:02:16 UTC	26.0						false
506	https://civicdb.org/links/variants/506	GNA11	2767	Mutation			19	3094408	3124002			ENST00000078429.4	75	GRCh37							2022-08-02 23:02:41 UTC	24.0						false
507	https://civicdb.org/links/variants/507	GNAQ	2776	Q209			9	80409487	80409489			ENST00000286548.4	75	GRCh37					protein_altering_variant		2022-04-12 21:22:01 UTC	20.0		375957,375956,375955	GLN209			false
508	https://civicdb.org/links/variants/508	PMS2	5395	K706FS*19			7	6022512	6022512			ENST00000265849.7	75	GRCh37					minus_1_frameshift_variant	NM_000535.6:c.2117delA,NP_000526.2:p.Lys706Serfs,NC_000007.13:g.6022512del	2022-04-15 13:56:43 UTC	10.0		142765	RS587782704,LYS706SERFS			false
509	https://civicdb.org/links/variants/509	KIT	3815	Exon 9 Mutation	In patients with gastrointestinal stromal tumors (GIST), imatinib has improved outcomes for patients with KIT mutations. However, acquired resistance to imatinib is common. Patients harboring exon 9 KIT mutations may benefit from higher imatinib doses (800mg/daily). Similarly, imatinib-refractory tumors showed sensitivity to sunitinib treatment. Improved responses to either treatment were not observed in patients with exon 11 mutations.		4	55592023	55592216			ENST00000288135.5	75	GRCh37					exon_variant		2021-02-26 00:06:31 UTC	102.5						false
510	https://civicdb.org/links/variants/510	PTEN	5728	Mutation			10	89622870	89731687			ENST00000371953.3	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	31.0		N/A				false
511	https://civicdb.org/links/variants/511	FGFR2	2263	Mutation			10	123239371	123357917			ENST00000457416.2	75	GRCh37					transcript_variant,gain_of_function_variant		2022-04-12 21:22:02 UTC	8.0		376157,376156,376317,13272				false
512	https://civicdb.org/links/variants/512	ALK	238	Mutation			2	29415640	30144432			ENST00000389048.3	75	GRCh37					gene_variant,gain_of_function_variant		2022-04-12 21:22:02 UTC	20.0		N/A				false
513	https://civicdb.org/links/variants/513	ALK	238	NPM::ALK		ALK Fusions	5	170814120	170818803			ENST00000517671.1	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-04-12 21:22:02 UTC	27.0		N/A	T(2;5)(P23;Q35),NPM-ALK			false
514	https://civicdb.org/links/variants/514	ALK	238	RANBP2::ALK		ALK Fusions	2	109335937	109375004			ENST00000283195.6	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-04-12 21:22:02 UTC	10.0		N/A	RANBP2-ALK			false
515	https://civicdb.org/links/variants/515	FGFR1	2260	N546K			8	38274849	38274849	G	T	ENST00000341462.5	75	GRCh37					missense_variant	NM_023110.2:c.1638C>A,NP_075598.2:p.Asn546Lys,ENST00000341462.5:c.1638C>A,NC_000008.10:g.38274849G>T	2022-05-11 16:48:16 UTC	8.0	CA357830	224896	ASN546LYS,RS779707422			false
516	https://civicdb.org/links/variants/516	ROS1	6098	CD74::ROS1 L2026M	The L2026M mutation is considered a gatekeeper mutation located in the inhibitor binding pocket of ROS1 and corresponding to L1196M in ALK and T790M in EGFR. This mutation has not been reportedly observed in a patient but inferred as a variant likely to emerge in crizotinib-resistant tumors. In vitro kinase activity, structural predictions and growth inhibition assays indicate the L2026M mutation in the CD74-ROS1 fusion provides crizotinib resistance. Additional preclinical assays have indicated that crizotinib resistant cells harboring this mutation are sensitive to PF-06463922 and foretinib.		6	117638365	117638365	G	T	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	NC_000006.11:g.117638365G>T,ENST00000368508.3:c.6076C>A,NM_002944.2:c.6076C>A,NP_002935.2:p.Leu2026Met	2022-03-10 19:58:01 UTC	9.0	CA365441006	NONE FOUND	CD74-ROS1 L2026M			false
517	https://civicdb.org/links/variants/517	ROS1	6098	CD74::ROS1 L2155S			6	117630062	117630062	A	G	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	NC_000006.11:g.117630062A>G,NM_002944.2:c.6464T>C,NP_002935.2:p.Leu2155Ser,ENST00000368508.3:c.6464T>C	2022-04-12 21:22:04 UTC	3.0	CA365440144	NONE FOUND	CD74-ROS1 L2155S,CD74::ROS1 L2149S,CD74-ROS1 L2149S			false
518	https://civicdb.org/links/variants/518	ROS1	6098	CD74::ROS1 G2101A			6	117631376	117631376	C	G	ENST00000368508.3	75	GRCh37					missense_variant,transcript_fusion	NC_000006.11:g.117631376C>G	2022-04-12 21:22:01 UTC	4.0	CA365440505	NONE FOUND	CD74-ROS1 G2101A			false
519	https://civicdb.org/links/variants/519	FLT3	2322	Mutation			13	28577411	28674729			ENST00000241453.7	75	GRCh37					transcript_variant,gain_of_function_variant		2022-04-12 21:22:06 UTC	85.0						false
520	https://civicdb.org/links/variants/520	ALK	238	CLTC::ALK	The t(2;17)(p23;q23) translocation results in the CLTC-ALK fusion protein, the most common ALK fusion observed in diffuse large B cell lymphoma (DLBCL). ALK-rearranged DLBCL is less responsive to CHOP chemotherapy. Preclinical work indicates that CLTC-ALK DLBCL is responsive to ALK inhibition in cell lines and mouse models, and two case studies show short response followed by progression when heavily pretreated and advanced ALK-positive DLBCL is treated with crizotinib (one case CLTC-ALK, one case an unknown ALK fusion).	ALK Fusions	17	57697219	57768072			ENST00000269122.3	75	GRCh37	2	29415640	29446394	ENST00000389048.3	transcript_fusion		2022-03-10 20:15:38 UTC	19.0		N/A	T(2;17)(P23;Q23),CLTC-ALK			false
521	https://civicdb.org/links/variants/521	U2AF1	7307	MUTATION			21	44513066	44527697			ENST00000291552.4	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	20.0		N/A				false
522	https://civicdb.org/links/variants/522	BRAF	673	DEL 485-490			7	140477838	140477855	AGGTGCTGTCACATTCAA		ENST00000288602.6	75	GRCh37					inframe_deletion	ENST00000288602.6:c.1453_1470del	2022-04-12 21:22:04 UTC	3.0	unregistered	NONE FOUND				false
524	https://civicdb.org/links/variants/524	DUX4	100288687	Fusion															transcript_fusion		2022-04-12 21:22:02 UTC	11.5		N/A				false
525	https://civicdb.org/links/variants/525	B4GALT1	2683	Overexpression			9	33110635	33167354			ENST00000379731.4	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	15.0		N/A				false
526	https://civicdb.org/links/variants/526	BCL2L11	10018	Deletion Polymorphism			2	111883195	111886097			ENST00000393256.3	75	GRCh37					polymorphic_sequence_variant		2022-08-02 14:49:20 UTC	40.0						false
527	https://civicdb.org/links/variants/527	ALK	238	ALK Fusion I1171	Multiple case reports indicate that the I1171T missense mutation in ALK-rearranged non-small cell lung cancer (NSCLC) confers resistance to crizotinib and alectinib but is sensitive to ceritinib treatment. These results have been validated in vitro. In vitro evidence indicates this mutation interferes with alectinib binding the active site of ALK and may explain the sensitivity to the structurally distinct ALK inhibitor ceritinib.		2	29445213	29445213	A	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3512T>C,NC_000002.11:g.29445213A>G,NM_004304.4:c.3512T>C,NP_004295.2:p.Ile1171Thr	2021-04-09 19:00:20 UTC	42.5	CA346462880	375888	ALK FUSION ILE1171			false
528	https://civicdb.org/links/variants/528	ALK	238	EML4::ALK  V1180L	The V1180L missense mutation was identified in a mutagenesis screen to find mutations that conferred resistance to alectinib in a non-small cell lung cancer cell line. This mutation shows resistance to crizotinib and alectinib but sensitivity to TAE684, ceritinib and more mild sensitivity to brigatinib. Similar to I1171T, it resides in the ATP pocket of ALK and likely interferes with alectinib and crizotinib binding as a mechanism of resistance.		2	29443679	29443679	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3538G>C,NC_000002.11:g.29443679C>G,NP_004295.2:p.Val1180Leu,NM_004304.5:c.3538G>C	2022-03-11 04:10:57 UTC	13.0	CA346473150	NONE FOUND	EML4-ALK VAL1180LEU,EML4-ALK  V1180L			false
529	https://civicdb.org/links/variants/529	SIRT1	23411	Overexpression			10	69644427	69678147			ENST00000212015.6	75	GRCh37					N/A		2022-08-02 14:21:43 UTC	16.0		N/A				false
530	https://civicdb.org/links/variants/530	KRAS	3845	G12R			12	25398285	25398285	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>C,NP_004976.2:p.Gly12Arg,NC_000012.11:g.25398285C>G,ENST00000256078.4:c.34G>C	2022-04-12 21:22:04 UTC	32.5	CA122531	12579	GLY12ARG,RS121913530			false
531	https://civicdb.org/links/variants/531	TP53	7157	P72R	This polymorphism is relatively widely studied across cancer types, but meta-analyses in breast, lung and cervical cancer cohorts have so far been inconclusive as to the significance of a patient's genotype at this locus as it relates to cancer susceptibility and prognosis.		17	7579472	7579472	G	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.215C>G,NP_000537.3:p.Pro72Arg,NC_000017.10:g.7579472G>C,ENST00000269305.4:c.215C>G	2018-11-30 14:43:09 UTC	45.0	CA000072	12351	PRO72ARG,P33R,RS1042522			false
532	https://civicdb.org/links/variants/532	PALB2	79728	Biallelic Inactivation			16	23614491	23652631			ENST00000261584.4	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:01 UTC	17.5		N/A				false
533	https://civicdb.org/links/variants/533	SMAD4	4089	Expression			18	48556583	48611409			ENST00000342988.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
534	https://civicdb.org/links/variants/534	FANCC	2176	Loss-of-function			9	97861336	98079984			ENST00000289081.3	75	GRCh37					loss_of_function_variant		2022-08-03 16:06:20 UTC	3.0		N/A				false
535	https://civicdb.org/links/variants/535	PDGFRB	5159	EBF1::PDGFRB	EBF1-PDGFRB fusions are associated with Ph-like acute lymphoblastic leukemia lacking the BCR-ABL fusion. Case reports have shown positive responses to imatinib treatment.		5	158134987	158526769			ENST00000517373.1	75	GRCh37	5	149493400	149505140	ENST00000261799.4	transcript_fusion		2022-03-10 21:07:34 UTC	32.5		N/A	EBF1-PDGFRB	19	https://civicdb.org/links/assertions/19	false
537	https://civicdb.org/links/variants/537	RB1	5925	EXPRESSION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
538	https://civicdb.org/links/variants/538	MLH1	4292	METHYLATION															N/A		2022-04-12 21:22:01 UTC	10.0		N/A				false
539	https://civicdb.org/links/variants/539	PTPN11	5781	Overexpression			12	112856718	112947717			ENST00000351677.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
540	https://civicdb.org/links/variants/540	FLT3	2322	T227M	FLT3 T227M (rs1933437) is a common polymorphism with a GMAF around .60 based on the Exome Aggregation Consortium (ExAC) data. Its role in cancer predisposition is still unknown, however it may be associated with the development of leukopenia in patients treated with sunitinib.		13	28624294	28624294	G	A	ENST00000241453.7	75	GRCh37					missense_variant,SNP	NM_004119.2:c.680C>T,NP_004110.2:p.Thr227Met,NC_000013.10:g.28624294G>A,ENST00000241453.7:c.680C>T	2018-11-30 14:43:26 UTC	15.0	CA159846	134447	RS1933437,THR227MET			false
541	https://civicdb.org/links/variants/541	PALB2	79728	L531FS*30			16	23646276	23646276			ENST00000261584.4	75	GRCh37					minus_1_frameshift_variant,SNP		2022-04-15 13:56:44 UTC	15.0			LEU531FS*30			false
542	https://civicdb.org/links/variants/542	MTOR	2475	S2215Y			1	11184573	11184573	G	T	ENST00000361445.4	75	GRCh37					missense_variant	ENST00000361445.4:c.6644C>A,NC_000001.10:g.11184573G>T,NM_004958.3:c.6644C>A,NP_004949.1:p.Ser2215Tyr	2022-04-12 21:22:04 UTC	2.0	CA16602587	376129	SER2215TYR			false
543	https://civicdb.org/links/variants/543	MTOR	2475	C1483Y			1	11217230	11217230	C	T	ENST00000361445.4	75	GRCh37					missense_variant	ENST00000361445.4:c.4448G>A,NC_000001.10:g.11217230C>T,NM_004958.3:c.4448G>A,NP_004949.1:p.Cys1483Tyr	2022-04-12 21:22:04 UTC	2.0	CA16602888	376453	CYS1483TYR			false
544	https://civicdb.org/links/variants/544	MTOR	2475	E1799K			1	11190804	11190804	C	T	ENST00000361445.4	75	GRCh37					missense_variant	NM_004958.3:c.5395G>A,NP_004949.1:p.Glu1799Lys,NC_000001.10:g.11190804C>T,ENST00000361445.4:c.5395G>A	2022-04-12 21:22:04 UTC	2.0	CA279594	217823	GLU1799LYS,RS863225264			false
545	https://civicdb.org/links/variants/545	FGFR2	2263	N550K			10	123258034	123258034	A	T	ENST00000457416.2	75	GRCh37					missense_variant,gain_of_function_variant	NM_022970.3:c.1650T>A,NP_075259.4:p.Asn550Lys,ENST00000457416.2:c.1650T>A,NC_000010.10:g.123258034A>T	2022-04-12 21:22:04 UTC	3.0	CA16602614	376157	ASN550LYS,N549K,RS121913476			false
546	https://civicdb.org/links/variants/546	ACTA1	58	EXPRESSION			1	229566992	229569841			ENST00000366684.3	75	GRCh37					N/A	N/A	2022-04-15 14:08:49 UTC	10.0		N/A				false
547	https://civicdb.org/links/variants/547	RB1	5925	Overexpression			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2022-08-02 22:56:35 UTC	2.0		N/A				false
548	https://civicdb.org/links/variants/548	PPP1R15A	23645	RS557806			19	49377242	49377242	G	C	ENST00000200453.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	NM_014330.3:c.752G>C,NP_055145.3:p.Arg251Pro,ENST00000200453.5:c.752G>C,NC_000019.9:g.49377242G>C	2022-04-12 21:22:04 UTC	5.0	CA9560103	NONE FOUND	ARG251PRO,R251P			false
549	https://civicdb.org/links/variants/549	ALK	238	F1245C			2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G	2022-04-12 21:22:06 UTC	10.5	CA279597	217856	PHE1245CYS,RS863225283			false
550	https://civicdb.org/links/variants/550	ALK	238	Exon 4-11 Deletion			2	29474528	29853656			ENST00000389048.3	75	GRCh37					inframe_deletion	NM_004304.5:c.953_2041del,NP_004295.2:p.Gly318_Val681delinsVal,NC_000002.11:g.29474528_29853656del	2022-04-12 21:22:06 UTC	3.0						false
551	https://civicdb.org/links/variants/551	ALK	238	ALK Fusion F1245C	In neuroblastoma, F1245 is one of three hotspot ALK mutations found at a high frequency. In a case study, a pretreated non-small cell lung cancer (NSCLC) patient with EML4-ALK F1245C mutation responded well to ceritinib after slow disease progression during crizotinib treatment. Crizotinib resistance was attributed to the F1245C mutation, although the ALK-rearrangement was not sequenced prior to crizotinib treatment. The patient's slow onset of disease progression during crizotinib treatment mirrors preclinical findings that indicate ALK-fusion with F1245C has moderate resistance to crizotinib compared to the fusion alone.		2	29436859	29436859	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	NM_004304.4:c.3734T>G,NP_004295.2:p.Phe1245Cys,NC_000002.11:g.29436859A>C,ENST00000389048.3:c.3734T>G	2021-04-09 18:59:47 UTC	14.5	CA279597	217856	RS863225283,ALK FUSION PHE1245CYS			false
552	https://civicdb.org/links/variants/552	ALK	238	ALK Fusion G1269A			2	29432682	29432682	C	G	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3806G>C,NC_000002.11:g.29432682C>G,NM_004304.4:c.3806G>C,NP_004295.2:p.Gly1269Ala	2022-04-12 21:22:04 UTC	10.0	CA16602590	376132	ALK FUSION GLY1269ALA,RS1057519781			false
553	https://civicdb.org/links/variants/553	CDK4	1019	Amplification			12	58141510	58146304			ENST00000257904.6	75	GRCh37					transcript_amplification		2022-08-02 22:56:47 UTC	30.0		N/A				false
554	https://civicdb.org/links/variants/554	CDKN2A	1029	Loss			9	21967752	21994623			ENST00000579755.1	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	42.5		N/A				false
555	https://civicdb.org/links/variants/555	CDKN2B	1030	Loss			9	22002902	22009362			ENST00000276925.6	75	GRCh37					transcript_ablation		2022-08-03 16:04:09 UTC	5.0		N/A				false
556	https://civicdb.org/links/variants/556	CDK4	1019	R24C			12	58145431	58145431	G	A	ENST00000257904.6	75	GRCh37					missense_variant	NM_000075.3:c.70C>T,NP_000066.1:p.Arg24Cys,ENST00000257904.6:c.70C>T,NC_000012.11:g.58145431G>A	2022-04-12 21:22:04 UTC	1.0	CA126982	16928	ARG24CYS,RS11547328			false
557	https://civicdb.org/links/variants/557	ASXL1	171023	EXON 12 MUTATION			20	31021087	31021720			ENST00000375687.4	75	GRCh37					exon_variant		2022-04-12 21:22:02 UTC	20.0						false
558	https://civicdb.org/links/variants/558	GNA11	2767	Q209			19	3118942	3118942			ENST00000078429.4	75	GRCh37					missense_variant		2022-04-15 14:12:41 UTC	15.0		376001				false
559	https://civicdb.org/links/variants/559	CALR	811	EXON 9 FRAMESHIFT	Exon 9 insertions and deletions have become part of the WHO diagnostic criteria for essential thrombocythemia (ET) and primary myelofibrosis (PMF) (Arber et al, 2016). These mutations are typically heterozygous and in the absence of JAK2 and MPL mutations. Approximately 80% of observed mutations are type 1 (p.L367fs*46), the result of a 52‚Äâbp deletion, or type 2 (p.K385fs*47), the result of a 5-bp TTGTC insertion, and studies have suggested phenotypic and prognostic differences between them. In PMF patients, CALR exon 9 mutations have been associated with improved median survival.		19	13054527	13054727			ENST00000316448.5	75	GRCh37					exon_variant		2017-12-01 14:40:33 UTC	80.0						false
560	https://civicdb.org/links/variants/560	CSF3R	1441	Mutation			1	36932096	36933444			ENST00000373106.1	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	30.0		N/A				false
562	https://civicdb.org/links/variants/562	EGFR	1956	S768I			7	55249005	55249005	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2303G>T,NC_000007.13:g.55249005G>T,NM_005228.4:c.2303G>T,NP_005219.2:p.Ser768Ile	2022-04-12 21:22:04 UTC	20.5	CA135840	45251	SER768ILE,RS121913465			false
563	https://civicdb.org/links/variants/563	BRAF	673	V600K		Other V600's	7	140453136	140453137	AC	TT	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1798_1799delinsAA,NC_000007.13:g.140453136_140453137delinsTT,NM_004333.4:c.1798_1799delGTinsAA,NP_004324.2:p.Val600Lys	2022-04-12 21:22:04 UTC	107.5	CA16602420	375941	VAL600LYS,RS121913227	13,11	https://civicdb.org/links/assertions/13	https://civicdb.org/links/assertions/11	false
564	https://civicdb.org/links/variants/564	SMAD4	4089	LOSS			18	48556583	48611409			ENST00000342988.3	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	15.0		N/A				false
565	https://civicdb.org/links/variants/565	SF3B1	23451	K700E		HEAT domain mutation	2	198266834	198266834	T	C	ENST00000335508.6	75	GRCh37					missense_variant	NM_012433.3:c.2098A>G,NP_036565.2:p.Lys700Glu,ENST00000335508.6:c.2098A>G,NC_000002.11:g.198266834T>C	2022-04-12 21:22:04 UTC	2.0	CA2042597	376004	LYS700GLU,RS559063155			false
566	https://civicdb.org/links/variants/566	MAP2K7	5609	E116K			19	7975157	7975157	G	A	ENST00000397979.3	75	GRCh37					missense_variant	NC_000019.9:g.7975157G>A	2022-04-12 21:22:04 UTC	25.0	CA304968685	NONE FOUND	GLU116LYS			false
567	https://civicdb.org/links/variants/567	PDGFRA	5156	Fusion															transcript_fusion		2022-04-12 21:22:02 UTC	100.0		N/A				false
568	https://civicdb.org/links/variants/568	PDGFRB	5159	Fusion															transcript_fusion		2022-04-12 21:22:02 UTC	140.0						false
569	https://civicdb.org/links/variants/569	FGFR1	2260	Fusion			8	38268656	38325363			ENST00000425967.3	75	GRCh37					transcript_fusion	N/A	2022-04-12 21:22:03 UTC	103.0		N/A				false
570	https://civicdb.org/links/variants/570	IDH2	3418	Mutation			15	90626277	90645736			ENST00000330062.3	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	94.0		N/A				false
571	https://civicdb.org/links/variants/571	JAK2	3717	PCM1::JAK2										GRCh37					transcript_fusion	N/A	2022-04-12 21:22:02 UTC	57.5		N/A	T(8;9)(P22;P24.1),PCM1-JAK2			false
572	https://civicdb.org/links/variants/572	MTOR	2475	E2014K and E2419K			1	11174420	11187857			ENST00000361445.4	75	GRCh37					missense_variant		2022-04-12 21:22:02 UTC	5.0		376131,156709				false
573	https://civicdb.org/links/variants/573	RICTOR	253260	Amplification			5	38938021	39074510			ENST00000357387.3	75	GRCh37					transcript_amplification	N/A	2022-08-02 22:57:14 UTC	12.5		N/A				false
574	https://civicdb.org/links/variants/574	PDGFRA	5156	FIP1L1::PDGFRA	Prospective trials of patients with hypereosinophilic syndrome harboring the FIP1L1-PDGFRA fusion identified marked response to imatinib treatment (Gotlib and Cool, Leukemia 2008). Imatinib is FDA approved for the treatment of &quot;adult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRŒ± fusion kinase&quot; (NDA021588).		4	54243812	54294350			ENST00000337488.6	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion		2022-03-11 00:22:13 UTC	63.5		N/A	FIP1L1-PDGFRA			false
576	https://civicdb.org/links/variants/576	ROS1	6098	TFG::ROS1			3	100428269	100447702			ENST00000240851.4	75	GRCh37	6	117609463	117642557	ENST00000368508.3	transcript_fusion		2022-04-12 21:22:02 UTC	7.5		N/A	TFG-ROS1			false
577	https://civicdb.org/links/variants/577	PDGFRA	5156	FIP1L1::PDGFRA T674I	A case study of relapsed myeloproliferative hypereosinophilic syndrome suggests that a T674I mutation in the PDGFRA split kinase domain of FIP1L1-PDGFRA fusions may confer resistance to imatinib.		4	55144547	55144547	C	T	ENST00000257290.5	75	GRCh37					missense_variant,transcript_fusion	NC_000004.11:g.55144547C>T,ENST00000257290.5:c.2021C>T,NM_006206.5:c.2021C>T,NP_006197.1:p.Thr674Ile	2022-03-11 00:20:19 UTC	15.5	CA123215	13550	THR674ILE,RS121908587,FIP1L1-PDGFRA T674I			false
578	https://civicdb.org/links/variants/578	BIRC5	332	Overexpression			17	76210267	76221717			ENST00000301633.4	75	GRCh37					N/A		2022-08-02 14:21:22 UTC	20.0		N/A				false
579	https://civicdb.org/links/variants/579	BRAF	673	D594A		Kinase Dead BRAF Mutation	7	140453154	140453154	T	G	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1781A>C,NC_000007.13:g.140453154T>G,NM_004333.4:c.1781A>C,NP_004324.2:p.Asp594Ala	2022-04-12 21:22:04 UTC	0.75	CA16602532	376070	ASP594ALA,RS121913338			false
580	https://civicdb.org/links/variants/580	BRAF	673	D594V		Kinase Dead BRAF Mutation	7	140453154	140453154	T	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1781A>T,NP_004324.2:p.Asp594Val,NC_000007.13:g.140453154T>A,ENST00000288602.6:c.1781A>T	2022-04-12 21:22:04 UTC	0.75	CA16602425	375946	ASP594VAL,RS121913338			false
581	https://civicdb.org/links/variants/581	BRAF	673	K483M	The K483M variant is a kinase dead loss-of-function variant in the catalytic site of BRAF. This engineered variant is often used as a control when evaluating other BRAF variants.	Kinase Dead BRAF Mutation	7	140477859	140477860	TT	CA	ENST00000288602.6	75	GRCh37					missense_variant,loss_of_function_variant	NC_000007.13:g.140477859_140477860delinsCA,ENST00000288602.6:c.1448_1449delinsTG	2019-07-30 00:01:03 UTC	0.75	CA913112072	NONE FOUND	LYS483MET			false
582	https://civicdb.org/links/variants/582	BRAF	673	L597S			7	140453145	140453146	AG	GA	ENST00000288602.6	75	GRCh37					missense_variant	NC_000007.13:g.140453145_140453146delinsGA,NM_004333.4:c.1789_1790delCTinsTC,NP_004324.2:p.Leu597Ser,ENST00000288602.6:c.1789_1790delCTinsTC	2022-04-12 21:22:04 UTC	9.5	CA16602421	375942	LEU597SER			false
583	https://civicdb.org/links/variants/583	BRAF	673	L597Q			7	140453145	140453145	A	T	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1790T>A,NP_004324.2:p.Leu597Gln,NC_000007.13:g.140453145A>T,ENST00000288602.6:c.1790T>A	2022-04-12 21:22:04 UTC	14.5	CA16602257	76687	LEU597GLN,RS121913366			false
584	https://civicdb.org/links/variants/584	BRAF	673	K601E			7	140453134	140453134	T	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1801A>G,NP_004324.2:p.Lys601Glu,NC_000007.13:g.140453134T>C,ENST00000288602.6:c.1801A>G	2022-04-12 21:22:04 UTC	3.0	CA123645	13966	LYS601GLU,RS121913364			false
585	https://civicdb.org/links/variants/585	BRAF	673	L597V			7	140453146	140453146	G	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1789C>G,NP_004324.2:p.Leu597Val,NC_000007.13:g.140453146G>C,ENST00000288602.6:c.1789C>G	2022-04-12 21:22:04 UTC	7.5	CA123651	13969	LEU597VAL,RS121913369			false
586	https://civicdb.org/links/variants/586	KIT	3815	Amplification			4	55524085	55606881			ENST00000288135.5	75	GRCh37					transcript_amplification		2022-04-12 21:22:02 UTC	15.0		N/A				false
587	https://civicdb.org/links/variants/587	NF1	4763	Mutation			17	29421945	29704695			ENST00000358273.4	75	GRCh37					protein_altering_variant,loss_of_function_variant		2022-04-12 21:22:02 UTC	32.0		N/A				false
588	https://civicdb.org/links/variants/588	ALK	238	HIP1::ALK I1171N			2	29445213	29445213	A	T	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3512T>A,NC_000002.11:g.29445213A>T,NM_004304.4:c.3512T>A,NP_004295.2:p.Ile1171Asn	2022-04-12 21:22:04 UTC	5.0	CA16602371	375888	HIP1-ALK ILE1171ASN,RS1057519698,HIP1-ALK I1171N			false
589	https://civicdb.org/links/variants/589	ALK	238	EML4::ALK I1171S			2	29445213	29445213	A	C	ENST00000389048.3	75	GRCh37					missense_variant,transcript_fusion	ENST00000389048.3:c.3512T>G,NC_000002.11:g.29445213A>C	2022-04-12 21:22:02 UTC	5.0	CA346462883	NONE FOUND	EML4-ALK ILE1171SER,EML4-ALK I1171S			false
590	https://civicdb.org/links/variants/590	BIRC3	330	TRUNCATING MUTATION			11	102201730	102207833			ENST00000263464.3	75	GRCh37					frameshift_variant		2022-04-12 21:22:02 UTC	10.0						false
591	https://civicdb.org/links/variants/591	RAF1	5894	Amplification			3	12625100	12705725			ENST00000251849.4	75	GRCh37					transcript_amplification		2022-08-02 22:57:48 UTC	10.0		N/A				false
592	https://civicdb.org/links/variants/592	KRAS	3845	Amplification			12	25362365	25403737			ENST00000256078.4	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	27.0		N/A				false
594	https://civicdb.org/links/variants/594	CEBPA	1050	BIALLELIC INACTIVATION			19	33790840	33793470			ENST00000498907.2	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	25.0		N/A				false
595	https://civicdb.org/links/variants/595	SRSF2	6427	MUTATION			17	74732402	74733113			ENST00000392485.2	75	GRCh37					gene_variant		2022-04-12 21:22:02 UTC	25.0						false
596	https://civicdb.org/links/variants/596	NRAS	4893	G12/G13			1	115258744	115258748			ENST00000369535.4	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	20.0		13901,40468,39648,177778,40471,13899,219097,40470,40469,375877,375876,376221				false
597	https://civicdb.org/links/variants/597	RET	5979	Overexpression			10	43572475	43625799			ENST00000355710.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	7.5		N/A				false
599	https://civicdb.org/links/variants/599	CTLA4	1493	CTLA4::CD28	A survey of 115 T-cell lymphoma samples of diverse subtypes identified this fusion in 26 of 45 cases of angioimmunoblastic T-cell lymphomas (58%), nine of 39 peripheral T-cell lymphomas, not otherwise specified (23%), and nine of 31 extranodal NK/T cell lymphomas (29%).		2	204732509	204736210			ENST00000302823.3	75	GRCh37	2	204599507	204603635	ENST00000324106.8	transcript_fusion		2022-03-10 20:18:57 UTC	5.0		N/A	CTLA4-CD28			false
600	https://civicdb.org/links/variants/600	AR	367	Mutation			X	66764465	66950461			ENST00000374690.3	75	GRCh37					transcript_variant		2022-08-02 14:42:40 UTC	20.0		N/A				false
601	https://civicdb.org/links/variants/601	NOTCH1	4851	Loss-of-function			9	139388896	139440314			ENST00000277541.6	75	GRCh37					loss_of_function_variant		2022-08-03 16:06:35 UTC	2.0		N/A				false
602	https://civicdb.org/links/variants/602	CDK6	1021	Overexpression			7	92234235	92463231			ENST00000265734.4	75	GRCh37					N/A		2022-08-02 14:21:05 UTC	24.0		N/A				false
603	https://civicdb.org/links/variants/603	FLT3	2322	Overexpression			13	28577411	28674729			ENST00000241453.7	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	7.5		N/A				false
604	https://civicdb.org/links/variants/604	GNAQ	2776	Q209P			9	80409488	80409488	T	G	ENST00000286548.4	75	GRCh37					missense_variant	NC_000009.11:g.80409488T>G,NM_002072.4:c.626A>C,NP_002063.2:p.Gln209Pro,ENST00000286548.4:c.626A>C	2022-04-12 21:22:04 UTC	8.0	CA16602436	375957	GLN209PRO,RS121913492			false
605	https://civicdb.org/links/variants/605	PTEN	5728	V317FS			10	89720799	89720802	TACT		ENST00000371953.3	75	GRCh37					frameshift_variant	ENST00000371953.3:c.950_953delTACT,NC_000010.10:g.89720799_89720802del	2022-04-12 21:22:04 UTC	3.0	CA000646	NONE FOUND	VAL317FS			false
606	https://civicdb.org/links/variants/606	RB1	5925	Loss-of-function			13	48877911	49056122			ENST00000267163.4	75	GRCh37					loss_of_function_variant		2022-08-03 16:05:38 UTC	6.0		N/A				false
607	https://civicdb.org/links/variants/607	ESR1	2099	Overexpression			6	152128686	152424406			ENST00000206249.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
609	https://civicdb.org/links/variants/609	MTOR	2475	M2327I			1	11177096	11177096	C	A	ENST00000361445.4	75	GRCh37					missense_variant	ENST00000361445.4:c.6981G>T,NC_000001.10:g.11177096C>A	2022-04-12 21:22:04 UTC	7.0	CA338383476	NONE FOUND	MET2327ILE			false
610	https://civicdb.org/links/variants/610	MTOR	2475	A2034V			1	11187796	11187796	G	A	ENST00000361445.4	75	GRCh37					missense_variant	ENST00000361445.4:c.6101C>T,NC_000001.10:g.11187796G>A	2022-04-12 21:22:04 UTC	8.0	CA338393920	NONE FOUND	ALA2034VAL			false
611	https://civicdb.org/links/variants/611	BRAF	673	D594G	This BRAF mutation has a markedly reduced kinase activity and leads to paradoxical MEK-pathway activation via CRAF binding.		7	140453154	140453154	T	C	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1781A>G,NP_004324.2:p.Asp594Gly,NC_000007.13:g.140453154T>C,ENST00000288602.6:c.1781A>G	2021-04-09 20:07:18 UTC	43.5	CA123657	13972	ASP594GLY,RS121913338			false
612	https://civicdb.org/links/variants/612	FLT3	2322	D835H			13	28592642	28592642	C	G	ENST00000241453.7	75	GRCh37					missense_variant	NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,ENST00000241453.7:c.2503G>C,NC_000013.10:g.28592642C>G	2022-04-12 21:22:04 UTC	9.5	CA280208	16273	ASP835HIS,RS121913488			false
613	https://civicdb.org/links/variants/613	FLT3	2322	D835H/Y			13	28592642	28592642	C	G/A	ENST00000241453.7	75	GRCh37					missense_variant	NM_004119.2:c.2503G>C,NP_004110.2:p.Asp835His,NM_004119.2:c.2503G>T,NP_004110.2:p.Asp835Tyr,ENST00000241453.7:c.2503G>C,ENST00000241453.7:c.2503G>T	2022-04-12 21:22:02 UTC	1.0		16273,16276	ASP835HIS,ASP835TYR			false
614	https://civicdb.org/links/variants/614	JAK1	3716	Q503*			1	65321333	65321333	G	A	ENST00000342505.4	75	GRCh37					stop_gained	NC_000001.10:g.65321333G>A,ENST00000342505.4:c.1507C>T	2022-04-12 21:22:04 UTC	10.0	CA340669637	NONE FOUND	Q503X,GLN503TER			false
615	https://civicdb.org/links/variants/615	JAK2	3717	c.1641+1dup			9	5070053	5070054		G	ENST00000381652.3	75	GRCh37						NC_000009.11:g.5070053_5070054insG	2022-04-12 21:22:04 UTC	10.0	CA913189235					false
616	https://civicdb.org/links/variants/616	B2M	567	S14FS			15	45003786	45003789	TCTT		ENST00000558401.1	75	GRCh37					frameshift_truncation	ENST00000558401.1:c.42_45delTCTT,NC_000015.9:g.45003786_45003789del	2022-04-12 21:22:04 UTC	7.5	CA645576720					false
617	https://civicdb.org/links/variants/617	BRAF	673	PPFIBP2::BRAF		BRAF Fusions	11	7535001	7586998			ENST00000299492.4	75	GRCh37	7	140434279	140481493	ENST00000288602.6	transcript_fusion		2022-04-12 21:22:02 UTC	5.0		N/A	PPFIBP2-BRAF			false
618	https://civicdb.org/links/variants/618	BRAF	673	KIAA1549::BRAF		BRAF Fusions	7	138545885	138666064			ENST00000440172.1	75	GRCh37	7	140434279	140487384	ENST00000288602.6	transcript_fusion		2022-05-07 00:09:00 UTC	110.5		N/A	KIAA1549-BRAF	26,27,25	https://civicdb.org/links/assertions/26	https://civicdb.org/links/assertions/27	https://civicdb.org/links/assertions/25	false
621	https://civicdb.org/links/variants/621	MET	4233	Overexpression			7	116312459	116436396			ENST00000318493.6	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	64.0		N/A				false
623	https://civicdb.org/links/variants/623	POT1	25913	MUTATION			7	124462440	124570035			ENST00000357628.3	75	GRCh37					protein_altering_variant,loss_of_function_variant		2022-04-12 21:22:02 UTC	15.0		N/A				false
624	https://civicdb.org/links/variants/624	MKI67	4288	EXPRESSION			10	129894923	129924649			ENST00000368654.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	35.0		N/A				false
625	https://civicdb.org/links/variants/625	RAD23B	5887	EXPRESSION			9	110045560	110094475			ENST00000358015.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
626	https://civicdb.org/links/variants/626	RET	5979	CCDC6::RET															transcript_fusion		2022-04-12 21:22:02 UTC	12.5		N/A	CCDC6-RET			false
627	https://civicdb.org/links/variants/627	MAP2K1	5604	C121S			15	66729154	66729154	G	C	ENST00000307102.5	75	GRCh37					missense_variant	ENST00000307102.5:c.362G>C,NC_000015.9:g.66729154G>C,NM_002755.3:c.362G>C,NP_002746.1:p.Cys121Ser	2022-04-12 21:22:04 UTC	10.0	CA16602455	375980	CYS121SER			false
628	https://civicdb.org/links/variants/628	FGFR3	2261	S249C	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1803568	1803568	C	G	ENST00000340107.4	75	GRCh37					missense_variant	NC_000004.11:g.1803568C>G,NM_000142.4:c.746C>G,NP_000133.1:p.Ser249Cys,ENST00000340107.4c.746C>G	2022-09-22 20:24:27 UTC	18.0	CA126380	16339	SER249CYS,RS121913483	47,53,55	https://civicdb.org/links/assertions/47	https://civicdb.org/links/assertions/53	https://civicdb.org/links/assertions/55	false
629	https://civicdb.org/links/variants/629	FGFR2	2263	Amplification			10	123239371	123357917			ENST00000457416.2	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	25.0		N/A				false
630	https://civicdb.org/links/variants/630	FGF3	2248	Amplification			11	69624992	69633792			ENST00000334134.2	75	GRCh37					transcript_amplification		2022-08-02 22:57:36 UTC	10.0		N/A				false
631	https://civicdb.org/links/variants/631	VHL	7428	R200W (c.598C>T)			3	10191605	10191605	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.598C>T,NP_000542.1:p.Arg200Trp,ENST00000256474.2:c.598C>T,NC_000003.11:g.10191605C>T	2022-04-12 21:22:04 UTC	10.0	CA020510	2232	ARG200TRP,C.598C>T,RS28940298			false
632	https://civicdb.org/links/variants/632	RB1	5925	PHOSPHORYLATION			13	48877911	49056122			ENST00000267163.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0						false
633	https://civicdb.org/links/variants/633	PIK3R1	5295	Mutation			5	67511548	67597649			ENST00000521381.1	75	GRCh37					missense_variant,gain_of_function_variant		2022-08-02 23:07:48 UTC	2.0						false
634	https://civicdb.org/links/variants/634	STK11	6794	D194E			19	1220489	1220489	C	A	ENST00000326873.7	75	GRCh37					missense_variant,loss_of_heterozygosity	NM_000455.4:c.582C>A,NP_000446.1:p.Asp194Glu,ENST00000326873.7:c.582C>A,NC_000019.9:g.1220489C>A	2022-04-12 21:22:04 UTC	5.0	CA023096	185384	ASP194GLU,RS786202134			false
635	https://civicdb.org/links/variants/635	AKT2	208	Amplification			19	40736224	40791302			ENST00000392038.2	75	GRCh37					transcript_amplification		2022-04-12 21:22:02 UTC	2.5		N/A				false
636	https://civicdb.org/links/variants/636	PTEN	5728	R130*			10	89692904	89692904	C	T	ENST00000371953.3	75	GRCh37					stop_gained	NM_000314.6:c.388C>T,NP_000305.3:p.Arg130Ter,ENST00000371953.3:c.388C>T,NC_000010.10:g.89692904C>T	2022-04-12 21:22:04 UTC	2.0	CA000433	7819	R130X,ARG130TER,RS121909224			false
637	https://civicdb.org/links/variants/637	FBXW7	55294	Loss-of-function			4	153242410	153457253			ENST00000281708.4	75	GRCh37					loss_of_function_variant		2022-08-03 16:05:53 UTC	4.5		N/A				false
638	https://civicdb.org/links/variants/638	RB1	5925	M695FS*26			13	49033946	49033947		A	ENST00000267163.4	75	GRCh37					frameshift_truncation	ENST00000267163.4:c.2083_2084insA,NC_000013.10:g.49033946_49033947insA	2022-04-12 21:22:04 UTC	2.0	CA913189236	NONE FOUND				false
639	https://civicdb.org/links/variants/639	JUN	3725	Overexpression			1	59246465	59249785			ENST00000371222.2	75	GRCh37					N/A		2022-08-02 22:51:33 UTC	5.0		N/A				false
640	https://civicdb.org/links/variants/640	FOS	2353	Overexpression			14	75745477	75748933			ENST00000303562.4	75	GRCh37					N/A		2022-08-02 22:51:25 UTC	5.0		N/A				false
641	https://civicdb.org/links/variants/641	CDKN2A	1029	RS3814960			9	21975017	21975017	C	T	ENST00000498124.1	75	GRCh37					5_prime_UTR_exon_variant	NC_000009.11:g.21975017C>T,NM_000077.4:c.-191G>A	2022-04-12 21:22:04 UTC	15.0	CA12951936	NONE FOUND				false
642	https://civicdb.org/links/variants/642	MDM2	4193	RS34886328			12	69234988	69234988	A		ENST00000462284.1	75	GRCh37					3_prime_UTR_truncation		2022-04-15 13:56:44 UTC	10.0	CA238461468					false
643	https://civicdb.org/links/variants/643	CBLB	868	RS2305035			3	105439026	105439026	G	A	ENST00000264122.4	75	GRCh37					synonymous_variant,polymorphic_sequence_variant	NC_000003.11:g.105439026G>A,NM_001321788.1:c.1272C>T,ENST00000264122.4:c.1272C>T	2022-04-12 21:22:04 UTC	10.0	CA2524814	NONE FOUND	D424D			false
644	https://civicdb.org/links/variants/644	PRDM1	639	MUTATION			6	106534195	106557813			ENST00000369096.4	75	GRCh37					transcript_variant,loss_of_function_variant		2022-04-12 21:22:02 UTC	20.0		N/A				false
645	https://civicdb.org/links/variants/645	IDH1	3417	Mutation			2	209101803	209116275			ENST00000415913.1	75	GRCh37					transcript_variant		2022-04-12 21:22:02 UTC	83.0						false
646	https://civicdb.org/links/variants/646	SMAD4	4089	Deletion			18	48556583	48611409			ENST00000342988.3	75	GRCh37					transcript_ablation		2022-04-12 21:22:02 UTC	15.0						false
647	https://civicdb.org/links/variants/647	LRP1B	53353	DELETION			2	140988992	142889270			ENST00000389484.3	75	GRCh37					transcript_ablation		2022-04-12 21:22:02 UTC	20.0						false
648	https://civicdb.org/links/variants/648	ATRX	546	Underexpression			X	76760356	77041702			ENST00000373344.5	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	39.0		N/A	UNDEREXPRESSION			false
649	https://civicdb.org/links/variants/649	MET	4233	D1228N			7	116423407	116423407	G	A	ENST00000397752.3	75	GRCh37					missense_variant	NC_000007.13:g.116423407G>A,NC_000007.14:g.116783353G>A,ENST00000397752.8:c.3682G>A,ENSP00000380860.3:p.Asp1228Asn,ENSP00000380860.3:p.Asp1228Asn,ENST00000397752.7:c.3682G>A,NM_000245.4:c.3682G>A,NP_000236.2:p.Asp1228Asn,NP_000236.2:p.Asp1228Asn,NM_000245.3:c.3682G>A	2022-04-12 21:22:04 UTC	5.0	CA257000	13884	D1246N,ASP1246ASN,ASP1228ASN			false
650	https://civicdb.org/links/variants/650	CASP8	841	D302H			2	202149589	202149589	G	C	ENST00000264275.5	75	GRCh37					missense_variant,polymorphic_sequence_variant	NM_001228.4:c.904G>C,NP_001219.2:p.Asp302His,ENST00000264275.5:c.904G>C,NC_000002.11:g.202149589G>C	2022-04-12 21:22:04 UTC	15.0	CA119051	7762	RS1045485,D285H,ASP302HIS			false
651	https://civicdb.org/links/variants/651	AXL	558	EXPRESSION			19	41725108	41767671			ENST00000301178.4	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	20.0		N/A				false
652	https://civicdb.org/links/variants/652	GAS6	2621	EXPRESSION			13	114523524	114567046			ENST00000357389.3	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	23.0		N/A				false
653	https://civicdb.org/links/variants/653	ETV4	2118	Overexpression			17	41605212	41623800			ENST00000319349.5	75	GRCh37					N/A		2022-08-02 14:22:28 UTC	15.0		N/A				false
654	https://civicdb.org/links/variants/654	STAG3	10734	Underexpression			7	99775186	99812003			ENST00000426455.1	75	GRCh37					N/A		2022-08-02 23:12:59 UTC	4.0		N/A				false
655	https://civicdb.org/links/variants/655	MAP2K1	5604	Q56_V60del			15	66727449	66727463	CCAGAAGCAGAAGGT		ENST00000307102.5	75	GRCh37					inframe_deletion	ENST00000307102.5:c.165_179del,NC_000015.9:g.66727449_66727463del	2022-04-12 21:22:04 UTC	10.0	CA912992484	NONE FOUND				false
656	https://civicdb.org/links/variants/656	BRAF	673	BRAF::CUL1		BRAF Fusions	7	140434279	140487384			ENST00000288602.6	75	GRCh37	7	148395737	148457588	ENST00000602748.1	transcript_fusion		2022-04-12 21:22:02 UTC	5.0		N/A	BRAF-CUL1			false
657	https://civicdb.org/links/variants/657	BRAF	673	ZKSCAN1::BRAF		BRAF Fusions	7	99613222	99627575			ENST00000426572.1	75	GRCh37	7	140434279	140482957	ENST00000288602.6	transcript_fusion		2022-04-12 21:22:02 UTC	7.5		N/A	ZKSCAN1-BRAF			false
658	https://civicdb.org/links/variants/658	BRAF	673	L505H			7	140477794	140477794	A	T	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.1514T>A,NC_000007.13:g.140477794A>T,NM_004333.4:c.1514T>A,NP_004324.2:p.Leu505His	2022-04-12 21:22:04 UTC	19.0	CA369588358	NONE FOUND	LEU505HIS			false
660	https://civicdb.org/links/variants/660	HIF1A	3091	EXPRESSION			14	62164340	62214489			ENST00000539097.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	10.0		N/A				false
661	https://civicdb.org/links/variants/661	BRCA2	675	D3095E			13	32968854	32968854	C	A	ENST00000544455.1	75	GRCh37					missense_variant	NM_000059.3:c.9285C>A,NP_000050.2:p.Asp3095Glu,ENST00000544455.1:c.9285C>A,NC_000013.10:g.32968854C>A	2022-04-12 21:22:06 UTC	7.5	CA10586089	252859	ASP3095GLU,RS80359198			false
662	https://civicdb.org/links/variants/662	MLH1	4292	EXPRESSION			3	37034823	37092409			ENST00000231790.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
663	https://civicdb.org/links/variants/663	BCOR	54880	Mutation			X	39910501	40036582			ENST00000342274.4	75	GRCh37					transcript_variant		2022-04-12 21:22:02 UTC	15.0						false
664	https://civicdb.org/links/variants/664	CDH1	999	MUTATION			16	68771128	68869451			ENST00000261769.5	75	GRCh37					transcription_variant		2022-04-12 21:22:02 UTC	0.5		N/A				false
665	https://civicdb.org/links/variants/665	RHOA	387	MUTATION			3	49396578	49449635			ENST00000418115.1	75	GRCh37					transcription_variant,gain_of_function_variant		2022-04-12 21:22:02 UTC	0.5						false
666	https://civicdb.org/links/variants/666	ERBB2	2064	Mutation			17	37868196	37881332			ENST00000269571.5	75	GRCh37					missense_variant		2022-04-12 21:22:02 UTC	37.5						false
667	https://civicdb.org/links/variants/667	MEN1	4221	FRAMESHIFT TRUNCATION			11	64572092	64572092	C		ENST00000337652.1	75	GRCh37					frameshift_truncation	NC_000011.9:g.64572092del	2022-04-12 21:22:04 UTC	5.0	CA16044439					false
668	https://civicdb.org/links/variants/668	KMT2C	58508	MUTATION			7	151832010	152133090			ENST00000262189.6	75	GRCh37					transcription_variant,loss_of_function_variant		2022-04-12 21:22:02 UTC	15.0						false
669	https://civicdb.org/links/variants/669	STAG2	10735	MUTATION			X	123176418	123217308			ENST00000218089.9	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	20.0		N/A				false
670	https://civicdb.org/links/variants/670	MYCL	4610	EXPRESSION			1	40361098	40367685			ENST00000397332.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	1.0						false
671	https://civicdb.org/links/variants/671	HGF	3082	EXPRESSION			7	81328322	81399514			ENST00000222390.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0						false
672	https://civicdb.org/links/variants/672	SOX10	6663	Loss			22	38368307	38380544			ENST00000396884.2	75	GRCh37					loss_of_function_variant		2022-08-03 16:04:20 UTC	4.0		N/A				false
673	https://civicdb.org/links/variants/673	FGF2	2247	EXPRESSION			4	123747863	123819391			ENST00000264498.3	75	GRCh37					N/A		2022-04-15 14:12:41 UTC	4.0						false
674	https://civicdb.org/links/variants/674	EIF1AX	1964	MUTATION			X	20156713	20159754			ENST00000379607.5	75	GRCh37					transcript_variant		2022-04-12 21:22:02 UTC	10.0						false
683	https://civicdb.org/links/variants/683	PAX8	7849	Expression			2	113973574	114036527			ENST00000429538.3	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	40.0		N/A				false
691	https://civicdb.org/links/variants/691	ERRFI1	54206	E384*			1	8073509	8073509	C	A	ENST00000377482.5	75	GRCh37					stop_gained,loss_of_function_variant	NC_000001.10:g.8073509C>A	2022-04-12 21:22:04 UTC	5.0	CA338219584	NONE FOUND	E384X,GLU384TER			false
692	https://civicdb.org/links/variants/692	ESR1	2099	S463P			6	152415537	152415537	T	C	ENST00000440973.1	75	GRCh37					missense_variant	ENST00000440973.1:c.1387T>C,NC_000006.11:g.152415537T>C,NM_000125.3:c.1387T>C,NP_000116.2:p.Ser463Pro	2022-04-12 21:22:04 UTC	2.0	CA16602414	375934	SER463PRO,RS1057519714			false
693	https://civicdb.org/links/variants/693	SGK1	6446	Overexpression			6	134490384	134639196			ENST00000367858.5	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	24.0		N/A				false
694	https://civicdb.org/links/variants/694	BRAF	673	G596C			7	140453149	140453149	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1786G>T,NP_004324.2:p.Gly596Cys,NC_000007.13:g.140453149C>A,ENST00000288602.6:c.1786G>T	2022-04-12 21:22:04 UTC	0.0	CA135098	44814	GLY596CYS,RS121913361			false
695	https://civicdb.org/links/variants/695	SMARCB1	6598	Underexpression			22	24129150	24176703			ENST00000344921.6	75	GRCh37					N/A		2022-08-02 14:54:23 UTC	2.0		N/A				false
696	https://civicdb.org/links/variants/696	SMARCB1	6598	Deletion			22	24129150	24176703			ENST00000344921.6	75	GRCh37					transcript_ablation		2022-08-02 14:50:11 UTC	3.0						false
697	https://civicdb.org/links/variants/697	NF2	4771	Loss			22	29999547	30094587			ENST00000338641.4	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	4.0		N/A				false
698	https://civicdb.org/links/variants/698	NF1	4763	Loss			17	29421945	29704695			ENST00000358273.4	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	3.0		N/A				false
699	https://civicdb.org/links/variants/699	SH2B3	10019	RS3184504			12	111884608	111884608	T	C	ENST00000341259.2	75	GRCh37					missense_variant,polymorphic_sequence_variant	NC_000012.11:g.111884608T>C,NM_005475.2:c.784T>C,ENST00000341259.2:c.784T>C	2022-04-12 21:22:04 UTC	10.0	CA6789733	NONE FOUND	ARG262TRP,R262W,TRP262ARG			false
700	https://civicdb.org/links/variants/700	KIF23	9493	EXPRESSION			15	69706688	69740756			ENST00000260363.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
701	https://civicdb.org/links/variants/701	ERBB3	2065	V104M			12	56478854	56478854	G	A	ENST00000267101.3	75	GRCh37					missense_variant	NC_000012.11:g.56478854G>A	2022-04-12 21:22:04 UTC	15.0	CA16602847	376410	VAL104MET			false
702	https://civicdb.org/links/variants/702	ERBB3	2065	R103G			12	56478851	56478851	C	G	ENST00000267101.3	75	GRCh37					missense_variant	NC_000012.11:g.56478851C>G	2022-04-12 21:22:04 UTC	15.0	CA385279657	NONE FOUND	ARG103GLY			false
703	https://civicdb.org/links/variants/703	ERBB3	2065	G284R			12	56481922	56481922	G	A	ENST00000267101.3	75	GRCh37					missense_variant	NC_000012.11:g.56481922G>A	2022-04-12 21:22:04 UTC	15.0	CA16602624	376167	GLY284ARG			false
705	https://civicdb.org/links/variants/705	GADD45A	1647	rs681673			1	68152388	68152388	T	C	ENST00000370986.4	75	GRCh37					coding_transcript_intron_variant		2022-04-12 21:22:04 UTC	15.0	CA10728634		1506T>C			false
706	https://civicdb.org/links/variants/706	EWSR1	2130	EWSR1::FLI1	In approximately 90% of Ewing sarcoma/primitive neuroectodermal tumor (ES/PNET) a translocation t(11;22)(q24; q12) is identified, fusing the 5‚Äô exons (containing the transactivatin domain, at least exon 1-7) of EWSR1, with the 3‚Äô exons (from exon 9, coding the DNA binding domain) of FLI1.		22	29664307	29688158			ENST00000414183.2	75	GRCh37	11	128638013	128683162	ENST00000527786.2	transcript_fusion		2022-03-11 00:31:49 UTC	45.0		N/A	EWS-FLI,T(11;22)(Q24;Q12),EWSR1-FLI1			false
708	https://civicdb.org/links/variants/708	BRCA2	675	TRUNCATING MUTATION															feature_truncation		2022-04-12 21:22:02 UTC	2.5						false
709	https://civicdb.org/links/variants/709	BRCA1	672	Alu insertion																	2022-04-12 21:22:02 UTC	7.5						false
711	https://civicdb.org/links/variants/711	KLLN	100144748	PROMOTER METHYLATION															gene_silenced_by_DNA_methylation		2022-04-12 21:22:02 UTC	30.0						false
712	https://civicdb.org/links/variants/712	EGFR	1956	D761Y			7	55242511	55242511	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2281G>T,NM_005228.4:c.2281G>T,NP_005219.2:p.Asp761Tyr,NC_000007.13:g.55242511G>T	2022-04-12 21:22:04 UTC	7.5	CA135827	45244	ASP761TYR,RS121913418			false
713	https://civicdb.org/links/variants/713	CRBN	51185	Mutation			3	3191695	3221394			ENST00000231948.4	75	GRCh37							2022-08-02 23:07:18 UTC	7.5						false
714	https://civicdb.org/links/variants/714	TSC1	7248	R1062W			9	135771933	135771933	G	A	ENST00000298552.3	75	GRCh37					missense_variant	NM_000368.3:c.3184C>T,NP_000359.1:p.Arg1062Trp,ENST00000298552.3:c.3184C>T,NC_000009.11:g.135771933G>A	2022-04-12 21:22:04 UTC	8.0	CA007223	49015	ARG1062TRP			false
715	https://civicdb.org/links/variants/715	STK11	6794	Mutation			19	1205740	1223074			ENST00000326873.7	75	GRCh37					gene_variant		2022-04-12 21:22:06 UTC	40.0		N/A				false
716	https://civicdb.org/links/variants/716	PDGFRA	5156	Amplification			4	55095264	55164414			ENST00000257290.5	75	GRCh37					transcript_amplification		2022-04-12 21:22:02 UTC	3.0		N/A				false
717	https://civicdb.org/links/variants/717	DDIT3	1649	EWSR1::DDIT3			22	29664307	29687588			ENST00000414183.2	75	GRCh37	12	57910376	57911536	ENST00000346473.3	transcript_fusion		2022-04-12 21:22:02 UTC	7.5		N/A	T(12;22)(Q13;Q12),EWS-CHOP,EWSR1-DDIT3			false
718	https://civicdb.org/links/variants/718	EGFR	1956	G719	This is a "bucket" variant for evidence that refers generically to missense variants happening at this position such as: G719A, G719D, G719S.		7	55241707	55241708			ENST00000275493.2	75	GRCh37					protein_altering_variant		2022-03-03 18:11:10 UTC	25.0		16612,45225,45224,16611,376075	GLY719,G719X			false
719	https://civicdb.org/links/variants/719	BRD4	23476	BRD4::NUTM1															transcript_fusion		2022-04-12 21:22:02 UTC	25.5		N/A	BRD4-NUTM1			false
720	https://civicdb.org/links/variants/720	EGFR	1956	S720			7	55241710	55241711			ENST00000275493.2	75	GRCh37					protein_altering_variant		2022-04-12 21:22:02 UTC	7.5		NONE FOUND	SER720			false
721	https://civicdb.org/links/variants/721	CYP2D6	1565	Loss-of-function			22	42522501	42526908			ENST00000360608.5	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	20.0		N/A				false
722	https://civicdb.org/links/variants/722	DDIT3	1649	FUS::DDIT3															transcript_fusion		2022-04-12 21:22:02 UTC	70.0			FUS-DDIT3			false
723	https://civicdb.org/links/variants/723	EGFR	1956	K757R			7	55242500	55242500	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2270A>G,NC_000007.13:g.55242500A>G,NM_005228.3:c.2270A>G,NP_005219.2:p.Lys757Arg,NM_005228.5:c.2270A>G,NC_000007.14:g.55174807A>G	2022-04-12 21:22:05 UTC	7.5	CA4266023	560009	LYS757ARG,RS397517102			false
724	https://civicdb.org/links/variants/724	EGFR	1956	E746G			7	55242467	55242467	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2237A>G,NC_000007.13:g.55242467A>G,NM_005228.3:c.2237A>G,NP_005219.2:p.Glu746Gly	2022-04-12 21:22:04 UTC	2.5	CA367584149	NONE FOUND	GLU746GLY			false
725	https://civicdb.org/links/variants/725	MLH1	4292	E13fs			3	37035075	37035075	G		ENST00000231790.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NM_000249.3:c.37delG,NP_000240.1:p.Glu13Argfs,ENST00000231790.2:c.37delG,NC_000003.11:g.37035075del	2022-04-12 21:22:04 UTC	2.5	CA010006	90190	GLU13ARGFS,RS63750081,E13FS*3			false
726	https://civicdb.org/links/variants/726	EGFR	1956	Exon 20 Insertion			7	55248991	55249022			ENST00000275493.2	75	GRCh37					inframe_insertion		2022-04-12 21:22:06 UTC	15.0						false
727	https://civicdb.org/links/variants/727	MSH2	4436	R383*			2	47656951	47656951	C	T	ENST00000233146.2	75	GRCh37					stop_gained	NM_000251.2:c.1147C>T,NP_000242.1:p.Arg383Ter,ENST00000233146.2:c.1147C>T,NC_000002.11:g.47656951C>T	2022-04-12 21:22:04 UTC	0.5	CA017356	90554	R383X,ARG383TER,RS63749849			false
728	https://civicdb.org/links/variants/728	MLH1	4292	V534R			3	37081718	37081719	GT	AG	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1600_1601delinsAG,NC_000003.11:g.37081718_37081719delinsAG	2022-04-12 21:22:01 UTC	2.5	CA913102764	NONE FOUND	VAL534ARG			false
729	https://civicdb.org/links/variants/729	UGT1A1	54658	UGT1A1*28			2	234668881	234668882		TATATATATATATA	ENST00000305208.5	75	GRCh37					microsatellite	NC_000002.11:g.234668881_234668882TA[7]	2022-04-12 21:22:04 UTC	50.0	unregistered	226028	RS8175347			false
730	https://civicdb.org/links/variants/730	MLH1	4292	G606FS*2			3	37089094	37089095	GG		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1816_1817delGG,NC_000003.11:g.37089094_37089095del	2022-04-12 21:22:04 UTC	2.5	CA913102766	NONE FOUND	GLY606FS			false
731	https://civicdb.org/links/variants/731	MLH1	4292	c.790+1G>A			3	37056036	37056036	G	A	ENST00000231790.2	75	GRCh37					splice_donor_variant	NM_000249.3:c.790+1G>A,NC_000003.11:g.37056036G>A,ENST00000231790.2:c.790+1G>A	2022-04-12 21:22:01 UTC	2.5	CA012109	90356	RS267607789			false
732	https://civicdb.org/links/variants/732	UGT1A1	54658	UGT1A1*60															microsatellite		2022-04-12 21:22:02 UTC	20.0						false
733	https://civicdb.org/links/variants/733	MLH1	4292	K618DEL			3	37089130	37089132	AAG		ENST00000231790.2	75	GRCh37					inframe_deletion	NC_000003.11:g.37089130_37089132del,ENST00000231790.2:c.1852_1854delAAG,NM_000249.3:c.1852_1854delAAG,NP_000240.1:p.Lys618del	2022-04-12 21:22:04 UTC	2.5	CA007087	17080	RS63751247,LYS618DEL			false
734	https://civicdb.org/links/variants/734	MLH1	4292	P138T																	2022-04-12 21:22:02 UTC	0.0						false
735	https://civicdb.org/links/variants/735	MLH1	4292	R687FS			3	37090464	37090464	C		ENST00000231790.2	75	GRCh37					frameshift_variant	NM_000249.3:c.2059delC,NP_000240.1:p.Arg687Glyfs,ENST00000231790.2:c.2059delC,NC_000003.11:g.37090464del	2022-04-12 21:22:04 UTC	2.5	CA279809	218022	ARG687GLYFS,RS863225381			false
736	https://civicdb.org/links/variants/736	EGFR	1956	V769_D770insASV			7	55249009	55249010		GCCAGCGTG	ENST00000275493.2	75	GRCh37					direct_tandem_duplication	NM_005228.4:c.2300_2308dupCCAGCGTGG,NP_005219.2:p.Val769_Asp770insAlaSerVal,ENST00000275493.2:c.2300_2308dupCCAGCGTGG	2022-04-15 13:56:44 UTC	7.5	CA180588	177678	VAL769_ASP770INSALASERVAL, V769_770INSASV			false
737	https://civicdb.org/links/variants/737	DPYD	1806	DPYD*2A HOMOZYGOSITY			1	97915614	97915614	C	T	ENST00000370192.3	75	GRCh37					splice_donor_variant	NC_000001.10:g.97915614C>T,NM_000110.3:c.1905+1G>A,ENST00000370192.3:c.1905+1G>A	2022-04-12 21:22:04 UTC	50.0	CA114277	432	RS3918290,DPYD*2A,DPYD:IVS14 + 1G>A,C.1905+1G>A			false
738	https://civicdb.org/links/variants/738	DPYD	1806	DPYD*13 HOMOZYGOSITY			1	97981343	97981343	A	C	ENST00000370192.3	75	GRCh37					missense_variant	NM_000110.3:c.1679T>G,NP_000101.2:p.Ile560Ser,ENST00000370192.3:c.1679T>G,NC_000001.10:g.97981343A>C	2022-04-12 21:22:04 UTC	50.0	CA228118	88975	RS55886062,ILE560SER,I560S			false
739	https://civicdb.org/links/variants/739	FOS	2353	TRUNCATING FUSION			14	75745477	75748127			ENST00000303562.4	75	GRCh37					stop_gained,transcript_fusion		2022-04-12 21:22:02 UTC	7.5						false
740	https://civicdb.org/links/variants/740	DPYD	1806	RS67376798 HOMOZYGOSITY															polymorphic_sequence_variant		2022-04-12 21:22:02 UTC	50.0		88974	C.2846A>T,P.ASP949VAL,N949V			false
741	https://civicdb.org/links/variants/741	MLH1	4292	R100*			3	37042536	37042536	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.298C>T,NP_000240.1:p.Arg100Ter,ENST00000231790.2:c.298C>T,NC_000003.11:g.37042536C>T	2022-04-12 21:22:04 UTC	2.5	CA009575	36550	ARG100TER,R100X,RS63751221			false
742	https://civicdb.org/links/variants/742	WWTR1	25937	WWTR1::CAMTA1			3	149235022	149290787			ENST00000465804.1	75	GRCh37	1	7721786	7829766	ENST00000303635.7	transcript_fusion		2022-04-12 21:22:02 UTC	20.0		N/A	T(1;3)(P36.3;Q25),WWTR1-CAMTA1			false
743	https://civicdb.org/links/variants/743	MLH1	4292	T117M			3	37045935	37045935	C	T	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.350C>T,NP_000240.1:p.Thr117Met,ENST00000231790.2:c.350C>T,NC_000003.11:g.37045935C>T	2022-04-12 21:22:04 UTC	2.5	CA009872	17094	THR117MET,RS63750781			false
744	https://civicdb.org/links/variants/744	MLH1	4292	Q426FS			3	37067365	37067365	C		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.1276delC,NC_000003.11:g.37067365del	2022-04-12 21:22:02 UTC	2.5	CA913102760	NONE FOUND	GLN426FS			false
745	https://civicdb.org/links/variants/745	MLH1	4292	V49A			3	37038139	37038139	T	C	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.146T>C,NC_000003.11:g.37038139T>C	2022-04-12 21:22:04 UTC	2.5	CA352035388	NONE FOUND	VAL49ALA			false
746	https://civicdb.org/links/variants/746	MLH1	4292	D667FS			3	37090406	37090406	C		ENST00000231790.2	75	GRCh37					frameshift_truncation	NC_000003.11:g.37090406del,ENST00000231790.2:c.2001del	2022-04-12 21:22:04 UTC	2.5	CA913102767	NONE FOUND	ASP667FS			false
747	https://civicdb.org/links/variants/747	MLH1	4292	M1L			3	37035039	37035039	A	T	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1A>T,NC_000003.11:g.37035039A>T	2022-04-12 21:22:04 UTC	2.5	CA352059785	NONE FOUND	MET1LEU			false
748	https://civicdb.org/links/variants/748	MLH1	4292	*757L			3	37092143	37092143	A	T	ENST00000231790.2	75	GRCh37					stop_lost	ENST00000231790.2:c.2270A>T,NC_000003.11:g.37092143A>T	2022-04-12 21:22:05 UTC	2.5	CA352069936	NONE FOUND	X757L			false
749	https://civicdb.org/links/variants/749	MLH1	4292	R265G			3	37058999	37058999	C	G	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.793C>G,NC_000003.11:g.37058999C>G	2022-04-12 21:22:02 UTC	2.5	CA352045752	NONE FOUND	ARG265GLY			false
750	https://civicdb.org/links/variants/750	MLH1	4292	V213FS			3	37053551	37053551	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	ENST00000231790.2:c.638delT,NC_000003.11:g.37053551del	2022-04-12 21:22:04 UTC	2.5	CA913102758	NONE FOUND	VAL213FS			false
751	https://civicdb.org/links/variants/751	MLH1	4292	N551T			3	37081770	37081770	A	C	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1652A>C,NP_000240.1:p.Asn551Thr,ENST00000231790.2:c.1652A>C,NC_000003.11:g.37081770A>C	2022-04-12 21:22:04 UTC	2.5	CA006238	89819	ASN551THR,RS63750271			false
752	https://civicdb.org/links/variants/752	MLH1	4292	A424T			3	37067359	37067359	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.1270G>A,NP_000240.1:p.Ala424Thr,ENST00000231790.2:c.1270G>A,NC_000003.11:g.37067359G>A	2022-04-12 21:22:04 UTC	2.5	CA028060	220203	ALA424THR,RS377433038			false
753	https://civicdb.org/links/variants/753	MLH1	4292	Q149*			3	37048546	37048546	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.445C>T,NP_000240.1:p.Gln149Ter,ENST00000231790.2:c.445C>T,NC_000003.11:g.37048546C>T	2022-04-12 21:22:03 UTC	2.5	CA010427	90219	Q149X,GLN149TER,RS63751302			false
754	https://civicdb.org/links/variants/754	MLH1	4292	R226*			3	37053589	37053589	C	T	ENST00000231790.2	75	GRCh37					stop_gained	NM_000249.3:c.676C>T,NP_000240.1:p.Arg226Ter,ENST00000231790.2:c.676C>T,NC_000003.11:g.37053589C>T	2022-04-12 21:22:04 UTC	2.5	CA011496	17087	R226X,ARG226TER,R128*,RS63751615			false
756	https://civicdb.org/links/variants/756	MLH1	4292	P536FS			3	37081726	37081726	T		ENST00000231790.2	75	GRCh37					frameshift_truncation	NC_000003.11:g.37081726del,ENST00000231790.2:c.1608del	2022-04-12 21:22:04 UTC	2.5	CA913102765	NONE FOUND	PRO536FS			false
757	https://civicdb.org/links/variants/757	MLH1	4292	G67R			3	37038192	37038192	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.199G>A,NP_000240.1:p.Gly67Arg,ENST00000231790.2:c.199G>A,NC_000003.11:g.37038192G>A	2022-04-12 21:22:04 UTC	2.5	CA008104	89992	GLY67ARG,RS63750206			false
758	https://civicdb.org/links/variants/758	MLH1	4292	I68S			3	37038196	37038196	T	G	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.203T>G,NC_000003.11:g.37038196T>G	2022-04-12 21:22:04 UTC	2.5	CA352035494	NONE FOUND	ILE68SER			false
759	https://civicdb.org/links/variants/759	MLH1	4292	G65D			3	37038187	37038187	G	A	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.194G>A,NP_000240.1:p.Gly65Asp,ENST00000231790.2:c.194G>A,NC_000003.11:g.37038187G>A	2022-04-12 21:22:04 UTC	2.5	CA007735	89955	GLY65ASP,RS63751465			false
760	https://civicdb.org/links/variants/760	MLH1	4292	A681V			3	37090447	37090447	C	T	ENST00000231790.2	75	GRCh37					missense_variant	NM_000249.3:c.2042C>T,NP_000240.1:p.Ala681Val,ENST00000231790.2:c.2042C>T,NC_000003.11:g.37090447C>T	2022-04-12 21:22:04 UTC	2.5	CA008313	90011	ALA681VAL,A440V,RS63750864			false
761	https://civicdb.org/links/variants/761	MSH6	2956	P138T			2	48018217	48018217	C	A	ENST00000234420.5	75	GRCh37					missense_variant	ENST00000234420.5:c.412C>A,NC_000002.11:g.48018217C>A	2022-04-12 21:22:04 UTC	2.5	CA346737117	NONE FOUND	PRO138THR			false
762	https://civicdb.org/links/variants/762	MSH2	4436	V273FS			2	47641433	47641433	T		ENST00000233146.2	75	GRCh37					frameshift_variant	ENST00000233146.2:c.818delT,NC_000002.11:g.47641433del	2022-04-12 21:22:04 UTC	2.5	CA913090558					false
763	https://civicdb.org/links/variants/763	MSH2	4436	E28FS			2	47630413	47630414		G	ENST00000233146.2	75	GRCh37					frameshift_elongation	NC_000002.11:g.47630414dupG	2022-04-12 21:22:04 UTC	2.5	CA913189237	NONE FOUND				false
764	https://civicdb.org/links/variants/764	VHL	7428	E55FS (c.163_164delGA)			3	10183694	10183695	GA		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NC_000003.11:g.10183694_10183695del,ENST00000256474.2:c.163_164delGA	2022-04-12 21:22:04 UTC	2.5	CA645524641	NONE FOUND	C.163_164DELGA,GLU55FS			false
765	https://civicdb.org/links/variants/765	MSH6	2956	I891FS			2	48027794	48027795	TC		ENST00000234420.5	75	GRCh37					frameshift_truncation	ENST00000234420.5:c.2672_2673delTC,NC_000002.11:g.48027794_48027795del	2022-04-12 21:22:02 UTC	2.5	CA913090565	NONE FOUND	ILE891FS			false
766	https://civicdb.org/links/variants/766	VHL	7428	E55RfsTer11 (c.163delG)			3	10183694	10183694	G		ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Glu55fs,NP_000542.1:p.Glu55ArgfsTer11,NM_000551.2:c.163delG,NC_000003.11:g.10183694del,ENST00000256474.2:c.163delG	2022-04-12 21:22:04 UTC	7.5	CA432536363	428800	C.163DELG,GLU55ARGFS			false
767	https://civicdb.org/links/variants/767	MSH6	2956	R1242H			2	48033421	48033421	G	A	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.3725G>A,NP_000170.1:p.Arg1242His,ENST00000234420.5:c.3725G>A,NC_000002.11:g.48033421G>A	2022-04-12 21:22:04 UTC	2.5	CA014077	140866	ARG1242HIS,RS63750119			false
768	https://civicdb.org/links/variants/768	PMS2	5395	R315*			7	6031649	6031649	G	A	ENST00000265849.7	75	GRCh37					stop_gained	NM_000535.6:c.943C>T,NP_000526.2:p.Arg315Ter,NC_000007.13:g.6031649G>A	2022-04-12 21:22:04 UTC	0.0	CA013335	91382	ARG315TER,RS200640585,R315X			false
769	https://civicdb.org/links/variants/769	MLH1	4292	M490T			3	37070334	37070334	T	C	ENST00000231790.2	75	GRCh37					missense_variant	ENST00000231790.2:c.1469T>C,NC_000003.11:g.37070334T>C	2022-04-12 21:22:04 UTC	2.5	CA352056416	NONE FOUND	MET490THR			false
770	https://civicdb.org/links/variants/770	MSH2	4436	K172*			2	47637380	47637380	A	T	ENST00000233146.2	75	GRCh37					stop_gained	ENST00000233146.2:c.514A>T,NC_000002.11:g.47637380A>T	2022-04-12 21:22:04 UTC	2.5	CA346730730	NONE FOUND	K172X,LYS172TER			false
771	https://civicdb.org/links/variants/771	VHL	7428	A56FS (c.164_165insG)			3	10183695	10183696		G	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insG,NC_000003.11:g.10183695_10183696insG,NC_000003.11:g.10183697dupG	2022-04-12 21:22:06 UTC	7.5	CA645524645	NONE FOUND	164INSG,C.164_165INSG,377_378INSG			false
772	https://civicdb.org/links/variants/772	HOXB13	10481	G84E			17	46805705	46805705	C	T	ENST00000290295.7	75	GRCh37					missense_variant	NC_000017.10:g.46805705C>T,NM_006361.5:c.251G>A,NP_006352.2:p.Gly84Glu,ENST00000290295.7:c.251G>A	2022-04-12 21:22:04 UTC	40.0	CA288225	128031	RS138213197,GLY84GLU			false
773	https://civicdb.org/links/variants/773	MSH2	4436	E483G			2	47690231	47690231	A	G	ENST00000233146.2	75	GRCh37					missense_variant	NC_000002.11:g.47690231A>G,ENST00000233146.2:c.1448A>G	2022-04-12 21:22:04 UTC	2.5	CA346726930	NONE FOUND	GLU483GLY			false
774	https://civicdb.org/links/variants/774	PDGFRA	5156	TNKS2::PDGFRA			10	93558069	93619405			ENST00000371627.4	75	GRCh37	4	55141008	55164414	ENST00000257290.5	transcript_fusion		2022-04-12 21:22:02 UTC	7.5		N/A	TNKS2-PDGFRA			false
775	https://civicdb.org/links/variants/775	MSH6	2956	V352I			2	48026176	48026176	G	A	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.1054G>A,NP_000170.1:p.Val352Ile,ENST00000234420.5:c.1054G>A,NC_000002.11:g.48026176G>A	2022-04-12 21:22:04 UTC	2.5	CA007915	182617	VAL352ILE,RS730881787			false
776	https://civicdb.org/links/variants/776	MSH6	2956	R1242C			2	48033420	48033420	C	T	ENST00000234420.5	75	GRCh37					missense_variant	NM_000179.2:c.3724C>T,NP_000170.1:p.Arg1242Cys,ENST00000234420.5:c.3724C>T,NC_000002.11:g.48033420C>T	2022-04-12 21:22:05 UTC	2.5	CA10578156	232375	ARG1242CYS,RS587779285			false
777	https://civicdb.org/links/variants/777	SLCO1B1	10599	RS4149056			12	21331549	21331549	T	C	ENST00000256958.2	75	GRCh37					missense_variant,polymorphic_sequence_variant	NC_000012.11:g.21331549T>C,NM_006446.4:c.521T>C,NP_006437.3:p.Val174Ala,ENST00000256958.2:c.521T>C	2022-04-12 21:22:04 UTC	15.0	CA6476722	37346	VAL174ALA,V174A			false
778	https://civicdb.org/links/variants/778	SLCO1B1	10599	N130D			12	21329738	21329738	A	G	ENST00000256958.2	75	GRCh37					missense_variant	NC_000012.11:g.21329738A>G	2022-04-12 21:22:04 UTC	15.0	CA6476674	259983	ASN130ASP,RS2306283			false
779	https://civicdb.org/links/variants/779	TYMS	7298	RS34743033			18	657646	657646	C	T	ENST00000323274.10	75								2022-04-12 21:22:02 UTC	15.0						false
780	https://civicdb.org/links/variants/780	GLI1	2735	ACTB::GLI1	Fusion of the hedgehog pathway component gene GLI1 to the Œ≤-actin gene (ACTB)  has been described as a mechanism of GLI1,and by extension hedgehog pathway, activation. These fusions have been described in histologically distinctive soft tissue tumours showing a pericytic phenotype.  Gene fusions retain the DNA-binding zinc finger domains of GLI1 and it is likely that the replacement of the promoter region of GLI1with that of the ubiquitously expressed ACTB gene leads to deregulation of GLI expression and its downstream target genes.														gene_fusion,transcript_fusion		2022-03-10 19:39:36 UTC	15.0		N/A	T(7;12)(P21-22;Q13-15),ACTB-GLI1			false
781	https://civicdb.org/links/variants/781	ERBB3	2065	V855A			12	56491672	56491672	T	C	ENST00000267101.3	75	GRCh37					missense_variant	NC_000012.11:g.56491672T>C,ENST000000267101.3:c.2564T>C	2022-04-12 21:22:04 UTC	2.0	CA385313732	NONE FOUND	VAL855ALA			false
782	https://civicdb.org/links/variants/782	FGFR2	2263	FGFR2::BICC1			10	123239371	123357917			ENST00000457416.2	75	GRCh37	10	60461834	60591195	ENST00000373886.3	transcript_fusion		2022-04-12 21:22:02 UTC	38.0		N/A	FGFR2-BICC1			false
783	https://civicdb.org/links/variants/783	FGFR2	2263	FGFR2::AHCYL1			10	123239371	123357917			ENST00000457416.2	75	GRCh37	1	110554984	110566357	ENST00000369799.5	transcript_fusion		2022-04-12 21:22:02 UTC	23.0		N/A	FGFR2-AHCYL1			false
784	https://civicdb.org/links/variants/784	CDKN2B	1030	METHYLATION			9	22009121	22009172			ENST00000276925.6	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
785	https://civicdb.org/links/variants/785	CHEK2	11200	1100DELC			22	29091857	29091857	G		ENST00000328354.6	75	GRCh37					frameshift_truncation	NC_000022.10:g.29091857delG,NM_007194.3:c.1100delC,NP_009125.1:p.Thr367Metfs,ENST00000328354.6:c.1100delC,NC_000022.10:g.29091857del	2022-04-12 21:22:04 UTC	15.0	CA288251	128042	THR367METFS,RS555607708			false
787	https://civicdb.org/links/variants/787	CHEK2	11200	I157T			22	29121087	29121087	A	G	ENST00000328354.6	75	GRCh37					missense_variant	NM_007194.3:c.470T>C,NP_009125.1:p.Ile157Thr,ENST00000328354.6:c.470T>C,NC_000022.10:g.29121087A>G	2022-04-12 21:22:04 UTC	15.0	CA117630	5591	ILE157THR,I200T,RS17879961			false
788	https://civicdb.org/links/variants/788	CHEK2	11200	IVS2+1G>A																	2022-04-12 21:22:02 UTC	10.0						false
792	https://civicdb.org/links/variants/792	PTPRD	5789	V253I			9	8521481	8521481	C	T	ENST00000381196.4	75	GRCh37					missense_variant	NM_002839.3:c.757G>A,NP_002830.1:p.Val253Ile,NC_000009.11:g.8521481C>T	2022-04-12 21:22:04 UTC	10.0	CA4984656	NONE FOUND	VAL253ILE			false
793	https://civicdb.org/links/variants/793	VHL	7428	A56fs (c.164_165insA)			3	10183695	10183696		A	ENST00000256474.2	75	GRCh37					frameshift_truncation	NP_000542.1:p.Ala56fs,NP_000542.1:p.Ala56GlyfsTer74,NM_000551.2:c.164_165insA,NC_000003.11:g.10183695_10183696insA,NC_000003.11:g.10183695dupA,NC_000003.12:g.10142011dup	2022-04-12 21:22:06 UTC	5.0	CA658795187	NONE FOUND	165INSA,C.164_165INSA			false
794	https://civicdb.org/links/variants/794	VHL	7428	E55= (c.165G>A)			3	10183696	10183696	G	A	ENST00000256474.2	75	GRCh37					synonymous_variant	NM_000551.2:c.165G>A,NC_000003.11:g.10183696G>A,ENST00000256474.2:c.165G>A,NP_000542.1:p.Glu55=	2022-04-12 21:22:04 UTC	5.0	CA432536364	486721	GLU55GLU,C.165G>A,RS1553619391,GLU55=,E55E (C.165G>A)			false
795	https://civicdb.org/links/variants/795	RRM1	6240	Overexpression			11	4116039	4160106			ENST00000300738.5	75	GRCh37					N/A	N/A	2022-04-12 21:22:02 UTC	2.0		N/A				false
796	https://civicdb.org/links/variants/796	RRM2	6241	OVEREXPRESSION			2	10262455	10271545			ENST00000360566.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	2.0		N/A				false
797	https://civicdb.org/links/variants/797	POLE	5426	Mutation			12	133202900	133256623			ENST00000320574.5	75	GRCh37					gene_variant		2022-08-02 23:04:33 UTC	15.0		N/A				false
798	https://civicdb.org/links/variants/798	MET	4233	D1228V			7	116423408	116423408	A	T	ENST00000397752.3	75	GRCh37					missense_variant	ENST00000318493.11:c.3737A>T,ENSP00000317272.6:p.Asp1246Val,NM_001127500.3:c.3737A>T,NP_001120972.1:p.Asp1246Val	2022-04-12 21:22:04 UTC	20.0	CA368991571	NONE FOUND	ASP1228VAL,D1246V,ASP1246VAL			false
799	https://civicdb.org/links/variants/799	RB1	5925	Mutation			13	48877911	49056122			ENST00000267163.4	75	GRCh37					gene_variant		2022-08-02 23:07:04 UTC	10.0						false
800	https://civicdb.org/links/variants/800	NTRK1	4914	SQSTM1::NTRK1		NTRK1 Fusions													transcript_fusion		2022-04-12 21:22:02 UTC	30.0		N/A	SQSTM1-NTRK1			false
801	https://civicdb.org/links/variants/801	NTRK3	4916	ETV6::NTRK3			12	11802788	12022903			ENST00000396373.4	75	GRCh37	15	88483984	88418230	ENST00000394480.2	transcript_fusion		2022-07-10 10:53:46 UTC	189.0		N/A	ETV6-NTRK3	61,39,56,59,60	https://civicdb.org/links/assertions/61	https://civicdb.org/links/assertions/39	https://civicdb.org/links/assertions/56	https://civicdb.org/links/assertions/59	https://civicdb.org/links/assertions/60	false
802	https://civicdb.org/links/variants/802	RUNX1	861	K83E			21	36259163	36259163	T	C	ENST00000344691.4	75	GRCh37					missense_variant	NC_000021.8:g.36259163T>C,NP_001001890.1:p.Lys83Glu,NM_001001890.2:c.247A>G,ENST00000344691.4:c.247A>G	2022-04-12 21:22:04 UTC	10.0	CA248613	14465	LYS83GLU,K110E,RS121912498			false
803	https://civicdb.org/links/variants/803	RUNX1	861	Y260*			21	36171704	36171704	G	T	ENST00000344691.4	75	GRCh37					stop_gained	NM_001001890.2:c.780C>A,NP_001001890.1:p.Tyr260Ter,NC_000021.8:g.36171704G>T,ENST00000344691.4:c.780C>A	2022-04-12 21:22:04 UTC	7.5	CA248619	14467	Y260X,TYR260TER,RS121912499			false
804	https://civicdb.org/links/variants/804	RUNX1	861	R135FSX177																	2022-04-12 21:22:02 UTC	10.0						false
805	https://civicdb.org/links/variants/805	NTRK3	4916	ETV6::NTRK3 G623R			15	88476265	88476265	C	T	ENST00000394480.2	75	GRCh37					missense_variant,transcript_fusion	NC_000015.9:g.88476265C>T,ENST00000394480.2:c.1867G>A	2022-04-12 21:22:04 UTC	10.0	CA393914380	NONE FOUND	GLY623ARG,ETV6-NTRK3 G623R			false
806	https://civicdb.org/links/variants/806	RUNX1	861	D198Y	D198Y was observed in a pedigree with a history of Familial platelet disorder with predisposition to acute myeloid leukemia. It occurs within the Runt domain of RUNX1, known to be associated with the disease.		21	36231792	36231792	C	A	ENST00000300305.3	75	GRCh37					missense_variant,loss_of_function_variant	NC_000021.8:g.36231792C>A	2018-11-30 14:44:38 UTC	7.5	CA410207975	NONE FOUND	ASP198TYR			false
807	https://civicdb.org/links/variants/807	RUNX1	861	A107P			21	36252962	36252962	C	G	ENST00000344691.4	75	GRCh37					missense_variant	NM_001754.4:c.400G>C,NP_001745.2:p.Ala134Pro,NC_000021.8:g.36252962C>G,ENST00000344691.4:c.400G>C	2022-04-12 21:22:04 UTC	12.5	CA248623	14468	A134P,ALA134PRO,RS74315451			false
808	https://civicdb.org/links/variants/808	MSH2	4436	Loss			2	47630108	47710367			ENST00000233146.2	75	GRCh37					loss_of_function_variant		2022-08-03 16:03:51 UTC	7.5		N/A				false
809	https://civicdb.org/links/variants/809	MSH6	2956	LOSS			2	48010221	48037240			ENST00000234420.5	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	7.5		N/A				false
810	https://civicdb.org/links/variants/810	RUNX1	861	T148HFSX9			21	36252913	36252920	GCTGCGGT		ENST00000300305.3	75	GRCh37					frameshift_truncation	NM_001754.4:c.442_449delACCGCAGC,NP_001745.2:p.Thr148Hisfs,NC_000021.8:g.36252913_36252920del,ENST00000300305.3:c.442_449delACCGCAGC	2022-04-12 21:22:04 UTC	5.0	CA248627	14470	C.442_449DEL,THR148HISFSX9,RS587776811			false
814	https://civicdb.org/links/variants/814	DDX41	51428	R164W			5	176942767	176942767	G	A	ENST00000507955.1	75	GRCh37					missense_variant		2022-04-12 21:22:04 UTC	7.5	CA358665					false
816	https://civicdb.org/links/variants/816	ERBB2	2064	G776L			17	37880997	37880998	GG	CT	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2326_2327delinsCT,NC_000017.10:g.37880997_37880998delinsCT,NP_001276866.1:p.Gly776Leu,NM_001289937.1:c.2326_2327delinsCT	2022-04-12 21:22:04 UTC	7.5	CA913189238	NONE FOUND	GLY776LEU			false
817	https://civicdb.org/links/variants/817	ERBB2	2064	G778_P780DUP			17	37881011	37881012		GGCTCCCCA	ENST00000269571.5	75	GRCh37					inframe_insertion	NM_004448.3:c.2332_2340dupGGCTCCCCA,ENST00000269571.5:c.2332_2340dupGGCTCCCCA	2022-04-12 21:22:04 UTC	15.0	CA135401	44993	GLY778_PRO780DUP			false
818	https://civicdb.org/links/variants/818	ERBB2	2064	M774DELINSWLV			17	37880991	37880991	A	TGGCTGG	ENST00000269571.5	75	GRCh37					inframe_indel		2022-04-12 21:22:02 UTC	7.5		NONE FOUND				false
819	https://civicdb.org/links/variants/819	PTPRB	5787	Loss-of-function			12	70910630	71031220			ENST00000334414.6	75	GRCh37					loss_of_function_variant		2022-04-12 21:22:02 UTC	3.0		N/A				false
820	https://civicdb.org/links/variants/820	VHL	7428	A149S (c.445G>T)			3	10188302	10188302	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NP_000542.1:p.Ala149Ser,NM_000551.2:c.445G>T,ENST00000256474.2:c.445G>T,NC_000003.11:g.10188302G>T	2022-04-12 21:22:04 UTC	17.5	CA020355	127829	ALA149SER,C.445G>T,RS587780077			false
821	https://civicdb.org/links/variants/821	HLA-C	3107	COPY-NEUTRAL LOSS OF HETEROZYGOSITY																	2022-04-12 21:22:02 UTC	7.5						false
822	https://civicdb.org/links/variants/822	JAK1	3716	S703I			1	65311203	65311203	C	A	ENST00000342505.4	75	GRCh37					missense_variant	ENST00000342505.4:c.2108G>T,NC_000001.10:g.65311203C>A	2022-04-12 21:22:04 UTC	4.0	CA340667333	NONE FOUND	SER703ILE			false
823	https://civicdb.org/links/variants/823	EPCAM	4072	3' Exon Deletion			2	47612305	47614173			ENST00000263735	75	GRCh37					disruptive_inframe_deletion		2022-09-27 15:29:28 UTC	20.0						false
825	https://civicdb.org/links/variants/825	ARAF	369	S490T			X	47429340	47429340	T	A	ENST00000377045.4	75	GRCh37					missense_variant		2022-04-12 21:22:04 UTC	2.5	CA412818377	NONE FOUND	SER490THR			false
826	https://civicdb.org/links/variants/826	GNAS	2778	R201C			20	57484420	57484420	C	T	ENST00000371085.3	75	GRCh37					missense_variant	NM_000516.5:c.601C>T,NP_000507.1:p.Arg201Cys,NC_000020.10:g.57484420C>T,ENST00000371085.3:c.601C>T	2022-04-12 21:22:04 UTC	5.0	CA126067	15933	ARG201CYS,R202C,RS11554273			false
827	https://civicdb.org/links/variants/827	FGFR3	2261	Mutation			4	1795039	1810599			ENST00000340107.4	75	GRCh37							2022-04-12 21:22:06 UTC	70.0						false
829	https://civicdb.org/links/variants/829	VHL	7428	M54IFS (c.162_166delGGAGG)			3	10183693	10183697	GGAGG		ENST00000256474.2	75	GRCh37					frameshift_truncation	NM_000551.2:c.162_166delGGAGG,NP_000542.1:p.Met54IlefsTer76,NC_000003.11:g.10183693_10183697del,ENST00000256474.2:c.162_166delGGAGG	2022-04-12 21:22:04 UTC	2.5	CA645524639	NONE FOUND	C.162_166DELGGAGG,MET54ILEFS			false
830	https://civicdb.org/links/variants/830	FGFR3	2261	FGFR3::TACC3			4	1795039	1808661			ENST00000340107.4	75	GRCh37	4	1741429	1746898	ENST00000313288.4	transcript_fusion		2022-04-12 21:22:04 UTC	22.5		495323	FGFR3-TACC3			false
838	https://civicdb.org/links/variants/838	PTEN	5728	R173C			10	89711899	89711899	C	T	ENST00000371953.3	75	GRCh37					missense_variant	NM_000314.6:c.517C>T,NP_000305.3:p.Arg173Cys,ENST00000371953.3:c.517C>T,NC_000010.10:g.89711899C>T	2022-04-12 21:22:04 UTC	13.0	CA000498	189500	ARG173CYS,RS121913293			false
839	https://civicdb.org/links/variants/839	ALK	238	Alternative Transcript (ATI)	This novel ALK transcript (alternative isoform) initiates from a de novo alternative transcription initiation (ATI) site in ALK intron 19.																2021-04-09 19:04:55 UTC	20.0			ALK(ATI),ALK INTRON 19 ATI ISOFORM,ALK ALTERNATIVE ISOFORM			false
843	https://civicdb.org/links/variants/843	VHL	7428	Exon 1-3 Deletion			3	10183532	10191649			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_642+?del	2022-04-12 21:22:02 UTC	17.5						false
844	https://civicdb.org/links/variants/844	VHL	7428	Exon 1 Deletion			3	10183532	10183871			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_340+?del	2022-04-12 21:22:02 UTC	20.0						false
845	https://civicdb.org/links/variants/845	VHL	7428	Exon 1-2 Deletion			3	10183532	10188320			ENST00000256474.2	75	GRCh37					exon_loss_variant	ENST00000256474.2:c.1-?_463+?del	2022-04-12 21:22:02 UTC	7.5						false
846	https://civicdb.org/links/variants/846	VHL	7428	M1FS (c.1_17del17)			3	10183532	10183548	ATGCCCCGGAGGGCGGA		ENST00000256474.2	75	GRCh37					start_lost	ENST00000256474.2:c.1_17del17,NC_000003.11:g.10183532_10183548del,NM_000551.3:c.1_17del	2022-04-12 21:22:04 UTC	2.5	CA645524623	NONE FOUND	C.1_17DEL17,MET1FS			false
847	https://civicdb.org/links/variants/847	VHL	7428	M1? (c.1-1_20del21)			3	10183531	10183551	AATGCCCCGGAGGGCGGAGAA		ENST00000256474.2	75	GRCh37					start_lost	NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.1-1_20del21,ENST00000256474.2:c.1-1_20del21,NC_000003.11:g.10183531_10183551del	2022-04-12 21:22:04 UTC	2.5	CA645524624	NONE FOUND	MET1 LOSS,START LOSS,NO INITIATION,C.1-1_20DEL21			false
848	https://civicdb.org/links/variants/848	VHL	7428	M1? (c.3G>A)			3	10183534	10183534	G	A	ENST00000256474.2	75	GRCh37					start_lost	NP_000542.1:p.0,NP_000542.1:p.Met1?,NM_000551.3:c.3G>A,ENST00000256474.2:c.3G>A,NC_000003.11:g.10183534G>A	2022-04-12 21:22:06 UTC	2.5	CA020331	135406	MET1 LOSS,START LOSS,NO INITIATION,C.3G>A,RS578091032			false
849	https://civicdb.org/links/variants/849	VHL	7428	N7D (c.19A>G)			3	10183550	10183550	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10183550A>G,NM_000551.3:c.19A>G,ENST00000256474.2:c.19A>G,NP_000542.1:c.Asn7Asp	2022-04-12 21:22:04 UTC	2.5	CA351747044	NONE FOUND	ASN7ASP,C.19A>G,RS1311403806			false
850	https://civicdb.org/links/variants/850	VHL	7428	P25L (c.74C>T)			3	10183605	10183605	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.74C>T,NP_000542.1:p.Pro25Leu,ENST00000256474.2:c.74C>T,NC_000003.11:g.10183605C>T	2022-04-12 21:22:04 UTC	7.5	CA020538	93330	PRO25LEU,C.74C>T,RS35460768			false
851	https://civicdb.org/links/variants/851	VHL	7428	P59fs (c.173_174insC)			3	10183704	10183705		C	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.173_174insC,NP_000542.1:p.Pro59AlafsTer73,NM_000551.3:c.173_174insC,NC_000003.11:g.10183704_10183705insC	2022-04-12 21:22:04 UTC	7.5	CA658795188	NONE FOUND	PRO59FS,C.173_174INSC			false
852	https://civicdb.org/links/variants/852	VHL	7428	Y98FS (c.291_310del20)			3	10183822	10183841	CTACCCAACGCTGCCGCCTG		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.291_310del,NC_000003.11:g.10183822_10183841del,NM_000551.3:c.291_310del,NP_000542.1:p.Tyr98HisfsTer27	2022-04-12 21:22:06 UTC	2.5	CA645524819	NONE FOUND	C.291_310DEL20,TYR98FS			false
860	https://civicdb.org/links/variants/860	NTRK1	4914	Overexpression			1	156830686	156851434			ENST00000524377.1	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	20.0		N/A				false
862	https://civicdb.org/links/variants/862	PDGFRA	5156	P577S			4	55141083	55141083	C	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.1729C>T,NP_006197.1:p.Pro577Ser,NC_000004.11:g.55141083C>T,ENST00000257290.5:c.1729C>T	2022-04-12 21:22:02 UTC	3.0	CA16602636	376181	PRO577SER,RS1057519811			false
863	https://civicdb.org/links/variants/863	PDGFRA	5156	R841K			4	55152090	55152090	G	A	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2522G>A,NP_006197.1:p.Arg841Lys,NC_000004.11:g.55152090G>A,ENST00000257290.5:c.2522G>A	2022-04-12 21:22:04 UTC	3.0	CA16602638	376183	ARG841LYS,RS1057519813			false
864	https://civicdb.org/links/variants/864	PDGFRA	5156	H845Y			4	55152101	55152101	C	T	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2533C>T,NP_006197.1:p.His845Tyr,NC_000004.11:g.55152101C>T,ENST00000257290.5:c.2533C>T	2022-04-12 21:22:04 UTC	3.0	CA16602639	376184	HIS845TYR,RS1057519814			false
865	https://civicdb.org/links/variants/865	PDGFRA	5156	G853D			4	55152126	55152126	G	A	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.4:c.2558G>A,NP_006197.1:p.Gly853Asp,NC_000004.11:g.55152126G>A,ENST00000257290.5:c.2558G>A	2022-04-12 21:22:04 UTC	3.0	CA16602640	376185	GLY853ASP,RS763576329			false
867	https://civicdb.org/links/variants/867	MTAP	4507	Underexpression																	2022-04-12 21:22:02 UTC	1.0						false
868	https://civicdb.org/links/variants/868	VPS37A	137492	Underexpression			8	17104080	17155533			ENST00000324849.4	75	GRCh37					N/A		2022-08-03 16:00:45 UTC	3.0		N/A				false
870	https://civicdb.org/links/variants/870	BTK	695	T316A			X	100613633	100613633	T	C	ENST00000308731.7	75	GRCh37					missense_variant	ENST00000308731.7:c.946T>C,NM_000061.2:c.946T>C,NC_000023.10:g.100613633T>C	2022-04-12 21:22:04 UTC	10.0	CA413928923	NONE FOUND	THR316ALA			false
871	https://civicdb.org/links/variants/871	ERBB2	2064	T862A			17	37881392	37881392	A	G	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2584A>G,NC_000017.10:g.37881392A>G,NM_001289937.1:c.2584A>G,NP_001276866.1:p.Thr862Ala	2022-04-12 21:22:04 UTC	3.0	CA399304738	NONE FOUND	THR862ALA			false
872	https://civicdb.org/links/variants/872	ERBB2	2064	V773A			17	37880989	37880989	T	C	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2318T>C,NC_000017.10:g.37880989T>C,NM_004448.3:c.2318T>C,NP_004439.2:p.Val773Ala	2022-04-12 21:22:04 UTC	1.0	CA399302815	NONE FOUND	VAL773ALA			false
873	https://civicdb.org/links/variants/873	ERBB2	2064	N857S			17	37881378	37881378	A	G	ENST00000269571.5	75	GRCh37					missense_variant	NC_000017.10:g.37881378A>G,NP_004439.2:p.Asn857Ser,NM_004448.3:c.2570A>G,ENST00000269571.5:c.2570A>G	2022-04-12 21:22:04 UTC	1.0	CA123601	13880	ASN857SER,N827S,N842S,RS28933370			false
874	https://civicdb.org/links/variants/874	ERBB2	2064	H878Y			17	37881440	37881440	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2632C>T,NC_000017.10:g.37881440C>T,NM_001289937.1:c.2632C>T,NP_001276866.1:p.His878Tyr	2022-04-12 21:22:04 UTC	1.0	CA399305170	NONE FOUND	HIS878TYR			false
875	https://civicdb.org/links/variants/875	ERBB2	2064	Overexpression															N/A		2022-04-12 21:22:05 UTC	77.5		N/A				false
876	https://civicdb.org/links/variants/876	GNAS	2778	R201															amino_acid_substitution		2022-04-12 21:22:03 UTC	15.0						false
877	https://civicdb.org/links/variants/877	GNAS	2778	c.393T>C			20	57428713	57428713	T	C	ENST00000371100.4	75	GRCh37					synonymous_variant	NC_000020.11:g.58903752C>T,NC_000020.10:g.57478807C>T,NM_000516.4:c.393C>T,NP_000507.1:p.Ile131=	2022-04-12 21:22:06 UTC	165.0	CA409455494	197681	I131=,RS7121,L131=			false
878	https://civicdb.org/links/variants/878	NRAS	4893	G12D			1	115258747	115258747	C	T	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.35G>A,NP_002515.1:p.Gly12Asp,NC_000001.10:g.115258747C>T,ENST00000369535.4:c.35G>A	2022-04-12 21:22:04 UTC	7.5	CA130425	39648	RS121913237,GLY12ASP			false
879	https://civicdb.org/links/variants/879	TP53	7157	G245S			17	7577548	7577548	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NC_000017.10:g.7577548C>T,NM_000546.5:c.733G>A,NP_000537.3:p.Gly245Ser,ENST00000269305.4:c.733G>A	2022-07-21 17:40:57 UTC	10.0	CA000367	12365	RS28934575			false
881	https://civicdb.org/links/variants/881	PIK3CA	5290	E545Q			3	178936091	178936091	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1633G>C,NP_006209.2:p.Glu545Gln,NC_000003.11:g.178936091G>C,ENST00000263967.3:c.1633G>C	2022-04-12 21:22:04 UTC	7.5	CA16602379	375896	RS104886003,GLU545GLN			false
883	https://civicdb.org/links/variants/883	PIK3CA	5290	E545G			3	178936092	178936092	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1634A>G,NP_006209.2:p.Glu545Gly,NC_000003.11:g.178936092A>G,ENST00000263967.3:c.1634A>G	2022-04-12 21:22:04 UTC	2.0	CA123336	13656	RS121913274,GLU545GLY			false
885	https://civicdb.org/links/variants/885	PIK3CA	5290	Q546K			3	178936094	178936094	C	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1636C>A,NP_006209.2:p.Gln546Lys,NC_000003.11:g.178936094C>A,ENST00000263967.3:c.1636C>A	2022-04-12 21:22:04 UTC	5.0	CA123338	13657	RS121913286,GLN546LYS			false
892	https://civicdb.org/links/variants/892	ABL1	25	BCR::ABL F359V			9	133748414	133748414	T	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1075T>G,NP_005148.2:p.Phe359Val,NC_000009.11:g.133748414T>G,ENST00000318560.5:c.1075T>G	2022-04-12 21:22:05 UTC	54.0	CA16602557	376096	RS121913452,BCR-ABL F378V,BCR-ABL PHE359VAL,BCR-ABL1 F359V,BCR-ABL1 PHE359VAL,BCR-ABL F359V			false
893	https://civicdb.org/links/variants/893	NRAS	4893	Q61H			1	115256528	115256528	T	G	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.183A>C,NP_002515.1:p.Gln61His,NC_000001.10:g.115256528T>G,ENST00000369535.4:c.183A>C	2022-04-12 21:22:04 UTC	0.0	CA16602358	375871	RS121913255,GLN61HIS			false
896	https://civicdb.org/links/variants/896	NRAS	4893	G13R			1	115258745	115258745	C	G	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.37G>C,NP_002515.1:p.Gly13Arg,NC_000001.10:g.115258745C>G,ENST00000369535.4:c.37G>C	2022-04-12 21:22:04 UTC	2.5	CA151261	13899	RS121434595,GLY13ARG			false
897	https://civicdb.org/links/variants/897	NRAS	4893	G12C			1	115258748	115258748	C	A	ENST00000369535.4	75	GRCh37					missense_variant	NM_002524.4:c.34G>T,NP_002515.1:p.Gly12Cys,NC_000001.10:g.115258748C>A,ENST00000369535.4:c.34G>T	2022-04-12 21:22:04 UTC	0.0	CA297020	40468	RS121913250,GLY12CYS			false
901	https://civicdb.org/links/variants/901	ATM	472	T2666A			11	108204681	108204681	A	G	ENST00000278616.4	75	GRCh37					missense_variant	NC_000011.9:g.108204681A>G	2022-04-12 21:22:04 UTC	3.0	CA349494	219594				false
903	https://civicdb.org/links/variants/903	ATM	472	R3008C			11	108236086	108236086	C	T	ENST00000278616.4	75	GRCh37					missense_variant	NC_000011.9:g.108236086C>T	2022-04-12 21:22:04 UTC	3.0	CA294307					false
905	https://civicdb.org/links/variants/905	KRAS	3845	A146P			12	25378562	25378562	C	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.436G>C,NP_004976.2:p.Ala146Pro,NC_000012.11:g.25378562C>G,ENST00000256078.4:c.436G>C	2022-04-12 21:22:04 UTC	7.5	CA16602441	375963	RS121913527,ALA146PRO			false
906	https://civicdb.org/links/variants/906	KRAS	3845	A146T			12	25378562	25378562	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.436G>A,NP_004976.2:p.Ala146Thr,NC_000012.11:g.25378562C>T,ENST00000256078.4:c.436G>A	2022-04-12 21:22:04 UTC	21.0	CA245262	197243	RS121913527,ALA146THR			false
907	https://civicdb.org/links/variants/907	KRAS	3845	Q61H			12	25380275	25380275	T	G	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.183A>C,NP_004976.2:p.Gln61His,NC_000012.11:g.25380275T>G,ENST00000256078.4:c.183A>C	2022-04-12 21:22:04 UTC	10.5	CA180922	177881	RS17851045,GLN61HIS			false
908	https://civicdb.org/links/variants/908	KRAS	3845	Q61L			12	25380276	25380276	T	A	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.182A>T,NP_004976.2:p.Gln61Leu,NC_000012.11:g.25380276T>A,ENST00000256078.4:c.182A>T	2022-04-12 21:22:04 UTC	7.5	CA210876	45116	RS121913240,GLN61LEU			false
909	https://civicdb.org/links/variants/909	KRAS	3845	Q61R			12	25380276	25380276	T	C	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.182A>G,NP_004976.2:p.Gln61Arg,NC_000012.11:g.25380276T>C,ENST00000256078.4:c.182A>G	2022-04-12 21:22:03 UTC	7.5	CA261702	45115	RS121913240,GLN61ARG			false
910	https://civicdb.org/links/variants/910	KRAS	3845	Q61K			12	25380277	25380277	G	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.181C>A,NP_004976.2:p.Gln61Lys,NC_000012.11:g.25380277G>T,ENST00000256078.4:c.181C>A	2022-04-12 21:22:03 UTC	7.5	CA180750	177777	RS121913238,GLN61LYS			false
913	https://civicdb.org/links/variants/913	KRAS	3845	G12S			12	25398285	25398285	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NM_004985.4:c.34G>A,NP_004976.2:p.Gly12Ser,NC_000012.11:g.25398285C>T,ENST00000256078.4:c.34G>A	2022-04-12 21:22:04 UTC	38.0	CA135565	12584	RS121913530,GLY12SER			false
915	https://civicdb.org/links/variants/915	TP53	7157	E286K										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
916	https://civicdb.org/links/variants/916	TP53	7157	R282W										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
918	https://civicdb.org/links/variants/918	TP53	7157	R273L			17	7577120	7577120	C	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.818G>T,NP_000537.3:p.Arg273Leu,NC_000017.10:g.7577120C>A,ENST00000269305.4:c.818G>T	2022-04-12 21:22:03 UTC	0.0	CA001530	376655	RS28934576,ARG273LEU			false
922	https://civicdb.org/links/variants/922	TP53	7157	Y220C			17	7578190	7578190	T	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.659A>G,NP_000537.3:p.Tyr220Cys,NC_000017.10:g.7578190T>C,ENST00000269305.4:c.659A>G	2022-04-12 21:22:05 UTC	15.5	CA000315	127819	RS121912666,TYR220CYS			false
924	https://civicdb.org/links/variants/924	TP53	7157	C135W			17	7578525	7578525	G	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.405C>G,NP_000537.3:p.Cys135Trp,NC_000017.10:g.7578525G>C,ENST00000269305.4:c.405C>G	2022-07-21 16:57:22 UTC	3.0	CA16602987	376561	CYS135TRP,C3W,C96W			false
929	https://civicdb.org/links/variants/929	PIK3CA	5290	R88Q			3	178916876	178916876	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NC_000003.12:g.179199088G>A,NC_000003.11:g.178916876G>A,NM_006218.4:c.263G>A,NP_006209.2:p.Arg88Gln	2022-04-12 21:22:06 UTC	0.0	CA16602516	376049	RS121913287,ARG88GLN			false
930	https://civicdb.org/links/variants/930	PIK3CA	5290	N345K			3	178921553	178921553	T	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1035T>A,NP_006209.2:p.Asn345Lys,NC_000003.11:g.178921553T>A,ENST00000263967.3:c.1035T>A	2022-04-12 21:22:04 UTC	0.0	CA16602517	376050	RS121913284,ASN345LYS			false
931	https://civicdb.org/links/variants/931	PIK3CA	5290	C420R			3	178927980	178927980	T	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1258T>C,NP_006209.2:p.Cys420Arg,NC_000003.11:g.178927980T>C,ENST00000263967.3:c.1258T>C	2022-04-12 21:22:04 UTC	12.5	CA180900	31945	RS121913272,CYS420ARG			false
940	https://civicdb.org/links/variants/940	PIK3CA	5290	G1049R			3	178952090	178952090	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3145G>C,NP_006209.2:p.Gly1049Arg,NC_000003.11:g.178952090G>C,ENST00000263967.3:c.3145G>C	2022-04-12 21:22:04 UTC	0.0	CA16602520	376053	RS121913277,GLY1049ARG			false
941	https://civicdb.org/links/variants/941	PDGFRA	5156	V561D			4	55141036	55141036	T	A	ENST00000257290.5	75	GRCh37					missense_variant	NM_006206.5:c.1682T>A,NP_006197.1:p.Val561Asp,NC_000004.11:g.55141036T>A,ENST00000257290.5:c.1682T>A	2022-04-12 21:22:04 UTC	8.5	CA123203	13546	RS121908586			false
943	https://civicdb.org/links/variants/943	PDGFRA	5156	D842_H845DELDIMH										GRCh37							2022-04-12 21:22:05 UTC	2.0						false
946	https://civicdb.org/links/variants/946	KIT	3815	Y503_F504insAY			4	55592185	55592186		GCCTAT	ENST00000288135.5	75	GRCh37					inframe_insertion	NC_000004.11:g.55592185_55592186insGCCTAT	2022-04-12 21:22:05 UTC	2.0	CA645516719					false
948	https://civicdb.org/links/variants/948	KIT	3815	K550_W557del			4	55593582	55593605	AAACCCATGTATGAAGTACAGTGG		ENST00000288135.5	75	GRCh37					inframe_deletion	ENST00000288135.5:c.1648_1671del AAACCCATGTATGAAGTACAGTGG	2022-04-15 13:56:44 UTC	2.0	CA645516733	NONE FOUND				false
949	https://civicdb.org/links/variants/949	KIT	3815	K550_K558del			4	55593582	55593608	AAACCCATGTATGAAGTACAGTGGAAG		ENST00000288135.5	75	GRCh37					inframe_deletion	NM_000222.2:c.1648_1674del27,NP_000213.1:p.Lys550_Lys558del,NC_000004.11:g.55593582_55593608del27,ENST00000288135.5:c.1648_1674del27	2022-04-12 21:22:05 UTC	5.0	CA123524	13857	RS121913234,KPMYEVQWK550-558DEL			false
961	https://civicdb.org/links/variants/961	KIT	3815	W557_K558del			4	55593603	55593608	TGGAAG		ENST00000288135.5	75	GRCh37					conservative_inframe_deletion		2022-04-12 21:22:05 UTC	14.5	CA356974	222957				false
964	https://civicdb.org/links/variants/964	KIT	3815	K558_V559del			4	55593606	55593611	AAGGTT		ENST00000288135.5	75	GRCh37						ENST00000288135.5:c.1672_1677delAAGGTT	2022-04-12 21:22:04 UTC	5.0	CA645516838	NONE FOUND				false
968	https://civicdb.org/links/variants/968	KIT	3815	V559D			4	55593610	55593610	T	A	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1676T>A,NP_000213.1:p.Val559Asp,NC_000004.11:g.55593610T>A,ENST00000288135.5:c.1676T>A	2022-04-12 21:22:05 UTC	11.5	CA123522	13856	RS121913517,VAL559ASP			false
971	https://civicdb.org/links/variants/971	KIT	3815	V560D			4	55593613	55593613	T	A	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.1679T>A,NM_000222.2:c.1679T>A,NP_000213.1:p.Val560Asp,NC_000004.11:g.55593613T>A	2022-04-12 21:22:02 UTC	14.5	CA16602396	375914	VAL560ASP,RS121913521			false
972	https://civicdb.org/links/variants/972	KIT	3815	V560G			4	55593613	55593613	T	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1679T>G,NP_000213.1:p.Val560Gly,NC_000004.11:g.55593613T>G,ENST00000288135.5:c.1679T>G	2022-04-12 21:22:05 UTC	5.0	CA16602398	375916,376735	RS121913521,VAL560GLY			false
977	https://civicdb.org/links/variants/977	KIT	3815	D579del			4	55593669	55593671	GAT		ENST00000288135.5	75	GRCh37					conservative_inframe_deletion	ENST00000288135.5:c.1735_1737delGAT,NM_000222.2:c.1735_1737delGAT,NP_000213.1:p.Asp579del,NC_000004.11:g.55593669_55593671delGAT	2022-04-12 21:22:05 UTC	12.5	CA16611553	409725	ASP579DEL,RS1060502543			false
978	https://civicdb.org/links/variants/978	KIT	3815	K642E			4	55594221	55594221	A	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.1924A>G,NP_000213.1:p.Lys642Glu,NC_000004.11:g.55594221A>G,ENST00000288135.5:c.1924A>G	2022-04-12 21:22:04 UTC	10.0	CA123547	13866	RS121913512,LYS642GLU			false
983	https://civicdb.org/links/variants/983	KIT	3815	D816H		KIT Exon 17	4	55599320	55599320	G	C	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2446G>C,NP_000213.1:p.Asp816His,NC_000004.11:g.55599320G>C,ENST00000288135.5:c.2446G>C	2022-04-12 21:22:04 UTC	7.5	CA123540	13863	ASP816HIS,RS121913506			false
986	https://civicdb.org/links/variants/986	KIT	3815	D820Y		KIT Exon 17	4	55599332	55599332	G	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2458G>T,NP_000213.1:p.Asp820Tyr,NC_000004.11:g.55599332G>T,ENST00000288135.5:c.2458G>T	2022-04-12 21:22:04 UTC	14.5	CA16602408	375928	ASP820TYR,RS1057519710			false
987	https://civicdb.org/links/variants/987	KIT	3815	N822H		KIT Exon 17	4	55599338	55599338	A	C			GRCh37					missense_variant		2022-04-12 21:22:05 UTC	0.0	CA356911968					false
989	https://civicdb.org/links/variants/989	KIT	3815	Y823D		KIT Exon 17	4	55599341	55599341	T	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2467T>G,NP_000213.1:p.Tyr823Asp,NC_000004.11:g.55599341T>G,ENST00000288135.5:c.2467T>G	2022-04-12 21:22:05 UTC	7.5	CA16602561	376101	TYR823ASP,RS1057519761			false
990	https://civicdb.org/links/variants/990	KIT	3815	A829P			4	55602664	55602664	G	C			GRCh37					missense_variant	NC_000004.11:g.55602664G>C,NM_000222.2:c.2485G>C,NP_000213.1:p.Ala829Pro	2022-04-12 21:22:02 UTC	8.0	CA16602413	375933	RS1057519713,ALA829PRO			false
992	https://civicdb.org/links/variants/992	BRAF	673	G469A			7	140481402	140481402	C	G	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1406G>C,NP_004324.2:p.Gly469Ala,NC_000007.13:g.140481402C>G,ENST00000288602.6:c.1406G>C	2022-04-12 21:22:04 UTC	5.0	CA123655	13971	RS121913355,GLY469ALA			false
993	https://civicdb.org/links/variants/993	BRAF	673	G469E	The BRAF G469E mutation has a markedly reduced kinase activity and thus activates the MEK pathway through CRAF binding.		7	140481402	140481402	C	T			GRCh37					missense_variant		2019-03-22 01:59:05 UTC	6.0	CA279970		RS121913355			false
994	https://civicdb.org/links/variants/994	EGFR	1956	R108K			7	55211080	55211080	G	A	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.323G>A,NP_005219.2:p.Arg108Lys,NC_000007.13:g.55211080G>A,ENST00000275493.2:c.323G>A	2022-04-12 21:22:02 UTC	3.0	CA16602662	376207	ARG108LYS			false
995	https://civicdb.org/links/variants/995	EGFR	1956	T263P			7	55221743	55221743	A	C	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.787A>C,NP_005219.2:p.Thr263Pro,NC_000007.13:g.55221743A>C,ENST00000275493.2:c.787A>C	2022-04-12 21:22:07 UTC	3.0	CA16602663	376208	THR263PRO			false
996	https://civicdb.org/links/variants/996	EGFR	1956	A289V			7	55221822	55221822	C	T	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.866C>T,NP_005219.2:p.Ala289Val,NC_000007.13:g.55221822C>T,ENST00000275493.2:c.866C>T	2022-04-12 21:22:04 UTC	3.0	CA16602664	376209	RS149840192,ALA289VAL			false
997	https://civicdb.org/links/variants/997	EGFR	1956	G598V			7	55233043	55233043	G	T	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.13:g.55233043G>T,NM_001346898.2:c.1793G>T,NP_001333827.1:p.Gly598Val	2022-04-12 21:22:03 UTC	0.0	CA4265696	376210	RS139236063			false
999	https://civicdb.org/links/variants/999	EGFR	1956	G719A			7	55241708	55241708	G	C	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2156G>C,NP_005219.2:p.Gly719Ala,NC_000007.13:g.55241708G>C,ENST00000275493.2:c.2156G>C	2022-04-12 21:22:04 UTC	5.0	CA135775	45225	RS121913428,GLY719ALA			false
1001	https://civicdb.org/links/variants/1001	EGFR	1956	V742A			7	55242455	55242455	T	C	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2225T>C,NP_005219.2:p.Val742Ala,NC_000007.13:g.55242455T>C,ENST00000275493.2:c.2225T>C	2022-04-12 21:22:02 UTC	0.0	CA16602541	376079	RS121913466			false
1002	https://civicdb.org/links/variants/1002	EGFR	1956	E746_A750del			7	55242465	55242479	GGAATTAAGAGAAGC		ENST00000275493.2	75	GRCh37					inframe_deletion		2022-04-12 21:22:04 UTC	17.5	CA175996	163343	RS121913421,E746_A750DELELREA			false
1003	https://civicdb.org/links/variants/1003	EGFR	1956	E746_T751>I										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1012	https://civicdb.org/links/variants/1012	EGFR	1956	L747_P753delinsS			7	55242470	55242487	TAAGAGAAGCAACATCTC		ENST00000275493.2	75	GRCh37					inframe_deletion		2022-04-12 21:22:03 UTC	0.0	CA126710	16608	RS121913438			false
1017	https://civicdb.org/links/variants/1017	EGFR	1956	R831H			7	55259434	55259434	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2492G>A,NC_000007.13:g.55259434G>A,NM_005228.4:c.2492G>A,NP_005219.2:p.Arg831His,NC_000007.14:g.55191741G>A	2022-04-12 21:22:04 UTC	0.0	CA4266102	560007	RS150036236,ARG831HIS			false
1018	https://civicdb.org/links/variants/1018	EGFR	1956	L838V			7	55259454	55259454	C	G	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2512C>G,NP_005219.2:p.Leu838Val,NC_000007.13:g.55259454C>G,ENST00000275493.2:c.2512C>G	2022-04-12 21:22:02 UTC	2.0	CA350916	208822	LEU838VAL			false
1020	https://civicdb.org/links/variants/1020	EGFR	1956	L861Q			7	55259524	55259524	T	A	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2582T>A,NP_005219.2:p.Leu861Gln,NC_000007.13:g.55259524T>A,ENST00000275493.2:c.2582T>A	2022-04-12 21:22:02 UTC	10.5	CA176021	163380	RS121913444			false
1021	https://civicdb.org/links/variants/1021	ABL1	25	BCR::ABL M244V			9	133738330	133738330	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.730A>G,NP_005148.2:p.Met244Val,NC_000009.11:g.133738330A>G,ENST00000318560.5:c.730A>G	2022-04-12 21:22:05 UTC	60.0	CA16602545	376084	RS121913456,M263V,MET263VAL,BCR-ABL MET244VAL,BCR-ABL1 M244V,BCR-ABL1 MET244VAL,BCR-ABL M244V			false
1022	https://civicdb.org/links/variants/1022	ABL1	25	BCR::ABL L248V			9	133738342	133738342	C	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.742C>G,NP_005148.2:p.Leu248Val,NC_000009.11:g.133738342C>G,ENST00000318560.5:c.742C>G	2022-04-12 21:22:05 UTC	33.0	CA16602546	376085	RS121913455,L267V,LEU248VAL,BCR-ABL L248V			false
1023	https://civicdb.org/links/variants/1023	ABL1	25	BCR::ABL G250E			9	133738349	133738349	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.749G>A,NP_005148.2:p.Gly250Glu,NC_000009.11:g.133738349G>A,ENST00000318560.5:c.749G>A	2022-04-12 21:22:05 UTC	62.0	CA16602547	376086	RS121913453,BCR-ABL G269E,BCR-ABL GLY250GLU,BCR-ABL1 G250E,BCR-ABL1 GLY250GLU,BCR-ABL G250E			false
1024	https://civicdb.org/links/variants/1024	ABL1	25	BCR::ABL Q252H			9	133738356	133738356	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.756G>C,NP_005148.2:p.Gln252His,NC_000009.11:g.133738356G>C,ENST00000318560.5:c.756G>C	2022-04-12 21:22:04 UTC	28.0	CA16602548	376087	RS121913458,BCR-ABL Q271H,BCR-ABL1 Q252H,BCR-ABL1 GLN252HIS,BCR-ABL Q252H			false
1025	https://civicdb.org/links/variants/1025	ABL1	25	BCR::ABL Y253H			9	133738357	133738357	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.757T>C,NP_005148.2:p.Tyr253His,NC_000009.11:g.133738357T>C,ENST00000318560.5:c.757T>C	2022-04-12 21:22:04 UTC	74.5	CA122584	12627	RS121913461,Y272H,TYR272HIS,BCR-ABL TYR253HIS,BCR-ABL1 Y253H,BCR-ABL1 TYR253HIS,BCR-ABL Y253H			false
1026	https://civicdb.org/links/variants/1026	ABL1	25	BCR::ABL Y253F			9	133738358	133738358	A	T	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.758A>T,NM_005157.5:c.758A>T,NP_005148.2:p.Tyr253Phe,NC_000009.11:g.133738358A>T	2022-04-12 21:22:04 UTC	6.5	CA16602550	376089	RS121913460,Y272F,TYR253PHE,TYR272PHE,BCR-ABL Y253F			false
1027	https://civicdb.org/links/variants/1027	ABL1	25	BCR::ABL D276G			9	133747520	133747520	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.827A>G,NP_005148.2:p.Asp276Gly,NM_005157.5:c.827A>G,NC_000009.11:g.133747520A>G	2022-04-12 21:22:04 UTC	18.0	CA200645023	NONE FOUND	RS121913447,BCR-ABL ASP276GLY,BCR-ABL D295G,BCR-ABL1 D295G,BCR-ABL D276G			false
1029	https://civicdb.org/links/variants/1029	ABL1	25	BCR::ABL M351T			9	133748391	133748391	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1052T>C,NP_005148.2:p.Met351Thr,NC_000009.11:g.133748391T>C,ENST00000318560.5:c.1052T>C	2022-04-12 21:22:06 UTC	60.5	CA122590	12629	RS121913457,BCR-ABL M370T,BCR-ABL MET351THR,BCR-ABL MET370THR,BCR-ABL M351T			false
1030	https://civicdb.org/links/variants/1030	ABL1	25	BCR::ABL H396R			9	133750356	133750356	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1187A>G,NP_005148.2:p.His396Arg,NC_000009.11:g.133750356A>G,ENST00000318560.5:c.1187A>G	2022-04-12 21:22:07 UTC	36.0	CA16602558	376097	RS121913454,BCR-ABL HIS415ARG,BCR-ABL HIS396ARG,BCR-ABL H415R,BCR-ABL1 H396R,BCR-ABL1 HIS396ARG,BCR-ABL H396R			false
1036	https://civicdb.org/links/variants/1036	TP53	7157	G245D										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1044	https://civicdb.org/links/variants/1044	TP53	7157	D281E										GRCh37							2022-04-21 08:08:54 UTC	3.0						false
1049	https://civicdb.org/links/variants/1049	TP53	7157	P278S										GRCh37							2022-04-12 21:22:03 UTC	0.0						false
1050	https://civicdb.org/links/variants/1050	TP53	7157	A276V			17	7577111	7577111	G	A	ENST00000269305.4	75	GRCh37					missense_variant	ENST00000269305.4:c.827C>T	2022-04-12 21:22:04 UTC	0.0	CA397836916	N/A	ALA276VAL			false
1053	https://civicdb.org/links/variants/1053	TP53	7157	F270S										GRCh37							2022-07-21 17:31:52 UTC	3.0						false
1055	https://civicdb.org/links/variants/1055	TP53	7157	G266R										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1060	https://civicdb.org/links/variants/1060	TP53	7157	G244S										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1064	https://civicdb.org/links/variants/1064	TP53	7157	C242Y			17	7577556	7577556	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.725G>A,NP_000537.3:p.Cys242Tyr,NC_000017.10:g.7577556C>T,ENST00000269305.4:c.725G>A	2022-04-12 21:22:04 UTC	0.0	CA000361	12354	RS121912655			false
1066	https://civicdb.org/links/variants/1066	TP53	7157	M237I			17	7577570	7577570	C	A	ENST00000269305.4	75	GRCh37					missense_variant	ENST00000269305.4:c.711G>T	2022-04-12 21:22:05 UTC	7.0	CA287488024	NONE FOUND	MET237ILE			false
1068	https://civicdb.org/links/variants/1068	TP53	7157	Y234C			17	7577580	7577580	T	C	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.701A>G,NP_000537.3:p.Tyr234Cys,NC_000017.10:g.7577580T>C,ENST00000269305.4:c.701A>G	2022-04-12 21:22:04 UTC	0.0	CA000337	127820	TYR234CYS,Y102C,Y195C,RS587780073			false
1082	https://civicdb.org/links/variants/1082	TP53	7157	H179R										GRCh37							2022-07-21 17:39:44 UTC	3.0						false
1083	https://civicdb.org/links/variants/1083	TP53	7157	H179Y										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1092	https://civicdb.org/links/variants/1092	TP53	7157	V157F			17	7578461	7578461	C	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.469G>T,NP_000537.3:p.Val157Phe,NC_000017.10:g.7578461C>A,ENST00000269305.4:c.469G>T	2022-04-12 21:22:05 UTC	4.0	CA000222	12353	RS121912654,VAL157PHE			false
1093	https://civicdb.org/links/variants/1093	TP53	7157	P151H										GRCh37							2022-04-12 21:22:02 UTC	0.0						false
1106	https://civicdb.org/links/variants/1106	BRAF	673	G464V			7	140481417	140481417	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1391G>T,NP_004324.2:p.Gly464Val,NC_000007.13:g.140481417C>A,ENST00000288602.6:c.1391G>T	2022-04-12 21:22:04 UTC	5.0	CA135076	40364	RS121913348,GLY464VAL			false
1108	https://civicdb.org/links/variants/1108	TP53	7157	R282L			17	7577093	7577093	C	A	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.845G>T,NP_000537.3:p.Arg282Leu,NC_000017.10:g.7577093C>A,ENST00000269305.4:c.845G>T	2022-04-12 21:22:04 UTC	0.0	CA000456	182938	ARG282LEU,R150L,R243L,RS730882008			false
1109	https://civicdb.org/links/variants/1109	TP53	7157	R213P			17	7578211	7578211	C	G	ENST00000269305.4	75	GRCh37					missense_variant	NM_000546.5:c.638G>C,NP_000537.3:p.Arg213Pro,NC_000017.10:g.7578211C>G,ENST00000269305.4:c.638G>C	2022-04-12 21:22:05 UTC	0.0	CA10580932	231214	ARG213PRO,R174P,R81P,RS587778720			false
1114	https://civicdb.org/links/variants/1114	TP53	7157	A161T			17	7578449	7578449	C	T			GRCh37					missense_variant		2022-04-12 21:22:02 UTC	3.0	CA000234					false
1151	https://civicdb.org/links/variants/1151	PIK3CA	5290	H1047L			3	178952085	178952085	A	T	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.3140A>T,NP_006209.2:p.His1047Leu,NC_000003.11:g.178952085A>T,ENST00000263967.3:c.3140A>T	2022-04-12 21:22:07 UTC	12.5	CA123328	13653	RS121913279,HIS1047LEU			false
1152	https://civicdb.org/links/variants/1152	ABL1	25	BCR::ABL F486S			9	133755488	133755488	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1457T>C,NC_000009.11:g.133755488T>C,NM_005157.5:c.1457T>C,NP_005148.2:p.Phe486Ser	2022-04-12 21:22:04 UTC	25.0	CA375251598	NONE FOUND	BCR-ABL F505S,BCR-ABL PHE486SER,BCR-ABL1 PHE486SER,BCR-ABL1 F486S,BCR-ABL F486S			false
1155	https://civicdb.org/links/variants/1155	ATM	472	K293*			11	108115729	108115729	A	T	ENST00000278616.4	75	GRCh37					stop_gained	ENST00000278616.4:c.877A>T,NM_000051.3:c.877A>T,NP_000042.3:p.Lys293Ter,NC_000011.9:g.108115729A>T	2022-04-12 21:22:04 UTC	3.0	CA16041383	370378	K293X,LYS293TER,RS1057516442			false
1158	https://civicdb.org/links/variants/1158	ATM	472	F1025L			11	108142131	108142131	T	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.3075T>G,NC_000011.9:g.108142131T>G,NM_000051.3:c.3075T>G,NP_000042.3:p.Phe1025Leu	2022-04-12 21:22:05 UTC	3.0	CA382547708	NONE FOUND	PHE1025LEU			false
1160	https://civicdb.org/links/variants/1160	ATM	472	D1930V			11	108180913	108180913	A	T	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.5789A>T,NC_000011.9:g.108180913A>T,NM_000051.3:c.5789A>T,NP_000042.3:p.Asp1930Val	2022-04-12 21:22:04 UTC	2.0	CA382548326	NONE FOUND	M72L,ASP1930VAL,MET72LEU			false
1162	https://civicdb.org/links/variants/1162	ATM	472	E2187*			11	108192134	108192134	G	T	ENST00000278616.4	75	GRCh37					stop_gained	ENST00000278616.4:c.6559G>T,NC_000011.9:g.108192134G>T,NM_000051.3:c.6559G>T,NP_000042.3:p.Glu2187Ter	2022-04-12 21:22:06 UTC	3.0	CA382554382	NONE FOUND	E2187X,GLU2187TER			false
1163	https://civicdb.org/links/variants/1163	ATM	472	L2427P			11	108199938	108199938	T	C	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.7280T>C,NC_000011.9:g.108199938T>C,NM_000051.3:c.7280T>C,NP_000042.3:p.Leu2427Pro	2022-04-12 21:22:04 UTC	3.0	CA382559785	NONE FOUND	LEU2427PRO			false
1164	https://civicdb.org/links/variants/1164	ATM	472	F2732V			11	108206614	108206614	T	G	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.8194T>G,NC_000011.9:g.108206614T>G,NM_000051.3:c.8194T>G,NP_000042.3:p.Phe2732Val	2022-04-12 21:22:06 UTC	3.0	CA16619250	422531	PHE2732VAL,RS876659619			false
1166	https://civicdb.org/links/variants/1166	ATM	472	K468FS			11	108121594	108121595	AA		ENST00000278616.4	75	GRCh37					frameshift_variant	NM_000051.3:c.1402_1403delAA,NP_000042.3:p.Lys468Glufs,NC_000011.9:g.108121594_108121595delAA,ENST00000278616.4:c.1402_1403delAA,NC_000011.9:g.108121594_108121595del	2022-04-12 21:22:04 UTC	2.0	CA163840	140889	LYS468GLUFS			false
1168	https://civicdb.org/links/variants/1168	ATM	472	D1682H			11	108170479	108170479	G	C	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.5044G>C,NP_000042.3:p.Asp1682His,NC_000011.9:g.108170479G>C,ENST00000278616.4:c.5044G>C	2022-04-12 21:22:06 UTC	3.0	CA115932	3026	RS121434217,ASP1682HIS			false
1169	https://civicdb.org/links/variants/1169	ATM	472	A2062V			11	108186827	108186827	C	T	ENST00000278616.4	75	GRCh37					missense_variant	ENST00000278616.4:c.6185C>T,NC_000011.9:g.108186827C>T,NM_000051.3:c.6185C>T,NP_000042.3:p.Ala2062Val	2022-04-12 21:22:05 UTC	3.0	CA382550752	NONE FOUND	ALA2062VAL			false
1172	https://civicdb.org/links/variants/1172	ATM	472	C2488Y			11	108201096	108201096	G	A	ENST00000278616.4	75	GRCh37					missense_variant	NM_000051.3:c.7463G>A,NP_000042.3:p.Cys2488Tyr,NC_000011.9:g.108201096G>A,ENST00000278616.4:c.7463G>A	2022-04-12 21:22:04 UTC	3.0	CA196568	187037	CYS2488TYR,RS774281788			false
1173	https://civicdb.org/links/variants/1173	ABL1	25	BCR::ABL E255V			9	133738364	133738364	A	T	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.764A>T,NP_005148.2:p.Glu255Val,NC_000009.11:g.133738364A>T,ENST00000318560.5:c.764A>T	2022-04-12 21:22:04 UTC	47.0	CA16602552	376091	RS121913449,BCR-ABL E274V,BCR-ABL GLU255VAL,BCR-ABL1 E274V,BCR-ABL1 GLU255VAL,BCR-ABL E255V			false
1178	https://civicdb.org/links/variants/1178	PIK3CA	5290	R93W			3	178916890	178916890	C	T	ENST00000263967.3	75	GRCh37					missense_variant	ENST00000263967.3:c.277C>T,NC_000003.11:g.178916890C>T,NM_006218.2:c.277C>T,NP_006209.2:p.Arg93Trp	2022-04-12 21:22:04 UTC	0.0	CA355272477	NONE FOUND	ARG93TRP			false
1181	https://civicdb.org/links/variants/1181	EGFR	1956	R776C			7	55249028	55249028	C	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2326C>T	2022-04-12 21:22:02 UTC	0.0	CA367578749	NONE FOUND	R723C,R731C			false
1183	https://civicdb.org/links/variants/1183	ABL1	25	BCR::ABL E292V			9	133747568	133747568	A	T	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.875A>T,NC_000009.11:g.133747568A>T,NM_005157.5:c.875A>T,NP_005148.2:p.Glu292Val	2022-04-12 21:22:06 UTC	2.0	CA375249260	NONE FOUND	E311V,GLU311VAL,BCR-ABL GLU292VAL,BCR-ABL1 E292V,BCR-ABL1 GLU292VAL,BCR-ABL E292V			false
1184	https://civicdb.org/links/variants/1184	ABL1	25	BCR::ABL F359C			9	133748415	133748415	T	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1076T>G,NP_005148.2:p.Phe359Cys,NC_000009.11:g.133748415T>G,ENST00000318560.5:c.1076T>G	2022-04-12 21:22:05 UTC	41.5	CA16602582	376124	F378C,RS1057519775,BCR-ABL PHE359CYS,BCR-ABL1 F359C,BCR-ABL1 PHE359CYS,BCR-ABL F359C			false
1186	https://civicdb.org/links/variants/1186	BRAF	673	N581S			7	140453193	140453193	T	C			GRCh37					missense_variant		2022-04-12 21:22:02 UTC	5.0	CA180747		N189S,N9S,RS121913370			false
1187	https://civicdb.org/links/variants/1187	EGFR	1956	A864T			7	55259532	55259532	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2590G>A,NC_000007.13:g.55259532G>A,NM_005228.3:c.2590G>A,NP_005219.2:p.Ala864Thr	2022-04-12 21:22:04 UTC	0.0	CA367580302	NONE FOUND	A811T,A819T,ALA864THR,RS1171287261			false
1188	https://civicdb.org/links/variants/1188	EGFR	1956	N826S			7	55259419	55259419	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2477A>G	2022-04-12 21:22:02 UTC	0.0	CA367580077	NONE FOUND	N773S,N781S			false
1198	https://civicdb.org/links/variants/1198	BRAF	673	A728V			7	140434515	140434515	G	A			GRCh37					missense_variant		2022-04-12 21:22:02 UTC	2.0	CA369537269		A336V			false
1207	https://civicdb.org/links/variants/1207	KRAS	3845	R164Q			12	25368454	25368454	C	T	ENST00000256078.4	75	GRCh37					missense_variant	NC_000012.11:g.25368454C>T,NC_000012.12:g.25215520C>T,NP_203524.1:p.Arg164Gln,NM_033360.4:c.491G>A	2022-04-12 21:22:06 UTC	3.0	CA6486860	NONE FOUND	ARG164GLN,RS758575947	54	https://civicdb.org/links/assertions/54	false
1227	https://civicdb.org/links/variants/1227	AKT3	10000	E17K			1	243859016	243859016	C	T	ENST00000366539.1	75	GRCh37					missense_variant	NM_001206729.1:c.49G>A,NP_001193658.1:p.Glu17Lys,NC_000001.10:g.243859016C>T,ENST00000366539.1:c.49G>A	2022-04-12 21:22:05 UTC	3.0	CA130584	39816	RS397514606,GLU17LYS			false
1230	https://civicdb.org/links/variants/1230	ABL1	25	BCR::ABL L384M			9	133750319	133750319	C	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1150C>A,NC_000009.11:g.133750319C>A,NM_005157.5:c.1150C>A,NP_005148.2:p.Leu384Met	2022-04-12 21:22:04 UTC	5.5	CA375249885	NONE FOUND	L403M,LEU403MET,LEU384MET,BCR-ABL1 L384M,BCR-ABL1 LEU384MET,BCR-ABL L384M			false
1231	https://civicdb.org/links/variants/1231	ABL1	25	BCR::ABL V299L			9	133747588	133747588	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.895G>C,NP_005148.2:p.Val299Leu,NC_000009.11:g.133747588G>C,ENST00000318560.5:c.895G>C	2022-04-12 21:22:05 UTC	22.0	CA16602575	376117	BCR-ABL VAL299LEU,BCR-ABL V318L,RS1057519771,BCR-ABL1 V299L,BCR-ABL1 VAL299LEU,BCR-ABL V299L			false
1232	https://civicdb.org/links/variants/1232	ABL1	25	BCR::ABL L387F			9	133750330	133750330	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1161G>C,NC_000009.11:g.133750330G>C,NM_005157.5:c.1161G>C,NP_005148.2:p.Leu387Phe	2022-04-12 21:22:04 UTC	7.0	CA375249910	NONE FOUND	L406F,LEU406PHE,LEU387PHE,BCR-ABL1 L387F,BCR-ABL1 LEU387PHE,BCR-ABL L387F			false
1233	https://civicdb.org/links/variants/1233	ABL1	25	BCR::ABL G398R			9	133750361	133750361	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1192G>C,NC_000009.11:g.133750361G>C,NM_005157.5:c.1192G>C,NP_005148.2:p.Gly398Arg	2022-04-12 21:22:03 UTC	5.0	CA375249980	NONE FOUND	BCR-ABL G417R,BCR-ABL GLY417ARG,BCR-ABL GLY398ARG,BCR-ABL1 G398R,BCR-ABL1 GLY398ARG,BCR-ABL G398R			false
1234	https://civicdb.org/links/variants/1234	PIK3CA	5290	K111N			3	178916946	178916946	G	C	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.333G>C,NP_006209.2:p.Lys111Asn,NC_000003.11:g.178916946G>C,ENST00000263967.3:c.333G>C	2022-04-12 21:22:07 UTC	12.0	CA16602917	376483	LYS111ASN,RS1057519934			false
1235	https://civicdb.org/links/variants/1235	PIK3CA	5290	I391M			3	178927410	178927410	A	G	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.1173A>G,NP_006209.2:p.Ile391Met,NC_000003.11:g.178927410A>G,ENST00000263967.3:c.1173A>G	2022-04-12 21:22:04 UTC	3.0	CA161490	135038	ILE391MET,RS2230461			false
1246	https://civicdb.org/links/variants/1246	BRCA1	672	Q1467*			17	41228590	41228590	G	A	ENST00000357654.3	75	GRCh37					stop_gained	NM_007294.3:c.4399C>T,NP_009225.1:p.Gln1467Ter,NC_000017.10:g.41228590G>A,ENST00000357654.3:c.4399C>T	2022-04-12 21:22:04 UTC	0.0	CA002821	55191	Q1467X,GLN1467TER,RS397509171			false
1247	https://civicdb.org/links/variants/1247	BRCA2	675	M1R			13	32890599	32890599	T	G	ENST00000544455.1		GRCh37					missense_variant	NM_000059.3:c.2T>G,NC_000013.10:g.32890599T>G,NP_000050.2:p.Met1Arg,ENST00000544455.1:c.2T>G	2022-04-12 21:22:04 UTC	0.0	CA017013	51385	MET1ARG,RS80358547			false
1248	https://civicdb.org/links/variants/1248	BRCA2	675	M1I			13	32890600	32890600	G	T	ENST00000544455.1	75	GRCh37					missense_variant	NC_000013.10:g.32890600G>T,NM_000059.3:c.3G>T,NP_000050.2:p.Met1Ile,ENST00000544455.1:c.3G>T	2022-04-12 21:22:04 UTC	0.0	CA019369	37871	MET1ILE,RS80358650			false
1249	https://civicdb.org/links/variants/1249	BRCA2	675	V159M			13	32900287	32900287	G	A	ENST00000544455.1	75	GRCh37					missense_variant	ENST00000544455.1:c.475G>A,NM_000059.3:c.475G>A,NP_000050.2:p.Val159Met,NC_000013.10:g.32900287G>A	2022-04-12 21:22:04 UTC	0.0	CA020781	51711	VAL159MET,RS80358702			false
1250	https://civicdb.org/links/variants/1250	BRCA2	675	V211L			13	32900751	32900751	G	C			GRCh37					missense_variant	NC_000013.10:g.32900751G>C	2022-04-12 21:22:05 UTC	0.0	CA16619647					false
1251	https://civicdb.org/links/variants/1251	BRCA2	675	V211I			13	32900751	32900751	G	A			GRCh37					missense_variant	NC_000013.10:g.32900751G>A	2022-04-12 21:22:04 UTC	0.0	CA023848					false
1252	https://civicdb.org/links/variants/1252	BRCA2	675	R2336P			13	32921033	32921033	G	C	ENST00000544455.1	75	GRCh37					missense_variant	NM_000059.3:c.7007G>C,NP_000050.2:p.Arg2336Pro,NC_000013.10:g.32921033G>C,ENST00000544455.1:c.7007G>C	2022-04-12 21:22:04 UTC	0.0	CA024716	52241	ARG2336PRO,RS28897743			false
1255	https://civicdb.org/links/variants/1255	MGMT	4255	Underexpression			10	131265448	131566271			ENST00000306010.7	75	GRCh37					N/A		2022-04-12 21:22:01 UTC	65.0		N/A				false
1257	https://civicdb.org/links/variants/1257	RRM1	6240	Underexpression			11	4116039	4160106			ENST00000300738.5	75	GRCh37					N/A		2022-04-12 21:22:03 UTC	100.0		N/A				false
1260	https://civicdb.org/links/variants/1260	RET	5979	C609Y	There is some functional evidence that this variant leads to reduced RET activity (PMID: 9230192) and increased cell proliferation and resistance to apoptosis (PMID: 16715139). It has been widely reported in both familial and sporadic cases of multiple endocrine neoplasia type 2 with medullary thyroid cancers. Despite extensive WGS and Exome coverage for a combined total of ~150k alleles in the GNOMAD browser, this variant has never been observed.		10	43609070	43609070	G	A	ENST00000355710.3	75	GRCh37					missense_variant	NM_020630.4:c.1826G>A,NC_000010.10:g.43609070G>A,NP_065681.1:p.Cys609Tyr,ENST00000355710.3:c.1826G>A	2018-11-30 14:43:21 UTC	20.0	CA007824	13933	CYS609TYR			false
1263	https://civicdb.org/links/variants/1263	KIT	3815	N822K		KIT Exon 17	4	55599340	55599340	T	A	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2466T>A,NP_000213.1:p.Asn822Lys,NC_000004.11:g.55599340T>A,ENST00000288135.5:c.2466T>A	2022-04-12 21:22:04 UTC	24.5	CA16602411	375931	ASN822LYS,RS121913514			false
1264	https://civicdb.org/links/variants/1264	KIT	3815	C809G		KIT Exon 17	4	55599299	55599299	T	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2425T>G,NC_000004.11:g.55599299T>G,NM_000222.2:c.2425T>G,NP_000213.1:p.Cys809Gly	2022-04-12 21:22:04 UTC	7.5	CA356911727	NONE FOUND	CYS809GLY			false
1265	https://civicdb.org/links/variants/1265	KIT	3815	D820A		KIT Exon 17	4	55599333	55599333	A	C	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2459A>C,NC_000004.11:g.55599333A>C,NM_000222.2:c.2459A>C,NP_000213.1:p.Asp820Ala	2022-04-12 21:22:04 UTC	7.5	CA356911952	NONE FOUND	ASP820ALA			false
1266	https://civicdb.org/links/variants/1266	KIT	3815	D820G		KIT Exon 17	4	55599333	55599333	A	G	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2459A>G,NP_000213.1:p.Asp820Gly,NC_000004.11:g.55599333A>G,ENST00000288135.5:c.2459A>G	2022-04-12 21:22:04 UTC	7.5	CA123516	13853	ASP820GLY,RS121913682			false
1267	https://civicdb.org/links/variants/1267	KIT	3815	T670I			4	55595519	55595519	C	T	ENST00000288135.5	75	GRCh37					missense_variant	NM_000222.2:c.2009C>T,NP_000213.1:p.Thr670Ile,NC_000004.11:g.55595519C>T,ENST00000288135.5:c.2009C>T	2022-04-12 21:22:04 UTC	21.5	CA16602525	376058	THR670ILE,RS121913516			false
1269	https://civicdb.org/links/variants/1269	BRAF	673	Amplification			7	140434279	140624564			ENST00000288602.6	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	17.5		N/A				false
1271	https://civicdb.org/links/variants/1271	ROS1	6098	G2032R			6	117638347	117638347	C	T	ENST00000368508.3	75	GRCh37					missense_variant	NC_000006.11:g.117638347C>T,NM_002944.2:c.6094G>A,NP_002935.2:p.Gly2032Arg,ENST00000368508.3:c.6094G>A	2022-04-12 21:22:06 UTC	2.5	CA16602597	376139	GLY2032ARG			true
1272	https://civicdb.org/links/variants/1272	MAP2K1	5604	K57N			15	66727455	66727455	G	T	ENST00000307102.5	75	GRCh37					missense_variant	NM_002755.3:c.171G>T,NP_002746.1:p.Lys57Asn,NC_000015.9:g.66727455G>T,ENST00000307102.5:c.171G>T,NG_008305.1:g.53245G>T	2022-04-12 21:22:02 UTC	17.0	CA356995	223140	LYS57ASN,RS869025608			false
1273	https://civicdb.org/links/variants/1273	CTAG1B	1485	Overexpression			X	153845865	153847522			ENST00000328435.2	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	15.0		N/A				false
1274	https://civicdb.org/links/variants/1274	CTAG2	30848	Overexpression			X	153880246	153881853			ENST00000247306.4	75	GRCh37					N/A		2022-04-12 21:22:06 UTC	15.0		N/A				false
1277	https://civicdb.org/links/variants/1277	NTRK3	4916	Fusion															transcript_fusion		2022-04-12 21:22:02 UTC	55.0		N/A				false
1278	https://civicdb.org/links/variants/1278	NTRK1	4914	LMNA::NTRK1		NTRK1 Fusions	1	156084498	156108548			ENST00000368300.4	75	GRCh37	1	156844363	156851434	ENST00000524377.1	transcript_fusion		2022-04-12 21:22:03 UTC	20.0		N/A	LMNA-NTRK1			false
1280	https://civicdb.org/links/variants/1280	NTRK1	4914	Amplification			1	156830686	156851434			ENST00000524377.1	75	GRCh37					transcript_amplification		2022-04-12 21:22:03 UTC	5.0		N/A				false
1281	https://civicdb.org/links/variants/1281	NTRK3	4916	Amplification			15	88418230	88799978			ENST00000394480.2	75	GRCh37					transcript_amplification	N/A	2022-04-12 21:22:02 UTC	5.0		N/A				false
1282	https://civicdb.org/links/variants/1282	NTRK1	4914	LMNA::NTRK1 G595R and G667C			1	156846342	156849107			ENST00000524377.1	75	GRCh37					missense_variant,transcript_fusion		2022-04-12 21:22:03 UTC	10.0		NONE FOUND	LMNA-NTRK1 G595R AND G667C			false
1284	https://civicdb.org/links/variants/1284	DCC	1630	EXPRESSION																	2022-04-12 21:22:02 UTC	15.0						false
1285	https://civicdb.org/links/variants/1285	CTNNB1	1499	T41A			3	41266124	41266124	A	G	ENST00000349496.5	75	GRCh37					missense_variant	NM_001904.3:c.121A>G,NP_001895.1:p.Thr41Ala,NC_000003.11:g.41266124A>G,ENST00000349496.5:c.121A>G	2022-04-12 21:22:04 UTC	55.0	CA127269	17580	THR41ALA,RS121913412			false
1286	https://civicdb.org/links/variants/1286	CTNNB1	1499	S45F			3	41266137	41266137	C	T	ENST00000349496.5	75	GRCh37					missense_variant	NM_001904.3:c.134C>T,NP_001895.1:p.Ser45Phe,NC_000003.11:g.41266137C>T,ENST00000349496.5:c.134C>T	2022-04-12 21:22:04 UTC	60.0	CA127283	17588	SER45PHE,RS121913409			false
1287	https://civicdb.org/links/variants/1287	CTNNB1	1499	S45P			3	41266136	41266136	T	C	ENST00000349496.5	75	GRCh37					missense_variant	NM_001904.3:c.133T>C,NP_001895.1:p.Ser45Pro,NC_000003.11:g.41266136T>C,ENST00000349496.5:c.133T>C	2022-04-12 21:22:04 UTC	35.0	CA127285	17589	SER45PRO,RS121913407			false
1293	https://civicdb.org/links/variants/1293	ARID1A	8289	Loss-of-function			1	27022524	27108595			ENST00000324856.7	75	GRCh37							2022-08-03 16:05:30 UTC	7.0		N/A				false
1294	https://civicdb.org/links/variants/1294	VHL	7428	W8* (c.24G>A)			3	10183555	10183555	G	A	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.24G>A,ENST00000256474.2:c.24G>A,NC_000003.11:g.10183555G>A,NP_000542.1:p.Trp8Ter	2022-04-12 21:22:05 UTC	0.0	CA351747069	NONE FOUND	TRP8X,TRP8STOP,C.24G>A			false
1295	https://civicdb.org/links/variants/1295	ALK	238	F1245V			2	29436860	29436860	A	C	ENST00000389048.3	75	GRCh37					missense_variant	NM_004304.4:c.3733T>G,NP_004295.2:p.Phe1245Val,NC_000002.11:g.29436860A>C,ENST00000389048.3:c.3733T>G	2022-04-12 21:22:05 UTC	7.5	CA345003	65671	PHE1245VAL,RS281864720			false
1296	https://civicdb.org/links/variants/1296	CTNNB1	1499	Activating Mutation			3	41240930	41281936			ENST00000349496.5	75	GRCh37					transcript_variant,gain_of_function_variant		2022-04-12 21:22:04 UTC	4.0		N/A				false
1299	https://civicdb.org/links/variants/1299	MERTK	10461	OVEREXPRESSION			2	112656056	112787138			ENST00000295408.4	75	GRCh37					N/A		2022-04-12 21:22:02 UTC	3.0		N/A				false
1300	https://civicdb.org/links/variants/1300	TP53	7157	CONSERVED DOMAIN MUT	This conserved domain mutation variant covers mutations in regions of p53 reported to be highly conserved during evolution. These regions span codons 117-143 (region II), 171-181 (region III), 234-258 (region (IV), and 270-286 (region V). Region I covers approximately codons 10 through 25 but does not appear in all studies on conserved domain mutations. There is overlap with these regions and reported regions of hotspot p53 mutations, where it is observed that hotspots for detrimental mutation correspond to more highly evolutionary conserved regions. While there is agreement and overlap between different reports, the literature does not seem to indicate an exact consensus on these regions of human p53 at this time, but the four highly conserved regions are part of the DNA binding domain, and are reported to exist within codons 97 to 292.		17	7577062	7579398			ENST00000269305.4	75								2018-07-06 14:54:43 UTC	15.0						false
1301	https://civicdb.org/links/variants/1301	AKT3	10000	Overexpression																	2022-08-02 22:51:18 UTC	7.0						false
1302	https://civicdb.org/links/variants/1302	FLT3	2322	D835V			13	28592641	28592641	T	A	ENST00000241453.7	75	GRCh37					missense_variant	ENST00000241453.7:c.2504A>T,NM_004119.2:c.2504A>T,NP_004110.2:p.Asp835Val,NC_000013.10:g.28592641T>A	2022-04-12 21:22:03 UTC	19.0	CA126344	16272	RS121909646,ASP835VAL			false
1303	https://civicdb.org/links/variants/1303	MYC	4609	Overexpression																	2022-04-12 21:22:02 UTC	9.0						false
1306	https://civicdb.org/links/variants/1306	TP53	7157	Overexpression			17	7571720	7590856			ENST00000269305.4	75	GRCh37					N/A		2022-04-12 21:22:03 UTC	65.0		N/A				false
1307	https://civicdb.org/links/variants/1307	TP53	7157	ALTERATION	P53 ALTERATION is a bucket type variant used in studies which is constructed by combining all cases of p53 mutation together with p53 overexpression. This includes cases which have p53 mutation or overexpression alone or as well as cases where both occur in combination.		17	7571720	7590856			ENST00000269305.4	75	GRCh37							2021-10-05 20:04:06 UTC	60.0		N/A				false
1319	https://civicdb.org/links/variants/1319	GNAS	2778	R201H																	2022-04-12 21:22:02 UTC	5.0						false
1400	https://civicdb.org/links/variants/1400	FGFR3	2261	K650E	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1807889	1807889	A	G	ENST00000340107.4	75	GRCh37					missense_variant	NC_000004.11:g.1807889A>G,NC_000004.12:g.1806162A>G,NM_000142.5:c.1948A>G,NP_000133.1:p.Lys650Glu	2022-07-30 17:57:34 UTC	9.0	CA126376	16331	RS78311289,LYS650GLU,K652E,LYS652GLU,TDII			false
1420	https://civicdb.org/links/variants/1420	EGFR	1956	G719D			7	55241708	55241708	G	A			GRCh37					missense_variant	NC_000007.14:g.55174015G>A,NC_000007.13:g.55241708G>A,ENST00000275493.7:c.2156G>A,ENSP00000275493.2:p.Gly719Asp,NM_005228.5:c.2156G>A,NP_005219.2:p.Gly719Asp	2022-04-12 21:22:03 UTC	7.5	CA16602537	376075	RS121913428,GLY719ASP			false
1445	https://civicdb.org/links/variants/1445	EGFR	1956	D770_N771insSVD			7	55249013	55249014		GCGTGGACA	ENST00000275493.2		GRCh37						NC_000007.14:g.55181312_55181320dup,NC_000007.13:g.55249005_55249013dup,ENST00000275493.7:c.2303_2311dup,ENSP00000275493.2:p.Asp770_Asn771insSerValAsp,NM_005228.5:c.2303_2311dup,NP_005219.2:p.Asp770_Asn771insSerValAsp	2022-04-12 21:22:03 UTC	0.0	CA135844	45253	S768_D770DUP,ASP770_ASN771INSSERVALASP			false
1446	https://civicdb.org/links/variants/1446	EGFR	1956	H773_V774insH			7	55249021	55249022		CAC	ENST00000275493.2	75	GRCh37						p.His773dup,c.55249019_55249021dup	2022-06-19 00:00:03 UTC	0.0	CA135866					false
1457	https://civicdb.org/links/variants/1457	EGFR	1956	L838P			7	55259455	55259455	T	C	ENST00000275493.2	75	GRCh37					missense_variant	NC_000007.14:g.55191762T>C,NC_000007.13:g.55259455T>C,ENST00000275493.7:c.2513T>C,ENSP00000275493.2:p.Leu838Pro,NM_005228.5:c.2513T>C,NP_005219.2:p.Leu838Pro	2022-04-12 21:22:03 UTC	7.5	CA367580150	NONE FOUND	LEU838PRO			false
1463	https://civicdb.org/links/variants/1463	EGFR	1956	T847I			7	55259482	55259482	C	T			GRCh37					missense_variant		2022-04-12 21:22:03 UTC	5.0	CA367580204					false
1466	https://civicdb.org/links/variants/1466	EGFR	1956	V851I			7	55259493	55259493	G	A			GRCh37					missense_variant		2022-04-12 21:22:01 UTC	5.0	CA367580229					false
1477	https://civicdb.org/links/variants/1477	EGFR	1956	L861R			7	55259524	55259524	T	G	ENST00000	75	GRCh37					missense_variant	NM_005228.4:c.2582T>G,NP_005219.2:p.Leu861Arg,NC_000007.13:g.55259524T>G,ENST00000275493.2:c.2582T>G	2022-04-12 21:22:03 UTC	7.5	CA135940	45287	RS121913444			false
1482	https://civicdb.org/links/variants/1482	EGFR	1956	E868G			7	55259545	55259545	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2603A>G,NC_000007.14:g.55191852A>G,NC_000007.13:g.55259545A>G,ENST00000275493.7:c.2603A>G,ENSP00000275493.2:p.Glu868Gly,NM_005228.5:c.2603A>G,NP_005219.2:p.Glu868Gly	2022-04-12 21:22:03 UTC	0.0	CA367580333	NONE FOUND	GLU868GLY			false
1487	https://civicdb.org/links/variants/1487	ABL1	25	BCR::ABL E355G			9	133748403	133748403	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1064A>G,NP_005148.2:p.Glu355Gly,NC_000009.11:g.133748403A>G,ENST00000318560.5:c.1064A>G	2022-04-12 21:22:05 UTC	34.5	CA16602556	376095	RS121913450,BCR-ABL GLU355GLY,BCR-ABL1 E355G,BCR-ABL1 GLU355GLY,BCR-ABL E355G			false
1488	https://civicdb.org/links/variants/1488	ABL1	25	BCR::ABL L387M			9	133750328	133750328	T	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1159T>A,NC_000009.11:g.133750328T>A,NM_005157.5:c.1159T>A,NP_005148.2:p.Leu387Met	2022-04-12 21:22:05 UTC	7.5	CA375249905	NONE FOUND	BCR-ABL LEU387MET,BCR-ABL1 L387M,BCR-ABL1 LEU387MET,BCR-ABL L387M			false
1497	https://civicdb.org/links/variants/1497	KIT	3815	P551_E554delPMYE			4	55593585	55593596					GRCh37					inframe_deletion		2022-04-12 21:22:03 UTC	6.0						false
1499	https://civicdb.org/links/variants/1499	PIK3CA	5290	S158L			3	178917598	178917598	C	T	ENST00000263967.3	75	GRCh37					missense_variant	ENST00000263967.3:c.473C>T,NC_000003.11:g.178917598C>T,NM_006218.2:c.473C>T,NP_006209.2:p.Ser158Leu	2022-04-12 21:22:04 UTC	0.0	CA355274155	NONE FOUND	SER158LEU			false
1500	https://civicdb.org/links/variants/1500	PIK3CA	5290	E81K			3	178916854	178916854	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NM_006218.3:c.241G>A,NP_006209.2:p.Glu81Lys,NC_000003.11:g.178916854G>A,ENST00000263967.3:c.241G>A	2022-04-12 21:22:05 UTC	5.0	CA16602912	376478	GLU81LYS,RS1057519929			false
1506	https://civicdb.org/links/variants/1506	ABL1	25	L298V			9	133747585	133747585	C	G	ENST00000318560.5	75	GRCh37					missense_variant	ENST00000318560.5:c.892C>G,NC_000009.11:g.133747585C>G,NM_005157.5:c.892C>G,NP_005148.2:p.Leu298Val	2022-04-12 21:22:05 UTC	2.5	CA375249299	NONE FOUND	L317V,LEU298VAL			false
1507	https://civicdb.org/links/variants/1507	ABL1	25	BCR::ABL F311I			9	133748270	133748270	T	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.931T>A,NC_000009.11:g.133748270T>A,NM_005157.5:c.931T>A,NP_005148.2:p.Phe311Ile	2022-04-12 21:22:04 UTC	5.0	CA375249388	NONE FOUND	F330I,RS137853304,BCR-ABL PHE311ILE,BCR-ABL1 F311I,BCR-ABL1 PHE311ILE,BCR-ABL F311I			false
1509	https://civicdb.org/links/variants/1509	ABL1	25	BCR::ABL E453Q			9	133753888	133753888	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1357G>C,NC_000009.11:g.133753888G>C,NM_005157.5:c.1357G>C,NP_005148.2:p.Glu453Gln	2022-04-12 21:22:05 UTC	5.0	CA375251170	NONE FOUND	E472Q,BCR-ABL GLU453GLN,BCR-ABL1 E453Q,BCR-ABL1 GLU453GLN,BCR-ABL E453Q			false
1510	https://civicdb.org/links/variants/1510	ARID1A	8289	Q456*			1	27057658	27057658	C	T	ENST00000324856.7	75	GRCh37					stop_gained	ENST00000324856.7:c.1366C>T	2022-04-12 21:22:05 UTC	0.0	CA339267901	NONE FOUND	Q73X			false
1511	https://civicdb.org/links/variants/1511	EGFR	1956	S768_D770dup										GRCh37					inframe_insertion		2022-12-16 18:28:35 UTC	7.5						false
1513	https://civicdb.org/links/variants/1513	EGFR	1956	H773_V774insNPH			7	55249012	55249013		AACCCCCAC	ENST00000275493.2		GRCh37					inframe_insertion		2022-04-12 21:22:05 UTC	7.5	CA180983	177911				false
1514	https://civicdb.org/links/variants/1514	EGFR	1956	D770_N771insGL			7	55249012	55249013		GGGTTA	ENST00000275493.2		GRCh37					inframe_insertion	NC_000007.13:g.55249012_55249013insGGGTTA,NM_005228.3:c.2310_2311insGGGTTA,NP_005219.2:p.Asp770_Asn771insGlyLeu	2022-04-12 21:22:06 UTC	10.0	CA645561585	45257	RS397517111			false
1515	https://civicdb.org/links/variants/1515	EGFR	1956	A763_Y764insFQEA			7	55248992	55248993		TCCAGGAAGCCT	ENST00000275493.2		GRCh37					inframe_insertion	NP_001333827.1:p.Ala763_Tyr764insPheGlnGluAla,NC_000007.13:g.55248992_55248993insTCCAGGAAGCCT,NM_001346898.1:c.2290_2291insTCCAGGAAGCCT	2022-12-16 17:54:42 UTC	5.0	CA135833	NONE FOUND	RS397517106			false
1517	https://civicdb.org/links/variants/1517	KRAS	3845	G13V			12	25398280	25398281	GC	AA	ENST00000256078.4	75	GRCh37					missense_variant	NC_000012.11:g.25398280_25398281delinsAA,ENST00000256078.4:c.38_39delinsTT,NM_004985.4:c.38_39delinsTT,NP_004976.2:p.Gly13Val	2022-04-12 21:22:04 UTC	5.0	CA645572107	45124	RS397517040,GLY13VAL			false
1523	https://civicdb.org/links/variants/1523	ABL1	25	BCR::ABL F359I			9	133748414	133748414	T	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.1075T>A,NP_005148.2:p.Phe359Ile,NC_000009.11:g.133748414T>A,ENST00000318560.5:c.1075T>A	2022-04-12 21:22:05 UTC	29.5	CA16602580	376122	RS121913452,F378I,BCR-ABL PHE359ILE,BCR-ABL1 F359I,BCR-ABL1 PHE359ILE,BCR-ABL F359I			false
1524	https://civicdb.org/links/variants/1524	ABL1	25	BCR::ABL M343T			9	133748367	133748367	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1028T>C,NC_000009.11:g.133748367T>C,NM_005157.5:c.1028T>C,NP_005148.2:p.Met343Thr	2022-04-12 21:22:05 UTC	2.0	CA375249596	NONE FOUND	M362T,BCR-ABL MET343THR,BCR-ABL1 M343T,BCR-ABL1 MET343THR,BCR-ABL M343T			false
1525	https://civicdb.org/links/variants/1525	ABL1	25	BCR::ABL F317V			9	133748288	133748288	T	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.949T>G,NP_005148.2:p.Phe317Val,NC_000009.11:g.133748288T>G,ENST00000318560.5:c.949T>G	2022-04-12 21:22:05 UTC	10.0	CA16602578	376120	F336V,RS1057519773,BCR-ABL PHE317VAL,BCR-ABL1 F317V,BCR-ABL1 PHE317VAL,BCR-ABL F317V			false
1526	https://civicdb.org/links/variants/1526	ABL1	25	BCR::ABL E279K			9	133747528	133747528	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.835G>A,NC_000009.11:g.133747528G>A,NM_005157.5:c.835G>A,NP_005148.2:p.Glu279Lys	2022-04-12 21:22:05 UTC	7.5	CA375249162	NONE FOUND	BCR-ABL1 E279K,BCR-ABL GLU279LYS,BCR-ABL1 GLU279LYS,BCR-ABL E298K,BCR-ABL E279K			false
1527	https://civicdb.org/links/variants/1527	ABL1	25	BCR::ABL Q300R			9	133747592	133747592	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.899A>G,NC_000009.11:g.133747592A>G,NM_005157.5:c.899A>G,NP_005148.2:p.Gln300Arg	2022-04-12 21:22:05 UTC	5.0	CA375249312	NONE FOUND	Q319R,BCR-ABL GLN300ARG,BCR-ABL1 Q300R,BCR-ABL1 GLN300ARG,BCR-ABL Q300R			false
1528	https://civicdb.org/links/variants/1528	ABL1	25	BCR::ABL F311L			9	133748270	133748270	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.931T>C,NP_005148.2:p.Phe311Leu,NC_000009.11:g.133748270T>C,ENST00000318560.5:c.931T>C	2022-04-12 21:22:05 UTC	7.0	CA122587	12628	RS137853304,F330L,BCR-ABL PHE311LEU,BCR-ABL1 F311L,BCR-ABL1 PHE311LEU,BCR-ABL F311L			false
1529	https://civicdb.org/links/variants/1529	ABL1	25	BCR::ABL N331S			9	133748331	133748331	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.992A>G,NC_000009.11:g.133748331A>G,NM_005157.5:c.992A>G,NP_005148.2:p.Asn331Ser	2022-04-12 21:22:04 UTC	2.5	CA5285356	NONE FOUND	N350S,RS144448357,BCR-ABL ASN331SER,BCR-ABL1 N331S,BCR-ABL1 ASN331SER,BCR-ABL N331S			false
1530	https://civicdb.org/links/variants/1530	ABL1	25	BCR::ABL L364P			9	133750260	133750260	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1091T>C,NC_000009.11:g.133750260T>C,NM_005157.5:c.1091T>C,NP_005148.2:p.Leu364Pro	2022-04-12 21:22:05 UTC	2.5	CA375249757	NONE FOUND	L383P,BCR-ABL LEU364PRO,BCR-ABL1 L364P,BCR-ABL1 LEU364PRO,BCR-ABL L364P			false
1531	https://civicdb.org/links/variants/1531	ABL1	25	BCR::ABL H396P			9	133750356	133750356	A	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1187A>C,NC_000009.11:g.133750356A>C,NM_005157.5:c.1187A>C,NP_005148.2:p.His396Pro	2022-04-12 21:22:04 UTC	15.0	CA375249969	NONE FOUND	BCR-ABL HIS396PRO,BCR-ABL1 H396P,BCR-ABL1 HIS396PRO,BCR-ABL H396P			false
1532	https://civicdb.org/links/variants/1532	ABL1	25	BCR::ABL D421G			9	133750431	133750431	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1262A>G,NC_000009.11:g.133750431A>G,NM_005157.5:c.1262A>G,NP_005148.2:p.Asp421Gly	2022-04-12 21:22:05 UTC	2.5	CA375250143	NONE FOUND	BCR-ABL1 D421G,BCR-ABL ASP421GLY,BCR-ABL1 ASP421GLY,BCR-ABL D421G			false
1534	https://civicdb.org/links/variants/1534	ABL1	25	BCR::ABL E450V			9	133753880	133753880	A	T	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1349A>T,NC_000009.11:g.133753880A>T,NM_005157.5:c.1349A>T,NP_005148.2:p.Glu450Val	2022-04-12 21:22:04 UTC	5.0	CA375251155	NONE FOUND	E469V,BCR-ABL GLU450VAL,BCR-ABL1 GLU450VAL,BCR-ABL1 E450V,BCR-ABL E450V			false
1535	https://civicdb.org/links/variants/1535	ABL1	25	BCR::ABL E453K			9	133753888	133753888	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1357G>A,NC_000009.11:g.133753888G>A,NM_005157.5:c.1357G>A,NP_005148.2:p.Glu453Lys	2022-04-12 21:22:05 UTC	2.5	CA375251169	NONE FOUND	E472K,BCR-ABL GLU453LYS,BCR-ABL1 E453K,BCR-ABL1 GLU453LYS,BCR-ABL E453K			false
1536	https://civicdb.org/links/variants/1536	ABL1	25	BCR::ABL E453A			9	133753889	133753889	A	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1358A>C,NC_000009.11:g.133753889A>C,NM_005157.5:c.1358A>C,NP_005148.2:p.Glu453Ala	2022-04-12 21:22:05 UTC	5.0	CA375251172	NONE FOUND	E472A,GLU453ALA,BCR-ABL1 E453A,BCR-ABL1 GLU453ALA,BCR-ABL E453A			false
1537	https://civicdb.org/links/variants/1537	ABL1	25	BCR::ABL P480A			9	133755469	133755469	C	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1438C>G,NC_000009.11:g.133755469C>G,NM_005157.5:c.1438C>G,NP_005148.2:p.Pro480Ala	2022-04-12 21:22:05 UTC	2.5	CA375251559	NONE FOUND	P499A,BCR-ABL PRO480ALA,BCR-ABL1 P480A,BCR-ABL1 PRO480ALA,BCR-ABL P480A			false
1549	https://civicdb.org/links/variants/1549	KIT	3815	K558NP			4	55593608	55593608	G	TCCT			GRCh37					inframe_insertion		2022-04-12 21:22:03 UTC	3.0						false
1550	https://civicdb.org/links/variants/1550	KIT	3815	V560_L576DEL			4	55593612	55593662					GRCh37					inframe_deletion		2022-04-12 21:22:03 UTC	6.0						false
1551	https://civicdb.org/links/variants/1551	KIT	3815	V569_L576DEL			4	55593639	55593662					GRCh37					inframe_deletion		2022-04-12 21:22:03 UTC	15.0						false
1555	https://civicdb.org/links/variants/1555	BRCA1	672	W1815X			17	41199682	41199682	C	T			GRCh37					stop_gained		2022-04-12 21:22:06 UTC	2.0	CA003600		W125X,W1519X,W1550X,W1576X,W1768X,W1836X,W306X,W48X,W632X,W664X,W673X,W711X			false
1558	https://civicdb.org/links/variants/1558	KIT	3815	A502_Y503insAY			4	55592182	55592183		GCCTAT			GRCh37					inframe_insertion		2022-04-12 21:22:06 UTC	7.0	unregistered					false
1559	https://civicdb.org/links/variants/1559	KIT	3815	D816E			4	55599322	55599322	C	G	ENST00000288135.5	75	GRCh37					missense_variant	ENST00000288135.5:c.2448C>G,NC_000004.11:g.55599322C>G,NM_000222.2:c.2448C>G,NP_000213.1:p.Asp816Glu	2022-04-12 21:22:05 UTC	8.0	CA356911882	NONE FOUND	D812E,ASP816GLU			false
1566	https://civicdb.org/links/variants/1566	EGFR	1956	D770_N771insGT			7	55249012	55249013		GGCACA	ENST00000275493.2		GRCh37					inframe_insertion	NC_000007.13:g.55249012_55249013insGGCACA,NM_005228.3:c.2310_2311insGGCACA,NP_005219.2:p.Cys770_Gly771insGlyThr,NC_000007.14:g.55181319_55181320insGGCACA,ENST00000275493.7:c.2310_2311insGGCACA,ENSP00000275493.2:p.Asp770_Asn771insGlyThr	2022-04-12 21:22:05 UTC	0.0	CA645561586	NONE FOUND	ASP770_ASN771INSGLYTHR			false
1569	https://civicdb.org/links/variants/1569	EGFR	1956	D770_N771insNPG			7	55249012	55249013		AACCCCGGC			GRCh37					inframe_insertion		2022-04-12 21:22:03 UTC	0.0	CA2573051057					false
1570	https://civicdb.org/links/variants/1570	SMO	6608	L412F			7	128846398	128846398	C	T	ENST00000249373.3	75	GRCh37					missense_variant	NM_005631.4:c.1234C>T,NP_005622.1:p.Leu412Phe,NC_000007.13:g.128846398C>T,ENST00000249373.3:c.1234C>T	2022-04-12 21:22:03 UTC	0.0	CA10584652	245609				false
1571	https://civicdb.org/links/variants/1571	EGFR	1956	W731L			7	55242422	55242422	G	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2192G>T	2022-04-12 21:22:03 UTC	3.0	CA367583965	NONE FOUND	W678L,W686L,RS397517089			false
1572	https://civicdb.org/links/variants/1572	EGFR	1956	E734Q			7	55242430	55242430	G	C	ENST00000	75	GRCh37					missense_variant	ENST00000275493.2:c.2200G>C	2022-04-12 21:22:07 UTC	0.0	CA367583997	NONE FOUND	RS121913420,E681Q,E689Q			false
1573	https://civicdb.org/links/variants/1573	EGFR	1956	T785A			7	55249055	55249055	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2353A>G	2022-04-12 21:22:03 UTC	0.0	CA367578819	NONE FOUND	T732A,T740A			false
1574	https://civicdb.org/links/variants/1574	EGFR	1956	C797Y			7	55249092	55249092	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2390G>A,NM_005228.3:c.2390G>A,NC_000007.13:g.55249092G>A,NP_005219.2:p.Cys797Tyr	2022-04-12 21:22:05 UTC	0.0	CA367578897	NONE FOUND	C744Y,C752Y,CYS797TYR			false
1575	https://civicdb.org/links/variants/1575	EGFR	1956	Y801H			7	55249103	55249103	T	C	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2401T>C	2022-04-12 21:22:01 UTC	3.0	CA4266065	NONE FOUND	Y748H,Y756H			false
1579	https://civicdb.org/links/variants/1579	EGFR	1956	A767_V769dupASV			7	55249000	55249001		GCCAGCGTG	ENST00000275493.2		GRCh37					inframe_insertion		2022-12-16 18:30:39 UTC	7.5	CA180588					false
1580	https://civicdb.org/links/variants/1580	EGFR	1956	L747_S752delinsQ			7	55242469	55242486	TTAAGAGAAGCAACATCT	CAA			GRCh37					inframe_insertion,inframe_deletion,delins	NC_000007.14:g.55174776_55174793delinsCAA,NC_000007.13:g.55242469_55242486delinsCAA,ENST00000275493.7:c.2239_2256delinsCAA,ENSP00000275493.2:p.Leu747_Ser752delinsGln,NM_005228.5:c.2239_2256delinsCAA,NP_005219.2:p.Leu747_Ser752delinsGln	2022-04-12 21:22:03 UTC	7.5	CA645561524	NONE FOUND	DEL L747-S752INSQ,LEU747_SER752DELINSGLN			false
1609	https://civicdb.org/links/variants/1609	ABL1	25	BCR::ABL V379I			9	133750304	133750304	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1135G>A,NC_000009.11:g.133750304G>A,NM_005157.5:c.1135G>A,NP_005148.2:p.Val379Ile	2022-04-12 21:22:05 UTC	19.5	CA375249852	NONE FOUND	V398I,BCR-ABL VAL379ILE,BCR-ABL1 V379I,BCR-ABL1 VAL379ILE,BCR-ABL V379I			false
1612	https://civicdb.org/links/variants/1612	ABL1	25	BCR::ABL A397P			9	133750358	133750358	G	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1189G>C,NC_000009.11:g.133750358G>C,NM_005157.5:c.1189G>C,NP_005148.2:p.Ala397Pro	2022-04-12 21:22:04 UTC	5.0	CA375249974	NONE FOUND	A416P,ALA397PRO,BCR-ABL1 A397P,BCR-ABL A397P			false
1613	https://civicdb.org/links/variants/1613	ABL1	25	BCR::ABL S417Y			9	133750419	133750419	C	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1250C>A,NC_000009.11:g.133750419C>A,NM_005157.5:c.1250C>A,NP_005148.2:p.Ser417Tyr	2022-04-12 21:22:05 UTC	0.0	CA375250115	NONE FOUND	SER417TYR,BCR-ABL1 S436Y,BCR-ABL S417Y			false
1625	https://civicdb.org/links/variants/1625	ABL1	25	BCR::ABL F317I			9	133748288	133748288	T	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.949T>A,NP_005148.2:p.Phe317Ile,NC_000009.11:g.133748288T>A,ENST00000318560.5:c.949T>A	2022-04-12 21:22:05 UTC	3.0	CA16602577	376119	F336I,RS1057519773,BCR-ABL PHE317ILE,BCR-ABL1 F317I,BCR-ABL1 PHE317ILE,BCR-ABL F317I			false
1627	https://civicdb.org/links/variants/1627	BRAF	673	G596R			7	140453149	140453149	C	G	ENST00000288602.6	75	GRCh37					missense_variant	NM_004333.4:c.1786G>C,NP_004324.2:p.Gly596Arg,NC_000007.13:g.140453149C>G,ENST00000288602.6:c.1786G>C	2022-04-12 21:22:05 UTC	5.0	CA16602422	375943	RS121913361,G204R,G24R,GLY596ARG			false
1639	https://civicdb.org/links/variants/1639	ABL1	25	C475V			9					ENST00000318560.5		GRCh37					splice_donor_variant	ENST00000318560.5:c.1423_1424delinsGT,NC_000009.11:g.133753954_133755455delinsGT,NM_005157.6:c.1423_1424delinsGT	2022-04-15 13:56:44 UTC	5.0	CA913189156	NONE FOUND	CYS475VAL			true
1640	https://civicdb.org/links/variants/1640	ABL1	25	BCR::ABL N336S			9	133748346	133748346	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1007A>G,NC_000009.11:g.133748346A>G,NM_005157.5:c.1007A>G,NP_005148.2:p.Asn336Ser	2022-04-12 21:22:06 UTC	5.0	CA375249553	NONE FOUND	N355S,BCR-ABL1 ASN336SER,BCR-ABL N336S,BCR-ABL1 N336S,BCR-ABL N336S			false
1647	https://civicdb.org/links/variants/1647	POLD1	5424	C284Y										GRCh37							2022-04-12 21:22:03 UTC	0.0						false
1648	https://civicdb.org/links/variants/1648	POLD1	5424	E374K										GRCh37							2022-04-12 21:22:03 UTC	0.0						false
1652	https://civicdb.org/links/variants/1652	PIK3R2	5296	N561D										GRCh37							2022-04-12 21:22:03 UTC	3.0						false
1653	https://civicdb.org/links/variants/1653	PIK3CA	5290	D350G			3	178921567	178921567	A	G	ENST00000263967.3	75	GRCh37					missense_variant	ENST00000263967.3:c.1049A>G,NC_000003.11:g.178921567A>G,NM_006218.2:c.1049A>G,NP_006209.2:p.Asp350Gly	2022-04-12 21:22:05 UTC	2.0	CA355281594	521363	ASP350GLY			false
1654	https://civicdb.org/links/variants/1654	NRAS	4893	Q179X										GRCh37							2022-04-12 21:22:03 UTC	0.0						false
1656	https://civicdb.org/links/variants/1656	ABL1	25	R351W			9	133748333	133748333	C	T	ENST00000372348.2	75	GRCh37					missense_variant	ENST00000372348.2:c.1051C>T,NC_000009.11:g.133748333C>T,NM_007313.2:c.1051C>T,NP_009297.2:p.Arg351Trp	2022-04-12 21:22:05 UTC	9.0	CA5285359	NONE FOUND	R332W,ARG351TRP,RS779478267			false
1657	https://civicdb.org/links/variants/1657	ABL1	25	G340L			9	133748300	133748301	GG	CT	ENST00000372348.2	75	GRCh37					coding_sequence_variant		2022-04-12 21:22:05 UTC	3.0	unregistered		GLY340LEU			false
1659	https://civicdb.org/links/variants/1659	KIT	3815	S628N			4	55594180	55594180	G	A			GRCh37					missense_variant		2022-04-12 21:22:05 UTC	9.5	CA356908374		S624N			false
1664	https://civicdb.org/links/variants/1664	EGFR	1956	M766_A767insAI			7	55249000	55249001		GCCATA	ENST00000275493.2	75	GRCh37					inframe_insertion		2022-04-14 20:05:43 UTC	0.0	CA645561560					false
1665	https://civicdb.org/links/variants/1665	EGFR	1956	Y764_V765insHH			7	55248994	55248995		CACCAC	ENST00000275493.2	75	GRCh37					inframe_insertion		2022-05-05 00:00:07 UTC	0.0	CA2573051277					false
1667	https://civicdb.org/links/variants/1667	EGFR	1956	P772_H773insYNP			7	55249018	55249019		TATAATCCC			GRCh37					inframe_insertion		2022-04-12 21:22:02 UTC	7.5	CA2573051294					false
1668	https://civicdb.org/links/variants/1668	EGFR	1956	P772_V774insPHV										GRCh37					inframe_insertion		2022-04-12 21:22:03 UTC	7.5						false
1681	https://civicdb.org/links/variants/1681	JAK2	3717	Splice Site (c.1641+2T>G)			9	5070054	5070054	T	G			GRCh37					splice_donor_variant	NC_000009.11:g.5070054T>G,NM_004972.3:c.1641+2T>G,NP_004963.1:p.=	2022-04-12 21:22:05 UTC	7.5	CA372825751	NONE FOUND	F547 SPLICE SITE MUTATION,(C.1641+2T>G) F547 SPLICE SITE			false
1682	https://civicdb.org/links/variants/1682	ARID1A	8289	P1175FS*5										GRCh37					frameshift_variant		2022-04-12 21:22:06 UTC	2.0						false
1686	https://civicdb.org/links/variants/1686	ACVR1	90	G328V		ACVR1 kinase domain mutation	2	158622516	158622516	C	A	ENST00000434821.1	75	GRCh37					missense_variant	NM_001105.4:c.983G>T,NP_001096.1:p.Gly328Val,NC_000002.11:g.158622516C>A,ENST00000434821.1:c.983G>T	2022-04-12 21:22:05 UTC	30.0	CA16602802	376363	GLY328VAL,RS387906589	9	https://civicdb.org/links/assertions/9	false
1687	https://civicdb.org/links/variants/1687	RET	5979	Fusion															transcript_fusion		2022-04-12 21:22:06 UTC	92.5		N/A				false
1691	https://civicdb.org/links/variants/1691	FGFR3	2261	Fusion															transcript_fusion		2022-04-12 21:22:01 UTC	7.5		N/A				false
1693	https://civicdb.org/links/variants/1693	CHEK1	1111	Overexpression																	2022-04-12 21:22:02 UTC	4.0						false
1695	https://civicdb.org/links/variants/1695	TP53	7157	R158H			17	7578457	7578457	C	T	ENST00000269305.4	75	GRCh37					missense_variant	ENST00000269305.4:c.473G>A	2022-07-21 17:11:17 UTC	9.0	CA000227	141963	ARG158HIS			false
1696	https://civicdb.org/links/variants/1696	TP53	7157	R249S																	2022-07-21 17:23:45 UTC	7.0						false
1697	https://civicdb.org/links/variants/1697	TP53	7157	R280K																	2022-04-12 21:22:02 UTC	4.0						false
1698	https://civicdb.org/links/variants/1698	TP53	7157	R280T																	2022-04-12 21:22:02 UTC	4.0						false
1699	https://civicdb.org/links/variants/1699	TP53	7157	R158L			17	7578457	7578457	C	A	ENST00000269305.4	75	GRCh37					missense_variant	ENST00000269305.4:c.473G>T	2022-04-12 21:22:05 UTC	4.0	CA397842028	528248	ARG158LEU			false
1733	https://civicdb.org/links/variants/1733	VHL	7428	E46* (c.136G>T)			3	10183667	10183667	G	T	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.136G>T,NC_000003.11:g.10183667G>T,NM_000551.3:c.136G>T,NP_000542.1:p.Glu46Ter	2022-04-12 21:22:05 UTC	10.0	CA351748085	NONE FOUND	GLU46TER,E46X,C.136G>T			false
1734	https://civicdb.org/links/variants/1734	VHL	7428	E52K (c.154G>A)			3	10183685	10183685	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.154G>A,NP_000542.1:p.Glu52Lys,NC_000003.11:g.10183685G>A,ENST00000256474.2:c.154G>A	2022-04-12 21:22:05 UTC	5.0	CA020056	161402	GLU52LYS,C.154G>A,RS373068386			false
1736	https://civicdb.org/links/variants/1736	VHL	7428	E55* (c.163G>T)			3	10183694	10183694	G	T	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.163G>T,NC_000003.11:g.10183694G>T,NC_000003.12:g.10142010G>T,NM_000551.4:c.163G>T,NP_000542.1:p.Glu55Ter	2022-04-12 21:22:03 UTC	7.5	CA351748495	NONE FOUND	GLU55TER			false
1738	https://civicdb.org/links/variants/1738	VHL	7428	L158P (c.473T>C)			3	10191480	10191480	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.473T>C,NP_000542.1:p.Leu158Pro,NC_000003.11:g.10191480T>C,ENST00000256474.2:c.473T>C	2022-04-12 21:22:05 UTC	22.5	CA020399	182980	C.473T>C,LEU158PRO,RS121913346			false
1739	https://civicdb.org/links/variants/1739	VHL	7428	R167Q (c.500G>A)	R167Q is the most common point mutation in hereditary Von Hippel-Lindau (VHL) disease and disrupts the VHL genes binding to elongin C reducing the levels of the VHL-elongin B-elongin C (VBC) E3 ligase complex and inhibiting the ability of VHL to regulate HIF2Œ±. This partial function in turn leads to an increased risk of tumorgenesis. VHL derived clear cell renal cell carcinoma models however have shown the proteasome inhibitors bortezomib and carfilzomib can act to stabilize mutant VHL-R167Q leading to downregulation of HIF2Œ± and suprressed tumorgenesis.		3	10191507	10191507	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.500G>A,NP_000542.1:p.Arg167Gln,NC_000003.11:g.10191507G>A,ENST00000256474.2:c.500G>A	2021-01-16 22:15:47 UTC	95.0	CA020454	2216	C.500G>A,ARG167GLN,RS5030821	4	https://civicdb.org/links/assertions/4	false
1741	https://civicdb.org/links/variants/1741	VHL	7428	Y98H (c.292T>C)			3	10183823	10183823	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.292T>C,NP_000542.1:p.Tyr98His,NC_000003.11:g.10183823T>C,ENST00000256474.2:c.292T>C	2022-04-12 21:22:03 UTC	67.5	CA020246	2223	C.292T>C,TYR98HIS,RS5030809			false
1742	https://civicdb.org/links/variants/1742	VHL	7428	H115Q (c.345C>A)			3	10188202	10188202	C	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.345C>A,NP_000542.1:p.His115Gln,NC_000003.11:g.10188202C>A,NM_000551.3:c.345C>A	2022-04-12 21:22:04 UTC	5.0	CA351753631	496057	C.345C>A,HIS115GLN,RS864622646			false
1743	https://civicdb.org/links/variants/1743	VHL	7428	F119L (c.357C>G)			3	10188214	10188214	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.357C>G,NC_000003.11:g.10188214C>G,NM_000551.3:c.357C>G,NP_000542.1:p.Phe119Leu	2022-04-12 21:22:05 UTC	22.5	CA351753726	625240	C.357C>G,PHE119LEU,RS1559428077			false
1744	https://civicdb.org/links/variants/1744	VHL	7428	A149T (c.445G>A)			3	10188302	10188302	G	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.445G>A,NM_000551.3:c.445G>A,NP_000542.1:p.Ala149Thr,NC_000003.11:g.10188302G>A	2022-04-12 21:22:05 UTC	5.0	CA357066	223213	C.445G>A,ALA149THR,RS587780077			false
1745	https://civicdb.org/links/variants/1745	VHL	7428	T157I (c.470C>T)			3	10191477	10191477	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.470C>T,NP_000542.1:p.Thr157Ile,NC_000003.11:g.10191477C>T,ENST00000256474.2:c.470C>T	2022-04-12 21:22:03 UTC	32.5	CA357133	223223	C.470C>T,THR157ILE,RS869025660			false
1746	https://civicdb.org/links/variants/1746	VHL	7428	R161Q (c.482G>A)			3	10191489	10191489	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.482G>A,NP_000542.1:p.Arg161Gln,NC_000003.11:g.10191489G>A,ENST00000256474.2:c.482G>A	2022-08-22 15:20:14 UTC	72.5	CA020413	182983	C.482G>A,ARG161GLN,RS730882035			false
1747	https://civicdb.org/links/variants/1747	VHL	7428	R167W (c.499C>T)			3	10191506	10191506	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.499C>T,NP_000542.1:p.Arg167Trp,NC_000003.11:g.10191506C>T,ENST00000256474.2:c.499C>T	2022-04-12 21:22:03 UTC	105.0	CA020450	2218	C.499C>T,ARG167TRP,R126W,RS5030820	42	https://civicdb.org/links/assertions/42	false
1748	https://civicdb.org/links/variants/1748	VHL	7428	L178P (c.533T>C)			3	10191540	10191540	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.533T>C,NM_000551.3:c.533T>C,NP_000542.1:p.Leu178Pro,NC_000003.11:g.10191540T>C	2022-04-12 21:22:04 UTC	42.5	CA351756245	428795	C.533T>C,LEU178PRO,RS5030822			false
1750	https://civicdb.org/links/variants/1750	VHL	7428	V62fs (c.180del)			3	10183711	10183711	G		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant	NM_000551.3:c.180delG,NP_000542.1:p.Val62fs,NC_000003.11:g.10183711del,NC_000003.12:g.10142027del	2022-04-12 21:22:05 UTC	10.0	CA020069	182986	C.180DELG,VAL62CYSFS,NP_000542.1:P.VAL62CYSFS			false
1752	https://civicdb.org/links/variants/1752	VHL	7428	Q73* (c.217C>T)			3	10183748	10183748	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.217C>T,NP_000542.1:p.Gln73Ter,NC_000003.11:g.10183748C>T,ENST00000256474.2:c.217C>T	2022-04-12 21:22:05 UTC	27.5	CA357036	223164	Q73X,C.217C>T,GLN73TER,RS869025619			false
1754	https://civicdb.org/links/variants/1754	VHL	7428	N78H (c.232A>C)			3	10183763	10183763	A	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.232A>C,NC_000003.11:g.10183763A>C,NM_000551.3:c.232A>C,NP_000542.1:p.Asn78His	2022-04-12 21:22:04 UTC	32.5	CA351749283	NONE FOUND	C.232A>C,ASN78HIS			false
1755	https://civicdb.org/links/variants/1755	VHL	7428	N78S (c.233A>G)			3	10183764	10183764	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.233A>G,NP_000542.1:p.Asn78Ser,NC_000003.11:g.10183764A>G,ENST00000256474.2:c.233A>G	2022-04-12 21:22:05 UTC	65.0	CA020131	93326	C.233A>G,ASN78SER,RS5030804			false
1756	https://civicdb.org/links/variants/1756	VHL	7428	N78T (c.233A>C)			3	10183764	10183764	A	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.233A>C,NP_000542.1:p.Asn78Thr,NC_000003.11:g.10183764A>C,ENST00000256474.2:c.233A>C	2022-04-12 21:22:05 UTC	5.0	CA357095	223168	C.233A>C,ASN78THR,RS5030804			false
1757	https://civicdb.org/links/variants/1757	VHL	7428	S80I (c.239G>T)			3	10183770	10183770	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.239G>T,NM_000551.3:c.239G>T,NP_000542.1:p.Ser80Ile,NC_000003.11:g.10183770G>T	2022-04-12 21:22:06 UTC	15.0	CA16621914	NONE FOUND	C.239G>T,SER80ILE,RS5030805			false
1758	https://civicdb.org/links/variants/1758	VHL	7428	P86fs (c.254_255insC)			3	10183785	10183786		C	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10183785_10183786insC,NM_000551.3:c.254_255insC,NC_000003.12:g.10142101_10142102insC,NP_000542.1:p.Pro86fs	2022-04-12 21:22:02 UTC	10.0	CA2497028737	NONE FOUND	P86AFS*46			false
1759	https://civicdb.org/links/variants/1759	VHL	7428	P86A (c.256C>G)			3	10183787	10183787	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.256C>G,NP_000542.1:p.Pro86Ala,NC_000003.11:g.10183787C>G,ENST00000256474.2:c.256C>G	2022-04-12 21:22:05 UTC	5.0	CA020174	93327	C.256C>G,PRO86ALA,RS398123481			false
1760	https://civicdb.org/links/variants/1760	VHL	7428	P86L (c.257C>T)			3	10183788	10183788	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.257C>T,NP_000542.1:p.Pro86Leu,NC_000003.11:g.10183788C>T,ENST00000256474.2:c.257C>T	2022-04-12 21:22:05 UTC	27.5	CA020186	182977	C.257C>T,PRO86LEU,RS730882034			false
1761	https://civicdb.org/links/variants/1761	VHL	7428	W88R (c.262T>A)			3	10183793	10183793	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.262T>A,NP_000542.1:p.Trp88Arg,NC_000003.11:g.10183793T>A,NM_000551.3:c.262T>A	2022-04-12 21:22:04 UTC	10.0	CA351750671	456577	C.262T>A,TRP88ARG,RS1553619431			false
1762	https://civicdb.org/links/variants/1762	VHL	7428	S111FS (c.331delA)			3	10183862	10183862	A		ENST00000256474.2	75	GRCh37					frameshift_truncation	NC_000003.12:g.10142178del,NC_000003.11:g.10183862del,NM_000551.3:c.331del,NM_198156.2:c.331del,NP_937799.1:p.Ser111AlafsTer7,NM_001354723.1:c.331del,NP_001341652.1:p.Ser111AlafsTer6,ENST00000256474.2:c.331del	2022-04-12 21:22:01 UTC	10.0	CA432420649	NONE FOUND	C.331DELA,SER111FS			false
1763	https://civicdb.org/links/variants/1763	VHL	7428	S111N (c.332G>A)			3	10183863	10183863	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.332G>A,NP_000542.1:p.Ser111Asn,NC_000003.11:g.10183863G>A,ENST00000256474.2:c.332G>A	2022-04-12 21:22:05 UTC	12.5	CA357091	223186	C.332G>A,SER111ASN,RS869025631			false
1764	https://civicdb.org/links/variants/1764	VHL	7428	S111R (c.333C>G)			3	10183864	10183864	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.333C>G,NP_000542.1:p.Ser111Arg,NC_000003.11:g.10183864C>G,ENST00000256474.2:c.333C>G	2022-04-12 21:22:04 UTC	15.0	CA040305	223187	C.333C>G,SER111ARG,RS765978945			false
1765	https://civicdb.org/links/variants/1765	EGFR	1956	Gain-of-function			7							GRCh37							2022-04-14 19:43:36 UTC	20.0			ACTIVATING MUTATION			false
1766	https://civicdb.org/links/variants/1766	VHL	7428	Y112* (c.336C>A)			3	10183867	10183867	C	A	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.336C>A,NC_000003.11:g.10183867C>A,NM_000551.3:c.336C>A,NP_000542.1:p.Tyr112Ter	2022-04-12 21:22:05 UTC	10.0	CA16602183	NONE FOUND	C.336C>A,Y112X,TYR112TER			false
1767	https://civicdb.org/links/variants/1767	VHL	7428	W117C (c.351G>T)			3	10188208	10188208	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.351G>T,NP_000542.1:p.Trp117Cys,NC_000003.11:g.10188208G>T,ENST00000256474.2:c.351G>T	2022-04-12 21:22:05 UTC	25.0	CA020294	167827	C.351G>T,TRP117CYS,RS727504215			false
1768	https://civicdb.org/links/variants/1768	VHL	7428	L129Q (c.386insAGA)																	2022-04-12 21:22:03 UTC	10.0						false
1769	https://civicdb.org/links/variants/1769	VHL	7428	L135* (c.404T>A)			3	10188261	10188261	T	A	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.404T>A,NC_000003.11:g.10188261T>A,NM_000551.3:c.404T>A,NP_000542.1:p.Leu135Ter	2022-04-12 21:22:05 UTC	10.0	CA351754021	NONE FOUND	C.404T>A,L135X,LEU135TER			false
1770	https://civicdb.org/links/variants/1770	VHL	7428	N150fs (c.449del)	There are no similar variants in ClinVar with this exact genomic location.			10188305	10188305	A		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NM_000551.3:c.449del,NP_000542.1:p.Asn150IlefsTer9,NC_000003.12:g.10146622del,NC_000003.11:g.10188306del	2020-11-14 05:28:37 UTC	7.5		NONE FOUND	N150IFS*9,N150FS (C.448DELA)			false
1771	https://civicdb.org/links/variants/1771	VHL	7428	P154fs (c.462delA)			3	10188319	10188319	A		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.462delA,NC_000003.11:g.10188319del,NM_000551.3:c.462del,NP_000542.1:p.Val155CysfsTer4	2022-04-12 21:22:05 UTC	7.5	CA432421926	NONE FOUND	C.462DELA,PRO154FS			false
1772	https://civicdb.org/links/variants/1772	VHL	7428	C162R (c.484T>C)			3	10191491	10191491	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.484T>C,NM_000551.3:c.484T>C,NC_000003.11:g.10191491T>C,NP_000542.1:p.Cys162Arg	2022-04-12 21:22:03 UTC	22.5	CA351756117	496067	RS1553620313,C.484T>C,CYS162ARG			false
1773	https://civicdb.org/links/variants/1773	VHL	7428	C162F (c.485G>T)			3	10191492	10191492	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.485G>T,NP_000542.1:p.Cys162Phe,NC_000003.11:g.10191492G>T,ENST00000256474.2:c.485G>T	2022-04-12 21:22:05 UTC	22.5	CA020418	43604	C.485G>T,CYS162PHE,RS397516444			false
1774	https://civicdb.org/links/variants/1774	VHL	7428	C162W (c.486C>G)			3	10191493	10191493	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.486C>G,NP_000542.1:p.Cys162Trp,NC_000003.11:g.10191493C>G,ENST00000256474.2:c.486C>G	2022-04-12 21:22:06 UTC	32.5	CA357016	223227	C.486C>G,CYS162TRP,RS869025662			false
1775	https://civicdb.org/links/variants/1775	VHL	7428	V166D (c.497T>A)			3	10191504	10191504	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.497T>A,NC_000003.11:g.10191504T>A,NM_000551.3:c.497T>A,NP_000542.1:p.Val166Asp	2022-04-12 21:22:05 UTC	10.0	CA351756176	625254	C.497T>A,VAL166ASP			false
1776	https://civicdb.org/links/variants/1776	VHL	7428	L184P (c.551T>C)			3	10191558	10191558	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.551T>C,NP_000542.1:p.Leu184Pro,NC_000003.11:g.10191558T>C,ENST00000256474.2:c.551T>C	2022-04-12 21:22:06 UTC	32.5	CA16617792	419447	C.551T>C,LEU184PRO,RS1064793878	41	https://civicdb.org/links/assertions/41	false
1777	https://civicdb.org/links/variants/1777	VHL	7428	E186* (c.556G>T)			3	10191563	10191563	G	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.556G>T,NP_000542.1:p.Glu186Ter,NC_000003.11:g.10191563G>T,ENST00000256474.2:c.556G>T	2022-04-12 21:22:05 UTC	15.0	CA16604432	381602	C.556G>T,E186X,GLU186TER,RS367545984			false
1778	https://civicdb.org/links/variants/1778	VHL	7428	E186K (c.556G>A)			3	10191563	10191563	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.556G>A,NP_000542.1:p.Glu186Lys,NC_000003.11:g.10191563G>A,ENST00000256474.2:c.556G>A	2022-04-12 21:22:05 UTC	5.0	CA020480	161403	C.556G>A,GLU186LYS,RS367545984			false
1780	https://civicdb.org/links/variants/1780	VHL	7428	R176fs (c.526del)			3	10191533	10191533	A		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.526delA,NC_000003.11:g.10191533del,NM_000551.3:c.526del,NP_000542.1:p.Arg176GlyfsTer26	2022-04-12 21:22:05 UTC	10.0	CA16602180	625257	C.526DELA,ARG176FS,RS1559429711,R176GFS*26 (C.526DEL)			false
1782	https://civicdb.org/links/variants/1782	VHL	7428	P154L (c.461C>T)			3	10188318	10188318	C	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.461C>T,NC_000003.11:g.10188318C>T,NM_000551.3:c.461C>T,NP_000542.1:p.Pro154Leu	2022-04-12 21:22:01 UTC	25.0	CA351754410	NONE FOUND	C.461C>T,PRO154LEU			false
1783	https://civicdb.org/links/variants/1783	VHL	7428	L158fs (c.471dupT)			3	10191478	10191479		T	ENST00000256474.2	75	GRCh37					frameshift_variant	NC_000003.11:g.10191478dup,NC_000003.12:g.10149794dup,NM_000551.3:c.471dup,NP_000542.1:p.Leu158SerfsTer16,ENST00000256474.2:c.471dup,ENSP00000256474.2:p.Leu158SerfsTer16	2022-04-12 21:22:03 UTC	5.0	CA357050	NONE FOUND	C.685INST			false
1784	https://civicdb.org/links/variants/1784	VHL	7428	S183* (c.548C>A)			3	10191555	10191555	C	A	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.548C>A,NP_000542.1:p.Ser183Ter,NC_000003.11:g.10191555C>A,ENST00000256474.2:c.548C>A	2022-04-12 21:22:05 UTC	15.0	CA020473	2215	C.548C>A,S183X,SER183TER,RS5030823			false
1785	https://civicdb.org/links/variants/1785	VHL	7428	A56fs (c.166_167insA)			3	10183697	10183698		A	ENST00000256474.2	75	GRCh37					frameshift_truncation	NC_000003.11:g.10183697_10183698insA,NC_000003.12:g.10142013_10142014insA,NM_000551.3:c.166_167insA,NP_000542.1:p.Ala56AspfsTer?,ENST00000256474.2:c.166_167insA	2022-04-12 21:22:05 UTC	5.0	CA432536366	NONE FOUND	L15409.1:380INSA,380INSA			false
1787	https://civicdb.org/links/variants/1787	VHL	7428	S65W (c.194C>G)			3	10183725	10183725	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.194C>G,NM_000551.3:c.194C>G,NP_000542.1:p.Ser65Trp,NC_000003.11:g.10183725C>G	2022-04-12 21:22:06 UTC	105.0	CA020099	43597	C.194C>G,SER65TRP,RS5030826			false
1788	https://civicdb.org/links/variants/1788	VHL	7428	S65L (c.194C>T)			3	10183725	10183725	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.194C>T,NP_000542.1:p.Ser65Leu,NC_000003.11:g.10183725C>T,ENST00000256474.2:c.194C>T	2022-04-12 21:22:05 UTC	72.5	CA020104	182975	C.194C>T,SER65LEU,RS5030826			false
1791	https://civicdb.org/links/variants/1791	VHL	7428	R79P (c.236G>C)			3	10183767	10183767	G	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.236G>C,NC_000003.11:g.10183767G>C,NM_000551.3:c.236G>C,NP_000542.1:p.Arg79Pro	2022-04-12 21:22:02 UTC	7.5	CA351749311	NONE FOUND	C.236G>C,ARG79PRO			false
1792	https://civicdb.org/links/variants/1792	VHL	7428	S80R (c.240T>G)			3	10183771	10183771	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.240T>G	2022-04-12 21:22:05 UTC	12.5	CA351750515	NONE FOUND	C.240T>G,SER80ARG			false
1793	https://civicdb.org/links/variants/1793	VHL	7428	L89P (c.266T>C)			3	10183797	10183797	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.266T>C,NP_000542.1:p.Leu89Pro,NC_000003.11:g.10183797T>C,ENST00000256474.2:c.266T>C	2022-04-12 21:22:05 UTC	27.5	CA020207	182979	C.266T>C,LEU89PRO,RS5030807			false
1794	https://civicdb.org/links/variants/1794	VHL	7428	E94* (c.280G>T)			3	10183811	10183811	G	T	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.280G>T,NM_198156.2:c.280G>T,NP_000542.1:p.Glu94Ter,NC_000003.11:g.10183811G>T	2022-04-12 21:22:02 UTC	40.0	CA70046202	584477	C.280G>T,E94X,GLU94TER,RS5030829			false
1795	https://civicdb.org/links/variants/1795	VHL	7428	P103FS (c.309_310delTG)			3	10183840	10183841	TG		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.309_310delTG,NC_000003.11:g.10183840_10183841del,NM_000551.3:c.309_310del,NP_000542.1:p.Gly104HisfsTer27	2022-04-12 21:22:04 UTC	7.5	CA658795178	NONE FOUND	C.309_310DELTG,PRO103FS			false
1796	https://civicdb.org/links/variants/1796	VHL	7428	R113* (c.337C>T)			3	10183868	10183868	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.337C>T,NP_000542.1:p.Arg113Ter,NC_000003.11:g.10183868C>T,ENST00000256474.2:c.337C>T	2022-04-12 21:22:01 UTC	37.5	CA348491	220414	C.337C>T,R113X,ARG113TER,RS5030810			false
1797	https://civicdb.org/links/variants/1797	VHL	7428	G114C (c.340G>T)			3	10183871	10183871	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.340G>T,NC_000003.11:g.10183871G>T,NM_000551.3:c.340G>T,NP_000542.1:p.Gly114Cys	2022-04-12 21:22:03 UTC	12.5	CA351751376	NONE FOUND	C.340G>T,GLY114CYS			false
1798	https://civicdb.org/links/variants/1798	VHL	7428	L118P (c.353T>C)			3	10188210	10188210	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.353T>C,NM_000551.3:c.353T>C,NP_000542.1:p.Leu118Pro,NC_000003.11:g.10188210T>C	2022-04-12 21:22:03 UTC	42.5	CA70049399	428807	C.353T>C,LEU118PRO,RS5030830			false
1800	https://civicdb.org/links/variants/1800	VHL	7428	N131fs (c.390_391del)			3	10188247	10188248	TA		ENST00000256474.2	75	GRCh37					minus_2_frameshift_variant	ENST00000256474.2:c.390_391delTA,NC_000003.11:g.10188247_10188248del,NC_000003.12:g.10146563_10146564del,NM_000551.3:c.390_391delTA,NP_000542.1:p.Asn131fs,NP_000542.1:p.Asn131ProfsTer3	2022-04-12 21:22:05 UTC	15.0	CA658795179	NONE FOUND	C.390_391DELTA,ASN131PRO,N131PFS*3,ASN131PROFSTER3			false
1801	https://civicdb.org/links/variants/1801	VHL	7428	F136S (c.407T>C)			3	10188264	10188264	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.407T>C,NC_000003.11:g.10188264T>C,NM_000551.3:c.407T>C,NP_000542.1:p.Phe136Ser	2022-04-12 21:22:05 UTC	47.5	CA040847	496064	C.407T>C,PHE136SER,RS5030833			false
1802	https://civicdb.org/links/variants/1802	VHL	7428	L153fs (c.457delC)	There are two similar variants in ClinVar at this exact genomic location with ClinVar IDs: 526670 and 486714.		3	10188317	10188317	C		ENST00000256474.2	75	GRCh37					deletion	NM_000551.3:c.457delC	2020-11-03 00:00:35 UTC	17.5	CA432421924	NONE FOUND	C.457DELC,LEU153FS			false
1803	https://civicdb.org/links/variants/1803	VHL	7428	L158V (c.472C>G)			3	10191479	10191479	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.472C>G,NC_000003.11:g.10191479C>G,NM_000551.3:c.472C>G,NP_000542.1:p.Leu158Val	2022-04-12 21:22:05 UTC	22.5	CA351756068	NONE FOUND	C.472C>G,LEU158VAL			false
1804	https://civicdb.org/links/variants/1804	VHL	7428	R161* (c.481C>T)			3	10191488	10191488	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.481C>T,NP_000542.1:p.Arg161Ter,NC_000003.11:g.10191488C>T,ENST00000256474.2:c.481C>T	2022-04-12 21:22:06 UTC	77.5	CA020408	2217	C.481C>T,R161X,ARG161TER,RS5030818			false
1806	https://civicdb.org/links/variants/1806	VHL	7428	V170F (c.508G>T)			3	10191515	10191515	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.508G>T,NC_000003.11:g.10191515G>T,NM_000551.3:c.508G>T,NP_000542.1:p.Val170Phe	2022-04-12 21:22:05 UTC	7.5	CA351756193	NONE FOUND	C.508G>T,VAL170PHE			false
1807	https://civicdb.org/links/variants/1807	VHL	7428	I180V (c.538A>G)			3	10191545	10191545	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.538A>G,NP_000542.1:p.Ile180Val,NC_000003.11:g.10191545A>G,ENST00000256474.2:c.538A>G	2022-04-12 21:22:05 UTC	7.5	CA020469	161401	C.538A>G,ILE180VAL,RS377715747			false
1808	https://civicdb.org/links/variants/1808	VHL	7428	L184R (c.551T>G)			3	10191558	10191558	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.551T>G,NC_000003.11:g.10191558T>G,NM_000551.3:c.551T>G,NP_000542.1:p.Leu184Arg	2022-04-12 21:22:05 UTC	7.5	CA351756355	NONE FOUND	C.551T>G,LEU184ARG			false
1809	https://civicdb.org/links/variants/1809	VHL	7428	Y185* (c.555C>G)			3	10191562	10191562	C	G	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.555C>G,NP_000542.1:p.Tyr185Ter,NC_000003.11:g.10191562C>G,ENST00000256474.2:c.555C>G	2022-04-12 21:22:05 UTC	15.0	CA357075	223233	C.555C>G,Y185X,TYR185TER,RS864622109			false
1810	https://civicdb.org/links/variants/1810	VHL	7428	Q195* (c.583C>T)			3	10191590	10191590	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.583C>T,NP_000542.1:p.Gln195Ter,NC_000003.11:g.10191590C>T,ENST00000256474.2:c.583C>T	2022-04-12 21:22:05 UTC	60.0	CA70052558	428794	C.583C>T,Q195X,GLN195TER,RS5030825	18	https://civicdb.org/links/assertions/18	false
1811	https://civicdb.org/links/variants/1811	VHL	7428	S65* (c.194C>A)			3	10183725	10183725	C	A	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.194C>A,NP_000542.1:p.Ser65Ter,NC_000003.11:g.10183725C>A,ENST00000256474.2:c.194C>A	2022-04-12 21:22:05 UTC	15.0	CA357085	223161	C.194C>A,S65X,SER65TER,RS5030826			false
1813	https://civicdb.org/links/variants/1813	VHL	7428	D121G (c.362A>G)			3	10188219	10188219	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.362A>G,NP_000542.1:p.Asp121Gly,NC_000003.11:g.10188219A>G,ENST00000256474.2:c.362A>G	2022-04-12 21:22:05 UTC	10.0	CA357083	223200	C.362A>G,ASP121GLY,RS5030832			false
1814	https://civicdb.org/links/variants/1814	VHL	7428	F136C (c.407T>G)			3	10188264	10188264	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.407T>G,NC_000003.11:g.10188264T>G,NM_000551.3:c.407T>G,NP_000542.1:p.Phe136Cys	2022-04-12 21:22:05 UTC	12.5	CA70049495	496065	C.407T>G,PHE136CYS,RS5030833			false
1815	https://civicdb.org/links/variants/1815	VHL	7428	V84L (c.250G>T)			3	10183781	10183781	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.250G>T,NP_000542.1:p.Val84Leu,NC_000003.11:g.10183781G>T,ENST00000256474.2:c.250G>T	2022-04-12 21:22:02 UTC	10.0	CA020170	2236	C.250G>T,VAL84LEU,RS5030827			false
1816	https://civicdb.org/links/variants/1816	VHL	7428	S72fs (c.214del)			3	10183745	10183745	T		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.214delT,NC_000003.12:g.10142061del,NM_000551.4:c.214del,NP_000542.1:p.Ser72ProfsTer?,NC_000003.11:g.10183745del	2022-04-12 21:22:03 UTC	10.0	CA658795180	NONE FOUND	C.214DELT,SER72FS,S72FS (C.214DELT)			false
1820	https://civicdb.org/links/variants/1820	VHL	7428	L116V (c.346C>G)			3	10188203	10188203	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.346C>G,NC_000003.11:g.10188203C>G,NM_000551.3:c.346C>G,NP_000542.1:p.Leu116Val	2022-04-12 21:22:05 UTC	10.0	CA351753642	NONE FOUND	C.346C>G,LEU116VAL			false
1824	https://civicdb.org/links/variants/1824	VHL	7428	C162Y (c.485G>A)			3	10191492	10191492	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.485G>A,NP_000542.1:p.Cys162Tyr,NC_000003.11:g.10191492G>A,ENST00000256474.2:c.485G>A	2022-04-12 21:22:03 UTC	20.0	CA357010	223225	C.485G>A,CYS162TYR,RS397516444			false
1825	https://civicdb.org/links/variants/1825	VHL	7428	V166F (c.496G>T)			3	10191503	10191503	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.496G>T,NP_000542.1:p.Val166Phe,NC_000003.11:g.10191503G>T,ENST00000256474.2:c.496G>T	2022-04-12 21:22:05 UTC	7.5	CA020436	2224	C.496G>T,VAL166PHE,RS104893825			false
1826	https://civicdb.org/links/variants/1826	VHL	7428	V170D (c.509T>A)			3	10191516	10191516	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.509T>A,NC_000003.11:g.10191516T>A,NM_000551.3:c.509T>A,NP_000542.1:p.Val170Asp	2022-04-12 21:22:05 UTC	40.0	CA351756195	625256	C.509T>A,VAL170ASP			false
1827	https://civicdb.org/links/variants/1827	VHL	7428	R177* (c.529A>T)			3	10191536	10191536	A	T	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.529A>T,NC_000003.11:g.10191536A>T,NM_000551.3:c.529A>T,NP_000542.1:p.Arg177Ter	2022-04-12 21:22:05 UTC	7.5	CA351756239	625258	C.529A>T,R177X,ARG177TER,RS1559429717			false
1830	https://civicdb.org/links/variants/1830	POLE	5426	P286R																	2022-04-12 21:22:03 UTC	15.0						false
1831	https://civicdb.org/links/variants/1831	POLE	5426	V411L																	2022-04-12 21:22:03 UTC	15.0						false
1832	https://civicdb.org/links/variants/1832	POLE	5426	S459F																	2022-04-12 21:22:03 UTC	15.0						false
1834	https://civicdb.org/links/variants/1834	VHL	7428	E70* (c.208G>T)			3	10183739	10183739	G	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.208G>T,NP_000542.1:p.Glu70Ter,NC_000003.11:g.10183739G>T,ENST00000256474.2:c.208G>T	2022-04-12 21:22:05 UTC	27.5	CA16602179	428806	C.208G>T,E70X,GLU70TER,RS5030802			false
1835	https://civicdb.org/links/variants/1835	VHL	7428	F76S (c.227T>C)			3	10183758	10183758	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.227T>C,NC_000003.11:g.10183758T>C,NM_000551.3:c.227T>C,NP_000542.1:p.Phe76Ser	2022-04-12 21:22:05 UTC	7.5	CA020125	182976	PHE76SER,C.277T>C,RS730882033			false
1836	https://civicdb.org/links/variants/1836	VHL	7428	L188V (c.562C>G)			3	10191569	10191569	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.562C>G,NP_000542.1:p.Leu188Val,NC_000003.11:g.10191569C>G,ENST00000256474.2:c.562C>G	2022-04-12 21:22:05 UTC	15.0	CA020488	2225	C.562C>G,LEU188VAL,RS5030824			false
1837	https://civicdb.org/links/variants/1837	VHL	7428	P81S (c.241C>T)			3	10183772	10183772	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.241C>T,NP_000542.1:p.Pro81Ser,NC_000003.11:g.10183772C>T,ENST00000256474.2:c.241C>T	2022-04-12 21:22:05 UTC	20.0	CA020148	2233	C.241C>T,PRO81SER,RS104893829			false
1838	https://civicdb.org/links/variants/1838	VHL	7428	L101G (c.301_302delinsGG)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.302T>C (p.Leu101Pro; L101P) (https://www.ncbi.nlm.nih.gov/clinvar/variation/480963/)		3	10183832	10183833	CT	GG	ENST00000256474.2	75	GRCh37					delins	NM_000551.3:c.301_302delinsGG,NP_000542.1:p.Leu101Gly,ENST00000256474.2:c.301_302delinsGG,ENSP00000256474.2:p.Leu101Gly,NC_000003.11:g.10183832_10183833delinsGG,NC_000003.12:g.10142148_10142149delinsGG	2020-10-30 00:00:11 UTC	5.0	CA915940707	NONE FOUND	C.301_302CT>GG			false
1839	https://civicdb.org/links/variants/1839	VHL	7428	T105P (c.313A>C)			3	10183844	10183844	A	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.313A>C,NC_000003.11:g.10183844A>C,NM_000551.3:c.313A>C,NP_000542.1:p.Thr105Pro	2022-04-12 21:22:03 UTC	12.5	CA351751116	496055	C.313A>C,THR105PRO,RS1553619461			false
1840	https://civicdb.org/links/variants/1840	VHL	7428	R107P (c.320G>C)			3	10183851	10183851	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.320G>C,NP_000542.1:p.Arg107Pro,NC_000003.11:g.10183851G>C,ENST00000256474.2:c.320G>C	2022-04-12 21:22:05 UTC	7.5	CA020262	36900	C.320G>C,ARG107PRO,RS193922609			false
1841	https://civicdb.org/links/variants/1841	VHL	7428	L118fs (c.352_353insA)			3	10188209	10188210		A	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant	NC_000003.11:g.10188209_10188210insA,NC_000003.12:g.10146525_10146526insA,NM_000551.3:c.352_353insA,NP_000542.1:p.Leu118fs	2022-04-12 21:22:03 UTC	7.5	CA357125	223198	LEU118FS,RS869025641			false
1843	https://civicdb.org/links/variants/1843	VHL	7428	T133fs (c.397del)			3	10188252	10188252	A		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10188254del,NP_000542.1:p.Thr133LeufsTer26,NP_000542.1:p.Thr133fs,NC_000003.12:g.10146570del,NM_000551.4:c.397del	2022-04-12 21:22:03 UTC	7.5	CA432421843	625244	Q132FS (C.395DELA),T133LFS*26			false
1844	https://civicdb.org/links/variants/1844	VHL	7428	D143fs (c.430delG)																	2022-04-12 21:22:03 UTC	7.5						false
1845	https://civicdb.org/links/variants/1845	VHL	7428	Q164* (c.490C>T)			3	10191497	10191497	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.490C>T,NP_000542.1:p.Gln164Ter,NC_000003.11:g.10191497C>T,ENST00000256474.2:c.490C>T	2022-04-12 21:22:05 UTC	30.0	CA357060	223228	C.490C>T,Q164X,GLN164TER,RS5030819			false
1846	https://civicdb.org/links/variants/1846	VHL	7428	Y175D (c.523T>G)			3	10191530	10191530	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.523T>G,NC_000003.11:g.10191530T>G,NM_000551.3:c.523T>G,NP_000542.1:p.Tyr175Asp	2022-04-12 21:22:05 UTC	7.5	CA351756228	NONE FOUND	C.523T>G,TYR175ASP			false
1847	https://civicdb.org/links/variants/1847	VHL	7428	V181fs (c.540_543del)			3	10191547	10191550	CGTC		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10191547_10191550del,NC_000003.12:g.10149863_10149866del,NM_000551.3:c.540_543del,NP_000542.1:p.Val181fs	2022-04-12 21:22:06 UTC	7.5	CA357022	223230	VAL181FS,C.540_543DELCGTC,RS869025664			false
1848	https://civicdb.org/links/variants/1848	VHL	7428	Q96* (c.286C>T)			3	10183817	10183817	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.286C>T,NP_000542.1:p.Gln96Ter,NC_000003.11:g.10183817C>T,ENST00000256474.2:c.286C>T	2022-04-12 21:22:06 UTC	22.5	CA351750811	428804	C.286C>T,Q96X,GLN96TER,RS1131690959			false
1849	https://civicdb.org/links/variants/1849	VHL	7428	P86R (c.257C>G)			3	10183788	10183788	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.257C>G,NP_000542.1:p.Pro86Arg,NC_000003.11:g.10183788C>G,ENST00000256474.2:c.257C>G	2022-04-12 21:22:03 UTC	17.5	CA357142	223170	C.257C>G,PRO86ARG,RS730882034			false
1850	https://civicdb.org/links/variants/1850	VHL	7428	G144* (c.430G>T)			3	10188287	10188287	G	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.430G>T,NP_000542.1:p.Gly144Ter,NC_000003.11:g.10188287G>T,ENST00000256474.2:c.430G>T	2022-04-12 21:22:05 UTC	7.5	CA357109	223208	C.430G>T,G144X,GLY144TER,RS869025650			false
1852	https://civicdb.org/links/variants/1852	VHL	7428	L188P (c.563T>C)			3	10191570	10191570	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.563T>C,NC_000003.11:g.10191570T>C,NM_000551.3:c.563T>C,NP_000542.1:p.Leu188Pro	2022-04-12 21:22:05 UTC	15.0	CA351756399	625266	C.563T>C,LEU188PRO			false
1853	https://civicdb.org/links/variants/1853	VHL	7428	S111C (c.330_331delinsTT)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar. Clinvar ID: 565557		3	10183861	10183862	CA	TT	ENST00000256474.2	75	GRCh37					delins	NP_000542.1:p.Ser111Cys,NP_001341652.1:p.Ser111Cys,NC_000003.11:g.10183861_10183862delinsTT,NC_000003.12:g.10142177_10142178delinsTT	2022-05-16 00:00:31 UTC	7.5	CA2573106137	NONE FOUND	S111C (C.330_331CA>TT)			false
1854	https://civicdb.org/links/variants/1854	EGFR	1956	Ex19 del L858R															missense_variant,inframe_deletion		2022-04-15 14:00:46 UTC	50.0						false
1855	https://civicdb.org/links/variants/1855	VHL	7428	R161P (c.482G>C)			3	10191489	10191489	G	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.482G>C,NC_000003.11:g.10191489G>C,NM_000551.3:c.482G>C,NP_000542.1:p.Arg161Pro	2022-04-12 21:22:05 UTC	7.5	CA351756111	NONE FOUND	C.482G>C,ARG161PRO			false
1856	https://civicdb.org/links/variants/1856	VHL	7428	Q164R (c.491A>G)			3	10191498	10191498	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.491A>G,NP_000542.1:p.Gln164Arg,NC_000003.11:g.10191498A>G,ENST00000256474.2:c.491A>G	2022-04-12 21:22:05 UTC	10.0	CA020429	2238	C.491A>G,GLN164ARG,RS267607170			false
1857	https://civicdb.org/links/variants/1857	VHL	7428	G114R (c.340G>C)			3	10183871	10183871	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.340G>C,NP_000542.1:p.Gly114Arg,NC_000003.11:g.10183871G>C,ENST00000256474.2:c.340G>C	2022-04-12 21:22:05 UTC	12.5	CA357101	223193	C.340G>C,GLY114ARG,RS869025636			false
1859	https://civicdb.org/links/variants/1859	VHL	7428	G93S (c.277G>A)			3	10183808	10183808	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.277G>A,NP_000542.1:p.Gly93Ser,NC_000003.11:g.10183808G>A,ENST00000256474.2:c.277G>A	2022-04-12 21:22:05 UTC	22.5	CA020230	2237	C.277G>A,GLY93SER,RS5030808			false
1861	https://civicdb.org/links/variants/1861	VHL	7428	L188Q (c.563T>A)			3	10191570	10191570	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.563T>A,NC_000003.11:g.10191570T>A,NM_000551.3:c.563T>A,NP_000542.1:p.Leu188Gln	2022-04-12 21:22:05 UTC	10.0	CA351756398	625265	C.563T>A,LEU188GLN			false
1863	https://civicdb.org/links/variants/1863	EGFR	1956	Rare Exon 18-21 Mutation	Rare exon 18-21 mutations in EGFR consist of all EGFR mutations excluding sensitizing L858R substitutions and exon 19 deletions, as well as resistance mutation T790M.		7	55241614	5525967			EGFR_ENST00000275493.2	75	GRCh37					exon_variant		2022-03-25 16:16:10 UTC	30.0						false
1865	https://civicdb.org/links/variants/1865	VHL	7428	Y112H (c.334T>C)			3	10183865	10183865	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.334T>C,NP_000542.1:p.Tyr112His,NC_000003.11:g.10183865T>C,ENST00000256474.2:c.334T>C	2022-04-12 21:22:03 UTC	5.0	CA020277	2222	C.334T>C,TYR112HIS,RS104893824			false
1866	https://civicdb.org/links/variants/1866	EGFR	1956	L861																	2022-04-15 14:02:55 UTC	15.0						false
1867	https://civicdb.org/links/variants/1867	VHL	7428	R64P (c.191G>C)			3	10183722	10183722	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.191G>C,NP_000542.1:p.Arg64Pro,NC_000003.11:g.10183722G>C,ENST00000256474.2:c.191G>C	2022-04-12 21:22:05 UTC	7.5	CA020089	2226	C.191G>C,ARG64PRO,RS104893826			false
1869	https://civicdb.org/links/variants/1869	VHL	7428	E189fs (c.565del)			3	10191572	10191572	G		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10191572del,NC_000003.12:g.10149888del,NM_000551.4:c.565del,NP_000542.1:p.Glu189fs	2022-04-12 21:22:03 UTC	15.0	CA432423686	625267	E189FS (C.565DELG),E189KFS*13 (C.565DEL),GLU189LYSFS*13			false
1871	https://civicdb.org/links/variants/1871	VHL	7428	I151T (c.452T>C)			3	10188309	10188309	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.452T>C,NP_000542.1:p.Ile151Thr,NC_000003.11:g.10188309T>C,ENST00000256474.2:c.452T>C	2022-04-12 21:22:05 UTC	17.5	CA351754359	428803	C.452T>C,ILE151THR,RS869025655			false
1872	https://civicdb.org/links/variants/1872	VHL	7428	K159fs (c.473dup)			3	10191480	10191480		T	ENST00000256474.2	75	GRCh37					frameshift_variant	NM_000551.3:c.473dup,NP_000542.1:p.Lys159GlufsTer15,ENST00000256474.2:c.473dup,ENSP00000256474.2:p.Lys159GlufsTer15,NC_000003.11:g.10191480dup,NC_000003.12:g.10149796dup	2022-04-12 21:22:03 UTC	7.5		NONE FOUND	C.473INST,C.473DUPT			false
1873	https://civicdb.org/links/variants/1873	VHL	7428	S68P (c.202T>C)			3	10183733	10183733	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.202T>C,NC_000003.11:g.10183733T>C,NM_000551.3:c.202T>C,NP_000542.1:p.Ser68Pro	2022-04-12 21:22:05 UTC	7.5	CA16621912	NONE FOUND	C.202T>C,SER68PRO			false
1874	https://civicdb.org/links/variants/1874	VHL	7428	S80N (c.239G>A)			3	10183770	10183770	G	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.239G>A,NC_000003.11:g.10183770G>A,NM_000551.3:c.239G>A,NP_000542.1:p.Ser80Asn	2022-04-12 21:22:05 UTC	25.0	CA70046108	NONE FOUND	C.239G>A,SER80ASN,RS5030805			false
1883	https://civicdb.org/links/variants/1883	VHL	7428	Q145* (c.433C>T)			3	10188290	10188290	C	T	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.433C>T,NC_000003.11:g.10188290C>T,NM_000551.3:c.433C>T,NP_000542.1:p.Gln145Ter	2022-04-12 21:22:05 UTC	10.0	CA351754219	625249	C.433C>T,Q145X,GLN145TER			false
1885	https://civicdb.org/links/variants/1885	VHL	7428	H115P (c.344A>C)			3	10188201	10188201	A	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.344A>C,NC_000003.11:g.10188201A>C,NM_000551.3:c.344A>C,NP_000542.1:p.His115Pro	2022-04-12 21:22:05 UTC	7.5	CA351753626	560744	C.344A>C,HIS115PRO,RS5030812			false
1886	https://civicdb.org/links/variants/1886	VHL	7428	L128R (c.383T>G)			3	10188240	10188240	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.383T>G,NC_000003.11:g.10188240T>G,NM_000551.3:c.383T>G,NP_000542.1:p.Leu128Arg	2022-04-12 21:22:05 UTC	10.0	CA351753891	NONE FOUND	C.383T>G,LEU128ARG			false
1887	https://civicdb.org/links/variants/1887	VHL	7428	L169P (c.506T>C)			3	10191513	10191513	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.506T>C,NP_000542.1:p.Leu169Pro,NC_000003.11:g.10191513T>C,ENST00000256474.2:c.506T>C	2022-04-12 21:22:05 UTC	17.5	CA351756191	428809	C.506T>C,LEU169PRO,RS1131690962			false
1888	https://civicdb.org/links/variants/1888	VHL	7428	L178R (c.533T>G)			3	10191540	10191540	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.533T>G,NC_000003.11:g.10191540T>G,NM_000551.3:c.533T>G,NP_000542.1:p.Leu178Arg	2022-04-12 21:22:05 UTC	15.0	CA351756248	625261	C.533T>G,LEU178ARG			false
1889	https://civicdb.org/links/variants/1889	VHL	7428	M54fs (c.161dup)			3	10183691	10183692	T		ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10183692dup,NM_000551.3:c.161dup,NP_000542.1:p.Met54IlefsTer?,NC_000003.12:g.10142008dup	2022-04-12 21:22:03 UTC	10.0	unregistered	NONE FOUND	M54IFS*78 (C.161DUP),M54FS (C.161INST),M54FS (C.161DUPT)			false
1891	https://civicdb.org/links/variants/1891	EGFR	1956	L747P			7	55242469	55242470	TT	CC	ENST00000275493.2	75	GRCh37					missense_variant	NM_005228.4:c.2239_2240delTTinsCC,NP_005219.2:p.Leu747Pro,NC_000007.13:g.55242469_55242470delTTinsCC,ENST00000275493.2:c.2239_2240delTTinsCC	2022-04-15 14:12:41 UTC	5.0	CA135800	45235	LEU747PRO			false
1892	https://civicdb.org/links/variants/1892	EGFR	1956	V774A			7	55249023	55249023	T	C	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2321T>C	2022-04-15 14:06:46 UTC	7.5	CA367578723	NONE FOUND	VAL774ALA			false
1893	https://civicdb.org/links/variants/1893	VHL	7428	F91* (c.272_273delinsAA)																	2022-04-12 21:22:03 UTC	10.0			C.272TC>AA			false
1894	https://civicdb.org/links/variants/1894	EGFR	1956	V774M			7	55249022	55249022	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2320G>A	2022-04-15 14:06:25 UTC	5.0	CA158928427	NONE FOUND	VAL774MET			false
1895	https://civicdb.org/links/variants/1895	EGFR	1956	K806E			7	55249118	55249118	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2416A>G,NM_001346898.1:c.2416A>G,NP_001333827.1:p.Lys806Glu,NC_000007.13:g.55249118A>G	2022-04-15 14:05:44 UTC	5.0	CA4266068	NONE FOUND	LYS806GLU,RS754652044			false
1896	https://civicdb.org/links/variants/1896	EGFR	1956	N826Y			7	55259418	55259418	A	T	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2476A>T,NC_000007.13:g.55259418A>T,NC_000007.14:g.55191725A>T,NM_005228.3:c.2476A>T,NP_005219.2:p.Asn826Tyr	2022-04-15 14:12:41 UTC	5.0	CA367580076	NONE FOUND	ASN826TYR			false
1897	https://civicdb.org/links/variants/1897	EGFR	1956	V834I																	2022-04-15 14:06:11 UTC	7.5						false
1899	https://civicdb.org/links/variants/1899	EGFR	1956	N842S			7	55259467	55259467	A	G	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2525A>G	2022-04-15 14:06:59 UTC	5.0	CA367580172	NONE FOUND	ASN842SER			false
1902	https://civicdb.org/links/variants/1902	VHL	7428	P86S (c.256C>T)			3	10183787	10183787	C	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.256C>T,NP_000542.1:p.Pro86Ser,NC_000003.11:g.10183787C>T,ENST00000256474.2:c.256C>T	2022-04-12 21:22:03 UTC	42.5	CA020180	178692	C.256C>T,PRO86SER,RS398123481			false
1903	https://civicdb.org/links/variants/1903	VHL	7428	S65P (c.193T>C)			3	10183724	10183724	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.193T>C,NC_000003.11:g.10183724T>C,NM_000551.3:c.193T>C,NP_000542.1:p.Ser65Pro	2022-04-12 21:22:05 UTC	10.0	CA351748798	547829	C.193T>C,SER65PRO,RS869025616			false
1904	https://civicdb.org/links/variants/1904	VHL	7428	S72P (c.214T>C)			3	10183745	10183745	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.214T>C,NP_000542.1:p.Ser72Pro,NC_000003.11:g.10183745T>C,ENST00000256474.2:c.214T>C	2022-04-12 21:22:03 UTC	10.0	CA357006	223163	C.214T>C,SER72PRO,RS869025618			false
1906	https://civicdb.org/links/variants/1906	VHL	7428	L135fs (c.404del)			3	10188260	10188260	T		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10188261del,NP_000542.1:p.Leu135TyrfsTer24,ENST00000256474.2:c.404del,NM_000551.3:c.404del,NC_000003.12:g.10146577del	2022-04-12 21:22:05 UTC	7.5	CA432421852	NONE FOUND	C.404DELT,LEU135FS,L135Y*24			false
1907	https://civicdb.org/links/variants/1907	VHL	7428	R177fs (c.528del)			3	10191535	10191535	G		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.528delG,NC_000003.11:g.10191535del,NM_000551.3:c.528del,NP_000542.1:p.Arg177AspfsTer25	2022-04-12 21:22:06 UTC	15.0	CA432423454	NONE FOUND	ARG176FS,C.528DELG,R177DFS*25 (C.528DELG),R176FS (C.528DELG),R176FS (C.528DEL)			false
1908	https://civicdb.org/links/variants/1908	VHL	7428	W88* (c.264G>A)			3	10183795	10183795	G	A	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.264G>A,NP_000542.1:p.Trp88Ter,NC_000003.11:g.10183795G>A,NM_000551.3:c.264G>A	2022-04-12 21:22:03 UTC	7.5	CA351750677	936684	C.264G>A,W88X,TRP88TER			false
1909	https://civicdb.org/links/variants/1909	VHL	7428	V155E (c.464T>A)			3	10191471	10191471	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.464T>A,NC_000003.11:g.10191471T>A,NM_000551.3:c.464T>A,NP_000542.1:p.Val155Glu	2022-04-12 21:22:03 UTC	10.0	CA351756032	NONE FOUND	C.464T>A,VAL155GLU			false
1912	https://civicdb.org/links/variants/1912	VHL	7428	F76fs (c.223_224insT)			3	10183754	10183755		T	ENST00000256474.2	75	GRCh37					frameshift_truncation	NC_000003.11:g.10183755dupT,NM_000551.3:c.224dupT,NP_000542.1:p.F76Lfs*56,NC_000003.12:g.10142071dupT,NP_937799.1:p.Phe76LeufsTer?,NP_001341652.1:p.Phe76LeufsTer?	2022-04-12 21:22:05 UTC	7.5	CA913189239		ILE75FS,C.224DUPT,C.223_224INST			false
1913	https://civicdb.org/links/variants/1913	VHL	7428	K196* (c.586A>T)			3	10191593	10191593	A	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.586A>T,NP_000542.1:p.Lys196Ter,NC_000003.11:g.10191593A>T,ENST00000256474.2:c.586A>T	2022-04-12 21:22:05 UTC	5.0	CA020507	196284	C.586A>T,K196X,LYS196TER,RS281860296			false
1914	https://civicdb.org/links/variants/1914	VHL	7428	R120G (c.358A>G)			3	10188215	10188215	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.358A>G,NP_000542.1:p.Arg120Gly,NC_000003.11:g.10188215A>G,ENST00000256474.2:c.358A>G	2022-04-12 21:22:05 UTC	22.5	CA357028	223199	C.358A>G,ARG120GLY,RS869025642			false
1915	https://civicdb.org/links/variants/1915	VHL	7428	R161G (c.481C>G)			3	10191488	10191488	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.481C>G,NC_000003.11:g.10191488C>G,NM_000551.3:c.481C>G,NP_000542.1:p.Arg161Gly	2022-04-12 21:22:05 UTC	7.5	CA16621941	NONE FOUND	C.481C>G,ARG161GLY,RS5030818			false
1916	https://civicdb.org/links/variants/1916	VHL	7428	R167L (c.500G>T)			3	10191507	10191507	G	T	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10191507G>T,NM_000551.3:c.500G>T,NP_000542.1:p.Arg167Leu,ENST00000256474.2:c.500G>T	2022-04-12 21:22:01 UTC	7.5	CA351756178	526685	RS5030821,C.500G>T,ARG167LEU			false
1918	https://civicdb.org/links/variants/1918	VHL	7428	D126FS (c.375_376insC)			3	10188232	10188233		C	ENST00000256474.2	75	GRCh37					inframe_insertion	ENST00000256474.2:c.375_376insC	2022-04-12 21:22:05 UTC	5.0	CA16621931	NONE FOUND	C.375_376INSC,ASP126FS			false
1919	https://civicdb.org/links/variants/1919	VHL	7428	E160FS (c.479_480delAG)			3	10191486	10191487	AG		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.479_480delAG,NC_000003.11:g.10191486_10191487delAG,NM_000551.3:c.479_480delAG,NP_000542.1:p.Glu160AlafsTer13	2022-04-12 21:22:04 UTC	5.0	CA16621940	NONE FOUND	GLU160FS,C.479_480DELAG			false
1920	https://civicdb.org/links/variants/1920	VHL	7428	G93R (c.277G>C)			3	10183808	10183808	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.277G>C,NP_000542.1:p.Gly93Arg,NC_000003.11:g.10183808G>C,ENST00000256474.2:c.277G>C	2022-04-12 21:22:05 UTC	10.0	CA357130	223174	C.277G>C,GLY93ARG,RS5030808			false
1921	https://civicdb.org/links/variants/1921	VHL	7428	H115Y (c.343C>T)			3	10188200	10188200	C	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.343C>T,NC_000003.11:g.10188200C>T,NM_000551.3:c.343C>T,NP_000542.1:p.His115Tyr	2022-04-12 21:22:05 UTC	10.0	CA16621930	NONE FOUND	C.343C>T,HIS115TYR,RS5030811			false
1923	https://civicdb.org/links/variants/1923	VHL	7428	L153P (c.458T>C)			3	10188315	10188315	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.458T>C,NC_000003.11:g.10188315T>C,NM_000551.3:c.458T>C,NP_000542.1:p.Leu153Pro	2022-04-12 21:22:05 UTC	7.5	CA16621942	NONE FOUND	C.458T>C,LEU153PRO			false
1924	https://civicdb.org/links/variants/1924	VHL	7428	L188R (c.563T>G)			3	10191570	10191570	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.563T>G,NC_000003.11:g.10191570T>G,NM_000551.3:c.563T>G,NP_000542.1:p.Leu188Arg	2022-04-12 21:22:05 UTC	7.5	CA351756400	NONE FOUND	C.563T>G,LEU188ARG			false
1928	https://civicdb.org/links/variants/1928	VHL	7428	P138T (c.412C>A)			3	10188269	10188269	C	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.412C>A,NC_000003.11:g.10188269C>A,NM_000551.3:c.412C>A,NP_000542.1:p.Pro138Thr	2022-04-12 21:22:05 UTC	10.0	CA16621932	NONE FOUND	PRO138THR,C.412C>A			false
1929	https://civicdb.org/links/variants/1929	VHL	7428	P59fs (c.176delC)			3	10183707	10183707	C		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.176delC,NC_000003.11:g.10183707del,NM_000551.3:c.176del,NP_000542.1:p.Pro59ArgfsTer8	2022-04-12 21:22:05 UTC	0.0	CA432536374	NONE FOUND	PRO59FS,C.176DELC,P59RFS*8 (C.176DELC)			false
1932	https://civicdb.org/links/variants/1932	VHL	7428	Y175* (c.525C>A)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar, which produces the same protein change. NM_000551.3(VHL):c.525C>G (p.Tyr175Ter), https://www-ncbi-nlm-nih-gov/clinvar/variation/182974/		3	10191532	10191532	C	A	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.525C>A,NP_000542.1:p.Tyr175Ter,NC_000003.11:g.10191532C>A,NM_000551.3:c.525C>A	2021-03-06 06:46:03 UTC	5.0	CA351756231	NONE FOUND	Y175X,TYR175TER,C.525C>A			false
1933	https://civicdb.org/links/variants/1933	VHL	7428	Y98C  (c.293A>G)			3	10183824	10183824	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.293A>G,NP_000542.1:p.Tyr98Cys,NC_000003.11:g.10183824A>G,ENST00000256474.2:c.293A>G	2022-04-12 21:22:05 UTC	5.0	CA357072	223176	C.293A>G,TYR98CYS,RS864321643			false
1934	https://civicdb.org/links/variants/1934	VHL	7428	V155G (c.464T>G)			3	10191471	10191471	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.464T>G,NC_000003.11:g.10191471T>G,NM_000551.3:c.464T>G,NP_000542.1:p.Val155Gly	2022-04-12 21:22:05 UTC	2.5	CA16621938	NONE FOUND	C.464T>G,VAL155GLY			false
1935	https://civicdb.org/links/variants/1935	VHL	7428	V170G (c.509T>G)			3	10191516	10191516	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.509T>G,NC_000003.11:g.10191516T>G,NM_000551.3:c.509T>G,NP_000542.1:p.Val170Gly	2022-04-12 21:22:05 UTC	15.0	CA351756196	NONE FOUND	C.509T>G,VAL170GLY			false
1938	https://civicdb.org/links/variants/1938	VHL	7428	Exon 2 Deletion																	2022-04-12 21:22:03 UTC	7.5						false
1939	https://civicdb.org/links/variants/1939	VHL	7428	Exon 3 Deletion			3	10191471	10193904			ENST00000256474.2	75	GRCh37							2022-04-12 21:22:06 UTC	25.0						false
1940	https://civicdb.org/links/variants/1940	VHL	7428	EXON 2-3 DELETION																	2022-04-12 21:22:03 UTC	7.5						false
1946	https://civicdb.org/links/variants/1946	VHL	7428	Y156C (c.467A>G)			3	10191474	10191474	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.467A>G,NP_000542.1:p.Tyr156Cys,NC_000003.11:g.10191474A>G,ENST00000256474.2:c.467A>G	2022-04-12 21:22:06 UTC	27.5	CA020394	43600	C.467A>G,TYR156CYS,RS397516441			false
1948	https://civicdb.org/links/variants/1948	VHL	7428	R69fs (c.204insG)																	2022-04-12 21:22:03 UTC	5.0			C.204DUPG			false
1949	https://civicdb.org/links/variants/1949	VHL	7428	G144fs (c.432insG)																	2022-04-12 21:22:03 UTC	5.0						false
1953	https://civicdb.org/links/variants/1953	VHL	7428	N131K (c.393C>A)			3	10188250	10188250	C	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.393C>A,NP_000542.1:p.Asn131Lys,NC_000003.11:g.10188250C>A,ENST00000256474.2:c.393C>A	2022-04-12 21:22:04 UTC	10.0	CA16617789	420074	C.393C>A,ASN131LYS,RS1064794272			false
1955	https://civicdb.org/links/variants/1955	VHL	7428	P71fs (c.211insT)																	2022-04-12 21:22:03 UTC	7.5						false
1956	https://civicdb.org/links/variants/1956	VHL	7428	E70K (c.208G>A)	The VHL gene has a low rate of benign missense variation and is known to be definitively associated with VHL disease. The E70K missense mutation, located in the Beta-domain of VHL, is rare in open-source genome databases (0.00001489 allele frequency in ExAC, 4.365e-6 allele frequency in gnomAD) and was identified in several individuals with VHL disease symptoms (see evidence statements). Thus, this variant could be assigned ACMG code 'PP2' - Missense mutation in a gene with a low rate of benign missense variation where missense variants are a common mechanism of disease. Although this variant is registered once in ExAC and gnomAD, 'PM2' could be applied (Absent from controls in ESP, 1000 Genomes or ExAC) because VHL manifestations sometimes emerge later in adulthood. Thus, the allele may have been detected in a proband who was not yet affected by symptoms.		3	10183739	10183739	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.208G>A,NP_000542.1:p.Glu70Lys,NC_000003.11:g.10183739G>A,ENST00000256474.2:c.208G>A	2019-05-16 23:33:44 UTC	45.0	CA020108	43598	C.208G>A,GLU70LYS,RS5030802	14	https://civicdb.org/links/assertions/14	false
1957	https://civicdb.org/links/variants/1957	VHL	7428	H115Q (c.345C>G)			3	10188202	10188202	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.345C>G,NC_000003.11:g.10188202C>G,NM_000551.3:c.345C>G,NP_000542.1:p.His115Gln	2022-04-12 21:22:05 UTC	12.5	CA351753634	496058	HIS115GLN,C.345C>G,RS864622646			false
1958	https://civicdb.org/links/variants/1958	VHL	7428	H191FS (c.571delC)			3	10191578	10191578	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.571delC,NC_000003.11:g.10191578del,NM_000551.3:c.571delC,NP_000542.1:p.His191ThrfsTer11	2022-04-12 21:22:05 UTC	7.5	CA658795182	NONE FOUND	C.571DELC,HIS191FS			false
1960	https://civicdb.org/links/variants/1960	VHL	7428	L140fs (c.417_418delTC)																	2022-04-12 21:22:03 UTC	7.5						false
1962	https://civicdb.org/links/variants/1962	VHL	7428	P154= (c.462A>C)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.462A>G (p.Pro154=).(https://www.ncbi.nlm.nih.gov/clinvar/variation/411977/)		3	10188319	10188319	A	C	ENST00000256474.2	75	GRCh37					synonymous_variant	ENST00000256474.2:c.462A>C,NC_000003.11:g.10188319A>C,NM_000551.3:c.462A>C,NP_000542.1:p.Pro154=	2020-10-29 00:46:33 UTC	15.0	CA16621934	NONE FOUND	C.462A>C,PRO154PRO,P154P (C.462A>C)			false
1963	https://civicdb.org/links/variants/1963	VHL	7428	S80R (c.238A>C)			3	10183769	10183769	A	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.238A>C,NC_000003.11:g.10183769A>C,NM_000551.3:c.238A>C,NP_000542.1:p.Ser80Arg	2022-04-12 21:22:05 UTC	22.5	CA16621913	496052	SER80ARG,C.238A>C,RS786202787			false
1964	https://civicdb.org/links/variants/1964	VHL	7428	R60FS (c.179delG)			3	10183710	10183710	G		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.179delG	2022-04-12 21:22:01 UTC	7.5	CA020069	NONE FOUND	C.179DELG,ARG60FS			false
1966	https://civicdb.org/links/variants/1966	VHL	7428	W88S (c.263G>C)			3	10183794	10183794	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.263G>C,NP_000542.1:p.Trp88Ser,NC_000003.11:g.10183794G>C,ENST00000256474.2:c.263G>C	2022-04-12 21:22:05 UTC	5.0	CA020202	2220	C.263G>C,TRP88SER,RS119103277			false
1967	https://civicdb.org/links/variants/1967	VHL	7428	Y156D (c.466T>G)			3	10191473	10191473	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.466T>G,NC_000003.11:g.10191473T>G,NM_000551.3:c.466T>G,NP_000542.1:p.Tyr156Asp	2022-04-12 21:22:05 UTC	7.5	CA351756043	NONE FOUND	C.466T>G,TYR156ASP			false
1968	https://civicdb.org/links/variants/1968	VHL	7428	Y156* (c.468T>G)			3	10191475	10191475	T	G	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.468T>G,NC_000003.11:g.10191475T>G,NM_000551.3:c.468T>G,NP_000542.1:p.Tyr156Ter	2022-04-12 21:22:03 UTC	7.5	CA351756053	NONE FOUND	C.468T>G,Y156X,TYR156TER			false
1969	https://civicdb.org/links/variants/1969	VHL	7428	Y175* (c.525C>G)			3	10191532	10191532	C	G	ENST00000256474.2	75	GRCh37					stop_gained	ENST00000256474.2:c.525C>G,NC_000003.11:g.10191532C>G,NM_000551.3:c.525C>G,NP_000542.1:p.Tyr175Ter	2022-04-12 21:22:03 UTC	15.0	CA020466	182974	C.525C>G,Y175X,TYR175TER,RS5030835			false
1970	https://civicdb.org/links/variants/1970	VHL	7428	V130L (c.388G>C)			3	10188245	10188245	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.388G>C,NP_000542.1:p.Val130Leu,NC_000003.11:g.10188245G>C,ENST00000256474.2:c.388G>C	2022-04-12 21:22:05 UTC	12.5	CA020325	2229	C.388G>C,VAL130LEU,RS104893830			false
1974	https://civicdb.org/links/variants/1974	VHL	7428	Splice Site (c.464-1G>A)			3	10191470	10191470	G	A	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NM_000551.3:c.464-1G>A,NC_000003.11:g.10191470G>A,ENST00000256474.2:c.464-1G>A	2022-04-12 21:22:03 UTC	5.0	CA020389	43603	C.464-1G>A,RS5030817			false
1977	https://civicdb.org/links/variants/1977	VHL	7428	V194fs (c.581_582del)			3	10191587	10191588	TG		ENST00000256474.2	75	GRCh37					minus_2_frameshift_variant	ENST00000256474.2:c.579_580delTG	2022-04-12 21:22:05 UTC	0.0	CA70052556	NONE FOUND	C.579_580DELTG,VAL194FSX39,C.581_582DELTG,V153FS,V194FS (C.581_582DELTG)			false
1980	https://civicdb.org/links/variants/1980	VHL	7428	R82P (c.245G>C)			3	10183776	10183776	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.245G>C,NP_000542.1:p.Arg82Pro,NC_000003.11:g.10183776G>C,ENST00000256474.2:c.245G>C	2022-04-12 21:22:05 UTC	7.5	CA020159	193118	C.245G>C,ARG82PRO,RS794726890			false
1986	https://civicdb.org/links/variants/1986	VHL	7428	*214L (c.641G>T)			3	10191648	10191648	G	T	ENST00000256474.2	75	GRCh37					stop_lost	NM_000551:c.641G>T,ENST00000256474.2:c.641G>T,NP_000542.1:p.Ter214Leu,NC_000003.11:g.10191648G>T	2022-04-12 21:22:03 UTC	10.0	CA357103	223236	X214L,*214LEXT*15,RS869025668			false
1987	https://civicdb.org/links/variants/1987	VHL	7428	*214W (c.642A>G)			3	10191649	10191649	A	G	ENST00000256474.2	75	GRCh37					stop_lost	NM_000551.3:c.642A>G,NP_000542.1:p.Ter214Trp,ENST00000256474.2:c.642A>G,NC_000003.11:g.10191649A>G	2022-04-12 21:22:03 UTC	5.0	CA351756723	36907,625269	C.642A>G,TER214TRP,NM_000551:*214WEXT*14			false
1988	https://civicdb.org/links/variants/1988	VHL	7428	*214C (c.642A>T)			3	10191649	10191649	A	T	ENST00000256474.2	75	GRCh37					stop_lost	ENST00000256474.2:c.642A>T,NC_000003.11:g.10191649A>T,NM_000551.3:c.642A>T,NP_000542.1:p.Ter214Cys	2022-04-12 21:22:05 UTC	5.0	CA351756724	625270	C.642A>T,X214C,TER214CYS,RS1559430011			false
1990	https://civicdb.org/links/variants/1990	VHL	7428	Splice Site (c.464-1G>T)	There are three similar variants in ClinVar with this exact genomic position with ClinVar IDs: 223221, 223220, and 43603 of which only 223221 is an exact match (NM_000551.3:c.464-1G>T).		3	10191470	10191470	G	T	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NC_000003.11:g.10191470G>T,NM_000551.3:c.464-1G>T,ENST00000256474.2:c.464-1G>T,NC_000003.12:g.10149786G>T,NP_000542.1:p.?	2021-02-18 23:40:51 UTC	12.5	CA357144	223221	C.464-1G>T,RS5030817,IVS2-1G>T			false
1991	https://civicdb.org/links/variants/1991	PIK3CA	5290	Exon 10 and Exon 21 Mutation	PIK3CA exon 10 and exon 21 mutations occasionally co-occur in the same tumor, same cell line, or same clone (if clonality information is available). Note that exons 10 and 21 are sometimes listed as exons 9 and 20 in publications, as it was once common to exclude non-coding exon 1.																2021-02-02 23:02:16 UTC	10.0			EXON 9 AND EXON 20 MUTATION			false
1992	https://civicdb.org/links/variants/1992	VHL	7428	Splice Site (c.464-2A>T)			3	10191469	10191469	A	T	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NM_000551.3:c.464-2A>T,NC_000003.11:g.10191469A>T,ENST00000256474.2:c.464-2A>T,NP_000542.1:p.=	2022-04-12 21:22:05 UTC	5.0	CA70052157	NONE FOUND	C.464-2A>T,RS5030816			false
1994	https://civicdb.org/links/variants/1994	VHL	7428	Q132* (c.394C>T)			3	10188251	10188251	C	T	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.394C>T,NP_000542.1:p.Gln132Ter,NC_000003.11:g.10188251C>T,ENST00000256474.2:c.394C>T	2022-04-12 21:22:05 UTC	10.0	CA10606205	288749	C.394C>T,Q132X,GLN132TER,RS5030813			false
1996	https://civicdb.org/links/variants/1996	VHL	7428	L129fs (c.384delT)			3	10188241	10188241	T		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.384delT	2022-04-12 21:22:05 UTC	7.5	CA70049452	NONE FOUND	C.384DELT,LEU129FS			false
1997	https://civicdb.org/links/variants/1997	VHL	7428	L178Q (c.533T>A)			3	10191540	10191540	T	A	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10191540T>A,NM_000551.3:c.533T>A,NP_000542.1:p.Leu178Gln,ENST00000256474.2:c.533T>A	2022-04-12 21:22:05 UTC	12.5	CA70052370	625260	C.533T>A,LEU178GLN,RS5030822			false
1998	https://civicdb.org/links/variants/1998	VHL	7428	Splice Site (c.463+1G>C)			3	10188321	10188321	G	C	ENST00000256474.2	75	GRCh37					splice_donor_variant	NM_000551.3:c.463+1G>C,NC_000003.11:g.10188321G>C,ENST00000256474.2:c.463+1G>C	2022-04-12 21:22:05 UTC	5.0	CA357023	223217	C.463+1G>C,RS869025657			false
1999	https://civicdb.org/links/variants/1999	VHL	7428	V74G (c.221T>G)			3	10183752	10183752	T	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.221T>G,NM_000551.3:c.221T>G,NP_000542.1:p.Val74Gly,NC_000003.11:g.10183752T>G	2022-04-12 21:22:05 UTC	15.0	CA70042528	NONE FOUND	C.221T>G,VAL74GLY,RS5030803			false
2000	https://civicdb.org/links/variants/2000	VHL	7428	H115R (c.344A>G)			3	10188201	10188201	A	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.344A>G,NC_000003.11:g.10188201A>G,NM_000551.3:c.344A>G,NP_000542.1:p.His115Arg	2022-04-12 21:22:05 UTC	10.0	CA70049376	664415	C.344A>G,HIS115ARG,RS5030812			false
2007	https://civicdb.org/links/variants/2007	VHL	7428	R107G  (c.319C>G)			3	10183850	10183850	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.319C>G,NP_000542.1:p.Arg107Gly,NC_000003.11:g.10183850C>G,ENST00000256474.2:c.319C>G	2022-04-12 21:22:05 UTC	7.5	CA020257	43599	C.319C>G,ARG107GLY,RS397516440			false
2008	https://civicdb.org/links/variants/2008	VHL	7428	G93C (c.277G>T)			3	10183808	10183808	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.277G>T,NM_000551.3:c.277G>T,NP_000542.1:p.Gly93Cys,NC_000003.11:g.10183808G>T	2022-04-12 21:22:05 UTC	7.5	CA357106	223175	C.277G>T,GLY93CYS,RS5030808			false
2009	https://civicdb.org/links/variants/2009	VHL	7428	G93V (c.278G>T)			3	10183809	10183809	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.278G>T,NC_000003.11:g.10183809G>T,NM_000551.3:c.278G>T,NP_000542.1:p.Gly93Val	2022-04-12 21:22:05 UTC	7.5	CA351750779	625232	C.278G>T,GLY93VAL			false
2010	https://civicdb.org/links/variants/2010	VHL	7428	L198Q  (c.593T>A)			3	10191600	10191600	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.593T>A,NC_000003.11:g.10191600T>A,NM_000551.3:c.593T>A,NP_000542.1:p.Leu198Gln	2022-04-12 21:22:05 UTC	12.5	CA351756548	NONE FOUND	C.593T>A,LEU198GLN			false
2011	https://civicdb.org/links/variants/2011	VHL	7428	S65A (c.193T>G)			3	10183724	10183724	T	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.193T>G,NP_000542.1:p.Ser65Ala,NC_000003.11:g.10183724T>G,ENST00000256474.2:c.193T>G	2022-04-12 21:22:05 UTC	7.5	CA357048	223160	C.193T>G,SER65ALA,RS869025616			false
2012	https://civicdb.org/links/variants/2012	VHL	7428	S68W (c.203C>G)	One similar submission at this exact genomic location has been entered into ClinVar (ClinVar ID: 625222 C>T).		3	10183734	10183734	C	G	ENST00000256474.2		GRCh37					missense_variant	NP_000542.1:p.Ser68Trp,NC_000003.11:g.10183734C>G,NC_000003.12:g.10142050C>G,NM_000551.3:c.203C>G	2020-10-27 00:32:09 UTC	7.5	CA351748895	NONE FOUND				false
2013	https://civicdb.org/links/variants/2013	VHL	7428	Y156N (c.466T>A)			3	10191473	10191473	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.466T>A,NC_000003.11:g.10191473T>A,NM_000551.3:c.466T>A,NP_000542.1:p.Tyr156Asn	2022-04-12 21:22:05 UTC	7.5	CA351756038	NONE FOUND	C.466T>A,TYR156ASN			false
2014	https://civicdb.org/links/variants/2014	VHL	7428	P61fs (c.183insC)																	2022-04-12 21:22:03 UTC	7.5						false
2020	https://civicdb.org/links/variants/2020	VHL	7428	L85P (c.254T>C)			3	10183785	10183785	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.254T>C,NP_000542.1:p.Leu85Pro,NC_000003.11:g.10183785T>C,ENST00000256474.2:c.254T>C	2022-04-12 21:22:05 UTC	5.0	CA16602675	376222	C.254T>C,LEU85PRO,RS5030828			false
2021	https://civicdb.org/links/variants/2021	VHL	7428	R108dup (c.322_324dup)			3	10183849	10183850		CGC	ENST00000256474.2	75	GRCh37					conservative_inframe_insertion	NC_000003.11:g.10183853_10183855dup,NC_000003.12:g.10142169_10142171dup,NP_000542.1:p.Arg108dup,NM_000551.4:c.322_324dup,NM_000551.3:c.322_324dup	2022-04-12 21:22:03 UTC	5.0	CA916832608	NONE FOUND	R107DUP,R108INS (C.324INSCGC)			false
2023	https://civicdb.org/links/variants/2023	VHL	7428	A149fs (c.449del14-nt)																	2022-04-12 21:22:03 UTC	5.0						false
2024	https://civicdb.org/links/variants/2024	VHL	7428	3'UTR alteration (c.639+10C>G)			3	10191656	10191656	C	G	ENST00000256474.2	75	GRCh37					3_prime_UTR_variant	ENST00000256474.2:c.639+10C>G	2022-04-12 21:22:03 UTC	5.0	CA16042064	NONE FOUND	C.639+10C>G			false
2026	https://civicdb.org/links/variants/2026	VHL	7428	G114S (c.340G>A)			3	10183871	10183871	G	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.340G>A,NC_000003.11:g.10183871G>A,NM_000551.3:c.340G>A,NP_000542.1:p.Gly114Ser	2022-04-12 21:22:05 UTC	5.0	CA351751372	583094	C.340G>A,GLY114SER			false
2027	https://civicdb.org/links/variants/2027	VHL	7428	W117fs (c.349dup)			3	10188206	10188207		T	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10188206dup,ENST00000256474.2:c.349dupT,NM_000551.3:c.349dup,NP_000542.1:p.cTrp117LeufsTer15	2022-04-12 21:22:05 UTC	5.0	CA432421788	NONE FOUND	TRP117LEUFS,C.349DUPT			false
2028	https://civicdb.org/links/variants/2028	VHL	7428	A122I (c.364_365GC>AT)			3	10188221	10188222	GC	AT	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.364_365delinsAT,ENST00000256474.2:c.364_365delinsAT,NC_000003.11:g.10188221_10188222delinsAT,NC_000003.12:g.10146537_10146538delinsAT	2022-04-12 21:22:05 UTC	12.5	CA658820874	NONE FOUND	C.364_365GC>AT,ALA122ILE			false
2029	https://civicdb.org/links/variants/2029	VHL	7428	N150fs (c.445_458del)			3	10188302	10188315	GCCAATATCACACT		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.445_458delGCCAATATCACACT	2022-04-12 21:22:05 UTC	5.0	CA658820719	NONE FOUND	C.445_458DEL,ASN150FS			false
2030	https://civicdb.org/links/variants/2030	VHL	7428	I151M (c.453C>G)			3	10188310	10188310	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.453C>G,NC_000003.11:g.10188310C>G,NM_000551.3:c.453C>G,NP_000542.1:p.Ile151Met	2022-04-12 21:22:05 UTC	5.0	CA351754364	NONE FOUND	C.453C>G,ILE151MET			false
2033	https://civicdb.org/links/variants/2033	VHL	7428	L163H (c.488T>A)			3	10191495	10191495	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.488T>A,NC_000003.11:g.10191495T>A,NM_000551.3:c.488T>A,NP_000542.1:p.Leu163His	2022-04-12 21:22:05 UTC	5.0	CA351756137	NONE FOUND	C.488T>A,LEU163HIS			false
2035	https://civicdb.org/links/variants/2035	VHL	7428	C162fs (c.483del)			3	10191490	10191490	A		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10191490del,NP_000542.1:p.Cys162AlafsTer8,ENST00000256474.2:c.483del,NM_000551.3:c.483del,NC_000003.12:g.10149806del	2022-04-12 21:22:05 UTC	5.0	CA658795183	928822	C.483DELA,CYS162FS,C162AFS*8			false
2036	https://civicdb.org/links/variants/2036	VHL	7428	Null (Partial deletion of Exons 2 & 3)																	2022-04-12 21:22:03 UTC	7.5						false
2037	https://civicdb.org/links/variants/2037	VHL	7428	N78I (c.233A>T)			3	10183764	10183764	A	T	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.233A>T,NP_000542.1:p.Asn78Ile,NC_000003.11:g.10183764A>T,ENST00000256474.2:c.233A>T	2022-04-12 21:22:05 UTC	5.0	CA357063	223169	C.233A>T,ASN78ILE,RS5030804			false
2039	https://civicdb.org/links/variants/2039	VHL	7428	W88FS (c.263_265delGGCinsTT)			3	10183794	10183796	GGC	TT	ENST00000256474.2	75	GRCh37					frameshift_variant,delins	ENST00000256474.2:c.263_265delGGCinsTT,NC_000003.11:g.10183794_10183796delinsTT,NM_000551.3:c.263_265delinsTT,NP_000542.1:p.Trp88PhefsTer?	2022-04-12 21:22:05 UTC	5.0	CA658683075	NONE FOUND	C.263_265DELGGCINSTT,TRP88FS			false
2040	https://civicdb.org/links/variants/2040	VHL	7428	K159fs (c.477_478insCA)			3	10191484	10191485		CA	ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.477_478insCA	2022-04-12 21:22:05 UTC	5.0	CA645525053	NONE FOUND	LYS159FS,C.477_478INSCA			false
2041	https://civicdb.org/links/variants/2041	VHL	7428	Q73FS (c.217delC)			3	10183748	10183748	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.217delC,NC_000003.11:g.10183748del,NM_000551.3:c.217del,NP_000542.1:p.Gln73ArgfsTer?	2022-04-12 21:22:05 UTC	5.0	CA432536422	NONE FOUND	C.217DELC,GLN73FS			false
2042	https://civicdb.org/links/variants/2042	VHL	7428	A149fs (c.445delG)			3	10188302	10188302	G		ENST00000256474.2	75	GRCh37					frameshift_variant,minus_1_frameshift_variant	ENST00000256474.2:c.445delG,NC_000003.11:g.10188302delG,NM_000551.3:c.445delG,NP_000542.1:p.Ala149ProfsTer10	2022-04-12 21:22:05 UTC	5.0	CA432421902	NONE FOUND	C.445DELG,ALA149FS			false
2043	https://civicdb.org/links/variants/2043	VHL	7428	G104A (c.311G>C)			3	10183842	10183842	G	C	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.311G>C,NP_000542.1:p.Gly104Ala,NC_000003.11:g.10183842G>C,ENST00000256474.2:c.311G>C	2022-04-12 21:22:05 UTC	5.0	CA16611067	411966	C.311G>C,GLY104ALA,RS869025630			false
2045	https://civicdb.org/links/variants/2045	VHL	7428	S111C (c.331A>T)			3	10183862	10183862	A	T	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10183862A>T,NM_000551.3:c.331A>T,NP_000542.1:p.Ser111Cys	2022-04-12 21:22:03 UTC	7.5	CA351751322	565557	SER111CYS,RS1559426203,C.331A>T			false
2050	https://civicdb.org/links/variants/2050	DICER1	23405	E1705K			14	95560476	95560476	C	T	ENST00000526495.1	75	GRCh37					missense_variant	ENST00000526495.1:c.5113G>A	2022-04-12 21:22:05 UTC	20.0	CA390865421	NONE FOUND	GLU1705LYS			false
2051	https://civicdb.org/links/variants/2051	DICER1	23405	D1709N																	2022-04-12 21:22:03 UTC	40.0						false
2052	https://civicdb.org/links/variants/2052	DICER1	23405	E1813Q			14	95557630	95557630	C	G	ENST00000526495.1	75	GRCh37					missense_variant	ENST00000526495.1:c.5437G>C	2022-04-12 21:22:05 UTC	25.0	CA390864655	NONE FOUND	GLU1813GLN			false
2055	https://civicdb.org/links/variants/2055	VHL	7428	P146fs (c.437del)			3	10188293	10188293	C		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.12:g.10146610del,ENST00000256474.2:c.437del,NC_000003.11:g.10188294del,NM_000551.3:c.437del,NP_000542.1:p.Pro146LeufsTer13	2022-04-12 21:22:05 UTC	7.5	CA432421892	NONE FOUND	C.436DELC,PRO146FS,C.437DELC,P146LFS*13			false
2056	https://civicdb.org/links/variants/2056	VHL	7428	W88R (c.262T>C)			3	10183793	10183793	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.262T>C,NC_000003.11:g.10183793T>C,NM_000551.3:c.262T>C,NP_000542.1:p.Trp88Arg	2022-04-12 21:22:05 UTC	7.5	CA351750667	496053	TRP88ARG,C.262T>C,RS1553619431			false
2057	https://civicdb.org/links/variants/2057	VHL	7428	H115fs (c.344del)			3	10188201	10188201	A		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10188201del,NM_000551.3:c.344delA,ENST00000256474.2:c.344del,NP_000542.1:p.His115ProfsTer44	2022-04-12 21:22:05 UTC	7.5	CA70049370	NONE FOUND	C.344DELA,HIS115FS,RS1553619937,HIS115PROFSTER44 (C.344DEL),H115FS (C.344DELA),H115PFS*44 (C.344DEL)			false
2058	https://civicdb.org/links/variants/2058	VHL	7428	P102fs (c.305delC)			3	10183836	10183836	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.305delC,NC_000003.11:g.10183836del,NM_000551.3:c.305del,NP_000542.1:p.Pro102ArgfsTer?	2022-04-12 21:22:05 UTC	7.5	CA658820710	NONE FOUND	C.305DELC,PRO102FS			false
2061	https://civicdb.org/links/variants/2061	ACVR1	90	Gain-of-Function																	2022-04-15 14:12:41 UTC	15.0						false
2066	https://civicdb.org/links/variants/2066	VHL	7428	Y175N (c.523T>A)			3	10191530	10191530	T	A	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.523T>A,NC_000003.11:g.10191530T>A,NM_000551.3:c.523T>A,NP_000542.1:p.Tyr175Asn	2022-04-12 21:22:05 UTC	7.5	CA351756226	NONE FOUND	C.523T>A,TYR175ASN			false
2067	https://civicdb.org/links/variants/2067	VHL	7428	Y175C (c.524A>G)			3	10191531	10191531	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.524A>G,NP_000542.1:p.Tyr175Cys,NC_000003.11:g.10191531A>G,ENST00000256474.2:c.524A>G	2022-04-12 21:22:03 UTC	0.0	CA020462	36905	C.524A>G,TYR175CYS,RS193922613			false
2075	https://civicdb.org/links/variants/2075	VHL	7428	Splice Site (c.463+2T>C)			3	10188322	10188322	T	C	ENST00000256474.2	75	GRCh37					splice_donor_variant	NM_000551.3:c.463+2T>C,NC_000003.11:g.10188322T>C,ENST00000256474.2:c.463+2T>C,NP_000542.1:p.?,NC_000003.12:g.10146638T>C	2022-04-12 21:22:05 UTC	27.5	CA16621936	569414	C.463+2T>C,RS5030814			false
2077	https://civicdb.org/links/variants/2077	VHL	7428	Splice Site (c.464-1G>C)	There are three variants in ClinVar at this exact position: (ClinVar ID: 223220, ClinVar ID:223221, and ClinVar ID:43603). ClinVar ID: 223220 is an exact match.		3	10191470	10191470	G	C	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NM_000551.3:c.464-1G>C,NC_000003.11:g.10191470G>C,ENST00000256474.2:c.464-1G>C,NP_000542.1:p.=,NC_000003.12:g.10149786G>C	2021-06-02 22:50:30 UTC	5.0	CA357081	223220	C.464-1G>C,RS5030817,IVS2-1G>C			false
2078	https://civicdb.org/links/variants/2078	VHL	7428	Splice Site (c.464-2A>G)			3	10191469	10191469	A	G	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NM_000551.3:c.464-2A>G,NC_000003.11:g.10191469A>G,ENST00000256474.2:c.464-2A>G	2022-04-12 21:22:06 UTC	15.0	CA357046	223222	C.464-2A>G,RS5030816			false
2079	https://civicdb.org/links/variants/2079	VHL	7428	Q164L (c.491A>T)			3	10191498	10191498	A	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.491A>T,NC_000003.11:g.10191498A>T,NM_000551.3:c.491A>T,NP_000542.1:p.Gln164Leu	2022-04-12 21:22:01 UTC	7.5	CA351756149	NONE FOUND	C.491A>T,GLN164LEU			false
2088	https://civicdb.org/links/variants/2088	VHL	7428	F76del (c.224_226delTCT)	Note that this variant occurs within a short TCT repeat and there are several variant notations that resolve to the same sequence when they are shifted or justified. Each results in the same in-frame single amino acid deletion (Phe76del aka F76del).		3	10183755	10183757	TCT		ENST00000256474.2	75	GRCh37					inframe_deletion	NP_000542.1:p.Phe76del,ENST00000256474.2:c.224_226delTCT,NC_000003.11:g.10183758_10183760del,NC_000003.12:g.10142074_10142076del,NM_000551.3:c.227_229del,ENSP00000256474.2:p.Phe76del	2020-07-17 16:11:50 UTC	120.0	CA357012	223166	PHE76DEL,C.224_226DELTCT,C.226_228DELTTC,C.227_229DELTCT,DELPHE76	17	https://civicdb.org/links/assertions/17	false
2089	https://civicdb.org/links/variants/2089	VHL	7428	R82_V84del (c.243_251del)			3	10183774	10183782	GCGCGTCGT		ENST00000256474.2	75	GRCh37					inframe_deletion	NC_000003.11:g.10183774_10183782del,NC_000003.12:g.10142092_10142100del,NM_000551.4:c.245_253del,NP_000542.1:p.Arg82_Val84del	2022-04-12 21:22:06 UTC	17.5	CA658820713	NONE FOUND	P81DELRVV (C.243_251DELGCGCGTCGT),ARG82_VAL84DEL			false
2090	https://civicdb.org/links/variants/2090	VHL	7428	P40fs (c.118ins)																	2022-04-12 21:22:03 UTC	7.5						false
2091	https://civicdb.org/links/variants/2091	VHL	7428	T152fs (c.455insA)																	2022-04-12 21:22:03 UTC	15.0						false
2092	https://civicdb.org/links/variants/2092	VHL	7428	T157fs (c.472ins)																	2022-04-12 21:22:03 UTC	7.5						false
2097	https://civicdb.org/links/variants/2097	VHL	7428	G93_Y98del (c.275_292del)			3	10183806	10183823	ACGGCGAGCCGCAGCCC		ENST00000256474.2	75	GRCh37					frameshift_variant		2022-04-12 21:22:03 UTC	7.5	CA891843321	574427	D92_Y98DEL			false
2098	https://civicdb.org/links/variants/2098	VHL	7428	E160fs (c.477del)			3	10191482	10191482	A		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.475del,NP_000542.1:p.Glu160SerfsTer10,NM_000551.3:c.477del,NC_000003.12:g.10149800del,NC_000003.11:g.10191484del	2022-04-12 21:22:05 UTC	7.5	CA020404	182959	C.475DELA,LYS159FS,E160SFS*10			false
2099	https://civicdb.org/links/variants/2099	VHL	7428	V66del (c.197_220del)			3	10183728	10183742	TGAACTCGCGCGAGC		ENST00000256474.2	75	GRCh37					inframe_deletion		2022-04-12 21:22:03 UTC	5.0	unregistered		197DEL24			false
2101	https://civicdb.org/links/variants/2101	VHL	7428	V84M (c.250G>A)			3	10183781	10183781	G	A	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.250G>A,NP_000542.1:p.Val84Met,NC_000003.11:g.10183781G>A,ENST00000256474.2:c.250G>A	2022-04-12 21:22:05 UTC	0.0	CA351750580	428813	C.250G>A,VAL84MET,RS5030827			false
2104	https://civicdb.org/links/variants/2104	VHL	7428	Splice Region (c.340+5G>C)			3	10183876	10183876	G	C	ENST00000256474.2	75	GRCh37					intron_variant	NM_000551.3:c.340+5G>C,NC_000003.11:g.10183876G>C,ENST00000256474.2:c.340+5G>C,NP_000542.1:p.?,NC_000003.12:g.10142192G>C	2022-04-12 21:22:05 UTC	5.0	CA020288	36901	C.340+5G>C,C.533+5G>C,IVS1+5G>C			false
2108	https://civicdb.org/links/variants/2108	ARID1A	8289	Underexpression			1	27022524	27108595			ENST00000324856.7	75	GRCh37					N/A		2022-04-12 21:22:03 UTC	34.0		N/A				false
2114	https://civicdb.org/links/variants/2114	VHL	7428	Splice Site (c.340+1G>A)			3	10183872	10183872	G	A	ENST00000256474.2	75	GRCh37					splice_donor_variant	NM_000551.3:c.340+1G>A,NC_000003.11:g.10183872G>A,ENST00000256474.2:c.340+1G>A	2022-04-12 21:22:05 UTC	50.0	CA357042	223190	C.340+1G>A,C.553+1G>A			false
2125	https://civicdb.org/links/variants/2125	VHL	7428	Q132P (c.395A>C)			3	10188252	10188252	A	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.395A>C,NC_000003.11:g.10188252A>C,NM_000551.3:c.395A>C,NP_000542.1:p.Gln132Pro	2022-04-12 21:22:05 UTC	17.5	CA351753958	496063	C.395A>C,GLN132PRO,RS1347416980			false
2127	https://civicdb.org/links/variants/2127	VHL	7428	E94FS (c.279delC)			3	10183810	10183810	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.279delC,NC_000003.11:g.10183810del,NM_000551.3:c.279del,NP_000542.1:p.Glu94SerfsTer?	2022-04-12 21:22:05 UTC	0.0	CA658820711	NONE FOUND	C.279DELC,GLY93FS,GLU94FS			false
2129	https://civicdb.org/links/variants/2129	VHL	7428	G114dup (c.342dupGGT)																	2022-04-12 21:22:03 UTC	5.0						false
2130	https://civicdb.org/links/variants/2130	VHL	7428	S65FS (c.194delC)			3	10183725	10183725	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.194delC,NC_000003.11:g.10183725delC,NM_000551.3:c.194delC,NP_000542.1:p.Ser65TrpfsTer2	2022-04-12 21:22:05 UTC	7.5	CA432536395	NONE FOUND	C.194DELC,SER65FS			false
2131	https://civicdb.org/links/variants/2131	VHL	7428	Q73fs (c.214insGCCC)																	2022-04-12 21:22:03 UTC	7.5						false
2132	https://civicdb.org/links/variants/2132	VHL	7428	C77fs (c.228dup)			3	10183758	10183759		C	ENST00000256474.2	75	GRCh37						NC_000003.11:g.10183759dup,NC_000003.12:g.10142075dup,NM_000551.3:c.228dup,ENST00000256474.2:c.228dup,NP_000542.1:p.Cys77LeufsTer?,ENSP00000256474.2:p.Cys77LeufsTer?	2022-04-12 21:22:06 UTC	17.5	CA658795177	NONE FOUND	440_441INSC,C.227_228INSC,F76FS,C.227INSC			false
2133	https://civicdb.org/links/variants/2133	VHL	7428	Splice Site (c.341-2A>C)			3	10188196	10188196	A	C	ENST00000256474.2	75	GRCh37					splice_acceptor_variant	NC_000003.11:g.10188196A>C,NM_000551.3:c.341-2A>C,ENST00000256474.2:c.341-2A>C	2022-04-12 21:22:06 UTC	12.5	CA351753579	NONE FOUND	C.341-2A>C			false
2134	https://civicdb.org/links/variants/2134	VHL	7428	Intronic deletion (c.341-13delCGTTTCCAACAATTTCTCGGTGT)																	2022-04-12 21:22:03 UTC	5.0						false
2135	https://civicdb.org/links/variants/2135	VHL	7428	G123fs (c.369_375delGACACAC)			3	10188226	10188232	GACACAC		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.369_375delGACACAC	2022-04-12 21:22:05 UTC	0.0	CA913189240	NONE FOUND	GLY123FS,C.369_375DELGACACAC			false
2136	https://civicdb.org/links/variants/2136	VHL	7428	H125fs (c.374insA)																	2022-04-12 21:22:03 UTC	7.5						false
2137	https://civicdb.org/links/variants/2137	VHL	7428	K159fs (c.474_476delGAAinsC)			3	10191481	10191483	GAA	C	ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.474_476delGAAinsC	2022-04-12 21:22:03 UTC	7.5		NONE FOUND	C.474_476DELGAAINSC,LEU158FS,LYS159FS,K159FS			false
2138	https://civicdb.org/links/variants/2138	VHL	7428	Y175* (c.525delC)			3	10191532	10191532	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.525delC,NP_000542.1:p.Tyr175Ter,NC_000003.11:g.10191532del,NM_000551.3:c.525del	2022-04-12 21:22:05 UTC	7.5	CA913185019	NONE FOUND	TYR175FS,C.525DELC			false
2139	https://civicdb.org/links/variants/2139	VHL	7428	L188fs (c.562delC)			3	10191569	10191569	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.562delC,NC_000003.11:g.10191569del,NM_000551.3:c.562delC,NP_000542.1:p.Leu188TrpfsTer14	2022-04-12 21:22:05 UTC	10.0	CA432423671	NONE FOUND	C.562DELC,LEU188FS			false
2140	https://civicdb.org/links/variants/2140	VHL	7428	K196fs (c.584_585delAG)			3	10191591	10191592	AG		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.584_585delAG	2022-04-12 21:22:05 UTC	10.0	CA645529570	NONE FOUND	C.584_585DELAG,GLN195FS			false
2141	https://civicdb.org/links/variants/2141	VHL	7428	D197FS (c.589delG)			3	10191596	10191596	G		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.589delG,NC_000003.11:g.10191596del,NM_000551.3:c.589del,NP_000542.1:p.Asp197ThrfsTer5	2022-04-12 21:22:05 UTC	7.5	CA913189233	NONE FOUND	C.589DELG,ASP197FS			false
2142	https://civicdb.org/links/variants/2142	VHL	7428	T202fs (c.606insA)																	2022-04-12 21:22:03 UTC	7.5			T202FS (C.606DUPA)			false
2143	https://civicdb.org/links/variants/2143	VHL	7428	R113FS (c.337delC)			3	10183868	10183868	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.337delC,NC_000003.11:g.10183868delC,NM_000551.3:c.337delC,NP_000542.1:p.Arg113GlufsTer?	2022-04-12 21:22:03 UTC	7.5	CA432420675	NONE FOUND	C.337DELC,ARG113FS			false
2144	https://civicdb.org/links/variants/2144	VHL	7428	A56fs (c.166dup)			3	10183696	10183697		G	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant	NP_000542.1:p.Ala56fs,NC_000003.11:g.10183697dup,NC_000003.12:g.10142013dup,NM_000551.3:c.166dup	2022-04-12 21:22:03 UTC	7.5	CA645524645	NONE FOUND	C.165DUP,C.165_166DUPG,A56GFS*76 (C.166DUP)			false
2145	https://civicdb.org/links/variants/2145	VHL	7428	P61FS (c.182_185delCCGT)			3	10183713	10183716	CCGT		ENST00000256474.2	75	GRCh37					frameshift_variant	ENST00000256474.2:c.182_185delCCGT,NC_000003.11:g.10183713_10183716del,NM_000551.3:c.182_185delCCGT,NP_000542.1:p.Pro61ArgfsTer5	2022-04-12 21:22:05 UTC	10.0	CA658820712	NONE FOUND	C.182_185DELCCGT,PRO61FS			false
2148	https://civicdb.org/links/variants/2148	VHL	7428	R161= (c.481C>A)			3	10191488	10191488	C	A	ENST00000256474.2	75	GRCh37					synonymous_variant	NC_000003.11:g.10191488C>A,NC_000003.12:g.10149804C>A,NP_000542.1:p.Arg161=	2022-04-12 21:22:03 UTC	5.0	CA432423146	NONE FOUND	R161R (C.481C>A)			false
2150	https://civicdb.org/links/variants/2150	VHL	7428	I151F (c.451A>T)			3	10188308	10188308	A	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.451A>T,NC_000003.11:g.10188308A>T,NM_000551.3:c.451A>T,NP_000542.1:p.Ile151Phe	2022-04-12 21:22:05 UTC	5.0	CA351754353	NONE FOUND	C.451A>T,ILE151PHE			false
2151	https://civicdb.org/links/variants/2151	VHL	7428	W88* (c.263G>A)			3	10183794	10183794	G	A	ENST00000256474.2	75	GRCh37					stop_gained	NM_000551.3:c.263G>A,NP_000542.1:p.Trp88Ter,NC_000003.11:g.10183794G>A,ENST00000256474.2:c.263G>A	2022-04-12 21:22:05 UTC	7.5	CA020197	182978	W88X,TRP88TER,C.263G>A,RS119103277			false
2152	https://civicdb.org/links/variants/2152	VHL	7428	3'UTR alteration (c.*70C>A)			3	10191719	10191719	C	A			GRCh37					3_prime_UTR_variant	NC_000003.11:g.10191719C>A,ENST00000256474.2:c.*70C>A,NM_000551.3:c.*70C>A,NP_000542.1:p.=	2022-04-12 21:22:05 UTC	5.0	CA658820858	NONE FOUND	C.*70C>A,(C.642+70C>A)			false
2160	https://civicdb.org/links/variants/2160	VHL	7428	Y98FS (c.291delC)			3	10183822	10183822	C		ENST00000256474.2	75	GRCh37					frameshift_truncation	ENST00000256474.2:c.291delC,NC_000003.11:g.10183822delC,NM_000551.3:c.291delC,NP_000542.1:p.Tyr98ThrfsTer	2022-04-12 21:22:05 UTC	10.0	CA432420512	NONE FOUND	TYR98FS,C.291DELC			false
2162	https://civicdb.org/links/variants/2162	VHL	7428	N150S (c.449A>G)			3	10188306	10188306	A	G	ENST00000256474.2	75	GRCh37					missense_variant	NM_000551.3:c.449A>G,NP_000542.1:p.Asn150Ser,NC_000003.11:g.10188306A>G,ENST00000256474.2:c.449A>G	2022-04-12 21:22:05 UTC	5.0	CA041030	371992	C.449A>G,ASN150SER,RS760184234			false
2166	https://civicdb.org/links/variants/2166	NRG1	3084	SLC3A2::NRG1		NRG1 gene fusions													transcript_fusion		2022-04-12 21:22:03 UTC	0.0			SLC3A2-NRG1			false
2168	https://civicdb.org/links/variants/2168	RAD50	10111	L1237F																	2022-04-12 21:22:03 UTC	10.0						false
2169	https://civicdb.org/links/variants/2169	BTK	695	MUTATION																	2022-04-12 21:22:03 UTC	20.0						false
2170	https://civicdb.org/links/variants/2170	PLCG2	5336	MUTATION																	2022-04-12 21:22:03 UTC	25.0						false
2174	https://civicdb.org/links/variants/2174	EGFR	1956	Wildtype			7	55086794	55279321			ENST00000275493.2	75	GRCh37					wild_type		2022-04-12 21:22:03 UTC	20.0		N/A				false
2178	https://civicdb.org/links/variants/2178	NRG1	3084	ATP1B1::NRG1		NRG1 gene fusions													transcript_fusion		2022-04-12 21:22:06 UTC	15.0			ATP1B1-NRG1			false
2179	https://civicdb.org/links/variants/2179	NRG1	3084	SDC4::NRG1		NRG1 gene fusions													transcript_fusion		2022-04-12 21:22:03 UTC	7.5			SDC4-NRG1			false
2181	https://civicdb.org/links/variants/2181	VHL	7428	R177ins (c.531insCTGAGAGTAAAGCCTGAA)																	2022-04-12 21:22:03 UTC	5.0						false
2182	https://civicdb.org/links/variants/2182	VHL	7428	Null (Large deletion)																	2022-04-12 21:22:03 UTC	7.5						false
2195	https://civicdb.org/links/variants/2195	DICER1	23405	D1709G																	2022-04-12 21:22:01 UTC	12.5						false
2196	https://civicdb.org/links/variants/2196	DICER1	23405	D1709E																	2022-04-12 21:22:01 UTC	10.0						false
2202	https://civicdb.org/links/variants/2202	FGFR2	2263	Fusion															transcript_fusion		2022-07-22 21:18:07 UTC	55.0						false
2203	https://civicdb.org/links/variants/2203	EGFR	1956	EGFR::RAD51															transcript_fusion		2022-04-12 21:22:01 UTC	12.5			EGFR-RAD51			false
2211	https://civicdb.org/links/variants/2211	BAP1	8314	ALTERNATIVE TRANSCRIPT (ATI)																	2022-04-12 21:22:01 UTC	3.0						false
2213	https://civicdb.org/links/variants/2213	EGFR	1956	M766_A767insASV																	2022-04-12 21:22:01 UTC	7.5						false
2214	https://civicdb.org/links/variants/2214	EGFR	1956	D770delinsGY								ENST00000275493.2	75						inframe_insertion,delins		2022-04-19 19:47:30 UTC	10.0						false
2218	https://civicdb.org/links/variants/2218	ALK	238	STRN::ALK															transcript_fusion		2022-04-12 21:22:01 UTC	0.0			STRN-ALK			false
2219	https://civicdb.org/links/variants/2219	BARD1	580	Loss-of-function																	2022-08-03 16:06:28 UTC	3.0						false
2221	https://civicdb.org/links/variants/2221	BRAF	673	G496A																	2022-04-12 21:22:01 UTC	5.0						false
2222	https://civicdb.org/links/variants/2222	BRAF	673	G466V			7	140481411	140481411	C	A	ENST00000288602.6	75	GRCh37					missense_variant	NC_000007.13:g.140481411C>A,NM_004333.4:c.1397G>T,NP_004324.2:p.Gly466Val,ENST00000288602.6:c.1397G>T	2022-04-12 21:22:04 UTC	14.0	CA123647	13967	GLY466VAL,RS121913351			false
2223	https://civicdb.org/links/variants/2223	BRAF	673	G606E			7	140453118	140453118	C	T	ENST00000288602.6	75	GRCh37					missense_variant		2022-04-12 21:22:04 UTC	5.0	CA369542941	NONE FOUND	GLY606GLU			false
2224	https://civicdb.org/links/variants/2224	BRAF	673	P731T			7	140434507	140434507	G	T	ENST00000288602.6	75	GRCh37					missense_variant	ENST00000288602.6:c.2193G>T	2022-04-12 21:22:04 UTC	5.0	CA369537254	NONE FOUND	PRO731THR			false
2225	https://civicdb.org/links/variants/2225	BRAF	673	intron 9 rearrangement																	2022-04-12 21:22:02 UTC	20.0						false
2226	https://civicdb.org/links/variants/2226	BRAF	673	intron 10 rearrangement																	2022-04-12 21:22:02 UTC	20.0						false
2227	https://civicdb.org/links/variants/2227	BRAF	673	MACF1::BRAF															transcript_fusion		2022-04-12 21:22:02 UTC	5.0			MACF1-BRAF			false
2228	https://civicdb.org/links/variants/2228	BRAF	673	WASFL::BRAF															transcript_fusion		2022-04-12 21:22:02 UTC	5.0			WASFL-BRAF			false
2229	https://civicdb.org/links/variants/2229	BRAF	673	CUX1::BRAF		BRAF Fusions													transcript_fusion		2022-04-12 21:22:02 UTC	5.0			CUX1-BRAF			false
2230	https://civicdb.org/links/variants/2230	ASS1	445	Loss																	2022-08-03 16:03:58 UTC	6.0						false
2233	https://civicdb.org/links/variants/2233	BCL2	596	Mutation			18	60790579	60987361			ENST00000398117.1	75	GRCh37							2022-04-12 21:22:02 UTC	15.0		N/A				false
2235	https://civicdb.org/links/variants/2235	RASA1	5921	Loss-of-function																	2022-08-03 16:06:08 UTC	3.0						false
2240	https://civicdb.org/links/variants/2240	TLK2	11011	Amplification																	2022-08-02 22:58:17 UTC	3.0						false
2264	https://civicdb.org/links/variants/2264	VHL	7428	R82_V84del (c.244_252del)			3	10183775	10183783	CGCGTCGTG		ENST00000256474.2	75	GRCh37					inframe_deletion		2022-04-12 21:22:05 UTC	10.0	CA658820713	NONE FOUND	C.244_252DEL,C.245_253DEL			false
2265	https://civicdb.org/links/variants/2265	VHL	7428	A56_P59del (c.166_178del)																	2022-04-12 21:22:03 UTC	7.5						false
2280	https://civicdb.org/links/variants/2280	ACVR1	90	G328W		ACVR1 kinase domain mutation	2	158622517	158622517	C	A	ENST00000263640.3	75	GRCh37					missense_variant	NM_001105.4:c.982G>T,NP_001096.1:p.Gly328Trp,NC_000002.11:g.158622517C>A,ENST00000263640.3:c.982G>T	2022-04-12 21:22:05 UTC	0.0	CA128481	29594	GLY328TRP			false
2283	https://civicdb.org/links/variants/2283	ACVR1	90	G328E	This mutation occurs within the kinase domain of ACVR1 and has been shown to be activating of downstream BMP signaling with increased cell proliferation in cells overexpressing this variant.	ACVR1 kinase domain mutation													missense_variant,gain_of_function_variant		2018-10-15 23:19:04 UTC	7.5						false
2286	https://civicdb.org/links/variants/2286	NRG1	3084	Fusion	NRG1 fusions have been described in cases of invasive mucinous adenocarcinoma of the lung, pancreatic ductal adenocarcinoma, cholangiocarcinoma and lung adenocarcinoma. In many cases these tumors were negative for the more common known driver genes of these diseases (e.g., KRAS wild-type pancreatic ductal adenocarcinoma). These events have been proposed as an attractive therapeutic target and some promising results have been observed with pan-HER inhibitors such as afatinib.																2021-03-12 00:45:22 UTC	10.0						false
2287	https://civicdb.org/links/variants/2287	NTRK2	4915	STRN::NTRK2															transcript_fusion		2022-04-12 21:22:03 UTC	7.5			STRN-NTRK2			false
2289	https://civicdb.org/links/variants/2289	NTRK1	4914	PDE4DIP::NTRK1															transcript_fusion		2022-04-12 21:22:04 UTC	12.5			PDE4DIP-NTRK1			false
2290	https://civicdb.org/links/variants/2290	VHL	7428	G144E (c.431G>A)			3	10188288	10188288	G	A	ENST00000256474.2	75	GRCh37							2022-04-12 21:22:03 UTC	5.0	CA351754206					false
2292	https://civicdb.org/links/variants/2292	VHL	7428	Splice Region (c.463+8C>T)			3	10188328	10188328	C	T	ENST00000256474.2	75	GRCh37					splicing_variant	NC_000003.11:g.10188328C>T,ENST00000256474.2:c.463+8C>T,NM_000551.3:c.463+8C>T	2022-04-12 21:22:06 UTC	5.0	CA020379	127830				false
2293	https://civicdb.org/links/variants/2293	VHL	7428	G104= (c.312C>G)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.312C>T (p.Gly104=; G104=) https://www-ncbi-nlm-nih-gov/clinvar/variation/456582/		3	10183843	10183843	C	G	ENST00000256474.2	75	GRCh37					synonymous_variant	NC_000003.11:g.10183843C>G,NC_000003.12:g.10142159C>G,NP_000542.1:p.Gly104=,NP_001341652.1:p.Gly104=	2020-10-17 00:00:14 UTC	0.0	CA432420538	NONE FOUND	G104G (C.312C>G)			false
2294	https://civicdb.org/links/variants/2294	VHL	7428	F91L (c.273C>G)	Note that there is a different variant reported at this amino acid position of VHL in ClinVar: NM_000551.3(VHL):c.273C>A (p.Phe91Leu; F91L) (https://www-ncbi-nlm-nih-gov/clinvar/variation/411978/)		3	10183804	10183804	C	G	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10183804C>G,NC_000003.12:g.10142120C>G,NP_000542.1:p.Phe91Leu	2021-04-13 23:21:43 UTC	5.0	CA351750747	NONE FOUND	C.273C>G,PHE91LEU			false
2299	https://civicdb.org/links/variants/2299	VHL	7428	W88fs (c.261dup)			3	10183791	10183792		A	ENST00000256474.3	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	NC_000003.11:g.10183792dup,NM_000551.3:c.261dup,NP_000542.1:p.Trp88MetfsTer44,ENST00000256474.3:c.261dup,NC_000003.12:g.10142108dup	2022-04-12 21:22:07 UTC	7.5	CA2573050932	NONE FOUND	C.261DUP,C.261INSA,TRP88METFSTER44,W88MFS*44			false
2331	https://civicdb.org/links/variants/2331	ERBB2	2064	T798I			17	37881064	37881064	C	T	ENST00000269571.5	75	GRCh37					missense_variant	ENST00000269571.5:c.2393C>T,NC_000017.10:g.37881064C>T,NM_001289937.1:c.2393C>T,NP_001276866.1:p.Thr798Ile	2022-04-12 21:22:04 UTC	0.0	CA399303242	NONE FOUND	THR798ILE			false
2333	https://civicdb.org/links/variants/2333	EGFR	1956	R705K			7	55241666	55241666	G	A	ENST00000275493.2	75	GRCh37					missense_variant	ENST00000275493.2:c.2114G>A,NC_000007.13:g.55241666G>A,NM_005228.3:c.2114G>A,NP_005219.2:p.Arg705Lys	2022-04-12 21:22:03 UTC	5.0	CA367583561	NONE FOUND	ARG705LYS			false
2334	https://civicdb.org/links/variants/2334	EGFR	1956	Rare Mutation	This subset of EGFR mutations consists of mutations other than L858R and exon 19 deletion. Reports of responsiveness to tyrosine kinase inhibitors in this EGFR mutation subgroup do not differ widely from those reported for known common sensitizing EGFR mutations.		7	55086794	55279321			ENST00000275493.2	75	GRCh37							2022-03-25 16:11:30 UTC	5.0						false
2335	https://civicdb.org/links/variants/2335	ABL1	25	BCR::ABL T315A			9	133748282	133748282	A	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	NM_005157.5:c.943A>G,NP_005148.2:p.Thr315Ala,NC_000009.11:g.133748282A>G,ENST00000318560.5:c.943A>G	2022-04-12 21:22:05 UTC	8.0	CA16602576	376118	THR315ALA,T334A,RS1057519772,BCR-ABL T315A			false
2340	https://civicdb.org/links/variants/2340	ABL1	25	BCR::ABL L248R			9	133738343	133738343	T	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.743T>G,NC_000009.11:g.133738343T>G,NM_005157.6:c.743T>G,NP_005148.2:p.Leu248Arg	2022-04-12 21:22:05 UTC	7.0	CA375263224	NONE FOUND	LEU248ARG,BCR-ABL L248R			false
2343	https://civicdb.org/links/variants/2343	ABL1	25	BCR::ABL F317S			9	133748289	133748289	T	C	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.950T>C	2022-04-12 21:22:05 UTC	1.0	CA375249431	NONE FOUND	PHE317SER,BCR-ABL F317S			false
2359	https://civicdb.org/links/variants/2359	ABL1	25	BCR::ABL F317C			9	133748289	133748289	T	G	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560:c.950T>G	2022-04-12 21:22:05 UTC	2.0	CA16602579	376121	PHE317CYS,F336C,BCR-ABL F317C			false
2360	https://civicdb.org/links/variants/2360	AKT1	207	Overexpression																	2022-04-12 21:22:04 UTC	3.0						false
2361	https://civicdb.org/links/variants/2361	BRAF	673	V600E/K and Amplification																	2022-04-12 21:22:04 UTC	10.0						false
2363	https://civicdb.org/links/variants/2363	PIK3R2	5296	Overexpression																	2022-08-02 22:56:41 UTC	2.0						false
2364	https://civicdb.org/links/variants/2364	PREX2	80243	R172I			8	68939530	68939530	G	T	ENST00000288368.4	75	GRCh37					missense_variant		2022-04-12 21:22:04 UTC	10.0	CA371196220	NONE FOUND	ARG172ILE			false
2367	https://civicdb.org/links/variants/2367	VHL	7428	3p26.3-25.3 11Mb del																	2022-04-12 21:22:03 UTC	7.5						false
2370	https://civicdb.org/links/variants/2370	ABL1	25	BCR::ABL E459K			9	133753906	133753906	G	A	ENST00000318560.5	75	GRCh37					missense_variant,transcript_fusion	ENST00000318560.5:c.1375G>A,NC_000009.11:g.133753906G>A,NM_005157.5:c.1375G>A,NP_005148.2:p.Glu459Lys	2022-04-12 21:22:05 UTC	20.0	CA200648598	NONE FOUND	BCR-ABL GLU459LYS,RS1064156,BCR-ABL1 E459K,BCR-ABL1 GLU459LYS,BCR-ABL E459K			false
2371	https://civicdb.org/links/variants/2371	ABL1	25	TKD MUTATION																	2022-04-12 21:22:03 UTC	60.0						false
2373	https://civicdb.org/links/variants/2373	VHL	7428	c.128-?_250+?																	2022-04-12 21:22:04 UTC	5.0						false
2375	https://civicdb.org/links/variants/2375	ABL1	25	P-Loop Mutation																	2022-04-12 21:22:03 UTC	25.0						false
2376	https://civicdb.org/links/variants/2376	ABL1	25	Non-P-Loop Mutation																	2022-04-12 21:22:03 UTC	30.0						false
2387	https://civicdb.org/links/variants/2387	CSF3R	1441	T618I			1	36933434	36933434	G	A	ENST00000373103.1	75	GRCh37					missense_variant	NP_724781.1:p.Thr618Ile,NM_156039.3:c.1853C>T,ENST00000373103.1:c.1853G>A,NC_000001.10:g.36933434G>A,NC_000001.11:g.36467833G>A	2022-04-12 21:22:04 UTC	14.0	CA204418	208339	THR618ILE			false
2388	https://civicdb.org/links/variants/2388	CALR	811	Mutation																	2022-04-12 21:22:04 UTC	50.0						false
2393	https://civicdb.org/links/variants/2393	NTRK1	4914	TRIM63::NTRK1															transcript_fusion		2022-04-12 21:22:04 UTC	0.5			NTRK1-TRIM63			false
2394	https://civicdb.org/links/variants/2394	NTRK1	4914	DDR2::NTRK1															transcript_fusion		2022-04-12 21:22:04 UTC	0.5			NTRK1-DDR2			false
2395	https://civicdb.org/links/variants/2395	NTRK1	4914	GON4L::NTRK1															transcript_fusion		2022-04-12 21:22:04 UTC	0.5			NTRK1-GON4L			false
2396	https://civicdb.org/links/variants/2396	NTRK2	4915	ETV6::NTRK2															transcript_fusion		2022-04-12 21:22:04 UTC	10.0			ETV6-NTRK2			false
2398	https://civicdb.org/links/variants/2398	BRAF	673	D594K																	2022-04-12 21:22:04 UTC	30.0						false
2400	https://civicdb.org/links/variants/2400	FGFR3	2261	V555M	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1807494	1807494	G	A	ENST00000440486.8		GRCh37					missense_variant	NM_022965.4:c.1327G>A,NC_000004.11:g.1807494G>A,NM_000142.5:c.1663G>A ,NP_000133.1:p.Val555Met,ENST00000440486.8:c.1663G>A,ENSP00000414914.2:p.Val555Met 	2022-07-07 03:02:27 UTC	0.0	CA355981674		VAL443MET,V443M,VAL555MET,ENSP00000414914.2:P.VAL555MET 			false
2403	https://civicdb.org/links/variants/2403	FGFR3	2261	R248C	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1803564	1803564	C	T	ENST00000340107.4	75	GRCh37					missense_variant	NC_000004.11:g.1803564C>T,NM_000142.4:c.742C>T,NP_000133.1:p.Arg248Cys,ENST00000340107.4:c.742C>T	2022-07-30 16:58:45 UTC	8.0	CA126378	16332	RS121913482,ARG248CYS			false
2404	https://civicdb.org/links/variants/2404	FGFR3	2261	Y373C	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1806099	1806099	A	G	ENST00000440486.2	75	GRCh37					missense_variant	NC_000004.11:g.1806099A>G,NM_001163213.1:c.1124A>G,NP_000133.1:p.Tyr373Cys,NM_000142.5:c.1118A>G,NC_000004.12:g.1804372A>G	2022-07-30 19:26:20 UTC	21.0	CA341413	16342	TYR375CYS,RS121913485,Y375C,TYR373CYS			false
2405	https://civicdb.org/links/variants/2405	FGFR3	2261	G380R	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1806119	1806119	G	C	ENST00000340107.4	75	GRCh37					missense_variant	NC_000004.11:g.1806119G>C,NC_000004.12:g.1804392G>C,NM_000142.5:c.1138G>C,NP_000133.1:p.Gly380Arg,NP_001156685.1:p.Gly382Arg,NM_001163213.1:c.1144G>C	2022-07-30 18:12:31 UTC	2.0	CA280218	16328	GLY380ARG,G382R,GLY382ARG			false
2406	https://civicdb.org/links/variants/2406	FGFR3	2261	G370C	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1806089	1806089	G	T	ENST00000440486.8	75	GRCh37					missense_variant	NC_000004.11:g.1806089G>T,NC_000004.12:g.1804362G>T,NM_000142.5:c.1108G>T,NP_000133.1:p.Gly370Cys,NP_001156685.1:p.Gly372Cys	2022-07-07 02:53:34 UTC	0.0	CA129946	16359	GLY370CYS,G372C,GLY372CYS			false
2408	https://civicdb.org/links/variants/2408	BRAF	673	Non-V600															protein_altering_variant		2022-04-15 14:12:41 UTC	25.0						false
2409	https://civicdb.org/links/variants/2409	ERCC1	2067	Underexpression			19	45916692	45926824			ENST00000013807.5	75	GRCh37					N/A		2022-04-12 21:22:04 UTC	15.0		N/A				false
2411	https://civicdb.org/links/variants/2411	SDHB	6390	p.193_196dupSTSC (c.577_588dupAGCACCAGCTGC)	ClinGen Canonical Allele Identifier: CA658820851		1	17350521	17350522		GCAGCTGGTGCT	ENST00000375499.3	75	GRCh37					inframe_insertion	NM_003000.2:c.577_588dupAGCACCAGCTGC,NP_002991.2:p.193_196dupSTSC,NC_000001.10:g.17350522_17350533dup	2020-02-03 00:08:00 UTC	5.0	CA658820851		C.589_600DUP			false
2416	https://civicdb.org/links/variants/2416	H3-3A	3020	K28M	K28M is a highly recurrent mutation in this gene in multiple cancer types but particularly well known in brain cancers. In amino acid position 27 of H3F3A there is an arginine (R). The medically relevant Lysine (K) is in position 28. Also UNIPROT records the lysine in position 28. However, K27M is common in the literature so is included as a synonym.		1	226064434	226064434	A	T	ENST00000366813.1	105	GRCh38					non_conservative_missense_variant	ENST00000366813.1:c.83A>T,ENSP00000355778.1:p.Lys28Met	2022-02-09 17:01:33 UTC	50.0	CA16602870	376435	K27M			false
2420	https://civicdb.org/links/variants/2420	H3-3B	3021	K36M																	2022-04-12 21:22:03 UTC	20.0						false
2421	https://civicdb.org/links/variants/2421	H3-3A	3020	G34W																	2022-04-12 21:22:03 UTC	20.0						false
2428	https://civicdb.org/links/variants/2428	VHL	7428	G104V (c.311G>T)			3	10183842	10183842	G	T	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.311G>T,NM_000551.3:c.311G>T,NP_000542.1:p.Gly104Val,NC_000003.11:g.10183842G>T	2022-04-12 21:22:05 UTC	7.5	CA357033	223183	C.311G>T,GLY104VAL,RS869025630			false
2431	https://civicdb.org/links/variants/2431	VHL	7428	c.‚àí213‚àí ?_463 ?del																	2022-04-12 21:22:03 UTC	0.0						false
2432	https://civicdb.org/links/variants/2432	VHL	7428	V87fs (c.259_260insA)			3	10183790	10183791		A	ENST00000256474.2	75	GRCh37					plus_1_frameshift_variant,frameshift_truncation	ENST00000256474.2:c.259_260insA,NC_000003.11:g.10183790_10183791insA,NM_000551.3:c.259_260insA,NP_000542.1:p.Val87AspfsTer?,NC_000003.12:g.10142106_10142107insA	2022-04-12 21:22:04 UTC	7.5	CA913189242	NONE FOUND	C.259_260INSA,VAL87FS,V87DFS*45			false
2435	https://civicdb.org/links/variants/2435	VHL	7428	c.341-59_341-14del																	2022-04-12 21:22:04 UTC	0.0						false
2437	https://civicdb.org/links/variants/2437	VHL	7428	V166A (c.497T>C)			3	10191504	10191504	T	C	ENST00000256474.2	75	GRCh37					missense_variant	NC_000003.11:g.10191504T>C,NM_000551.3:c.497T>C,NP_000542.1:p.Val166Ala,ENST00000256474.2:c.497T>C	2022-04-12 21:22:04 UTC	0.0	CA020442	43605	VAL166ALA			false
2439	https://civicdb.org/links/variants/2439	VHL	7428	Rearrangement																	2022-04-12 21:22:04 UTC	10.0						false
2440	https://civicdb.org/links/variants/2440	VHL	7428	P138R (c.413C>G)			3	10188270	10188270	C	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.413C>G,NC_000003.11:g.10188270C>G,NM_000551.3:c.413C>G,NP_000542.1:p.Pro138Arg	2022-04-12 21:22:04 UTC	2.5	CA351754085	NONE FOUND	C.413C>G,PRO138ARG			false
2447	https://civicdb.org/links/variants/2447	VHL	7428	V66Gfs*89 (c.197_209del)																	2022-04-12 21:22:04 UTC	5.0						false
2448	https://civicdb.org/links/variants/2448	VHL	7428	R79_S80del (c.236_241delGCAGTC)																	2022-04-12 21:22:04 UTC	5.0						false
2449	https://civicdb.org/links/variants/2449	VHL	7428	D92G (c.275A>G)			3	10183806	10183806	A	G	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.275A>G,NC_000003.11:g.10183806A>G,NM_000551.3:c.275A>G,NP_000542.1:p.Asp92Gly	2022-04-12 21:22:04 UTC	5.0	CA351750765	NONE FOUND	C.275A>G,ASP92GLY			false
2455	https://civicdb.org/links/variants/2455	VHL	7428	G114Vfs*45 (c.339delA)																	2022-04-12 21:22:04 UTC	7.5						false
2458	https://civicdb.org/links/variants/2458	VHL	7428	R167P (c.500G>C)			3	10191507	10191507	G	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.500G>C,NM_000551.3:c.500G>C,NP_000542.1:p.Arg167Pro,NC_000003.11:g.10191507G>C	2022-04-12 21:22:04 UTC	7.5	CA351756177	428799	RS5030821,C.500G>C,ARG167PRO			false
2459	https://civicdb.org/links/variants/2459	VHL	7428	L178P (c.532C>T)																	2022-04-12 21:22:06 UTC	7.5						true
2468	https://civicdb.org/links/variants/2468	PRKCB	5579	D427N																	2022-04-12 21:22:04 UTC	3.0						false
2488	https://civicdb.org/links/variants/2488	VHL	7428	*214G (c.640T>G)			3	10191647	10191647	T	G	ENST00000256474.2	75	GRCh37					stop_lost	ENST00000256474.2:c.640T>G,NM_000551.3:c.640T>G,NP_000542.1:p.Ter214Gly,ENSP00000256474.2:p.Ter214Gly	2022-04-12 21:22:05 UTC	5.0	CA351756720	NONE FOUND	X214G,TER214GLY,C.640T>G,X > GLY + 14AA			false
2489	https://civicdb.org/links/variants/2489	VHL	7428	*214C (c.641_642insC)			3	10191648	10191649		C	ENST00000256474.2	75	GRCh37					stop_lost	ENST00000256474.2:c.641_642insC,NC_000003.11:g.10191648_10191649insC,NM_000551.3:c.641_642insC,NP_000542.1:p.Ter214CysextTer?	2022-04-12 21:22:05 UTC	5.0	CA913189243	NONE FOUND	X214C,TER214CYS,C.641INSC			false
2508	https://civicdb.org/links/variants/2508	VHL	7428	L129P (c.386T>C)			3	10188243	10188243	T	C	ENST00000256474.2	75	GRCh37					missense_variant	ENST00000256474.2:c.386T>C,NC_000003.11:g.10188243T>C,NM_000551.3:c.386T>C,NP_000542.1:p.Leu129Pro,ENSP00000256474.2:p.Leu129Pro,NC_000003.12:g.10146559T>C	2022-04-12 21:22:06 UTC	0.0	CA351753904	625242	L129P (C.386T>G)			false
2511	https://civicdb.org/links/variants/2511	VHL	7428	S80fs (c.239del)			3	10183770	10183770	G		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NP_000542.1:p.Ser80IlefsTer,ENST00000256474.2:c.239del,NC_000003.11:g.10183770del,NM_000551.3:c.239del	2022-04-12 21:22:04 UTC	7.5	CA913189245	NONE FOUND	C.239DELG,SER80ILEFS*79,S80IFS*79 (C.239DELG)			false
2553	https://civicdb.org/links/variants/2553	VHL	7428	D121_A122del (c.361_366del)																	2022-04-12 21:22:04 UTC	0.0						false
2561	https://civicdb.org/links/variants/2561	VHL	7428	N150fs (c.447del)			3	10188303	10188303	C		ENST00000256474.2	75	GRCh37					minus_1_frameshift_variant,frameshift_truncation	NP_000542.1:p.Asn150IlefsTer9,ENST00000256474.2:c.447del,NC_000003.12:g.10146620del,NC_000003.11:g.10188304del,NM_000551.3:c.447del	2022-04-12 21:22:05 UTC	0.0	CA432421904	NONE FOUND	C.446DELC,N150IFS*9,A149FS			false
2570	https://civicdb.org/links/variants/2570	HRAS	3265	Q61																	2022-04-12 21:22:04 UTC	10.0						false
2571	https://civicdb.org/links/variants/2571	ABL2	27	Fusion																	2022-04-12 21:22:04 UTC	3.0						false
2575	https://civicdb.org/links/variants/2575	ABL1	25	ETV6::ABL1		ABL1 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:04 UTC	12.5			ETV6-ABL1			false
2580	https://civicdb.org/links/variants/2580	VHL	7428	N131T (c.392A>C)	A similar but distinct variant the same position has been reported in ClinVar (c.392A>G (p.Asn131Ser); https://www.ncbi.nlm.nih.gov/clinvar/variation/496062/). It involves the same base position but a different nucleotide change leading to a different amino acid change.		3	10188249	10188249	A	C	ENST00000256474.2	75	GRCh37					non_conservative_missense_variant	NC_000003.11:g.10188249A>C,CM000665.1:g.10188249A>C,NP_000542.1:p.Asn131Thr,NM_000551.3:c.392A>C	2020-08-20 05:29:35 UTC	7.5	CA351753944	NONE FOUND				false
2581	https://civicdb.org/links/variants/2581	NCOA2	10499	HEY1::NCOA2	HEY1-NCOA2 is a specific and recurrent translocation in mesenchymal chondrosarcoma.  The resulting chimeric transcription factor consists of the HEY1 DNA binding domain (exons 1-4) and two activating domains and a histone methyltransferase-interacting domain from NCOA2 (exon 13-23).		8	80	80			ENST00000337919.9	94	GRCh37	8	71	71	ENST00000452400.6	transcript_fusion		2022-04-14 15:37:27 UTC	70.0			HEY1-NCOA2	21	https://civicdb.org/links/assertions/21	false
2582	https://civicdb.org/links/variants/2582	FOXO1	2308	PAX3::FOXO1															transcript_fusion		2022-04-12 21:22:01 UTC	35.0			PAX3-FOXO1			false
2583	https://civicdb.org/links/variants/2583	FOXO1	2308	PAX7::FOXO1															transcript_fusion		2022-04-12 21:22:01 UTC	35.0			PAX7-FOXO1			false
2586	https://civicdb.org/links/variants/2586	PARP1	142	OVEREXPRESSION																	2022-04-12 21:22:01 UTC	3.0						false
2587	https://civicdb.org/links/variants/2587	JAK2	3717	F694L																	2022-04-12 21:22:01 UTC	5.0						false
2590	https://civicdb.org/links/variants/2590	PIK3CA	5290	Wildtype			3	178866311	178957881			ENST00000263967.3	75	GRCh37					wild_type		2022-04-12 21:22:01 UTC	15.0						false
2593	https://civicdb.org/links/variants/2593	NUP98	4928	NUP98::NSD1															transcript_fusion		2022-04-12 21:22:01 UTC	0.0			NUP98-NSD1			false
2613	https://civicdb.org/links/variants/2613	EGFR	1956	V441F		ECD MUTATION	7	55227854	55227854	G	T	ENST00000275493.2	75	GRCh37					missense_variant		2022-04-12 21:22:01 UTC	0.0	CA367579353	NONE FOUND	VAL441PHE			false
2620	https://civicdb.org/links/variants/2620	KIT	3815	T417_D419delinsY																	2022-04-15 14:12:41 UTC	5.0						false
2621	https://civicdb.org/links/variants/2621	KIT	3815	F506_F508DUP			4	55592192	55592200		TTTGCATTT	ENST00000288135.5	75							p.Phe506_Phe508dup,c.55592192_55592200dup	2022-04-15 14:05:04 UTC	2.5						false
2622	https://civicdb.org/links/variants/2622	KIT	3815	K484_G487DEL																	2022-04-15 14:12:41 UTC	2.5						false
2623	https://civicdb.org/links/variants/2623	PDGFRA	5156	Exon 18 Mutation																	2022-04-12 21:22:01 UTC	2.5						false
2640	https://civicdb.org/links/variants/2640	NTRK2	4915	Fusion																	2022-07-12 18:57:46 UTC	20.0						false
2643	https://civicdb.org/links/variants/2643	KIT	3815	Exon 13 Mutation			4	55594177	55594287			ENST00000288135.5	75	GRCh37							2022-04-14 20:05:26 UTC	5.0						false
2644	https://civicdb.org/links/variants/2644	SMARCA4	6597	Loss																	2022-08-02 15:12:59 UTC	4.0						false
2648	https://civicdb.org/links/variants/2648	TP53	7157	C238Y			17	7577568	7577568	C	T	ENST00000269305.4	75	GRCh37					missense_variant	NC_000017.10:g.7577568C>T,NM_000546.5:c.713G>A,NP_000537.3:p.Cys238Tyr,ENST00000269305.4:c.713G>A	2022-04-12 21:22:05 UTC	0.75	CA000351	182935	CYS238TYR			false
2650	https://civicdb.org/links/variants/2650	BRAF	673	Exon 15 Mutation																	2022-04-12 21:22:05 UTC	7.5						false
2651	https://civicdb.org/links/variants/2651	KIT	3815	WILDTYPE			4	55524085	55606881			ENST00000288135.5	75	GRCh37					wild_type		2022-04-12 21:22:05 UTC	10.0		N/A				false
2652	https://civicdb.org/links/variants/2652	H3-3A	3020	MUTATION																	2022-04-12 21:22:05 UTC	20.0						false
2654	https://civicdb.org/links/variants/2654	CDKN2A	1029	Deletion																	2022-04-12 21:22:05 UTC	20.0						false
2655	https://civicdb.org/links/variants/2655	MYB	4602	AMPLIFICATION																	2022-04-12 21:22:05 UTC	20.0						false
2659	https://civicdb.org/links/variants/2659	FGFR1	2260	Internal Duplication																	2022-04-12 21:22:05 UTC	20.0						false
2660	https://civicdb.org/links/variants/2660	ABL1	25	NUP214::ABL1	The NUP214 -ABL1 fusion is composed of part of the NUP214 (Nucleoporin 214) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 34 of NUP214 to exon 2 of ABL1 (NUP214-ABL1 34-2). In T-ALL, the fusion is typically expressed from amplified extrachromosomal bodies (episomes) that arise when the genomic region from ABL1 to NUP214 circularizes to generate the NUP214-ABL1 fusion. In B-ALL, the fusion commonly results from an intrachromosomal duplication involving chromosome 9, with breakpoints within the NUP214 and ABL1 genes. The fusion has been identified in 6% of cases of T-lymphoblastic leukemia and rare cases of B-lymphoblastic leukemia by multiplex ligation-dependent probe amplification, single nucleotide polymorphism array, real-time polymerase chain reaction, and fluorescence in situ hybridization targeting the ABL1 gene. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the WD40 repeat and coiled-coil domains of NUP214 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and MAPK and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The case report that illustrates the clinical significance of the NUP214-ABL1 fusion describes a 6-year-old boy and a 15-year-old girl with BCR-ABL1-like B-lymphoblastic leukemia with normal karyotype. Both patients demonstrated minimal residual disease after induction chemotherapy, and later experienced relapse after either consolidation therapy or bone marrow transplant. Dasatinib was then prescribed and follow-up information is available for the older child, who successfully achieved a complete response for three months before succumbing to the disease. The clinical details of this case could predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).	ABL1 fusions in B-ALL	9	134000948	134106156			ENST00000359428.5	75	GRCh37	9	133730188	133763062	ENST00000318560.5	transcript_fusion		2022-03-10 20:11:44 UTC	27.0			NUP214-ABL1			false
2661	https://civicdb.org/links/variants/2661	JAK2	3717	SSBP2::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:05 UTC	25.0			SSBP2-JAK2			false
2663	https://civicdb.org/links/variants/2663	CRLF2	64109	IGH::CRLF2															transcript_fusion		2022-04-12 21:22:05 UTC	20.0			IGH-CRLF2			false
2666	https://civicdb.org/links/variants/2666	EZH2	2146	Y646S			7	148508727	148508727	T	G	ENST00000320356.7		GRCh37					missense_variant	NC_000007.14:g.148811635,NC_000007.13:g.148508727,ENST00000320356.7:c.1937A>C,ENSP00000320147.2:p.Tyr646Ser,NM_004456.5:c.1937A>C,NP_004447.2:p.Tyr646Ser	2022-12-10 00:00:02 UTC	3.0	CA16602671	376218	Y641S,TYR641SER,TYR646SER			false
2671	https://civicdb.org/links/variants/2671	CDKN1A	1026	rs1801270																	2022-04-12 21:22:05 UTC	0.0						false
2678	https://civicdb.org/links/variants/2678	ABL1	25	SNX2::ABL1	The SNX2-ABL1 fusion is composed of part of the SNX2 (Sorting Nexin 2) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 3 of SNX2 to exon 4 of ABL1 (SNX2-ABL1 3-4). The fusion is the result of a reciprocal translocation t(5;9)(p23.2;q34.12) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the sorting nexin, N-terminal domain of SNX2 and the SH2, tyrosine kinase, and F actin binding domains of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The SNX2-ABL1 fusion has been documented in six young men between the ages of 7 and 29 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (imatinib and dasatinib + imatinib) added to their chemotherapy regimens that, while producing initially encouraging results, ultimately did not prevent these individuals from succumbing to their disease. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors and is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).	ABL1 fusions in B-ALL	5	122110691	122135550			ENST00000379516.2	75	GRCh37	9	133738150	133763062	ENST00000372348.2	transcript_fusion		2022-03-10 22:24:08 UTC	30.5			SNX2-ABL1	43	https://civicdb.org/links/assertions/43	false
2681	https://civicdb.org/links/variants/2681	ABL1	25	RCSD1::ABL1	The RCSD1-ABL1 fusion is composed of part of the RCSD1 (RCS Domain Containing 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 2 or, more frequently, exon 3 of RCSD1 to exon 4 of ABL1 (RCSD1-ABL1 3-4). The fusion is the result of a reciprocal translocation t(1;9)(q24.2;q34.12) and has been identified by FISH/karyotype, RT-PCR, Sanger sequencing, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the ABL1 SH2, actin binding domain, and tyrosine kinase domain, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RCSD1-ABL1 fusion has been documented in greater than fifteen pediatric and adult patients with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. The majority that that were exposed to tyrosine kinase inhibitors (TKIs: imatinib, dasatinib, or ponatinib) experienced durable remissions until the TKIs were discontinued. The clinical details of these cases may predict response to treatment with TKIs and are the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).	ABL1 fusions in B-ALL													transcript_fusion		2022-12-05 05:37:39 UTC	80.5			RCSD1-ABL1			false
2682	https://civicdb.org/links/variants/2682	ABL1	25	FOXP1::ABL1	The FOXP1-ABL1 fusion is composed of part of the FOXP1 (Forkhead box P1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 27 of FOXP1to exon 4 of ABL1 (FOXP1-ABL1). The fusion is the result of a reciprocal translocation t(3;9)(p12;q34) and has been identified by RT-PCR, Sanger sequencing, and NGS. FOXP1 is critical for the transcriptional regulatory network of B lymphopoiesis; it may also act as a tumor suppressor gene. Absence or deficiency of FOXP1 during early B-cell development may block pro-B cell to pre-B cell development. The FOXP1-ABL1 fusion protein leads to activated tyrosine kinase and may further alter the critical cellular function of these 2 genes. Clinical significance: The FOXP1-ABL1 fusion has been documented in 3 young adult patients (2 male, 1 female) with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. One patient had tyrosine kinase inhibitors (dasatinib) added to the chemotherapy regimens, who had bone marrow tested negative for MRD at end of consolidation. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.	ABL1 fusions in B-ALL													transcript_fusion		2022-03-11 17:36:58 UTC	10.0			FOXP1-ABL1			false
2693	https://civicdb.org/links/variants/2693	ROS1	6098	Fusion															transcript_fusion		2022-04-12 21:22:05 UTC	0.0				37	https://civicdb.org/links/assertions/37	false
2695	https://civicdb.org/links/variants/2695	KIT	3815	V555_V559DEL																	2022-04-12 21:22:05 UTC	5.0						false
2696	https://civicdb.org/links/variants/2696	KIT	3815	K550_K559DEL			4	55593582	55593611	AAACCCATGTATGAAGTACAGTGGAAGGTT		ENST00000288135.5	75	GRCh37							2022-04-15 13:56:44 UTC	5.0	CA645516734					false
2704	https://civicdb.org/links/variants/2704	CDKN2A	1029	Mutation			9	21968055	21974865			ENST00000498124.1	75	GRCh37							2022-04-12 21:22:06 UTC	40.0		N/A				false
2743	https://civicdb.org/links/variants/2743	FGFR1	2260	FGFR1OP2::FGFR1															transcript_fusion		2022-04-12 21:22:06 UTC	2.0			FGFR1OP2-FGFR1			false
2744	https://civicdb.org/links/variants/2744	IKZF1	10320	IKZF1 deletion and mutation																	2022-04-12 21:22:05 UTC	0.0						false
2749	https://civicdb.org/links/variants/2749	NFE2L2	4780	Mutation																	2022-08-02 14:43:31 UTC	15.0						false
2769	https://civicdb.org/links/variants/2769	ALK	238	CAD::ALK															transcript_fusion		2022-04-12 21:22:06 UTC	7.5			CAD-ALK			false
2770	https://civicdb.org/links/variants/2770	ROS1	6098	GOPC::ROS1															transcript_fusion		2022-04-12 21:22:03 UTC	3.0			GOPC-ROS1			false
2772	https://civicdb.org/links/variants/2772	NRG1	3084	APP::NRG1															transcript_fusion		2022-04-12 21:22:03 UTC	0.0			APP-NRG1			false
2774	https://civicdb.org/links/variants/2774	MET	4233	R1004G			7	116412025	116412025	C	G	ENST00000397752.8		GRCh37					missense_variant	NC_000007.14:g.116771971C>G,NC_000007.13:g.116412025C>G,ENST00000397752.8:c.3010C>G,ENSP00000380860.3:p.Arg1004Gly,NM_000245.4:c.3010C>G,NP_000236.2:p.Arg1004Gly	2022-12-02 00:00:03 UTC	7.5	CA368987455	NONE FOUND	ARG1004GLY			false
2777	https://civicdb.org/links/variants/2777	TP53	7157	S241F																	2022-04-12 21:22:05 UTC	0.0						false
2784	https://civicdb.org/links/variants/2784	FGF19	9965	Overexpression																	2022-04-12 21:22:06 UTC	0.0		N/A				false
2794	https://civicdb.org/links/variants/2794	BRAF	673	N486_P490del																	2022-04-12 21:22:06 UTC	7.5						false
2820	https://civicdb.org/links/variants/2820	BRAF	673	V600_K601>E																	2022-04-12 21:22:06 UTC	7.5						false
2822	https://civicdb.org/links/variants/2822	BRAF	673	G469																	2022-04-12 21:22:03 UTC	15.0						false
2826	https://civicdb.org/links/variants/2826	BRAF	673	A598V			7	140453142	140453142	G	A	ENST00000288602.6	75	GRCh37					missense_variant		2022-04-12 21:22:06 UTC	7.5	CA369543099	NONE FOUND	ALA598VAL			false
2846	https://civicdb.org/links/variants/2846	JAK2	3717	ATF7IP::JAK2	The ATF7IP-JAK2 fusion is composed of part of the ATF7IP (Activating Transcription Factor 7 Interacting Protein) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 10 of ATF7IP to exon 8 of JAK2 (ATF7IP-JAK2 10-8), exon 13 of ATF7IP to exon 16 of JAK2 (ATF7IP-JAK2 13-16), or exon 13 of ATF7IP to exon 17 of JAK2 (ATF7IP-JAK2 13-17). The fusion is predicted to result from a reciprocal translocation t(9;12) (p24;p13.1), and has been identified by RNA sequencing and Sanger sequencing in three adult patients with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil and MDN1 domains from ATF7IP and the JH2 pseudokinase and JH1 kinase domains from JAK2. The coiled coil domain is hypothesized to constitutively activate the JAK2 kinase domain, thereby upregulating the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel ATF7IP-JAK2 fusion has been documented in three cases for which specific clinical information is unavailable. A pre-clinical xenograft model containing the fusion was sensitive to exposure to the JAK2 inhibitor, ruxolitinib. Therefore, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	JAK2 fusions in B-ALL													transcript_fusion		2022-03-10 20:21:16 UTC	15.0			ATF7IP-JAK2			false
2847	https://civicdb.org/links/variants/2847	JAK2	3717	EBF1::JAK2	The EBF1-JAK2 fusion is composed of part of the EBF1 (Early B-Cell Factor Transcription Factor 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 14 of EBF1 to exon 17 of JAK2 (EBF1-JAK2 14-17). The fusion is predicted to result from a reciprocal translocation t(5;9) (q33.3;p24), and has been identified by RNA sequencing in one adolescent patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA binding, immunoglobulin-life fold, and helix-loop-helix domains from EBF1 and an intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the EBF1-JAK2 fusion protein has not been performed. Clinical significance: The novel EBF1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 21:04:40 UTC	0.0			EBF1-JAK2			false
2848	https://civicdb.org/links/variants/2848	JAK2	3717	PPFIBP1::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:06 UTC	7.5			PPFIBP1-JAK2			false
2849	https://civicdb.org/links/variants/2849	JAK2	3717	STRN3::JAK2	The STRN3-JAK2 fusion is composed of part of the STRN3 (Striatin 3) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 9 of STRN3 to exon 17 of JAK2 (STRN3 -JAK2 9-17). The fusion is predicted to result from a reciprocal translocation t(9;14) (p24;q12), and has been identified by RNA sequencing in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the Striatin domain from STRN3 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the STRN3-JAK2 fusion protein has not been performed. Clinical significance: The novel STRN3-JAK2 fusion has been documented in a single case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	JAK2 fusions in B-ALL													transcript_fusion		2022-03-10 21:46:30 UTC	0.0			STRN3-JAK2			false
2850	https://civicdb.org/links/variants/2850	JAK2	3717	TPR::JAK2	The TPR-JAK2 fusion is composed of part of the TPR (Translocated Promoter Region, Nuclear Basket Protein) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 39 of TPR to exon 17 of JAK2 (TPR -JAK2 39-17). The fusion stems from a reciprocal translocation t(1;9) (q31.1;p24), and has been identified by FISH and RNA sequencing in one young adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the TPR/MLP1/MLP2-like protein domain from TERF2 and the JH2 pseudokinase domain and intact JH1 kinase domain from JAK2, as confirmed by RT-PCR and Sanger sequencing. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the TPR-JAK2 fusion protein has not been performed. Clinical significance: The novel TPR-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	JAK2 fusions in B-ALL													transcript_fusion		2022-03-10 20:24:38 UTC	0.0			TPR-JAK2			false
2851	https://civicdb.org/links/variants/2851	SMAD4	4089	R361C																	2022-04-12 21:22:06 UTC	0.0						false
2854	https://civicdb.org/links/variants/2854	ERBB2	2064	Exon 20 Insertion																	2022-04-12 21:22:06 UTC	0.0						false
2859	https://civicdb.org/links/variants/2859	JAK2	3717	ETV6::JAK2	The ETV6-JAK2 fusion is composed of part of the ETV6 (ETS Variant Transcription Factor 6) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 4 of ETV6 to exon 17 of JAK2 (ETV6-JAK2 4-17), exon 5 of ETV6 to exon 12 of JAK2 (ETV6-JAK2 5-12), or exon 5 of ETV6 to exon 19 of JAK2 (ETV6-JAK2 5-19). The fusion results from the reciprocal translocation t(9;12)(p24;p13), cytogenetically cryptic, and has been identified by FISH and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the PNT domain from ETV6 and JH1 kinase domain from JAK2. The ETV6 PNT domain is hypothesized to result in dimerization, which leads to aberrant JAK2 kinase domain activation. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. The inclusion of the JH1 domain may affect functional effects and disease specificity of the abnormal fusion. Functionally, the fusion results in aberrant activation of JAK2 kinase, leading to activation of downstream signaling through the signal transducers and activators of transcription (STATs). The ETV6-JAK2 fusion is associated with hematologic malignancies and has been observed in B-lymphoblastic leukemia (~10%), T-lymphoblastic leukemia (isolated cases), and myeloid/lymphoid neoplasms with eosinophilia and gene rearrangements (rare cases). Clinical significance: As a diagnostic biomarker, the ETV6-JAK2 fusion in B-lymphoblastic leukemia is associated with the BCR-ABL1-like subtype. As a prognostic marker, the ETV6-JAK2 fusion has been associated with high-risk disease. As a predictive marker, the ETV6-JAK2 fusion has been shown by limited pre-clinical data and case reports to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).	JAK2 fusions in B-ALL													transcript_fusion		2022-03-11 03:59:51 UTC	25.0			ETV6-JAK2			false
2860	https://civicdb.org/links/variants/2860	JAK2	3717	BCR::JAK2	The BCR-JAK2 fusion is composed of part of the BCR (Breakpoint Cluster Region) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. Known breakpoint/splice variants join exon 14 of BCR to exon 17 of JAK2 (BCR-JAK2 4-17) and exon 1 of BCR to exons 15 (BCR-JAK2 1-15), 17 (BCR-JAK2 1-17), or 19 (BCR-JAK2 1-19). The fusion results from the reciprocal translocation t(9;22)(p24;p11.2), and has been identified by karyotype analysis, FISH, RT-PCR, targeted ligation amplification (TLA), and RNA sequencing. The fusion gene is expressed from the der(9) chromosome. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from BCR and the JH1 kinase domain from JAK2. Depending on the breakpoint variant, the fusion protein may also contain the JAK2 JH2 pseudokinase domain. In pre-clinical studies, the coiled coil domain of BCR has been shown to mediate oligomeric activation of the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). The BCR-JAK2 fusion is associated with hematologic malignancies and has been observed in myeloproliferative neoplasms with eosinophilia (multiple cases), B-lymphoblastic leukemia (multiple cases), acute myeloid leukemia (a rare case), and B-cell lymphoma (rare case of Burkitt lymphoma). Clinical significance: As a diagnostic biomarker in B-lymphoblastic leukemia, the BCR-JAK2 fusion is frequently observed in the BCR-ABL1-like subtype. As a prognostic marker, the fusion appears to be associated with high-risk disease in pediatric and adult populations. As a predictive marker, patients whose diseases exhibit the BCR-JAK2 fusion have experienced partial responses or even complete remission with hydroxyurea and/or interferon alfa. Case reports have demonstrated the limited utility of tyrosine kinase inhibitors. One patient diagnosed with a myeloid neoplasm initially responded to the JAK2 inhibitor ruxolitinib, but relapsed after 18 months. Current research has suggested a survival advantage following allogeneic or autologous stem cell transplantation.	JAK2 fusions in B-ALL													transcript_fusion		2022-03-11 04:20:06 UTC	35.0			BCR-JAK2			false
2861	https://civicdb.org/links/variants/2861	JAK2	3717	PAX5::JAK2	The PAX5-JAK2 fusion is composed of part of the PAX5 (Paired Box 5) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 5 of PAX5 to exon 19 of JAK2 (PAX5-JAK2 5-19). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p13 and p24), and has been identified by RNA sequencing, RT-PCR, Sanger sequencing, and FISH in patients B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the DNA-binding paired domain from PAX5 and the JH1 kinase domain from JAK2. A pre-clinical study has revealed that this fusion protein deregulates the PAX5 transcriptional pathway while also autophosphorylating the JAK2 kinase domain, thereby promoting downstream signaling by signal transducers and activators of transcription (STATs). Clinical significance: As a diagnostic biomarker, the PAX5-JAK2 fusion in B-lymphoblastic leukemia is frequently associated with the BCR-ABL1-like subtype. As a prognostic marker, the fusion has been associated with intermediate to high-risk disease. As a predictive marker, the PAX5-JAK2 fusion has been shown in pre-clinical data to predict response to treatment with JAK2 inhibitors. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 20:36:57 UTC	30.0			PAX5-JAK2			false
2862	https://civicdb.org/links/variants/2862	JAK2	3717	TERF2::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:06 UTC	0.0			TERF2-JAK2			false
2863	https://civicdb.org/links/variants/2863	JAK2	3717	USP25::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:06 UTC	0.0			USP25-JAK2			false
2864	https://civicdb.org/links/variants/2864	JAK2	3717	ZNF274::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:06 UTC	7.5			ZNF274-JAK2			false
2865	https://civicdb.org/links/variants/2865	JAK2	3717	RFX3::JAK2		JAK2 fusions in B-ALL													transcript_fusion		2022-04-12 21:22:06 UTC	7.5			RFX3-JAK2			false
2871	https://civicdb.org/links/variants/2871	BRCA2	675	K3326*																	2022-04-12 21:22:06 UTC	7.5						false
2883	https://civicdb.org/links/variants/2883	BRAF	673	NRF1::BRAF															transcript_fusion		2022-04-12 21:22:02 UTC	7.5			NRF1-BRAF			false
2884	https://civicdb.org/links/variants/2884	CDKN2A	1029	c.151-1G>C																	2022-09-22 20:58:35 UTC	7.5						false
2885	https://civicdb.org/links/variants/2885	ABL1	25	BCR::ABL T315V															missense_variant,transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL THR315VAL,BCR-ABL1 T315V,BCR-ABL1 THR315VAL,BCR-ABL T315V			false
2886	https://civicdb.org/links/variants/2886	ABL1	25	BCR::ABL E279K															missense_variant,transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL1 E279K,BCR-ABL GLU279LYS,BCR-ABL1 GLU279LYS,BCR-ABL E279K			false
2887	https://civicdb.org/links/variants/2887	ABL1	25	BCR::ABL E292L															missense_variant,transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL1 E292L,BCR-ABL GLY292LEU,BCR-ABL1 GLY292LEU,BCR-ABL E292L			false
2888	https://civicdb.org/links/variants/2888	ABL1	25	BCR::ABL F317R															missense_variant,transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL1 F317R,BCR-ABL PHE317ARG,BCR-ABL1 PHE317ARG,BCR-ABL F317R			false
2889	https://civicdb.org/links/variants/2889	ABL1	25	BCR::ABL L248R and F359I															missense_variant,transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL1 L248R F359I,BCR-ABL L248R F359I,BCR-ABL1 L248R AND F359I			false
2890	https://civicdb.org/links/variants/2890	ABL1	25	BCR::ABL E255K V299L															transcript_fusion		2022-04-12 21:22:04 UTC	2.0			BCR-ABL1 E255K V299L,BCR-ABL E255K V299L			false
2892	https://civicdb.org/links/variants/2892	CTNNB1	1499	Exon 3 Mutation			3	41266017	41266244			ENST00000349496.5	75	GRCh37							2022-04-12 21:22:04 UTC	55.0				31	https://civicdb.org/links/assertions/31	false
2893	https://civicdb.org/links/variants/2893	DPYD	1806	EXON 11-19 DELETION			1	97700408	98039526			ENST00000370192.3	75	GRCh37					inframe_deletion		2022-04-12 21:22:04 UTC	10.0						false
2894	https://civicdb.org/links/variants/2894	MET	4233	MET::ATXN7L1															transcript_fusion		2022-04-12 21:22:04 UTC	0.0			MET-ATXN7L1			false
2896	https://civicdb.org/links/variants/2896	NT5C2	22978	R238W			10	104857107	104857107	G	A	ENST00000343289.5	75	GRCh37							2022-04-12 21:22:05 UTC	13.0	CA377975023					false
2897	https://civicdb.org/links/variants/2897	NT5C2	22978	S445F			10	104850483	104850483	G	A	ENST00000343289.5	75	GRCh37					missense_variant,gain_of_function_variant		2022-04-12 21:22:05 UTC	9.0	CA377969059	NONE FOUND				false
2898	https://civicdb.org/links/variants/2898	NT5C2	22978	Mutation																	2022-04-12 21:22:05 UTC	20.0						false
2900	https://civicdb.org/links/variants/2900	ABL1	25	BCR::ABL D363G															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	2.5			BCR-ABL1 D363G,BCR-ABL D363G			false
2901	https://civicdb.org/links/variants/2901	ABL1	25	BCR::ABL E98G															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	2.5			BCR-ABL1 E98G,BCR-ABL GLU98GLY,BCR-ABL1 GLU98GLY,BCR-ABL E98G			false
2902	https://civicdb.org/links/variants/2902	ABL1	25	BCR::ABL L364I															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	2.5			BCR-ABL1 L364I,BCR-ABL LEU364ILE,BCR-ABL1 LEU364ILE,BCR-ABL L364I			false
2905	https://civicdb.org/links/variants/2905	FGFR2	2263	P253R																	2022-07-13 23:18:15 UTC	7.5						false
2909	https://civicdb.org/links/variants/2909	ABL1	25	BCR::ABL Y253F															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	7.5			BCR-ABL TYR253PHE,BCR-ABL1 Y253F,BCR-ABL1 TYR253PHE,BCR-ABL Y253F			false
2911	https://civicdb.org/links/variants/2911	IL6	3569	Overexpression																	2022-04-12 21:22:05 UTC	0.0						false
2915	https://civicdb.org/links/variants/2915	ABCB1	5243	Overexpression															N/A		2022-04-12 21:22:05 UTC	5.0						false
2916	https://civicdb.org/links/variants/2916	PRPS1	5631	PRPS1 MUTATION																	2022-04-12 21:22:05 UTC	20.0						false
2917	https://civicdb.org/links/variants/2917	LYN	4067	OVEREXPRESSION																	2022-04-12 21:22:05 UTC	3.0						false
2918	https://civicdb.org/links/variants/2918	PRPS1	5631	T303S																	2022-04-12 21:22:05 UTC	4.0						false
2919	https://civicdb.org/links/variants/2919	PRPS1	5631	L191F																	2022-04-12 21:22:05 UTC	6.0						false
2920	https://civicdb.org/links/variants/2920	PRPS1	5631	D183E																	2022-04-12 21:22:06 UTC	4.0						false
2921	https://civicdb.org/links/variants/2921	PRPS1	5631	K176N																	2022-04-12 21:22:05 UTC	4.0						false
2923	https://civicdb.org/links/variants/2923	PRPS1	5631	N144S																	2022-04-12 21:22:06 UTC	7.0						false
2925	https://civicdb.org/links/variants/2925	PRPS1	5631	S103I																	2022-04-12 21:22:06 UTC	0.0						false
2926	https://civicdb.org/links/variants/2926	PRPS1	5631	S103N																	2022-04-12 21:22:06 UTC	4.0						false
2927	https://civicdb.org/links/variants/2927	PRPS1	5631	S103T																	2022-04-12 21:22:06 UTC	5.0						false
2929	https://civicdb.org/links/variants/2929	PRPS1	5631	A190T																	2022-04-12 21:22:06 UTC	23.0						false
2930	https://civicdb.org/links/variants/2930	VHL	7428	106insR (c.316insGCC)																	2022-04-12 21:22:06 UTC	7.5						false
2932	https://civicdb.org/links/variants/2932	VHL	7428	Deletion																	2022-04-12 21:22:06 UTC	0.0						false
2935	https://civicdb.org/links/variants/2935	PRPS1	5631	D139G																	2022-04-12 21:22:05 UTC	0.0						false
2936	https://civicdb.org/links/variants/2936	PRPS1	5631	C77S																	2022-04-12 21:22:06 UTC	0.0						false
2937	https://civicdb.org/links/variants/2937	PRPS1	5631	I72V																	2022-04-12 21:22:06 UTC	0.0						false
2938	https://civicdb.org/links/variants/2938	PRPS1	5631	V53A																	2022-04-12 21:22:06 UTC	0.0						false
2939	https://civicdb.org/links/variants/2939	PRPS1	5631	A87T																	2022-04-12 21:22:06 UTC	0.0						false
2940	https://civicdb.org/links/variants/2940	PRPS1	5631	M115T																	2022-04-12 21:22:06 UTC	0.0						false
2944	https://civicdb.org/links/variants/2944	PDGFRA	5156	Overexpression																	2022-04-12 21:22:02 UTC	3.0						false
2948	https://civicdb.org/links/variants/2948	ABL1	25	BCR::ABL E450Q															missense_variant,transcript_fusion		2022-04-12 21:22:03 UTC	10.0			BCR-ABL1 E450Q,BCR-ABL GLU450GLN,BCR-ABL1 GLU450GLN,BCR-ABL E450Q			false
2949	https://civicdb.org/links/variants/2949	ABL1	25	BCR::ABL M244V and L364I															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	0.0			BCR-ABL M244V AND L364I			false
2951	https://civicdb.org/links/variants/2951	ABL1	25	BCR::ABL N146S															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	0.0			BCR-ABL ASN146SER,BCR-ABL1 N146S,BCR-ABL1 ASN146SER,BCR-ABL N146S			false
2952	https://civicdb.org/links/variants/2952	ABL1	25	BCR::ABL V298I															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	0.0			BCR-ABL VAL298ILE,BCR-ABL1 V298I,BCR-ABL1 VAL298ILE,BCR-ABL V298I			false
2953	https://civicdb.org/links/variants/2953	ABL1	25	BCR::ABL S438C															missense_variant,transcript_fusion		2022-04-12 21:22:05 UTC	7.5			BCR-ABL SER438CYS,BCR-ABL1 SER438CYS,BCR-ABL1 S438C,BCR-ABL S438C			false
2954	https://civicdb.org/links/variants/2954	ABL1	25	BCR::ABL M388L															missense_variant,transcript_fusion		2022-04-12 21:22:03 UTC	0.0			BCR-ABL1 M388L,BCR-ABL MET388LEU,BCR-ABL1 MET388LEU,BCR-ABL M388L			false
2959	https://civicdb.org/links/variants/2959	CHEK2	11200	R474C c.1420C>T																	2022-04-12 21:22:03 UTC	7.5						false
2960	https://civicdb.org/links/variants/2960	BCL2	596	G101V			18	60985598	60985598	C	A	ENST00000398117.1	75	GRCh37					missense_variant	ENST00000398117.1:c.302G>T	2022-05-03 19:20:23 UTC	8.0	CA402632336	NONE FOUND	GLY101VAL			false
2971	https://civicdb.org/links/variants/2971	PDGFRA	5156	BCR::PDGFRA															transcript_fusion		2022-04-12 21:22:06 UTC	0.0			BCR-PDGFRA			false
2972	https://civicdb.org/links/variants/2972	PDGFB	5155	COL1A1::PDGFB															transcript_fusion		2022-04-12 21:22:06 UTC	27.5			COL1A1-PDGFB			false
2973	https://civicdb.org/links/variants/2973	PDGFRB	5159	Overexpression																	2022-04-12 21:22:04 UTC	7.5						false
2974	https://civicdb.org/links/variants/2974	JAK2	3717	OFD1::JAK2	The OFD1-JAK2 fusion is composed of part of the OFD1 (Oral-Facial-Digital Syndrome 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. OFD1 is a centrosomal protein of primary cilia implicated in Oral-Facial-Digital Syndrome type 1, but it has not been previously described in hematologic malignancies. The published breakpoint joins exon 22 of OFD1 to exon 13 of JAK2 (OFD1-JAK2 22-13). This fusion is predicted to result from a reciprocal translocation t(X;9)(p22;p24), and has been identified in two patients by RNA sequencing, one of which demonstrated the abnormal karyotype 46,XY,-17+mar[11]/46,XY[9]. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the FERM and SH2 domains from OFD1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the OFD1-JAK2 fusion protein is reportedly underway. Clinical significance: The novel OFD1-JAK2 fusion has been documented in one 3-year-old and one 11-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia. Both children successfully maintained first complete remission following induction chemotherapy and allogeneic hematopoietic stem cell transplantation, with as long as 6 years of follow up. While neither patient was treated with a JAK2 inhibitor, the JH1 kinase domain present within the OFD1-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 20:20:22 UTC	10.0			OFD1-JAK2			false
2975	https://civicdb.org/links/variants/2975	JAK2	3717	SMU1::JAK2	The SMU1-JAK2 fusion is composed of part of the SMU1 (SMU1 DNA Replication Regulator and Splicesomal Factor) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of SMU1 to exon 12 of JAK2 (SMU1-JAK2 18-12). The fusion is hypothesized to result from an intrachromosomal translocation, inversion, or deletion of chromosome 9 (involving loci p21 and p24), and has been identified by RNA sequencing in an older adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the LisH, CTLH, HisP, and Wd40 domains from SMU1 and the JH2 pseudokinase and JH1 kinase domains from JAK2. Pre-clinical data demonstrates increased JH1 kinase expression as a result of the SMU1-JAK2 fusion event, which is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Clinical significance: The novel SMU1-JAK2 fusion has been documented in one case for which specific clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 21:05:36 UTC	0.0			SMU1-JAK2			false
2976	https://civicdb.org/links/variants/2976	JAK2	3717	SNX29::JAK2	The SNX29-JAK2 fusion is composed of part of the SNX29 (Sorting Nexin 29) gene at the 5‚Äô end (N-terminus of the fusion protein), and a part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion. The published breakpoint joins exon 18 of SNX29 to exon 13 of JAK2 (SNX29 -JAK2 18-13). It is predicted to result from a reciprocal translocation t(9;16) (p24;q13.13), and has been identified by RNA sequencing in one normal-karyotype adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the RUN and PX_RUN domains from SNX29 and the JH2 pseudokinase and JH1 kinase domains from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the SNX29-JAK2 fusion protein has not been performed. Clinical significance: The novel SNX29-JAK2 fusion has been documented in a single case that successfully maintained complete remission without relapse following induction chemotherapy. While the patient was not treated with a JAK2 inhibitor, the JH1 kinase domain present within the SNX29-JAK2 fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 22:24:24 UTC	0.0			SNX29-JAK2			false
2977	https://civicdb.org/links/variants/2977	JAK2	3717	ZNF430::JAK2	The ZNF430-JAK2 fusion is composed of part of the ZNF430 (Zinc Finger Protein 430) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 4 of ZNF430 to exon 19 of JAK2 (ZNF430-JAK2 4-19). The fusion is predicted to result from a reciprocal translocation t(9;19)(p24;p12), and has been identified by RNA sequencing in one adult patient with BCR-ABL1-like B-lymphoblastic leukemia. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the KRAB_A-box domain from ZNF430 and the JH1 kinase domain from JAK2. The inclusion of the JH1 kinase domain is hypothesized to upregulate the pathway shared with signal transducers and activators of transcription (STATs). Functional analysis of the ZNF430-JAK2 fusion protein has not been performed. Clinical significance: The novel ZNF430-JAK2 fusion has been documented in one case for which clinical information is unavailable. However, the presence of the JAK2 JH1 kinase domain in the fusion protein may offer a target for therapeutic inhibition. Prospective clinical trials are ongoing to evaluate the efficacy of adding JAK2 inhibitors to the treatment of pediatric B-lymphoblastic leukemia patients with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-10 19:40:33 UTC	7.5			ZNF430-JAK2			false
2979	https://civicdb.org/links/variants/2979	KRAS	3845	A146																	2022-04-15 14:12:41 UTC	15.0						false
2983	https://civicdb.org/links/variants/2983	ACVR1	90	Mutation																	2022-08-02 14:45:09 UTC	0.0						false
2989	https://civicdb.org/links/variants/2989	EZH2	2146	Y646F	Y646F has been reported as one of the most recurrent alterations of EZH2 in DLBCL, FL and other malignancies. This mutation is thought to alter methyltransferase activity of EZH2 and confer sensitivity to EZH2 inhibitors such as tazemetostat.		7	148508727	148508727	T	A	ENST00000320356.7		GRCh37					missense_variant	ENST00000320356.7:c.1937A>T,NC_000007.14:g.148811635T>A,NC_000007.13:g.148508727T>A,ENSP00000320147.2:p.Tyr646Phe,ENST00000460911.5:c.1922A>T,ENSP00000419711.1:p.Tyr641Phe,NM_004456.5:c.1937A>T,NP_004447.2:p.Tyr646Phe,NM_001203247.2:c.1922A>T,NP_001190176.1:p.Tyr641Phe	2022-06-29 06:43:49 UTC	10.0	CA16602259	76768	Y641F,TYR641PHE,TYR646PHE	50	https://civicdb.org/links/assertions/50	false
2992	https://civicdb.org/links/variants/2992	NTRK1	4914	TPM3::NTRK1															transcript_fusion		2022-04-12 21:22:04 UTC	17.5			TPM3-NTRK1			false
3001	https://civicdb.org/links/variants/3001	PIK3CA	5290	V955I			3	178948091	178948091	G	A	ENST00000263967.3	75	GRCh37					missense_variant	NC_000003.11:g.178948091G>A,NM_006218.2:c.2863G>A,ENST00000263967.3:c.2863G>A,NP_006209.2:p.Val955Ile	2022-04-12 21:22:06 UTC	10.0	CA355281422	NONE FOUND	VAL955ILE			false
3002	https://civicdb.org/links/variants/3002	NF2	4771	c.1396C>T																	2022-04-12 21:22:05 UTC	5.0						false
3009	https://civicdb.org/links/variants/3009	ABL1	25	Double Ph																	2022-04-12 21:22:05 UTC	10.0			DOUBLE PHILADELPHIA CHROMOSOME			false
3011	https://civicdb.org/links/variants/3011	FLT3	2322	D835Y																	2022-04-12 21:22:04 UTC	6.0						false
3032	https://civicdb.org/links/variants/3032	MYOD1	4654	L122R			11	17741694	17741694	T	G	ENST00000250003.3	75	GRCh37					missense_variant		2022-04-12 21:22:05 UTC	65.0	CA379790889	NONE FOUND	LEU122ARG			false
3042	https://civicdb.org/links/variants/3042	CDK6	1021	EXPRESSION																	2022-04-15 13:59:50 UTC	2.0						false
3049	https://civicdb.org/links/variants/3049	ATM	472	c.902-1G>T																	2022-04-15 14:12:41 UTC	3.0						false
3050	https://civicdb.org/links/variants/3050	ATM	472	c.7089+1del																	2022-04-15 14:12:41 UTC	3.0						false
3051	https://civicdb.org/links/variants/3051	ATM	472	c.7515+1_2del																	2022-04-15 14:12:41 UTC	3.0						false
3066	https://civicdb.org/links/variants/3066	VHL	7428	L128F (c.382C>T)			3	10188239	10188239	C	T	ENST00000256474.2	75	GRCh37					missense_variant		2022-04-12 21:22:04 UTC	0.0	CA351753886					false
3070	https://civicdb.org/links/variants/3070	FLT3	2322	Y842C																	2022-04-12 21:22:04 UTC	17.0						false
3071	https://civicdb.org/links/variants/3071	FLT3	2322	F691L																	2022-04-12 21:22:04 UTC	6.0						false
3075	https://civicdb.org/links/variants/3075	FLT3	2322	D835I																	2022-04-12 21:22:06 UTC	0.0						false
3082	https://civicdb.org/links/variants/3082	BCL2	596	F104I			18	60985590	60985590	A	T	ENST00000398117.1	75	GRCh37					missense_variant	NC_000018.10:g.63318357A>T,NC_000018.9:g.60985590A>T,NM_000633.3:c.310T>A,NP_000624.2:p.Phe104Ile	2022-04-12 21:22:06 UTC	8.0	CA402632320	NONE FOUND	PHE104ILE			false
3096	https://civicdb.org/links/variants/3096	VHL	7428	C77_N78insL (c.230_231insTCT)			3	10183761	10183762		TCT	ENST00000256474.2	75	GRCh37					disruptive_inframe_insertion	NC_000003.12:g.10142077_10142078insTCT,NC_000003.11:g.10183761_10183762insTCT,NM_000551.3:c.230_231insTCT,NP_000542.1:p.Cys77_Asn78insLeu	2022-04-12 21:22:06 UTC	0.0	CA2499214029	NONE FOUND	77INSL			false
3157	https://civicdb.org/links/variants/3157	VHL	7428	F76del (c.227_229del)																	2022-04-12 21:22:06 UTC	7.5						false
3158	https://civicdb.org/links/variants/3158	NTRK2	4915	KANK1::NTRK2															transcript_fusion		2022-06-01 00:39:34 UTC	22.5			KANK1-NTRK2	51,57	https://civicdb.org/links/assertions/51	https://civicdb.org/links/assertions/57	false
3200	https://civicdb.org/links/variants/3200	KRAS	3845	Wildtype			12	25362365	25403737			ENST00000256078.4	75	GRCh37					wild_type		2022-04-12 21:22:06 UTC	2.0						false
3202	https://civicdb.org/links/variants/3202	SMARCB1	6598	LOSS																	2022-04-12 21:22:06 UTC	20.0						false
3203	https://civicdb.org/links/variants/3203	ATRX	546	Mutation			X	76760356	77041702			ENST00000373344.5	75	GRCh37							2022-04-12 21:22:06 UTC	15.0		N/A				false
3214	https://civicdb.org/links/variants/3214	JAK2	3717	GOLGA5::JAK2	The GOLGA5-JAK2 fusion is composed of part of the GOLGA5 (Golgin A5) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the JAK2 (Janus Kinase 2) gene at the 3‚Äô end (C-terminus of the fusion protein). JAK2 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 10 of GOLGA5 to exon 12 of JAK2 (GOLGA5-JAK2 10-12). The fusion is predicted to result from a reciprocal translocation t(9;14)(p24;q32), and has been identified in one patient by RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, containing the coiled coil domain from GOLGA5 and an aberrantly activated JH1 kinase domain from JAK2, which is thought to upregulate the pathway shared with signal transducers and activators of transcription (STATs). The inclusion of the JH1 domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The novel GOLGA5-JAK2 fusion has been documented in one 10-year-old boy with BCR-ABL1-like B-lymphoblastic leukemia with complex karyotype. The clinical details of this case could predict response to treatment with JAK2 inhibitors. A xenograft model created from the patient's malignant cells demonstrated clearance of the leukemic clone in murine peripheral blood upon exposure to ruxolitinib. Moreover, this drug was added to the child's treatment regimen, resulting in nearly undetectable levels of the GOLGA5-JAK2 fusion measured after 64 days of therapy. The patient has reportedly remained in remission 20 months after CAR T-cell infusion and allogeneic hematopoietic stem cell transplantation. This child was included in the currently ongoing prospective clinical trial evaluating the efficacy of JAK2 inhibitors in treating pediatric B-lymphoblastic leukemia with JAK2 fusions (Clinicaltrials.gov Identifier: NCT02723994).														transcript_fusion		2022-03-11 00:18:20 UTC	0.0			GOLGA5-JAK2			false
3222	https://civicdb.org/links/variants/3222	PIK3CA	5290	Rare Mutation			3	178866311	178957881			ENST00000263967.3	75	GRCh37							2022-04-12 21:22:06 UTC	0.0						false
3223	https://civicdb.org/links/variants/3223	NTRK1	4914	LMNA::NTRK1 e2-e10																	2022-04-12 21:22:06 UTC	7.5			LMNA-NTRK1 E2-E10			false
3224	https://civicdb.org/links/variants/3224	NTRK1	4914	LMNA::NTRK1 e2-e11															transcript_fusion		2022-04-12 21:22:06 UTC	8.0			LMNA-NTRK1 E2-E11			false
3225	https://civicdb.org/links/variants/3225	NTRK1	4914	LMNA::NTRK1 e11-e10			1	156084498	156108548			ENST00000368300.4	75	GRCh37	1	156844363	156851434	ENST00000524377.1	transcript_fusion		2022-04-12 21:22:06 UTC	18.5			LMNA-NTRK1 E11-E10			false
3244	https://civicdb.org/links/variants/3244	VHL	7428	R120fs (c.358_359insAC)			3	10188215	10188216		AC	ENST00000256474.2	75	GRCh37					frameshift_truncation,plus_2_frameshift_variant	NC_000003.12:g.10146531_10146532insAC,NC_000003.11:g.10188215_10188216insAC,NM_000551.3:c.358_359insAC,NP_000542.1:p.Arg120AsnfsTer?	2022-05-30 00:03:38 UTC	7.5	CA2573106245	NONE FOUND	R120NFS*40			false
3245	https://civicdb.org/links/variants/3245	VHL	7428	C77fs (c.230del)																	2022-04-12 21:22:02 UTC	0.0						false
3246	https://civicdb.org/links/variants/3246	VHL	7428	Q96_P97delinsH (c.288_290del)			3	10183819	10183821	GCC		ENST00000256474.2	75	GRCh37					disruptive_inframe_deletion	NC_000003.12:g.10142135_10142137del,NC_000003.11:g.10183819_10183821del,NM_000551.3:c.288_290del,NP_000542.1:p.Gln96_Pro97delinsHis	2022-05-30 00:00:44 UTC	7.5	CA2573106244	NONE FOUND	C.288DELGCC,C.288_290DELGCC			false
3247	https://civicdb.org/links/variants/3247	VHL	7428	G144fs (c.429_439del)			3	10188285	10188295	ACGGACAGCCT		ENST00000256474.2	75	GRCh37					frameshift_truncation,minus_2_frameshift_variant	NC_000003.12:g.10146602_10146612del,NC_000003.11:g.10188286_10188296del,NM_000551.3:c.429_439del,NP_000542.1:p.Gly144PhefsTer26	2022-05-30 00:00:44 UTC	7.5	CA2573106247	NONE FOUND	G144FFS*26,C.428_438DEL			false
3257	https://civicdb.org/links/variants/3257	AKT1	207	S473 Phosphorylation																	2022-04-12 21:22:05 UTC	0.0						false
3259	https://civicdb.org/links/variants/3259	IGF1R	3480	Overexpression																	2022-04-12 21:22:05 UTC	0.0		N/A				false
3268	https://civicdb.org/links/variants/3268	ABL1	25	RANBP2::ABL1	The RANBP2-ABL1 fusion is composed of part of the RANBP2 (RAN Binding Protein 2) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 18 of RANBP2 to exon 2 of ABL1 (RANBP2-ABL1 18-2). The fusion is the result of a reciprocal translocation t(2;9)(p12.3;q34.12) and has been identified by FISH/karyotype and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, includes the leucine zipper of RANBP2 and the tyrosine kinase of ABL1, which is thought to upregulate the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Specifically, the inclusion of the tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. Clinical significance: The RANBP2-ABL1 fusion has been documented in several juvenile and young adult patients with B-lymphoblastic leukemia, some of which were further classified as BCR-ABL1 (Ph)-like subtype. Most of the documented patients were treated with a tyrosine kinase inhibitor (specifically dasatinib) added to their chemotherapy regimens, but they eventually experienced relapse and succumbed to their disease. The use of tyrosine kinase inhibitors is the focus of an ongoing prospective clinical trial evaluating the efficacy of these drugs when treating young patients with high-risk and BCR-ABL1-like B-lymphoblastic leukemia (Clinicaltrials.gov Identifier: NCT02883049).	ABL1 fusions in B-ALL	2	109336063	109375004			ENST00000283195	75	GRCh37	9	133729451	133763062	ENST00000372348.2	transcript_fusion		2022-03-10 23:38:29 UTC	10.0			RANBP2-ABL1			false
3269	https://civicdb.org/links/variants/3269	ABL1	25	ZMIZ1::ABL1	The ZMIZ1-ABL1 fusion is composed of part of the ZMIZ1 (Zinc Finger MIZ-Type Containing 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The most commonly published breakpoint joins exon 18 of ZMIZ1 to exon 2 of ABL1 (ZMIZ1-ABL1 18-2). The fusion is the result of a reciprocal translocation t(9;10)(q34.12;q22.3) and has been identified by FISH/karyotype, RT-PCR, and RNA sequencing. The fusion is in-frame and results in production of an abnormal hybrid protein, which contains one of the proline-rich domains of ZMIZ1 and the ABL1 tyrosine kinase domain. Similar to other oncogenic fusion proteins, the proline-rich domain of ZMIZ1 is involved in protein-protein interactions, and therefore the fusion may encode a constitutively activated tyrosine kinase that upregulates the mitogen-activate protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. Patients harboring the ZMIZ1-ABL1 fusion are hypothesized to be eligible for imatinib therapy.	ABL1 fusions in B-ALL	10	80828792	81061969			ENST00000334512.5	75	GRCh37	9	133729451	133763062	ENST00000318560.5	transcript_fusion		2022-03-10 19:47:28 UTC	32.5			ZMIZ1-ABL1			false
3270	https://civicdb.org/links/variants/3270	ABL1	25	CENPC::ABL1	The CENPC-ABL1 fusion is composed of part of the CENPC (Centromere Protein C) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The CENPC-ABL1 fusion is in-frame and it has been documented in one pediatric patient with high risk BCR-ABL1-like B-lymphoblastic leukemia.	ABL1 fusions in B-ALL													transcript_fusion		2022-03-10 20:13:09 UTC	5.0		NONE FOUND	CENPC-ABL1			false
3271	https://civicdb.org/links/variants/3271	ABL1	25	NUP153::ABL1	The NUP153-ABL1 fusion is composed of part of the NUP153 (Nucleoporin 153) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein, and the inclusion of the ABL1 tyrosine kinase domain may affect functionality and offer a target for therapeutic inhibition. The NUP153-ABL1 has been documented in one pediatric patient with BCR-ABL1-like B-lymphoblastic leukemia, as detected by RNA kinome capture and transcriptome sequencing.	ABL1 fusions in B-ALL													transcript_fusion		2022-03-11 17:35:08 UTC	5.0			NUP153-ABL1			false
3272	https://civicdb.org/links/variants/3272	ABL1	25	LSM14A::ABL1	The LSM14A-ABL1 fusion is composed of part of the LSM14A (LSM14A mRNA processing body assembly factor) gene at the 5‚Äô end (N-terminus of the fusion protein) and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The fusion is in-frame and it has been documented in two patients with BCR-ABL1-like B-lymphoblastic leukemia (Ph-like ALL). The first patient was a child with high risk Ph-like ALL and the second patient was a 36 years old male who had a poor prednisone response and did not reach complete remission after vincristine-dexamethasone-rituximab or a combination of dasatinib and chemotherapy. The second patient died early of sepsis in a context of uncontrolled disease (survival 2 months).	ABL1 fusions in B-ALL													transcript_fusion		2022-03-11 17:37:22 UTC	10.0		NONE FOUND	LSM14A-ABL1			false
3274	https://civicdb.org/links/variants/3274	PDGFRA	5156	Mutation																	2022-04-12 21:22:06 UTC	0.0						false
3287	https://civicdb.org/links/variants/3287	ABL1	25	SFPQ::ABL1	The SFPQ -ABL1 fusion is composed of part of the SFPQ (Splicing factor proline and glutamine rich) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (ABL proto-oncogene 1, non-receptor tyrosine kinase) gene at the 3‚Äô end (C-terminus of the fusion protein). ABL1 is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The published breakpoint joins exon 9 of SFPQ to exon 4 of ABL1 (SFPQ -ABL1). The fusion is the result of a reciprocal translocation t(1;9)(p34;q34) and has been identified by RT-PCR, Sanger sequencing, and RNA sequencing. The role of the partner gene SFPQ in this fusion remains to be investigated. SFPQ encodes for a protein belonging to a new functionally related group of fusion partners for tyrosine kinases involved in pre-mRNA processing. The presence of 2 coiled-coil domains in the 9 remaining exons of SFPQ could theoretically lead to SFPQ‚ÄìABL1 oligomerization, thus leading to constitutive activation of the resulting tyrosine kinase, as reported with other partner genes. Though uncommon, this translocation might be targeted by tyrosine kinase inhibitors. Clinical significance: The SFPQ -ABL1 fusion has been documented in six patients (3 male, 3 female) between the ages of 10 and 34 years with B-lymphoblastic leukemia, some of which were further diagnosed with BCR-ABL1 (Ph)-like subtype. Two patients had tyrosine kinase inhibitors (dasatinib + imatinib) added to their chemotherapy regimens, who did not have relapse. One additional patient who did not have tyrosine kinase inhibitor also did not suffer from relapse. The clinical details of these cases may predict response to treatment with tyrosine kinase inhibitors. Functional studies are needed to substantiate the efficacy of TKI treatment of this particular ABL-class fusion.	ABL1 fusions in B-ALL													transcript_fusion		2022-03-10 23:22:23 UTC	32.5			SFPQ-ABL1			false
3299	https://civicdb.org/links/variants/3299	PPP2R1A	5518	P179R																	2022-04-12 21:22:03 UTC	0.0						false
3304	https://civicdb.org/links/variants/3304	EGFR	1956	N771_P772insL																	2022-12-16 18:19:00 UTC	2.5						false
3309	https://civicdb.org/links/variants/3309	ATRX	546	Deletion			X	76760356	77041702			ENST00000373344.5	75	GRCh37					deletion		2022-04-12 21:22:03 UTC	0.0						false
3311	https://civicdb.org/links/variants/3311	PIK3CA	5290	Exon 10 or Exon 21 Mutation																	2022-04-12 21:22:06 UTC	0.0						false
3313	https://civicdb.org/links/variants/3313	CDKN1A	1026	rs1059234																	2022-04-12 21:22:03 UTC	0.0						false
3318	https://civicdb.org/links/variants/3318	TP53	7157	P250L																	2022-04-12 21:22:04 UTC	5.0						false
3341	https://civicdb.org/links/variants/3341	KRAS	3845	G10_A11insG																	2022-04-12 21:22:06 UTC	4.0						false
3342	https://civicdb.org/links/variants/3342	KRAS	3845	A11_G12insGA																	2022-04-12 21:22:06 UTC	4.0						false
3344	https://civicdb.org/links/variants/3344	EGFR	1956	R222C			7	55220274	55220274	C	T	ENST00000275493.2	75	GRCh37					missense_variant		2022-04-12 21:22:06 UTC	0.0	CA367577392	1000203	ARG222CYS			false
3350	https://civicdb.org/links/variants/3350	KDR	3791	R1032Q																	2022-04-12 21:22:06 UTC	0.0						false
3359	https://civicdb.org/links/variants/3359	CSF1R	1436	TBL1XR1::CSF1R	The TBL1XR1-CSF1R fusion is composed of part of the TBL1XR1 (Transducin Beta Like 1 X-Linked Receptor 1) gene at the 5‚Äô end (N-terminus of the fusion protein), and part of the ABL1 (Colony Stimulating Factor 1 Receptor) gene at the 3‚Äô end (C-terminus of the fusion protein). CSF1R is considered as the key partner that defines the functional/oncogenic effects of the fusion protein. The breakpoint is not published, but is predicted to be the result of a reciprocal translocation t(3;5)(q26.32;q32) and has been identified by RNA sequencing in a single pediatric patient. The consequence of this fusion with respect to treatment response and disease outcome is unknown.														transcript_fusion		2022-03-10 21:45:01 UTC	7.5			TBL1XR1-CSF1R			false
3364	https://civicdb.org/links/variants/3364	EZH2	2146	Y646H			7	148508728	148508728	A	G	ENST00000320356.7		GRCh37					missense_variant	ENST00000320356.7:c.1936T>C,NC_000007.14:g.148811636A>G,NC_000007.13:g.148508728A>G,ENSP00000320147.2:p.Tyr646His,ENST00000460911.5:c.1921T>C,ENSP00000419711.1:p.Tyr641His,NM_004456.5:c.1936T>C,NP_004447.2:p.Tyr646His,NM_001203247.2:c.1921T>C,NP_001190176.1:p.Tyr641His	2022-12-09 20:35:35 UTC	5.0	CA16602260	76769	Y641H,TYR641HIS,TYR646HIS			false
3371	https://civicdb.org/links/variants/3371	ALK	238	I1171T																	2022-04-12 21:22:06 UTC	0.0						false
3373	https://civicdb.org/links/variants/3373	CD44	960	CD44v6																	2022-04-12 21:22:06 UTC	20.0				48	https://civicdb.org/links/assertions/48	false
3381	https://civicdb.org/links/variants/3381	PIK3R2	5296	G373R																	2022-04-12 21:22:06 UTC	0.0						false
3382	https://civicdb.org/links/variants/3382	PTEN	5728	C136R																	2022-04-12 21:22:06 UTC	0.0						false
3390	https://civicdb.org/links/variants/3390	TP53	7157	R181P																	2022-07-21 17:40:25 UTC	3.0						false
3401	https://civicdb.org/links/variants/3401	TP53	7157	D259V																	2022-04-12 21:22:02 UTC	0.0						false
3432	https://civicdb.org/links/variants/3432	BRAF	673	G463E																	2022-04-12 21:22:06 UTC	3.0						false
3457	https://civicdb.org/links/variants/3457	NFE2L2	4780	G31A																	2022-04-12 21:22:07 UTC	0.0						false
3468	https://civicdb.org/links/variants/3468	NTRK3	4916	F617L																	2022-12-16 17:31:59 UTC	5.0						false
3469	https://civicdb.org/links/variants/3469	NTRK1	4914	G595R and G667S																	2022-12-16 17:20:14 UTC	5.0						false
3579	https://civicdb.org/links/variants/3579	TP53	7157	R342P																	2022-04-12 21:22:07 UTC	3.0						false
3580	https://civicdb.org/links/variants/3580	TP53	7157	L330P																	2022-04-12 21:22:07 UTC	3.0						false
3581	https://civicdb.org/links/variants/3581	TP53	7157	L330R																	2022-04-12 21:22:07 UTC	3.0						false
3582	https://civicdb.org/links/variants/3582	TP53	7157	R337P																	2022-04-12 21:22:07 UTC	3.0						false
3583	https://civicdb.org/links/variants/3583	TP53	7157	L344P																	2022-04-12 21:22:07 UTC	3.0						false
3607	https://civicdb.org/links/variants/3607	EZH2	2146	Y646C			7	148508727	148508727	T	C	ENST00000320356.7		GRCh37					missense_variant	NC_000007.14:g.148811635T>C,NC_000007.13:g.148508727T>C,ENST00000320356.7:c.1937A>G,ENSP00000320147.2:p.Tyr646Cys,NM_004456.5:c.1937A>G,NP_004447.2:p.Tyr646Cys	2022-12-10 00:00:06 UTC	0.0	CA369713035	NONE FOUND	TYR646CYS			false
3643	https://civicdb.org/links/variants/3643	PIM1	5292	L2V																	2022-04-12 21:22:06 UTC	3.0						false
3644	https://civicdb.org/links/variants/3644	PIM1	5292	P81S																	2022-04-12 21:22:07 UTC	3.0						false
3645	https://civicdb.org/links/variants/3645	PIM1	5292	S97N																	2022-04-12 21:22:07 UTC	3.0						false
3661	https://civicdb.org/links/variants/3661	ACVR1	90	R206H																	2022-04-12 21:22:07 UTC	0.0						false
3662	https://civicdb.org/links/variants/3662	ACVR1	90	G356D																	2022-04-12 21:22:07 UTC	0.0						false
3666	https://civicdb.org/links/variants/3666	PIK3CA	5290	K944N																	2022-05-03 23:06:03 UTC	10.0						false
3667	https://civicdb.org/links/variants/3667	PIK3CA	5290	F930S																	2022-05-03 22:47:02 UTC	10.0						false
3668	https://civicdb.org/links/variants/3668	PIK3CA	5290	V955G																	2022-05-03 23:02:44 UTC	10.0						false
3669	https://civicdb.org/links/variants/3669	PIK3CA	5290	K966E																	2022-05-03 23:08:25 UTC	10.0						false
3670	https://civicdb.org/links/variants/3670	PIK3CA	5290	L938*																	2022-05-03 23:16:25 UTC	7.5						false
3684	https://civicdb.org/links/variants/3684	TP53	7157	T125T																	2022-04-12 21:22:07 UTC	0.0						false
3695	https://civicdb.org/links/variants/3695	FGFR3	2261	K650N	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1807891	1807891	G	C	ENST00000440486.8		GRCh37					missense_variant	NC_000004.12:g.1806164G>C,NC_000004.11:g.1807891G>C,ENST00000440486.8:c.1950G>C,NM_000142.5:c.1950G>C,ENSP00000414914.2:p.Lys650Asn,NP_000133.1:p.Lys650Asn	2022-07-07 02:58:27 UTC	2.0	CA280221	16347,16346	LYS650ASN			false
3727	https://civicdb.org/links/variants/3727	FLCN	201163	c.1285dupC			17	17119708	17119709		G	ENST00000285071.9	75	GRCh37						NM_144997.7:c.1285dup,NP_659434.2:p.His429fs	2022-04-12 21:22:07 UTC	2.5	CA090951	3363	HIS429FS			false
3728	https://civicdb.org/links/variants/3728	SLC29A1	2030	Overexpression																	2022-04-12 21:22:07 UTC	20.0		N/A				false
3737	https://civicdb.org/links/variants/3737	EZH2	2146	Activating Mutation																	2022-04-12 21:22:07 UTC	15.0						false
3745	https://civicdb.org/links/variants/3745	CTCF	10664	K365T																	2022-04-12 21:22:07 UTC	0.0						false
3752	https://civicdb.org/links/variants/3752	SSTR5	6755	expression																	2022-04-12 21:22:01 UTC	0.0						false
3760	https://civicdb.org/links/variants/3760	TP53	7157	P98S																	2022-04-12 21:22:02 UTC	0.0						false
3761	https://civicdb.org/links/variants/3761	TP53	7157	P98L																	2022-04-12 21:22:02 UTC	0.0						false
3762	https://civicdb.org/links/variants/3762	TP53	7157	Y126D																	2022-04-12 21:22:02 UTC	0.0						false
3763	https://civicdb.org/links/variants/3763	TP53	7157	Y126S																	2022-04-12 21:22:02 UTC	0.0						false
3764	https://civicdb.org/links/variants/3764	TP53	7157	K139E																	2022-04-12 21:22:02 UTC	0.0						false
3765	https://civicdb.org/links/variants/3765	TP53	7157	P151S																	2022-04-12 21:22:02 UTC	0.0						false
3766	https://civicdb.org/links/variants/3766	PIK3CA	5290	H1047L or H1047R																	2022-04-12 21:22:02 UTC	0.0						false
3767	https://civicdb.org/links/variants/3767	TP53	7157	P152L																	2022-07-21 16:58:52 UTC	6.0						false
3768	https://civicdb.org/links/variants/3768	TP53	7157	I162F																	2022-04-12 21:22:02 UTC	0.0						false
3769	https://civicdb.org/links/variants/3769	TP53	7157	Y163H																	2022-04-12 21:22:02 UTC	0.0						false
3770	https://civicdb.org/links/variants/3770	TP53	7157	Y236S																	2022-04-12 21:22:02 UTC	0.0						false
3771	https://civicdb.org/links/variants/3771	TP53	7157	L252F																	2022-04-12 21:22:02 UTC	0.0						false
3772	https://civicdb.org/links/variants/3772	TP53	7157	E258K																	2022-04-12 21:22:02 UTC	0.0						false
3773	https://civicdb.org/links/variants/3773	TP53	7157	G262D																	2022-04-12 21:22:01 UTC	0.0						false
3774	https://civicdb.org/links/variants/3774	TP53	7157	G266E																	2022-07-21 17:19:50 UTC	6.0						false
3775	https://civicdb.org/links/variants/3775	TP53	7157	L308M																	2022-04-12 21:22:02 UTC	0.0						false
3776	https://civicdb.org/links/variants/3776	TP53	7157	L323P																	2022-04-12 21:22:02 UTC	0.0						false
3777	https://civicdb.org/links/variants/3777	TP53	7157	Q144P																	2022-04-12 21:22:02 UTC	0.0						false
3778	https://civicdb.org/links/variants/3778	TP53	7157	P219H																	2022-04-12 21:22:02 UTC	0.0						false
3779	https://civicdb.org/links/variants/3779	TP53	7157	Y220H																	2022-04-12 21:22:02 UTC	0.0						false
3780	https://civicdb.org/links/variants/3780	TP53	7157	E224K																	2022-04-12 21:22:02 UTC	0.0						false
3781	https://civicdb.org/links/variants/3781	TP53	7157	Y234H																	2022-04-12 21:22:02 UTC	0.0						false
3782	https://civicdb.org/links/variants/3782	TP53	7157	T230S																	2022-04-12 21:22:02 UTC	0.0						false
3783	https://civicdb.org/links/variants/3783	TP53	7157	H168Y																	2022-04-12 21:22:02 UTC	0.0						false
3784	https://civicdb.org/links/variants/3784	TP53	7157	P177S																	2022-04-12 21:22:02 UTC	0.0						false
3785	https://civicdb.org/links/variants/3785	TP53	7157	P177F																	2022-04-12 21:22:02 UTC	0.0						false
3786	https://civicdb.org/links/variants/3786	TP53	7157	P177H																	2022-04-12 21:22:02 UTC	0.0						false
3787	https://civicdb.org/links/variants/3787	TP53	7157	N239S																	2022-04-12 21:22:02 UTC	0.0						false
3788	https://civicdb.org/links/variants/3788	TP53	7157	S241T																	2022-04-12 21:22:02 UTC	0.0						false
3789	https://civicdb.org/links/variants/3789	TP53	7157	M246L																	2022-04-12 21:22:02 UTC	0.0						false
3790	https://civicdb.org/links/variants/3790	TP53	7157	V274F																	2022-05-06 03:54:20 UTC	3.0						false
3791	https://civicdb.org/links/variants/3791	TP53	7157	G279E																	2022-04-21 08:06:48 UTC	3.0						false
3792	https://civicdb.org/links/variants/3792	TP53	7157	D281N																	2022-04-21 08:08:14 UTC	3.0						false
3794	https://civicdb.org/links/variants/3794	TP53	7157	P152T																	2022-04-12 21:22:02 UTC	0.0						false
3795	https://civicdb.org/links/variants/3795	TP53	7157	R156P																	2022-04-12 21:22:03 UTC	0.0						false
3796	https://civicdb.org/links/variants/3796	TP53	7157	R181C																	2022-04-12 21:22:03 UTC	0.0						false
3797	https://civicdb.org/links/variants/3797	TP53	7157	R181G																	2022-04-12 21:22:03 UTC	0.0						false
3798	https://civicdb.org/links/variants/3798	TP53	7157	R181H																	2022-04-12 21:22:03 UTC	0.0						false
3799	https://civicdb.org/links/variants/3799	TP53	7157	R283H																	2022-04-12 21:22:03 UTC	0.0						false
3800	https://civicdb.org/links/variants/3800	TP53	7157	Y163N																	2022-04-12 21:22:03 UTC	0.0						false
3801	https://civicdb.org/links/variants/3801	TP53	7157	L257P																	2022-04-12 21:22:03 UTC	0.0						false
3991	https://civicdb.org/links/variants/3991	PDGFB	5155	COL1A1-PDGFB fusion																	2022-05-12 04:40:25 UTC	25.0						false
4001	https://civicdb.org/links/variants/4001	ALK	238	KANK4::ALK																	2022-11-07 23:05:34 UTC	7.5			KANK4-ALK			false
4013	https://civicdb.org/links/variants/4013	FGFR3	2261	K650M	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1807890	1807890	A	T	ENST00000440486.8		GRCh37					missense_variant	NC_000004.12:g.1806163A>T,NC_000004.11:g.1807890A>T,ENST00000440486.8:c.1949A>T,ENSP00000414914.2:p.Lys650Met,NM_000142.5:c.1949A>T,NP_000133.1:p.Lys650Met	2022-07-07 02:58:15 UTC	1.0	CA126382	16341	LYS650MET			false
4018	https://civicdb.org/links/variants/4018	MS4A1	931	Mutation																	2022-07-14 18:35:03 UTC	15.0						false
4019	https://civicdb.org/links/variants/4019	FGFR3	2261	K650Q	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1807889	1807889	A	C	ENST00000440486.8		GRCh37					missense_variant	NC_000004.12:g.1806162A>C,NC_000004.11:g.1807889A>C,ENST00000440486.8:c.1948A>C,NM_000142.5:c.1948A>C,ENSP00000414914.2:p.Lys650Gln ,NP_000133.1:p.Lys650Gln	2022-07-07 02:58:44 UTC	4.0	CA170755	16348	LYS650GLN,LYS652GLN,LYS538GLN,LYS651GLN,K652Q,K538Q,K651Q			false
4023	https://civicdb.org/links/variants/4023	FGFR3	2261	A391E	This is a pilot variant of the FGFR ClinGen Somatic Cancer Variant Curation Expert Panel (SC-VCEP) used to establish FGFR specific modifications to the ClinGen/CGC/VICC procedure for classification of somatic variant oncogenicity.		4	1806153	1806153	C	A	ENST00000440486.8		GRCh37					missense_variant	NC_000004.11:g.1806153C>A,NC_000004.12:g.1804426C>A,NM_000142.5:c.1172C>A,ENST00000440486.8:c.1172C>A,ENSP00000414914.2:p.Ala391Glu,NP_000133.1:p.Ala391Glu 	2022-07-07 02:51:15 UTC	0.0	CA249860	16329	ALA391GLU,ALA393GLU,A393E			false
4024	https://civicdb.org/links/variants/4024	FGFR3	2261	K650D			4	1807889	1807891	GAC	AAG	ENST00000440486.8		GRCh37					delins	NC_000004.12:g.1806162_1806164delinsGAC,NC_000004.11:g.1807889_1807891delinsGAC,ENST00000440486.8:c.1948_1950delinsGAC,ENSP00000414914.2:p.Lys650Asp ,NM_000142.5:c.1948_1950delinsGAC,NP_000133.1:p.Lys650Asp	2022-06-24 00:00:11 UTC	3.0	unregistered	NONE FOUND	LYS650ASP			false
4025	https://civicdb.org/links/variants/4025	FGFR3	2261	K650L			4	1807889	1807890	AA	CT	ENST00000440486.8		GRCh37						NC_000004.12:g.1806162_1806163delinsCT,NC_000004.11:g.1807889_1807890delinsCT,ENST00000440486.8:c.1948_1949delinsCT,ENSP00000414914.2:p.Lys650Leu,NM_000142.5:c.1948_1949delinsCT,NP_000133.1:p.Lys650Leu	2022-06-24 00:00:10 UTC	2.0	CA2573130207	NONE FOUND	LYS650LEU			false
4090	https://civicdb.org/links/variants/4090	EZH2	2146	Y646N			7	148508728	148508728	A	T	ENST00000320356.7		GRCh37					missense_variant	NC_000007.14:g.148811636A>T,NC_000007.13:g.148508728A>T,ENST00000320356.7:c.1936T>A,ENSP00000320147.2:p.Tyr646Asn,NM_004456.5:c.1936T>A,NP_004447.2:p.Tyr646Asn,NM_001203247.2:c.1921T>A,NP_001190176.1:p.Tyr641Asn,ENST00000460911.5:c.1921T>A,ENSP00000419711.1:p.Tyr641Asn	2022-12-10 00:00:04 UTC	0.0	CA16602670	376217	Y641N,TYR646ASN,TYR641ASN			false
4102	https://civicdb.org/links/variants/4102	TP53	7157	R156H																	2022-07-21 17:37:01 UTC	3.0						false
4103	https://civicdb.org/links/variants/4103	TP53	7157	H178P																	2022-07-21 17:38:56 UTC	3.0						false
4106	https://civicdb.org/links/variants/4106	TP53	7157	E68G																	2022-07-21 17:07:22 UTC	3.0						false
4111	https://civicdb.org/links/variants/4111	TP53	7157	L111R																	2022-07-21 17:09:01 UTC	3.0						false
4112	https://civicdb.org/links/variants/4112	TP53	7157	H115Y																	2022-07-21 17:04:48 UTC	3.0						false
4113	https://civicdb.org/links/variants/4113	TP53	7157	C124R																	2022-07-21 17:01:43 UTC	3.0						false
4114	https://civicdb.org/links/variants/4114	TP53	7157	L139N																	2022-07-21 16:52:29 UTC	3.0						false
4115	https://civicdb.org/links/variants/4115	TP53	7157	R158G																	2022-07-21 17:00:19 UTC	3.0						false
4122	https://civicdb.org/links/variants/4122	TP53	7157	G266V																	2022-07-21 17:34:32 UTC	3.0						false
4123	https://civicdb.org/links/variants/4123	TP53	7157	V272G																	2022-07-21 17:30:41 UTC	3.0						false
